Author Index—1989

Aaronson, KD, 862(ab)
Aaronson, RA, 932(ab)
Abbott, GL, 911(ab)
Abdel-Dayem, HM, 842(ab), 857(ab), 864(ab), 876(ab), 921(ab), 942(ab), 943(ab), 959(ab), 968(ab)
Abdel-Nabi, H, 747(ab), 748(ab), 818(ab), 906(ab), 908(ab)
Abe, Y, 33
Abello, R, 834(ab), 858(ab), 909(ab)
Abello, RR, 901(ab)
Abeyseka, BF, 1916(le)
Abitbol, C, 798(ab), 841(ab), 915(ab)
Abraham, T, 959(ab)
Abramovici, J, 897(ab)
Abrams, DN, 523
Abrams, P, 779(ab), 818(ab)
Abrams, PG, 25, 216
Abrashkin, S, 450, 538
Aburano, T, 844(ab), 997
Abu-Ziadan, F, 942(ab)
Acharya, K, 770(ab)
Achong, DM, 941(ab)
Ackerhalt, R, 818(ab)
Ackerman, RH, 782(ab)
Ackerman, RJ, 895(ab)
Ackermann, RF, 838(ab), 900(ab)
Ackery, D, 903(ab)
Adam, MJ, 923(ab), 924(ab)
Adam, WE, 813(ab), 835(ab), 1393
Adams, HR, 1249
Adams, R, 320
Adelstein, SJ, 826(ab), 882(ab), 883(ab), 932(ab), 1856
Adkins, R, 857(ab)
Adzamli, IK, 839(ab)
Aengevaeren, W, 861(ab)
Aengevaeren, WRM, 1723
Afeworth, M, 798(ab)
Affana, RS, 857(ab)
Agnew, JE, 744(ab)
Agostini, D, 810(ab)
Agostini, M, 779(ab)
Agrawal, M, 474
Aguilar, F, 863(ab)
Ahmad, M, 817(ab), 840(ab), 901(ab), 917(ab), 1095
Ahmed, A, 905(ab)
Ahonen, A, 912(ab)
Aikawa, T, 917(ab)
Aizawa, T, 811(ab)
Akanabe, H, 458
Akers, MS, 288, 638, 770(ab), 801(ab), 810(ab), 828(ab), 871(ab)
Akiyama, Y, 885(ab)
Akkermans, L, 795(ab)
Akoun, G, 746(ab)
Alajaji, G, 821(ab)
Alavi, A, 88, 328, 692, 731(ab), 733(ab), 753(ab), 754(ab), 762(ab), 772(ab), 773(ab), 802(ab), 811(ab), 830(ab), 834(ab), 898(ab), 965(ab), 1106, 1589, 1607
Albert, R, 730(ab)
Alberti, W, 845(ab)
Albright, MJ, 813(ab)
Alderson, PO, 787(ab), 819(ab), 936(ab)
Al-Doohan, S, 902(ab)
Alexander, M, 961(ab)
Alexopoulos, D, 834(ab)
Al-Ghussain, NM, 857(ab)
Al-Hasani, S, 922(ab)
Ali, A, 769(ab), 855(ab)
Allen, A, 844(ab)
Allilaire, JF, 897(ab)
Allison, DJ, 841(ab)
Allsop, P, 738(ab)
Allwright, S, 799(ab)
Allwright, SJ, 857(ab)
Al-Mohannadi, S, 943(ab)
Al-Nahhas, AA, 823(ab)
Alpert, N, 961(ab)
Alpert, NM, 776(ab), 782(ab), 797(ab)
Alvarez, VL, 778(ab), 831(ab)
Alves, W, 802(ab), 898(ab), 965(ab)
Alves, WM, 1607
Alyea, K, 786(ab)
Ambrose, J, 834(ab)
Ambrose, KR, 923(ab)
Amini, SB, 867(ab)
Aronar, IA, 817(ab)
Amox, D, 778(ab)
Anders, G, 880(ab)
Andersen, AR, 896(ab)
Anderson, G, 874(ab)
Anderson, HL, 767(ab)
Anderson, LE, 827(ab), 907(ab)
Anderson, LL, 933(ab)
Anderson, QN, 858(ab)
Ando, A, 921(ab)
Ando, I, 921(ab)
Andreu, J, 1470
Andrew, M, 1819
Andrews, J, 836(ab)
Anema, PC, 806(ab)
Angelberger, P, 731(ab)
Angello, DA, 1172
Ansari, A, 886(ab)
Ansari, S, 803(ab)
Antar, MA, 859(ab)
Antich, P, 902(ab)
Antico, VF, 1885, 1946
Antman, EM, 821(ab)
Antonescu, A, 740(ab)
Antoni, G, 782(ab), 783(ab)
Antonovic, A, 905(ab)
Apicella, A, 93, 772(ab), 802(ab)
Apostolides, DL, 1257
Appelbaum, FR, 828(ab)
Appelbaum, J, 779(ab)
Appelman, EH, 930(ab)
Applebaum, FR, 826(ab)
Applegate, GR, 700
Arano, Y, 832(ab)
Araujo, LI, 775(ab), 808(ab)
Arcamano, M, 833(ab)
Archer, CM, 773(ab), 818(ab), 939(ab)
Archer CM, 773(ab)
Areeda, J, 739(ab)
Arevalo, M, 794(ab)
Arimizu, N, 738(ab), 858(ab), 865(ab), 910(ab)
Arnold, RJ, N576, N994
Arnold, S, 747(ab)
Arnot, RN, 738(ab)
Aroesty, JM, 870(ab)
Arrington, ER, 2046
Arsenault, A, 800(ab), 807(ab)
Ashley, CA, 968(ab)
Assayag, P, 820(ab)
Atcher, R, 832(ab), 834(ab), 925(ab)
Atkins, HL, 165, 811(ab), 1848
Atkinson, D, 813(ab)
Auerbach, B, 786(ab)
Aulich, A, 771(ab)
Ausema, L, 768(ab)
Austin, M, 751(ab), 831(ab)
Austin, ML, 787(ab)
Autran, B, 746(ab)
Avedissian, MG, 1281
Avioli, LV, 774(ab)
Awdeh, M, 842(ab)
Axworthy, D, 779(ab)
Axworthy, DB, 793(ab)
Azar, H, 883(ab)

Babich, J, 809(ab)
Babich, JW, 474, 836(ab), 911(ab)
Bacharach, SL, 420, 780(ab), 807(ab), 1966
Bachelor, MA, 926(ab)
Bachur, R, 750(ab)
Badach, V, 845(ab)
Badenhorst, PN, 914(ab)
Badger, CC, 826(ab), 828(ab)
Bading, JR, 852(ab)
Baerga, ID, 742(ab), 920(ab)
Bahar, RH, 942(ab)
Bailey, DL, 872(ab), 964(ab), 1865
Baillet, GY, 38
Baird, F, 786(ab)
Baker, J, 764(ab), 887(ab)
Baker, SR, 843(ab)
Bakker, WH, 768(ab)
Bakr, SA, 922(ab)
Balasubramanian, N, 748(ab), 941(ab)
Balch, CM, 844(ab)
Baldas, J, 1240
Ballard, JG, 497, 756(ab)
Ballardie, FW, 784(ab)
Ballem, PJ, 629
Ballester, M, 862(ab)
Balliet, R, 965(ab)
Ballinger, J, 760(ab), 829(ab)
Ballinger, JR, 812(ab), 1621
Balon, H, 850(ab), 959(ab)
Balu, D, 1464
Ban, R, 770(ab), 944(ab)
Ban, T, 866(ab), 1302, 1775
Bandyopadhyay, D, 859(ab)
Bannochie, CJ, 848(ab)
Banzo, I, 1277(le)
Baranczuk, RA, 844(ab)
Baranowska-Kortylewica, J, 883(ab)
Baranowska-Kortylewicz, J, 882(ab), 919(ab)
Barbagallo, S, 764(ab), 887(ab), 964(ab)
Barber, HB, 891(ab)
Barbet, J, 907(ab), 1358
Bares, R, 841(ab)
Baris, I, 913(ab)
Barker, W, 93
Barker, WW, 772(ab)
Barker WW, 802(ab)
Barnes, J, 903(ab)
Barnette, MS, 794(ab)
Barnhart, AJ, 848(ab)
Baron, JC, 897(ab)
Baron, LA, 832(ab)
Barone, FC, 794(ab)
Barrett, HH, 891(ab), 892(ab)
Barrett, J, 847(ab)
Barrett, JS, 815(ab)
Barrio, JR, 735(ab), 752(ab), 761(ab)
Barron, BJ, 270, 967(ab)
Bartenstein, P, 856(ab)
Barton, D, 799(ab)
Barzilai, B, 771(ab)
Bash, SA, 894(ab)
Bassingthwaighte, JB, 798(ab), 808(ab)
Bauer, J, 751(ab)
Baum, RP, 786(ab), 847(ab), 904(ab)
Bauman, JM, 1737(le)
Bazzochi, G, 887(ab)
Beachler, A, 861(ab)
Beaney, RP, 843(ab)
Beaumier, P, 779, 793(ab)
Beaumier, PA, 216, 933(ab)
Beaumier, PL, 777(ab), 932(ab)
Becher, R, 867(ab)
Beck, N, 965(ab)
Becker, DV, 833(ab)
Becker, J, 963(ab)
Becker, LC, 755(ab), 757(ab)
Beckers, C, 815(ab), 929(ab)
Beekhuis, H, 605
Behrenbeck, T, 801(ab)
Bejany, D, 841(ab)
Bekdik, CF, 913(ab)
Belinka, BA, 831(ab)
Belisle, EH, 828(ab)
Bellani, N, 864(ab), 959(ab)
Beller, GA, 301, 756(ab), 790(ab), 1456
Belletire, J, 742(ab)
Bellil, D, 729(ab), 750(ab), 780(ab)
Bellinger, RL, 959(ab)
Bellon, EM, 734(ab)
Belzberg, AS, 962(ab)
Bendreim, B, 730(ab)
Bendriem, B, 741(ab), 801(ab), 893(ab), 898(ab), 932(ab)
Bendrlem, B, 761(ab)
Benedetto, AR, 269, 561, 566
Benjamin, R, 901(ab)
Benti, R, 888(ab)
Bentley, SJ, 748(ab)
Berg, G, 581, 1386
Berg, J, 497
Berger, H, 859(ab), 901(ab)
Berger, HJ, 787(ab), 934(ab)
Berger, MS, 838(ab)
Bergh, JR, 966(ab), 1737(le)
Bergin, JD, 756(ab)
Bergin, P, 837(ab)
Bergman, SR, 730(ab)
Bergmann, SR, 187, 351, 768(ab), 807(ab), 808(ab), 825(ab), 837(ab), 1489, 1798, 1843
Bergsland, J, 1464
Bergstein, P, 773(ab)
Berkopec, JM, 826(ab), 906(ab)
Berkovic, SF, 751(ab), 831(ab)
Berman, D, 729(ab), 739(ab), 740(ab), 750(ab), 757(ab), 795(ab)
Berman, DS, 301, 729(ab), 750(ab), 780(ab), 837(ab), 853(ab), 1718
Bergman, RM, 882(ab)
Berná, L, 862(ab)
Bernay, I, 913(ab)
Bernstein, I, 828(ab)
Bernstein, T, 756(ab)
Berridge, MS, 927(ab), 928(ab)
Berry, JM, 924(ab)
Besozzi, MC, 960(ab)
Bettinardi, V, 892(ab)

Page numbers followed by (ab) indicate abstracts.
Page numbers followed by (le) indicate letters.
N preceding a page number indicates an article appearing in *Newsline*.

Bettman, L, 737(ab)
Beyar, R, 1657
Bhadkamkar, V, 819(ab)
Bhadkamkar, VA, 844(ab)
Bhat, S, 1563
Bianco, JA, 797(ab)
Bice, AN, 797(ab), 825(ab), 879(ab), 893(ab), 1554
Bidwell, JK, 412
Biersack, HJ, 110, 744(ab), 758(ab), 805(ab), 856(ab), 879(ab), 922(ab), 923(ab), N1765
Bietendorf, J, 1718
Bigler, RE, 777(ab), 833(ab)
Bigner, DD, 778(ab)
Bihl, H, 804(ab)
Bijvoet, OLM, 775(ab)
Bilaniuk, L, 1607
Billard, C, 812(ab)
Billick, S, 811(ab)
Billinghurst, MW, 523
Billings, J, 88, 731(ab), 761(ab), 762(ab), 803(ab), 830(ab), 834(ab)
Billings, JJ, 773(ab)
Bilodeau, L, 800(ab)
Bischof-Delaloye, A, 301, 1018, 1646
Bischof-Delaloye, B, 809(ab)
Bishop, N, 45
Bishop, PT, 773(ab)
Bisi, G, 820(ab)
Biskupiak, JE, 808(ab)
Bisson, G, 117
Black, KL, 913(ab)
Blackman, M, 812(ab)
Bladin, PF, 751(ab), 831(ab)
Blahd, W, 894(ab)
Blasberg, R, 792(ab)
Blasberg, RG, 839(ab), 899(ab), 1676
Blaser, CB, 787(ab)
Blau, M, 839(ab)
Blaufox, MD, 666, 723, 841(ab)
Blayney, D, 813(ab)
Blend, MJ, 884(ab)
Block, N, 841(ab)
Blokland, JAK, 775(ab)
Blomqvist, G, 927(ab)
Blood, DK, 312, 863(ab)
Blood, KMT, 965(ab)
Bloomfield, PM, 775(ab)
Blue, PW, 127
Blumenthal, RD, 826(ab)
Blumhardt, R, 860(ab), 1737(le)
Boazi, M, 106
Bochner, M, 887(ab)
Bockisch, A, 110, 758(ab), 805(ab), 856(ab), 879(ab), 922(ab)
Boer, Hde, 885(ab)
Bok, B, 820(ab)
Bokhari, F, 908(ab)
Bol, A, 797(ab)
Bolgos, GL, 767(ab)
Bolman, RM III, 781(ab)
Bomanji, J, 758(ab), 823(ab)
Bonifacc, GR, 683
Bonino, C, 742(ab)
Bonnyman, J, 1240
Bonow, RO, 420, 780(ab), 807(ab), 1966
Bonte, FJ, 719
Bonte FJ, 771(ab)
Boogaerts, M, 2022
Bookman, M, 909(ab)
Boothe, TE, 93
Borges-Neto, S, 790(ab)
Bormans, G, 743(ab), 936(ab), 940(ab)
Borrero, G, 967(ab)
Boruchowsky, S, 768(ab)
Bosley, M, 772(ab)
Bosley, T, 802(ab)
Bosslet, K, 904(ab)
Bossuyt, A, 741(ab), 875(ab), 1342
Bossuyt-Piron, C, 741(ab), 921(ab), 925(ab)
Botelho, MF, 744(ab)
Botsch, H, 812(ab)
Böttger, A, 875(ab)
Botvinick, E, 810(ab)
Botvinick, EH, 760(ab), 861(ab), 869(ab)
Boucher, CA, 301, 740(ab)
Boudreau, R, 961(ab), 967(ab)
Boudreau, RJ, 1399, 1881
Bough, EW, 872(ab)
Boulet, A, 787(ab)
Boulos, P, 808(ab), 809(ab), 908(ab), 909(ab)
Bourdreau, RJ, 732(ab)
Bourgoigne, J, 944(ab)
Bourguignon, M, 812(ab)
Bourguignon, MH, 810(ab)
Boutin, R, 793, 934(ab)
Bouvier, A, 766(ab)
Boxer, DI, 1318
Boyce, TM, 760(ab)
Boyers, AS, 796(ab)
Boyko, OB, 752(ab)
Braat, SH, 791(ab)
Brachman, M, 844(ab)
Bradford, J, 812(ab)
Bradley, E, 826(ab)
Bradshaw, J, 776(ab)
Brand, R, 845(ab)
Brandhorst, I, 758(ab), 917(ab)
Brasch, RC, 840(ab)
Braun, AR, 899(ab)
Braunstein, P, 700
Brechbiel, MW, 672, 763(ab), 848(ab)
Brechner, RR, 851(ab)
Breedveld, FC, 889(ab), 2017
Breeman, WAP, 768(ab)
Breitz, H, 779(ab)
Brendel, AJ, 904(ab), 916(ab)
Brennan, K, 932(ab)
Brenner, J, 844(ab)
Bresnahan, DR, 801(ab)
Bresnahan, JF, 801(ab)
Breznock, B, 1702
Briandet, P, 961(ab)
Briele, B, 758(ab), 805(ab), 856(ab)
Brihaye, C, 817(ab), 818(ab), 1025
Brill, AB, 796(ab), 828(ab), 833(ab), 908(ab), 1848
Brill, DR, N133, N1431
Bristow, D, 964(ab)
Britcher, SF, 930(ab)
Britton, KE, 748(ab), 758(ab), 823(ab), 942(ab)
Brixner, D, 940(ab)
Broadhurst, P, 868(ab)
Brocchini, SJ, 832(ab)
Brochet, E, 820(ab)
Brodack, JW, 788(ab), 910(ab), 968(ab)
Broder, S, 581
Brodie, JD, 741(ab)
Brodin, T, 1224
Brökelmann, J, 758(ab)
Bronca, GA, 1616
Brookeman, V, 1456
Broussard, W, 905(ab)
Brown, D, 860(ab)
Brown, EJ, Jr, 165
Brown, J, 841(ab)
Brown, MA, 187, 1798
Brown, ML, 764(ab), 804(ab), 1280(le)
Brown, MP, N1582
Brown, MW, 848(ab)
Brown, P, 826(ab)
Brown, PH, 873(ab)
Brown, RS, 759(ab)
Brown, S, 828(ab)
Brücke, T, 731(ab)
Bruix, J, 1279(le)
Brunetti, A, 51, 581, 1676
Brunken, R, 729(ab), 837(ab)
Brunken, RC, 838(ab), 846(ab), 863(ab), 867(ab)
Bruns, HD, 741(ab)
Bruonanno, FS, 782(ab)
Brush, JE, 780(ab)
Bubeck, B, 720
Buchegger, F, 809(ab), 1646
Buchi, M, 845(ab), 846(ab)
Buchsbaum, D, 912(ab)
Buck, JL, 622
Budd, J, 967(ab)
Budinger, TF, 745(ab), 760(ab), 765(ab)
Buell, U, 791(ab), 805(ab), 819(ab), 841(ab), 1018
Buhr, W, 744(ab)
Buijs, W, 758(ab), 885(ab)
Bull, JMC, 789(ab)
Bunko, H, 870(ab)
Buonanno, F, 961(ab)
Buonanno, FS, 782(ab)
Buonocore, E, 925(ab), 960(ab)
Burchell, J, 758(ab)
Burchiel, SW, 1351
Burgess, BA, 1892
Burgess, J, 810(ab)
Burgin, J, 766(ab)
Burgua, B, 779(ab)
Burke, JF, 1538
Burns, A, 895(ab)
Burns, HD, 849(ab), 923(ab), 930(ab), 931(ab)
Burt, RW, 422
Busche, HS, 833(ab)
Bushe, H, 833(ab)
Busuttil, RW, 1507
Butler, SP, 787(ab), 819(ab), 936(ab)
Butler, WF, 894(ab)
Buxton, RB, 782(ab), 797(ab)
Buzdar, A, 819(ab)
Byrd, BF, 1737(le)
Byrd, BL, 763(ab), 935(ab)

Caccamo, L, 888(ab)
Cahoon, JL, 765(ab)
Caldwell, JH, 194, 798(ab), 846(ab)
Callaghan, JJ, 1321
Callahan, AP, 848(ab)
Callahan, RJ, 385, 805(ab), 817(ab)
Calvert, X, 1279(le)
Camargo, EE, 916(ab)
Camilleri, M, 764(ab)
Camin, L, 301
Camli, U, 811(ab)
Camponovo, E, 622
Camps, JAJ, 889(ab), 2017
Canales, M, 866(ab)
Caner, BE, 913(ab)
Cannon, PJ, 312
Cannon, RO, III, 1966
Cantineau, R, 926(ab)
Carabell, SC, 827(ab)
Cardella, JF, 1399
Carey, J, 836(ab), 1476
Cargill, EB, 892(ab)
Caride, VJ, 1424
Carlson, KE, 821(ab), 928(ab)
Carlson, RA, 893(ab), 963(ab)
Carney, PL, 374, 935(ab)
Carnochan, P, 911(ab)
Carpenter, D, 932(ab)
Carr, EA, Jr, 1464
Carrasquillo, JA, 320, 903(ab), 906(ab), 909(ab), 915(ab), 1311
Carrera, GF, 754(ab)
Carril, JM, 1277(le)
Carrió, I, 862(ab)
Carroll, M, 1464
Carroll, MJ, 823(ab)
Carroll, TR, 773(ab)
Carry, MM, 288
Carson, RE, 745(ab), 746(ab), 807(ab), 824(ab), 825(ab), 839(ab), 899(ab), 1386
Carter, R, 474, 836(ab)
Carton, E, 896(ab)
Caruana, V, 1408
Carvacho, OF, 849(ab)
Carvalho, PA, 821(ab)
Cashman, P, 868(ab)
Cassidy, E, 927(ab)
Castaigne, A, 810(ab)
Castaneda, AR, 1176
Castle, VP, 1819
Catafau, AM, 1470
Catz, Z, 836(ab), 914(ab)
Caudry, M, 904(ab)
Caunt, JF, 891(ab)
Cawthon, MA, 1737(le)
Cayla, J, 762(ab), 825(ab), 877(ab)
Celentano, L, 51
Cerino, M, 1271
Cerqueira, M, 194, 629, 769(ab)
Cerqueira, MD, 703
Cha, SD, 867(ab)
Chamberlain, MJ, 1627
Chan, B, 731(ab)
Chanana, AD, 1342
Chandraratna, PA, 821(ab)
Chang, AE, 320
Chang, JY, 93, 772(ab), 802(ab)
Chang, W, 731(ab), 834(ab), 851(ab)
Chaovapong, W, 762(ab)
Chapman, NJ, 764(ab)
Chapman, PR, 1589
Charalambous, C, 876(ab)
Charalel, J, 944(ab), 945(ab)
Charkes, ND, 794(ab)
Charnsangavej, C, 1012
Charuzi, Y, 780(ab)
Chase, TN, 896(ab)
Chatterton, B, 765(ab), 795(ab)
Chaudhuri, M, 815(ab)
Chaudhuri, T, 787(ab)
Chaudhuri, TK, 815(ab)
Chawluk, J, 772(ab)
Chawluk, JB, 965(ab), 1607
Chayes, Z, 944(ab), 945(ab)
Checkneva, YY, 66
Cheesman, EH, 1892
Chelliah, M, 792(ab)
Chen, C, 1280(le)
Chen, C-A, 924(ab), 930(ab)
Chen, C-T, 880(ab), 960(ab)
Chen, DCP, 886(ab)
Chen, GTY, 777(ab)
Chen, J-J, 1249
Chen, LF, 810(ab)
Cheng, M, 789(ab)
Cherry, SR, 766(ab), 911(ab)
Chesis, PL, 732(ab), 931(ab)
Chiang, K, T26D
Chieng, PU, 861(ab)
Chierchia, S, 869(ab)
Chierchia, SL, 873(ab)
Child, JS, 836(ab)
Chin, M, 810(ab)
Chin, O, 886(ab)
Chines, A, 774(ab)
Chinol, M, 856(ab), 1047
Chiou, PF, 871(ab)
Chiron, C, 812(ab)
Chiu, KW, 773(ab), 818(ab)
Chiu, M, 757(ab)
Chiueh, CC, 1249
Choi, Y, 735(ab)
Chouraqui, P, 729(ab), 780(ab)
Chow, SP, 774(ab)
Chowdhury, S, 804(ab)
Chowdhury, SC, 921(ab)
Choy, D, 918(ab)
Christiaens, L, 752(ab), 926(ab)
Christie, MS, 563
Christman, D, 730(ab), 761(ab), 801(ab)
Christman, DR, 741(ab), 771(ab), 776(ab), 893(ab), 898(ab)
Chua, EL, 959(ab)
Chugani, HT, 801(ab), 896(ab)
Chumpradit, S, 803(ab),

830(ab)
Cnung, J-K, 903(ab), 906(ab), 915(ab)
Chung, WS, 760(ab), 869(ab)
Cianflone, D, 873(ab)
Ciaravino, J, 771(ab)
Cios, KJ, 816(ab)
Civelek, AC, 885(ab)
Claessens, R, 758(ab)
Claessens, RAMJ, 943(ab)
Clanton, J, 803(ab)
Clanton, JA, 563
Clarke, G, 808(ab), 809(ab)
Clarke, L, 884(ab)
Clarke, LP, 876(ab)
Clarke, SE, 174
Clausen, M, 813(ab), 835(ab), 1393
Clavo, A, 759(ab)
Clavo, AC, 832(ab)
Cleator, IG, 962(ab)
Clement, R, 859(ab)
Clements, IP, 1280(le)
Clinthorne, N, 777(ab)
Clorius, JH, 784(ab), 789(ab), 909(ab), 910(ab), 911(ab)
Coakley, AJ, 562
Coates, G, 853(ab), 1819
Coca, FJ, 398
Cocanougher, MK, 749(ab)
Coenen, HH, 110, 895(ab), 1367
Coffey, JL, 1117
Cogneau, M, 797(ab)
Cohan, ES, 882(ab)
Cohen, A, 809(ab)
Cohen, MB, 1616
Cohen, RM, 581, 1249
Cohen, VI, 1079
Cohn, PF, 165
Colcher, D, 320, 672
Coleman, M, 755(ab), 756(ab)
Coleman, R, 755(ab), 1318
Coleman, RE, 752(ab), 790(ab), 968(ab)
Colina, M, 760(ab)
Collen, MJ, 233
Collier, BD, 120, 857(ab)
Collier-Geulette, A, 897(ab)
Collins, C, 25
Collins, J, 908(ab), 918(ab)
Collins, JA, 407
Collins, L, 776(ab), 839(ab)
Collins, LT, 1946
Collins, P, 887(ab)
Collmann, J, 960(ab)
Colombo, F, 742(ab), 831(ab), 869(ab)
Colston, JT, 860(ab)
Comar, D, 766(ab)
Comerota, A, 782(ab)
Conandini, A, 908(ab)
Connett, JM, 763(ab)
Connor, W, 817(ab)
Conrady, A, 757(ab)
Constantinides, C, 864(ab), 959(ab)
Conte, F, 959(ab)
Conti, PS, 929(ab)
Conversano, A, 869(ab)
Conway, T, 783(ab)
Cooke, CD, 806(ab)
Cooper, E, 760(ab)
Cooper, JA, 743(ab), 744(ab), 852(ab)
Cooper, MD, 899(ab)
Cooper, SG, 1111
Cootjans, J, 896(ab)
Coppola, R, 896(ab)
Corbett, JR, 288, 638, 770(ab), 801(ab), 810(ab), 828(ab), 871(ab)
Corlija, M, 939(ab)
Correia, J, 961(ab)
Correia, JA, 776(ab), 782(ab)
Corstens, F, 736(ab), 758(ab), 861(ab), 885(ab)
Corstens, FHM, 943(ab), 1723
Corwin, LA, 966(ab)
Costa, DC, 895(ab), 1917(le)
Côté, C, 1727
Couch, MW, 1916(le)
Coughlin, DJ, 831(ab)
Coulter, SE, 1133
Counsell, RE, 768(ab), 849(ab), 1088
Courey, M, 883(ab), 884(ab)
Courtenay-Luck, N, 1636
Courter, JH, 928(ab)
Cousin, N, 871(ab)
Coutris, G, 855(ab)
Covell, DG, 903(ab)
Coveney, J, 773(ab)
Coveney, JR, 937(ab)
Cradduck, TD, 815(ab)
Crass, JR, 1881
Crawley, JCW, 818(ab)
Creasey, AA, 819(ab)
Crews, L, 789(ab)
Croft, BY, 882(ab), N277, N992
Croghan, G, 908(ab)
Crombez, D, 936(ab)
Cronin, B, 813(ab)
Crook, JE, 763(ab), 935(ab)
Crossman, D, 841(ab)
Crouzel, C, 825(ab), 877(ab)
Crouzel, M, 825(ab), 877(ab)
Cukier, A, 916(ab)
Cullom, S, 884(ab)
Cullom, SJ, 876(ab)
Cunningham, TM, 869(ab)
Cuocolo, A, 51, 780(ab), 807(ab), 941(ab), 1422(le)
Curchod, S, 1646
Custer, TR, 907(ab)
Cutler, C, 732(ab), 743(ab)
Cyr, S, 773(ab)
Czerniak, A, 737(ab), 768(ab)

Dach, JL, 960(ab)
DaCosta, MC, 1875
Daddona, P, 787(ab)
Daddona, PE, 906(ab)
Dae, M, 760(ab)
Dae, MW, 810(ab), 861(ab), 869(ab)
Daemen, BJG, 789(ab)
Daghighian, F, 791(ab)
Daher, S, 933(ab)
Dahlen, DD, 852(ab)
Dalal, K, 932(ab)
Dalinka, MK, 754(ab)
Daly, MJ, 1422(le)
Dam, M, 896(ab)
Damjanov, A, 936(ab)
Damjanov, I, 936(ab)
Danaie, J, 963(ab)
Danais, S, 781(ab)
Danielsen, R, 1972
Danielski, E, 490
Danilov, SM, 1686
Dannals, R, 838(ab)
Dannals, RF, 423, 731(ab), 740(ab), 741(ab), 750(ab), 849(ab), 929(ab), 930(ab), 931(ab)
Dansereau, R, 886(ab)
Das, DK, 859(ab)
Das Gupta, AK, 921(ab)
Dasgupta, P, 868(ab)
Daube-Witherspoon, ME, 745(ab), 746(ab), 824(ab), 825(ab), 1386
Daugherty, A, 763(ab)
David, R, 424
Davidson, B, 808(ab), 809(ab), 908(ab), 909(ab)
Davidson, BR, 891(ab)
Davidson, G, 765(ab)
Davies, R, 760(ab), 829(ab)
Davis, C, N1144
Davis, JL, 2002
Davis, JW, 1166, 1273
Davis, LP, 967(ab)
Davis, MA, 1047
Davis, MJ, 548, 1738(le)
Davison, A, 757(ab), 938(ab)
De Abrew, S, 913(ab)
Dean, C, 808(ab), 809(ab)
Dean, GW, 1297
Dean, RT, 793(ab), 794(ab), 934(ab)
De Backker, C, 2022
deBlaquiere, P, 819(ab)
de Bruiine, F, 781(ab)
DeCarle, D, 851(ab)
Decoster, P, 797(ab)
Dedrick, RL, 839(ab)
Deecke, L, 731(ab)
Dees, SM, 1559
DeForge, LE, 768(ab)
DeFulvio, J, 747(ab), 901(ab), 936(ab)
De Geeter, F, 875(ab), 926(ab)
DeGeorge, JJ, 928(ab)
de Goeij, JJM, 650
DeGrado, TR, 1211
de Groot, TJ, 929(ab)
Dehdashti, F, 754(ab)
Dehmer, GJ, 861(ab)
de Jesus, OT, 927(ab)
DeJesus, OT, 924(ab), 930(ab), 9256b)
de Jong, PE, 635
Delaage, M, 907(ab), 1358
de la Fuente, C, 1277(le)
Delaloye, B, 809(ab), 1646
DeLand, FH 1129
Delaney, MJ, 1875
de Lange, MJ, 1219
Delbeke, D, 15, 1917(le)
Deleide, C, 742(ab)
de Leon, MJ, 771(ab)
DeLorge, J, 825(ab), 877(ab)
de Lima, JJP, 744(ab)
Delmon-Moingeon, L, 938(ab)
Delooye, B, 301
del Rosario, RB, 832(ab)
Delvecchio, A, 817(ab)
Demer, L, 846(ab)
Demer, LL, 838(ab)
Demonceau, G, 1902
DeNardo, GL, 763(ab), 778(ab), 827(ab), 884(ab)
DeNardo, SJ, 763(ab), 778(ab), 827(ab), 884(ab), 907(ab)
Denays, R, 798(ab), 915(ab), 966(ab), 1337, 1825, 1982
Dence, C, 351
Dence, CS, 730(ab)
Denecke, H, 907(ab)
Denis, M, 746(ab)
Dent, J, 795(ab)
de Pauiis, T, 803(ab)
DePuey, EG, 441
Depuey, EG, 757(ab)
DePuey, EG, 419, 740(ab), 749(ab), 795(ab)
Derbekyan, V, 181
Derenzo, SE, 745(ab), 765(ab)
De Roo, M, 743(ab), 795(ab), 896(ab), 936(ab), 940(ab), 1902, 2022
DeRoo, MC, 1018
Desai, J, 734(ab)
Deshpande, SV, 763(ab)
DeSisto, WC, 821(ab)
DesLauriers, AG, 897(ab)
DeSombre, E, 925(ab)
DeSombre, ER, 833(ab), 883(ab), 924(ab)
de Swart, H, 791(ab)
Deutch, R, 876(ab)
Deutsch, E, 732(ab), 742(ab), 743(ab), 772(ab), 831(ab), 849(ab), 936(ab)
Deutsch, EA, 837(ab)
Deveny, DM, 916(ab)
DeVito, RP, 2029
Devos, P, 896(ab)
Devous, MD, 719
Devous, MD, Sr, 742(ab), 751(ab), 771(ab)
deVries, DJ, 806(ab)
DeVroom, HL, 839(ab)
Dewanjee, M, 859(ab), 890(ab)
Dewanjee, MK, 737(ab), 921(ab), 922(ab)
Dewey, S, 730(ab), 761(ab), 801(ab)
Dewey, SL, 741(ab), 821(ab), 898(ab), 932(ab)
Dexeus, F, 836(ab)
de Zeeuw, D, 605, 1219
Dezsi, L, 781(ab)
Dhawan, V, 839(ab), 1483
Dhekne, RD, 725, 786(ab), 941(ab)
Dhokia, B, 1636
Diamanti, CI, 762(ab)
Diamond, M, 899(ab)
Diamond, PD, 744(ab)
Diaz, P, 817(ab)
Diaz-Ball, FL, 962(ab)
DiChiro, G, 581
Diedrich, K, 922(ab)
Diehl, V, 843(ab)
Dietz, H, 910(ab)
Digby, W, 791(ab)
Digby, WM, 892(ab), 824(ab)(ab)
Diksic, M, 783(ab), 913(ab)
Dilehay, GL, 1870
Dilmanian, FA, 796(ab)
Dilsizian, V, 740(ab), 1149
Dilworth, JA, 773(ab)
Dilworth, JR, 939(ab)
Dimitrakopoulou, A, 789(ab), 909(ab), 910(ab), 911(ab)
Ding, Y-S, 753(ab), 782(ab), 783(ab)
DiSimone, RN, 127
Divgi, CR, 746(ab), 809(ab)
Dobbeleir, A, 794(ab), 817(ab), 818(ab)
Dobbeleir, AA, 1025
Dobkin, JA, 965(ab)
Doddona, PE, 859(ab)
Doerr, R, 747(ab), 748(ab)
Doerr, RJ, 908(ab)
Dom, R, 896(ab)
Domogatsky, SP, 66
Don, S, 799(ab)
Dondi, M, 615
Donohoe, KJ, 874(ab)
Doo, E, 873(ab)
Dorsky, S, 1408
Dorst, JK, 737(ab)
Dosio, F, 888(ab)
Dougan, H, 925(ab)
Douglass, KH, 740(ab)
Dowd, M, 899(ab)
Dowdey, JE, 542
Dowell, S, 750(ab)
Drane, WE, 622, 1568
Drasne, D, 407
Drealan, BF, 918(ab)
Dreikorn, K, 784(ab)
Driedger, AA, 1627
Driscoll, E, 767(ab)
Driver, MS, 832(ab)
Drouin, G, 944(ab)
Drozynski, CA, 1351
Duara, R, 93, 772(ab), 802(ab)
Dubovsky, E, 774(ab)
Dubovsky, EV, 823(ab), 2054
Dubovsky, J, 774(ab)
duCret, R, 961(ab), 967(ab)
duCret, RP, 1399, 1881
Dudley, NE, 1420(le)
Dulac, O, 812(ab)
Duman, Y, 913(ab)
Duncan, C, 905(ab)
Dunn, D, 796(ab)
Dunn, E, 855(ab)
Dunn, EK, 1563
Dunn, J, 773(ab)
Dunn, TJ, 937(ab)
Dunning, AJ, 780(ab)
Dupon, JW, 840(ab)
Dupont, F, 791(ab)
Dupras, G, 800(ab), 807(ab)
DuPree, ES, 895(ab)
Durack, L, 814(ab), 826(ab)
Durski, K, 885(ab)
Dutta, A, 761(ab)
Dworkin, HJ, N12, 265,

736(ab), 869(ab), 1559
Dwyer, JH, 729(ab)
Dydek, GJ, 127
Dylewski, J, 859(ab)

Eary, JF, 25, 814(ab), 826(ab), 828(ab), 969(ab)
Ebbe, S, 932(ab)
Ebert, M, 803(ab)
Eckelman, WC, 1079, 1830
Eckerman, K, 833(ab)
Eckerman, KF, 2002
Eddy, J, 581
Edgerton, ER, 497
Edwards, B, 773(ab), 818(ab)
Edwards, DS, 773(ab)
Edwards, PG, 773(ab)
Eersels, J, 921(ab)
Efange, SMN, 732(ab), 761(ab)
Egan, R, 781(ab)
Eggli, DF, 233
Ehrenkaufer, R, 783(ab)
Ehrenkaufer, RLE, 920(ab)
Ehrhardt, G, 849(ab)
Eisenberg, B, 2046
Eisner, RL, 796(ab)
Ejiri, K, 897(ab)
Eklem, M, 873(ab)
Elashoff, J, 750(ab)
Elder, RC, 732(ab)
El-Etri, M, 772(ab)
Elgazzar, AH, 943(ab)
Ell, P, 808(ab)
Ell, PJ, 895(ab), 1917(le), 1018
Elliott, D, 961(ab)
Elmaleh, DR, 797(ab), 928(ab)
El-Sayed, M, 943(ab)
Elsinga, PhH, 789(ab)
Elson, MK, 857(ab), 906(ab), 918(ab)
El-Tahtawy, A, 814(ab)
Emran, AM, 725, 1741
Emrich, D, 779, 757(ab), 800(ab)
Endo, K, 747(ab), 785(ab), 786(ab), 832(ab), 840(ab), 862(ab), 885(ab), 889(ab), 919(ab), 2050
Endo, M, 865(ab), 866(ab), 892(ab)
Eng, W, 741(ab)
Eng, W-S, 923(ab), 930(ab), 931(ab)
Engelbretson, D, 775(ab)
Engelman, K, 328
Engelman, R, 859(ab)
Engelstad, BL, 840(ab), 968(ab)
Engenhart, R, 909(ab), 911(ab)
English, R, 821(ab)
Enrich, D, 758(ab)
Ensminger, W, 836(ab)
Epenetos, AA, 819(ab), 1636
Epps, LA, 787(ab), 794(ab)
Epstein, AL, 827(ab)
Ercan, MT, 913(ab)
Erdman, KL, N438
Erlandsson, K, 722
Erlemann, R, 856(ab)
Ernstthal, HL, 566
Erwin, WD, 769(ab), 855(ab), 902(ab)
Eschner, W, 757(ab), 800(ab)
Eshima, D, 720, 743(ab), 823(ab), 943(ab), 1955
Esperanza, L, 819(ab)
Esposito, S, 51
Esquerré, J-P, 398, 1738(le)
Esser, PD, 124
Essiambre, R, 790(ab)
Estabrook, A, 936(ab)
Esterbrooks, D, 730(ab)
Esterhai, JL, 754(ab)
Estorch, M, 862(ab)
Eterović, D, 417, 560
Eto, K, 942(ab)
Ettinger, R, 942(ab)
Evans, A, 776(ab), 839(ab)
Evans, AC, 765(ab), 1056, 1483
Evans, H, 775(ab)
Evans, ML, 852(ab)
Ezquerra, NF, 806(ab)

Fabbender, D, 800(ab)
Faber, TL, 638, 770(ab), 801(ab), 871(ab)
Fabian, C, 844(ab)
Fahey, FH, 227, 233
Falke, THM, 769(ab)
Fand, I, 848(ab)
Fantinato, LC, 940(ab)
Faraggi, M, 820(ab)
Farhangi, M, 966(ab), 1814
Farlow, DC, 1885, 1946
Farnsworth, APH, 933(ab)
Farrell, E, 747(ab), 818(ab)
Faubion, C, 818(ab)
Fawcett, HD, 57
Fawdry, RM, 1946
Fawwaz, RA, 819(ab), 890(ab), 936(ab)
Fayad, F, 798(ab), 890(ab), 944(ab)
Fazekas, F, 1607
Fazio, F, 742(ab), 831(ab), 869(ab), 873(ab), 888(ab)
Fazzini, PF, 820(ab)
Feiglin, DH, 734(ab)
Feine, U, 804(ab)
Feinendegen, LE, 739(ab), 771(ab), 829(ab), 895(ab)
Feinsod, M, 240
Feinstein-Jaffe, I, 106
Feistel, H, 751(ab)
Feitsma, HIJ, 2017
Feitsma, RIJ, 889(ab)
Feld, T, 1830
Fennesy, DR, 941(ab)
Fer, M, 779(ab)
Ferency, GF, 466, 784(ab)
Ferris, SH, 771(ab)
Ferrone, S, 390, 936(ab)
Fetterman, RC, 800(ab), 863(ab)
Fettich, G, 943(ab)
Feyerabend, A, 874(ab), 944(ab)
Fiedotin, AF, 845(ab)
Fielding, S, 903(ab)
Fields, ALA, 836(ab)
Fiete, RD, 892(ab)
Fig, L, 740(ab)
Fig, LM, 481, 833(ab), 843(ab), 850(ab), 1476
Figulla, HR, 779(ab)
Filippone, A, 850(ab)
Filmer, RB, 799(ab)
Findley, DO, 1373
Fink-Bennett, D, 850(ab)
Finkler, NJ, 904(ab)
Finn, R, 320, 807(ab)
Finn, RD, 581, 899(ab), 928(ab), 1249, 1676
Fioravanti, C, 923(ab)
Fiore, F, 823(ab)
Fischman, 1123
Fischman, A, 859(ab)
Fischman, AJ, 385, 556, 817(ab), 889(ab), 890(ab), 901(ab), 917(ab), 1095, 1149, 1538, 1911
Fishbein, M, 750(ab)
Fisher, D, 779(ab), 828(ab)
Fisher, P, 1702
Fisher, RS, 750(ab), 764(ab)
Fisher, S, 815(ab), 847(ab), 884(ab), 912(ab)
Fisher, SJ, 832(ab)
Fishman, AJ, 805(ab)
Fitten, LJ, 1616
Flanagan, RJ, 925(ab)
Fleming, CJ, 799(ab)
Fletcher, JE, 903(ab)
Fletcher, JW, 840(ab), 856(ab)
Flickinger, FW, 754(ab)
Flores, F, 915(ab)
Floru, S, 737(ab)
Flower, M, 813(ab), 903(ab)
Flower, MA, 766(ab)
Floyd, C, 755(ab)
Flynn, B, 1176
Fogelman, I, 1318
Fogler, WE, 794(ab)
Folks, R, 757(ab), 795(ab)
Folks, RD, 806(ab), 894(ab)
Ford, EH, 809(ab), 828(ab), 1550
Fordham, EW, 769(ab), 855(ab)
Forell, BW, 1373
Formiconi, AR, 880(ab)
Forstrom, LA, 804(ab)
Foster, N, 895(ab)
Foster, NL, 895(ab)
Foulon, M, 798(ab), 1825
Fowble, BF, 1113
Fowler, D, 811(ab), 823(ab), 943(ab)
Fowler, DR, 729(ab)
Fowler, J, 771(ab), 801(ab)
Fowler, JS, 730(ab), 741(ab), 753(ab), 761(ab), 776(ab), 782(ab), 783(ab), 821(ab), 898(ab), 932(ab)
Fox, MR, 940(ab)
Fox, PT, 141
Fragasso, G, 869(ab), 873(ab)
Franceschi, G, 779(ab)
Franceschini, M, 928(ab)
Franchi, R, 615
Francis, B, 320
Francis, BE, 1249
Franck, N, 897(ab)
Frank, R, 965(ab)
Frank, TL, 755(ab)
Frankel, A, 246
Franken, PR, 817(ab), 818(ab), 1025
Fraser, R, 795(ab)
Fratkin, MJ, 1257
Freasier, RE, 816(ab)
Freeman, GL, 860(ab)
Freeman, LM, 723
Freeman, S, 838(ab)
Freitas, JE, 736(ab), 1559
French, WJ, 38
Frenkel, A, 240, 737(ab), 1657
Freshler, A, 761(ab)
Freundlich, M, 841(ab)
Frey, GD, 872(ab)
Frick, D, 730(ab)
Frick, MP, 876(ab)
Fridrich, R, 301
Friedberg, C, 841(ab)
Friedland, B, 806(ab)
Friedland, RP, 771(ab), 1386
Friedman, HS, 778(ab)
Friedman, J, 729(ab), 740(ab), 750(ab), 1718
Frincke, J, 778(ab)
Frincke, JM, 905(ab)
Fritzberg, A, 779(ab), 793(ab), 849(ab)
Fritzberg, AR, 25, 216, 743(ab), 777(ab), 793(ab), 832(ab), 924(ab), 932(ab), 933(ab), 940(ab)
Froelich, JM, 725
Front, D, 240, 246, 737(ab), 1657, 1731
Frost, JJ, 740(ab), 750(ab), 849(ab), 930(ab), 931(ab)
Fuccello, AJ, 805(ab)
Fuchs, H, 835(ab)
Fudo, T, 863(ab), 866(ab)
Fuentes, RT, 917(ab), 965(ab)
Fujibayashi, Y, 923(ab), 1838
Fujii, R, 783(ab), 866(ab)
Fujii, T, 918(ab), 943(ab)
Fujimori, K, 903(ab)
Fujisawa, Y, 965(ab)
Fujita, T, 150, 862(ab), 1977
Fujiwara, S, 902(ab)
Fujiwara, T, 33, 2012, 739(ab), 788(ab), 1421(le)
Fujiwara, Y, 864(ab)
Fukuchi, M, 919(ab)
Fukuda, H, 33, 866(ab), 885(ab)
Fukuda, N, 865(ab), 866(ab)
Fukuyama, H, 150
Fulham, MJ, 581
Fullager, P, N1144
Fulton, RR, 872(ab), 964(ab), 1865
Fünfgeld, M, 812(ab)
Furrer, T, 1960
Furunishi, H, 914(ab)
Fuster, V, 1445

Gaab, MR, 910(ab)
Gachon, P, 860(ab)
Gacioch, GM, 829(ab), 862(ab)
Gaffney, GR, 966(ab)
Gaffney, R, 765(ab)
Gaggi, R, 615
Gagne, GM, 747(ab), 940(ab)
Gagnon, A, 865(ab), 1271
Gagnon, D, 800(ab), 807(ab)
Gal, R, 770(ab)
Gale, B, 841(ab)
Galey, WT, 905(ab)
Galie, E, 729(ab), 811(ab)
Gallagher, BM, 1351
Gallagher, KP, 860(ab)
Galmarini, D, 888(ab)
Galt, JR, 894(ab)
Gambhir, SS, 359, 735(ab), 824(ab), 838(ab), 846(ab), 867(ab), 1507
Gan, M, 1616
Gandsman, EJ, 872(ab)
Ganey, MV, 1892
Gansow, OA, 320, 672, 848(ab)
Ganti, G, 775(ab), 880(ab), 964(ab), 1787
Ganz, W, 798(ab), 841(ab), 915(ab), 922(ab), 944(ab)
Ganz, WI, 890(ab), 1935
Garcia, A, 1470
Garcia, E, 757(ab), 795(ab)
Garcia, EV, 441, 806(ab), 894(ab)
Garcia, O, 787(ab)
Gardner, KA, 873(ab)
Garg, PK, 778(ab)
Garland, DE, 857(ab)
Garrity, ST, 1892
Garty, I, 15, 748(ab), 1917(le)
Garty, II, 890(ab)
Garza, D, 859(ab), 865(ab), 866(ab)
Gasparaitis, A, 963(ab)
Gasper, SR, 808(ab)
Gasperoni, R, 779(ab)
Gaston-Parry, D, 764(ab), 887(ab)
Gatley, J, 925(ab)
Gatley, SJ, 833(ab), 883(ab), 924(ab), 1211
Gautherot, E, 907(ab), 1358
Gauthier, G, 766(ab)
Geatti, O, 1476
Geltman, EM, 771(ab), 837(ab), 1489, 1798
Genna, S, 796(ab)
Gennarelli, T, 802(ab)
Gentili, A, 734(ab)
George, AE, 771(ab)
George, JK, 802(ab)
George, T, 750(ab)
Gerbrands, JJ, 806(ab)
Gerdes, J, 822(ab)
Germano, G, 745(ab)
Gernsheimer, T, 629
Gersh, BJ, 801(ab)
Gerson, R, 796(ab)
Gerundini, P, 869(ab), 873(ab), 888(ab), 1018, 1415
Geuting, B, 739(ab)
Geyer, AB, 745(ab), 765(ab)
Ghaddar, FK, 876(ab)
Ghiron, J, 920(ab)
Ghrayeb, J, 794(ab), 934(ab)
Giandinoto, S, 920(ab)

Gibbons, RJ, 801(ab), 1280(le)
Gibbs, B, 964(ab)
Gibson, RE, 736(ab), 741(ab), 896(ab), 923(ab), 930(ab), 931(ab), 1079
Gilardi, MC, 869(ab)
Gilbert, S, 786(ab), 873(ab)
Gildersleeve, DL, 733(ab), 752(ab), 767(ab), 783(ab), 859(ab), 929(ab)
Gilgien, W, 1646
Gilland, DR, 756(ab), 882(ab)
Gillespie, D, 803(ab)
Gillum, K, 928(ab)
Gilyon, K, 827(ab)
Gin, N, 918(ab)
Ginsberg, HN, 787(ab)
Ginsberg, MD, 93, 772(ab)
Giuliani, DC, 1550
Givel, J-C, 1646
Gjedde, A, 731(ab)
Glaser, AM, 886(ab)
Glazebrook, GA, 914(ab)
Gldman, S, 741(ab)
Gleason, T, 754(ab)
Gleishman, S, 844(ab)
Glick, SJ, 755(ab), 756(ab), 816(ab), 876(ab), 881(ab), 1666
Glisson, B, 819(ab)
Glöckner, W, 805(ab), 819(ab)
Glowniak, JV, 767(ab), 873(ab), 1182
Go, RT, 759(ab), 861(ab)
Godoy-Sanchez, N, 772(ab)
Gofinch, S, 793(ab)
Golazeski, T, 817(ab)
Goldberg, R, 798(ab)
Goldberg, RK, 749(ab)
Golden, RN, 814(ab)
Goldenberg, DM, 748(ab), 809(ab), 826(ab), 828(ab), 848(ab), 888(ab), 962(ab)
Goldenberg, H, 809(ab)
Goldman, ME, 1445
Goldman, S, 750(ab), 849(ab)
Goldman-Leiken, RE, 827(ab), 888(ab)
Goldman-Leikin, R, 888(ab)
Goldsmith, SJ, N276, 490, 599, 737(ab), 754(ab), 785(ab), 804(ab), 815(ab), 856(ab), 1018, 1445, 1875, N1921
Goldstein, RA, 707, 846(ab)
Gona, J, 748(ab), 818(ab)
Gona, JM, 1464
Gonzales, AC, 1737(le)
Gonzalez, A, 811(ab)
Goodenday, LS, 816(ab)
Goodgold, HM, 267, 856(ab)
Goodman, MM, 925(ab), 960(ab)
Goodwin, DA, 762(ab)
Goossens, I, 841(ab)
Gordon, DG, 871(ab)
Gordon, RE, 856(ab)
Goris, ML, 826(ab)
Gose, EE, 961(ab)
Gottschalk, A, 916(ab)
Gould, K, 866(ab)
Gould, KL, 707, 775(ab), 845(ab), 846(ab), 859(ab), 865(ab), 880(ab), 909(ab), 964(ab), 966(ab), 1787
Grady, CL, 771(ab), 899(ab), 1386
Graf, G, 835(ab)
Grafton, S, 735(ab), 791(ab), 913(ab)
Grafton, ST, 752(ab), 761(ab), 879(ab)
Graham, LS, 851(ab), 1616
Graham, MM, 466, 735(ab), 784(ab), 789(ab), 838(ab), 852(ab), 873(ab), 879(ab), 911(ab)
Gralla, RJ, 746(ab)
Granowska, M, 748(ab)
Granowski, M, 758(ab)
Gransow, OA, 763(ab)
Grant, LM, 924(ab)
Graves, W, 935(ab)
Gray, LL, 1182
Gray, MA, 832(ab), 933(ab)
Green, MA, 742(ab), 768(ab), 791(ab), 807(ab), 848(ab), 920(ab), 1843
Green, MR, 778(ab)
Green, MV, 420, 807(ab), 1966
Greenberg, H, 759(ab), 883(ab), 884(ab), 918(ab)
Greenberg, J, 811(ab)
Greenberg, JH, 781(ab)
Greene, J, 823(ab)
Greer, K, 755(ab)
Gregg, GM, 852(ab)
Grégoire, J, 800(ab), 807(ab)
Gregory, C, 944(ab)
Grenier, R, 770(ab)
Grierson, JR, 342, 789(ab), 846(ab)
Griffin, M, 774(ab)
Griffin, T, 828(ab)
Griffin, TW, 908(ab)
Griffiths, DV, 773(ab), 818(ab)
Gripenberg, J, 1546
Grobmann, K, 739(ab)
Groch, MW, 422, 769(ab), 855(ab), 902(ab)
Groshar, D, 246
Gross, MD, 768(ab), 849(ab), 1088
Gross-Glenn, K, 802(ab)
Grossman, HB, 912(ab)
Grossman, ZD, 747(ab), 963(ab)
Gruenewald, SM, 1885, 1946
Grunbaum, Z, 194, 814(ab)
Grund, FM, 906(ab)
Grütter, D, 1960
Guérin, J, 916(ab)
Guerraty, A, 1297
Guiberteau, MJ, T26A
Guilarte, T, 741(ab)
Guilarte, TR, 930(ab)
Guillaume, M, 752(ab), 817(ab), 818(ab), 821(ab), 926(ab), 1025
Guillon, JM, 746(ab)
Guiraud, RF, 398
Gulechyn, K, 760(ab)
Gulenchyn, KY, 812(ab), 1621
Gullberg, GT, 497, 755(ab), 756(ab), 882(ab)
Guns, M, 741(ab)
Gupta, N, 730(ab)
Gupta, NC, 876(ab)
Gurll, NJ, 1264
Gustilo, RB, 858(ab)
Guth, WR, 852(ab)
Guth-Tougelidis, B, 845(ab), 867(ab)
Gutkowski, RF, 265
Guyot, M, 904(ab), 916(ab)
Guze, BH, 913(ab)
Guzzardi, R, 128
Gwalter, I, 891(ab)
Gwilliam, ME, 738(ab)

Haber, E, 785(ab)
Haber, SB, 1351
Habif, DV, 819(ab)
Hackney, D, 1607
Haden, HT, 1032
Hadjian, RA, 1351
Hadley, SW, 216, 793(ab), 832(ab), 924(ab), 932(ab)
Hagius, JT, 643(ab)
Haka, MS, 735(ab), 767(ab), 783(ab)
Hakim, TS, 1297
Halama, JR, 1870
Halbfab, HG, 748(ab)
Halgren, E, 894(ab)
Hall, GM, 738(ab)
Hall, JT, 1012
Hall, TC, 809(ab), 828(ab), 962(ab)
Hall, TR, 1507
Halldin, C, 742(ab), 783(ab), 927(ab)
Hallman, C, 538
Halmqvist, F, 927(ab)
Halpern, S, 778(ab)
Halpern, SE, 894(ab)
Ham, H, 915(ab), 1337, 1825
Ham, HR, 794(ab), 798(ab), 817(ab), 818(ab), 966(ab), 1025, 1982
Hamada, S, 1713
Hamamoto, K, 760(ab), 792(ab), 805(ab), 864(ab), 878(ab), 918(ab), 943(ab), 1192
Hamill, JJ, 2029
Hanabery, JW, 407
Hanelin, L, 779(ab), 793(ab)
Hanelin, LG, 959(ab)
Hanna, M, Jr, 909(ab)
Hanner, JS, 1568
Hanrath, P, 791(ab)
Hansen, HE, 796(ab)
Hansen, HJ, 809(ab), 828(ab)
Hansen, WP, 385
Hanson, MW, 752(ab)
Hantraye, PH, 731(ab), 762(ab)
Harada, K, 150
Harcke, HT, 799(ab)
Harding, P, 795(ab)
Hardman, N, 809(ab)
Hardy, M, 890(ab)
Hardy, P, 897(ab)
Harisiadis, L, 827(ab)
Harold, WH, 830(ab)
Harp, G, 769(ab)
Harper, PV, 833(ab), 883(ab)
Harre, R, 910(ab)
Harrington, A, 812(ab)
Harris, CC, 129, 962(ab), 968(ab)
Harris, JM, 965(ab)
Harrison, C, 778(ab)
Harrold, WH, 1342
Hartley, C, 131
Hartman, KM, 733(ab)
Hartshorne, MF, 1577, 1737(le), 2046
Hartsough, NE, 891(ab)
Hartz, RK, 964(ab)
Hasegawa, N, 770(ab), 944(ab)
Hashimoto, M, 770(ab)
Hashimoto, S, 809(ab), 853(ab)
Haspel, MV, 909(ab)
Hassan, IM, 842(ab), 864(ab), 959(ab)
Hassan, N, 784(ab)
Hatabu, H, 786(ab)
Hatano, K, 515
Hatano, Y, 718
Hatazawa, J, 33, 515, 917(ab), 1809
Hathaway, G, 960(ab)
Hauler, JA, 778(ab)
Hauman, H, 896(ab)
Haumont, D, 1337, 1982
Hawk, TC, 735(ab)
Hawkins, PN, 847(ab)
Hawkins, R, 1136
Hawkins, RA, 735(ab), 863(ab), 877(ab), 879(ab), 913(ab), 942(ab), 1507
Hawkins, WG, 881(ab)
Haxby, JV, 771(ab)
Hayashi, H, 738(ab)
Hayashi, M, 863(ab), 1713
Hayashida, K, 591, 1713
Haynie, T, 738(ab)
Haynie, TP, 836(ab), 844(ab), 858(ab), 905(ab), 909(ab), 966(ab), 1012, 2058
Heal, A, 759(ab), 884(ab)
Heal, AV, 876(ab), 883(ab), 918(ab)
Healy, SA, 786(ab)
Heckmatt, J, 784(ab)
Hedrick, WR, 127
Heeg, MJ, 936(ab)
Hegge, J, 797(ab)
Heiba, S, 841(ab)
Heidendal, G, 791(ab)
Heidenreich, P, 835(ab)
Heim, ME, 910(ab)
Heineman, WR, 732(ab), 936(ab)
Heironimus, JD, 1737(le)
Heller, LI, 863(ab)
Helling, D, 773(ab)
Helling, DE, 937(ab)
Hellman, C, 450
Hellman, R, 737(ab), 859(ab), 922(ab)
Hellman, RS, 120, 599, 754(ab), 1018
Hellstrom, I, 907(ab)
Hellstrom, KE, 907(ab)
Hellwig, B, 659
Helm, L, 743(ab)
Helus, F, 789(ab), 909(ab), 910(ab), 911(ab)
Hemingway, A, 1636
Hemmila, JM, 857(ab)
Hendel, RC, 730(ab)
Hendricks, JL, 835(ab)
Henes, CG, 771(ab), 837(ab), 1489, 1798
Henkin, R, 729(ab)
Henkin, RE, N1294, 1577, 1870
Henn, F, 730(ab)
Henning, A, 867(ab)
Henrich, M, 739(ab)
Henry, LA, 875(ab)
Henze, E, 813(ab), 835(ab), 1393
Heo, J, 749(ab), 820(ab), 862(ab), 863(ab)
Herberman, R, 905(ab)
Herbst, AL, 883(ab)
Hermansen, F, 775(ab)
Hermle, L, 812(ab)
Herold, T, 921(ab)
Herranz, R, 1470
Herrero, P, 807(ab), 825(ab)
Herrmann, A, 786(ab)
Herry, JY, 941(ab)
Herscovitch, P, 807(ab), 824(ab), 825(ab), 839(ab), 899(ab)
Hersovitch, P, 899(ab)
Hertel, A, 786(ab), 847(ab), 904(ab)
Hertzerg, VS, 837(ab)
Herzog, H, 771(ab), 895(ab)
Heurich, AE, 1563
Heusser, Ch, 809(ab)
Heyl, B, 787(ab), 860(ab)
Heyman, S, 697, 1268
Heynen, MJ, 2022
Heyns, ADP, 914(ab)
Hichwa, RD, 873(ab)
Hicks, K, 775(ab), 865(ab), 1787
Hidaka, A, 786(ab)
Higaki, S, 813(ab)
Higashino, H, 760(ab)
Higazi, E, 857(ab)
Higginbotham-Ford, EA, 748(ab)
Higley, B, 773(ab), 818(ab)
Higuchi, S, 830(ab)
Hijdra, A, 781(ab)
Hilger, HH, 903(ab)
Hill, TC, 1018, 1892
Hilleman, D, 730(ab)
Hilliard, S, 818(ab)
Hilson, AJW, 744(ab)
Himelman, R, 760(ab)
Himi, T, 865(ab), 866(ab)
Hines, J, 834(ab)
Hiraki, T, 921(ab)
Hirata, K, 1302
Hirata, Y, 853(ab)
Hirota, Y, 508
Hirsch, JI, 1257
Hiruma, A, 796(ab)

Hisada, K, 844(ab), 870(ab), 897(ab), 907(ab), 921(ab), 939(ab), 997
Hishinuma, T, 902(ab)
Hitchens, RE, 964(ab)
Hitzemann, R, 730(ab), 741(ab), 761(ab), 801(ab)
Hixon, JB, 760(ab)
Hladik, WB, 1351
Hnatowich, DJ, 793(ab), 819(ab), 828(ab), 908(ab), 1575(le)
Hochberg, RB, 209
Hodgson, GS, 913(ab)
Hoefnagel, CA, 912(ab)
Hoesel, Qv, 758(ab)
Hoffer, PB, 209
Hoffman, EJ, 745(ab), 791(ab), 892(ab)
Hoffman, JM, 735(ab), 752(ab), 761(ab), 791(ab), 879(ab)
Hoffman, TJ, 874(ab), 877(ab), 920(ab), 938(ab), 939(ab)
Hoffmann, A, 842(ab)
Hoffmann, RG, 754(ab)
Hoh, CK, 821(ab)
Holcomb, HH, 816(ab)
Holden, J, 797(ab)
Holden, JE, 1211
Holder, LE, 843(ab)
Hollerman, JJ, 858(ab)
Holm, L-E, 720
Holm, S, 796(ab)
Holman, BL, 301, 757(ab), 821(ab), 938(ab), 1018
Holmes, RA, 1814, 874(ab), 877(ab), 917(ab), 920(ab), 938(ab), 939(ab), 964(ab), 965(ab), 966(ab), N1440, N1931
Holohan, KM, 788(ab)
Holt, P, 820(ab)
Holte, S, 765(ab)
Hom, J, 771(ab)
Homna, H, 780(ab)
Honda, N, 770(ab), 944(ab)
Hong, WP, 940(ab)
Honos, G, 790(ab)
Hood, T, 833(ab)
Hoogma, RPLM, 769(ab)
Hoogmartens, M, 743(ab)
Hooker, GR, 1636
Hooper, HR, 812(ab), 836(ab), 961(ab)
Hooper, PM, 961(ab)
Hoory, S, 859(ab)
Hör, G, 786(ab), 847(ab), 904(ab)
Hori, M, 881(ab)
Horii, H, 783(ab), 866(ab)
Horning, SJ, 826(ab)
Hornof, WJ, 1702
Horowitz, JA, 809(ab), 828(ab), 962(ab)
Horowitz, M, 765(ab), 795(ab), 887(ab)
Horrocks, JA, 891(ab)
Hosain, F, 737(ab)
Hoshi, H, 157, 337, 1101
Hosoba, M, 267, 870(ab)
Hosono, M, 885(ab)
Hotze, A, 758(ab), 805(ab), 856(ab), 879(ab), 922(ab)
Hovinga, TKK, 605
Howard, JL, 967(ab)
Hows, JM, 784(ab)
Hoy, K, 924(ab)
Hu, X, 880(ab)
Huang, SC, 359, 735(ab), 752(ab), 761(ab), 791(ab), 824(ab), 867(ab), 879(ab), 1507
Huang, S-J, 1249
Huberty, JP, 968(ab)
Hubner, KF, 960(ab)
Hubner, KH, 925(ab)
Huda, W, 260, 2062
Huesman, RH, 745(ab), 765(ab)
Hughes, A, 924(ab)
Hundeshagen, H, 910(ab), 1278(le)
Hung, G, 857(ab)
Hung, GL, 886(ab)
Hung, JC, 804(ab)
Hunter, R, 828(ab)
Huntley, TE, 857(ab)
Huret, JD, 897(ab)
Hurley, JR, 833(ab)
Hurtig, HI, 965(ab), 1607
Hurwitz, GA, 1627
Hussein, A, 968(ab)
Hutchins, G, 912(ab)
Hutchins, GD, 735(ab), 767(ab), 829(ab), 837(ab), 860(ab), 892(ab)
Hutchinson, RJ, 884(ab)
Hutton, BF, 872(ab), 964(ab), 1865
Hutton, I, 818(ab)
Huysmans, D, 736(ab)
Hwang, D-R, 351, 730(ab), 930(ab), 1205
Hylarides, MD, 216, 793(ab), 832(ab), 924(ab)
Hyun, M, 729(ab)

Ichiya, Y, 802(ab)
Ida, M, 915(ab)
Ido, T, 33, 515, 739(ab), 783(ab), 788(ab), 930(ab), 965(ab), 1809, 2012
Idoine, J, 165
Igarashi, M, 811(ab)
Iida, H, 796(ab), 830(ab), 878(ab)
Iida, Y, 786(ab), 803(ab)
Iinuma, T, 866(ab)
Iinuma, TA, 885(ab)
Iio, A, 760(ab), 792(ab), 805(ab), 864(ab), 878(ab)
Iio, M, 813(ab)
Ikehira, H, 885(ab)
Ikkala, E, 1546
Imahori, Y, 783(ab)
Imakita, S, 591
Imazeki, K, 738(ab), 910(ab)
Inaba, T, 824(ab)
Inagaki, Y, 865(ab), 866(ab)
Inglese, E, 301
Ingvar, C, 1224
Inoue, T, 895(ab)
Intenzo, CM, 856(ab), 858(ab), 942(ab)
Interrante, VL, 835(ab)
Inuzuka, E, 796(ab)
Iosilevsky, G, 240, 246, 737(ab)
Iqbal, A, 883(ab)
Irngartinger, G, 784(ab)
Irvin, GL, III, 886(ab)
Isacson, O, 762(ab)
Ishibashi, A, 853(ab)
Ishibashi, M, 868(ab), 869(ab), 942(ab)
Ishida, Y, 868(ab), 881(ab)
Ishii, Y, 840(ab)
Ishikawa, A, 830(ab)
Ishikawa, M, 150
Ishimura, J, 919(ab)
Ishiwata, K, 33, 515, 739(ab), 1809, 2012
Ishiyama, N, 897(ab)
Isitman, AT, 120, 754(ab)
Iskandrian, A, 749(ab), 820(ab)
Iskandrian, AS, 862(ab), 863(ab)
Isoda, H, 258
Israel, O, 240, 246, 737(ab), 1731
Issachar, D, 450, 538
Itami, J, 738(ab), 910(ab)
Ito, H., 916(ab)
Ito, K, 33
Ito, M, 788(ab), 917(ab)
Ito, S, 883(ab)
Itoh, H, 1192
Itoh, K, 2042
Itoh, M, 33, 515, 813(ab), 1809
Iuliucci, JD, 787(ab)
Ivanov, Z, 1240
Ivanovic, M, 875(ab)
Iversen, L, 741(ab)
Iwai, K, 930(ab)
Iwasaki, R, 718
Iwasaki, Y, 887(ab), 900(ab), 1977
Iwata, R, 33, 930(ab), 965(ab)
Izard, ME, 683

Jabir, A, 963(ab)
Jabir, AM, 890(ab), 893(ab)
Jabir, M, 761(ab)
Jackson, CB, 1865
Jackson, G, 759(ab), 777(ab)
Jackson, GA, 832(ab)
Jackson, JS, 918(ab)
Jackson, RE, 1737(le)
Jacobs, GI, 746(ab), 825(ab)
Jacobs, L, 824(ab)
Jacobson, AF, 703
Jaffe, D, 944(ab)
Jafri, RA, 823(ab)
Jagust, WJ, 765(ab)
James, HL, 807(ab)
Jamieson, D, 898(ab)
Jamieson, DG, 965(ab), 1607
Jansen, DE, 845(ab)
Jansons, D, 874(ab)
Janssen, AGM, 650
Janssen, C, 741(ab)
Janssens, J, 795(ab)
Jarden, JO, 839(ab)
Jardez, H, 788(ab)
Jarritt, PH, 891(ab)
Jaszczak, R, 755(ab)
Jay, M, 836(ab)
Jeandot, R, 904(ab), 916(ab)
Jensen, M, 402
Jeremy, RW, 755(ab)
Jerushalmi, J, 240
Jewell, WR, 844(ab)
Jewett, DM, 822(ab), 926(ab), 927(ab), 930(ab)
Jhingran, S, 775(ab)
Jiang, Z, 742(ab)
Jin, YT, 367
Jinnouchi, S, 157, 337, 1101
Jivan, S, 923(ab)
Jobling, T, 758(ab)
Joel, DD, 1342
Joensuu, H, 912(ab)
Joestgen, TM, 120
John, C, 832(ab), 938(ab), 939(ab)
John, CS, 773(ab)
John, E T57(ab)
Johns, WD, 855(ab)
Johnson, D, 836(ab)
Johnson, DK, 374, 908(ab), 935(ab)
Johnson, JA, 563
Johnson, JW, 767(ab), 777(ab)
Johnson, LL, 312, 863(ab)
Johnson, M, 782(ab)
Johnson, RF, Jr, 840(ab)
Johnson, T, 814(ab)
Johnson, TK, 1133, 1399
Johnson, VE, 880(ab)
Johnston, GS, 412
Jolesz, FA, 839(ab)
Joliot, M, 766(ab)
Jolles, PR, 1589
Jones, AG, 757(ab), 938(ab)
Jones, DW, 896(ab)
Jones, ME, 806(ab)
Jones, RH, 420, 790(ab)
Jones, T, 775(ab), 808(ab)
Jones, WT, 784(ab)
Jonk, A, 912(ab)
Jönsson, P-E, 1224
Jouve, B, 810(ab)
Joyce, M, 767(ab)
Joyner, AR, 873(ab)
Julian, B, 774(ab)
Julien, P, 734(ab), 853(ab)
Jung, Y-W, 929(ab)
Jungehülsing, M, 842(ab)
Jungkind, D, 747(ab)
Juni, J, 1280(le)
Juni, JE, 869(ab)

Kabalka, GW, 960(ab)
Kadmon, D, 1205
Kadowaki, K, 830(ab)
Kagan, A, 564
Kagaya, A, 865(ab), 866(ab), 908(ab)
Kahn, D, 754(ab), 914(ab)
Kahn, JK, 288, 801(ab), 810(ab), 828(ab)
Kaiser, HJ, 791(ab)
Kaiser, KP, 739(ab)
Kait, H, 729(ab)
Kalbhen, C, 899(ab)
Kalff, V, 837(ab)
Kallus, MA, 833(ab), 884(ab)
Kalofonos, HP, 819(ab), 1636
Kaltenbach, M, 847(ab)
Kalus, ME, 829(ab)
Kam, J, 960(ab)
Kamada, T, 868(ab), 881(ab)
Kamano, T, 770(ab), 944(ab)
Kambara, H, 863(ab), 866(ab), 1775
Kameyama, M, 1809
Kamholz, SL, 1563
Kaminski, MS, 227
Kaneko, M, 258
Kanno, I, 830(ab), 878(ab)
Kanno, T, 897(ab)
Kano, K, 853(ab)
Kanoh, T, 2050
Kao, Ch, 871(ab)
Kao, S, 754(ab)
Kaplan, EH, 827(ab), 888(ab)
Kaplan, IL, 874(ab), 1408
Kaplan, ME, 918(ab)
Kaplan, P, 833(ab)
Kaplan, WD, 845(ab)
Kapoor, R, 838(ab), 911(ab)
Karczewski, DA, 940(ab)
Karimeddini, M, 730(ab)
Karp, JS, 766(ab)
Karpowicz, W, 751(ab)
Karstens, JH, 819(ab)
Kasabali, B, 884(ab)
Kasagi, K, 786(ab)
Kashab, M, 110
Kashi, R, 826(ab)
Kasina, S, 25, 743(ab), 933(ab), 940(ab)
Kasliwal, R, 792(ab)
Kassabian, V, 944(ab)
Kassis, AI, 826(ab), 827(ab), 882(ab), 883(ab), 904(ab), 919(ab), 932(ab), 933(ab), 1856
Katabuchi, T, 767(ab), 1713
Katada, K, 897(ab)
Kataoka, M, 864(ab)
Kato, K, 811(ab)
Katz, PG, 1032
Katzenellenbogen, JA, 753(ab), 788(ab), 821(ab), 910(ab), 928(ab)
Kaufman, D, 811(ab)
Kawahara, S, 853(ab)
Kawai, C, 862(ab), 863(ab), 866(ab), 1775
Kawai, R, 899(ab)
Kawakami, K, 743(ab), 915(ab)
Kawamura, M, 792(ab), 805(ab), 864(ab), 878(ab), 938(ab)
Kawamura, Y, 747(ab), 785(ab), 840(ab), 885(ab), 889(ab), 919(ab)
Kawanaka, M, 919(ab)
Kawashima, K, 515
Kayden, DS, 800(ab)
Kayden DS, 770(ab)
Kazikiewicz, JM, 827(ab), 888(ab), 933(ab)
Kearfott, KJ, 1378
Keating, MJ, 905(ab)
Keeling, AA, 843(ab)
Keeling, C, 2063(le)

Keeling, CA, 255
Keen, RL, 127
Keenan, AM, 733(ab), 753(ab)
Kelley, RE, 93
Kelly, JD, 773(ab), 818(ab)
Kemeny, N, 809(ab)
Kemper, D, 867(ab)
Kemshead, J, 903(ab)
Kenemans, P, 758(ab)
Kennedy, RL, 879(ab)
Ker, M, 892(ab)
Kermani, S, 913(ab)
Kessler, RM, 803(ab)
Kester, RC, 45
Ketring, AR, 966(ab), 1814
Kewan, Y, 864(ab)
Keyeux, A, 788(ab)
Keyser, R, 964(ab)
Khafagi, FA, 481
Khalifah, RG, 924(ab)
Khan, N, 864(ab)
Khare, SS, 836(ab)
Khaw, B-A, 385, 762(ab), 785(ab), 817(ab), 859(ab), 901(ab), 1911
Kiat, H, 739(ab), 740(ab), 750(ab)
Kiefer, H, 908(ab)
Kiesewetter, DO, 899(ab), 928(ab)
Kiethelm, AG, 825(ab)
Kiffel, T, 855(ab)
Kikuchi, H, 150
Kilbourn, MR, 753(ab), 822(ab), 926(ab)
Kim, C, 966(ab)
Kim, CK, 737(ab), 754(ab), 785(ab), 804(ab), 815(ab)
Kim, CS, 859(ab), 1268
Kim, E, 738(ab)
Kim, EE, 834(ab), 858(ab), 901(ab), 905(ab), 909(ab), 966(ab), 1012, T26B
Kim, KT, 913(ab)
Kim, S, 856(ab)
Kim, SM, 858(ab), 942(ab)
Kimmig, B, 909(ab), 911(ab)
Kimura, K, 868(ab), 881(ab)
Kimura, S, 930(ab)
Kimura, Y, 918(ab), 943(ab)
Kinders, RJ, 828(ab)
King, D, 764(ab), 887(ab)
King, J, 861(ab)
King, M, 813(ab)
King, MA, 755(ab), 756(ab), 816(ab), 835(ab), 876(ab), 881(ab), 1616, 1666
King, PT, 741(ab)
King, RB, 873(ab)
King, SB, 740(ab)
Kinomura, S, 739(ab), 2012
Kinoshita, K, 157, 337, 1101
Kinser, JA, 1960
Kinsey, B, 928(ab)
Kinuya, K, 897(ab)
Kinuya, S, 844(ab), 907(ab), 997
Kira, Y, 866(ab)
Kirchgessner, H, 390
Kirchhoff, JR, 936(ab)
Kirchner, PT, 851(ab), 872(ab)
Kirk, GA, 894(ab), 905(ab)
Kirk, KL, 1249
Kirkeeide, RL, 845(ab), 846(ab)
Kirkwood, J, 905(ab)
Kirsch, C-M, 907(ab)
Kirsh, R, 794(ab)
Kirshenbaum, J, 821(ab)
Kitabatake, A, 868(ab), 881(ab)
Kiyosawa, M, 772(ab), 802(ab)
Klam, S, 920(ab)
Klaushenke, G, 779(ab)
Kleerup, EC, 834(ab)
Klein, HA, 850(ab), 905(ab)
Klein, HH, 757(ab)
Klein, MJ, 856(ab)
Kleinhans, E, 791(ab), 841(ab)
Klibanov, A, 762(ab)
Klibanov, AL, 1686
Kling, AS, 1616
Kling, GA, 967(ab)
Kling, P, 1367
Klinkowstein, RE, 964(ab)
Kloppenborg, D, 885(ab)
Kloppenborg, P, 736(ab)
Kluger, A, 771(ab)
Knapp, FF, 797(ab), 817(ab), 818(ab)
Knapp, FF, Jr, 829(ab), 848(ab), 923(ab), 925(ab), 1025, N1765
Knapp, RC, 904(ab)
Knapp, WH, 798(ab), 800(ab)
Knaw, BA, 1095
Knešaurek, K, 755(ab), 816(ab), 876(ab), 881(ab), 1666
Knight, LC, 817(ab)
Knoop, BO, 880(ab)
Knopf, WD, 845(ab)
Knopp, R, 879(ab)
Knox, SJ, 826(ab)
Knust, EJ, 798(ab)
Kobayashi, A, 70, 864(ab)
Kober, G, 847(ab)
Koblik, P, 1702
Kochanny, MJ, 821(ab)
Koehler, U, 829(ab)
Koeppe, R, 895(ab)
Koeppe, RA, 873(ab)
Koga, S, 897(ab)
Koh, WJ, 789(ab)
Kohlen, S, 797(ab)
Koizumi, M, 747(ab), 832(ab), 885(ab), 889(ab), 919(ab)
Kojima, A, 508
Kojima, T, 813(ab)
Kolanowski, J, 797(ab)
Kolkmeier, J, 797(ab)
Kollmann, M, 817(ab)
Kolodny, GM, 240, 737(ab), 874(ab)
Komatani, A, 719
Komtebedde, J, 1702
Kondo, M, 866(ab)
Kong, B, 749(ab), 820(ab), 862(ab), 863(ab)
Konietzko, N, 845(ab)
Konings, AWT, 789(ab)
Konishi, J, 150, 747(ab), 785(ab), 786(ab), 803(ab), 832(ab), 840(ab), 862(ab), 863(ab), 866(ab), 885(ab), 887(ab), 889(ab), 900(ab), 916(ab), 919(ab), 923(ab), 1302, 1775, 1838, 1977, 2050
Konishi, Y, 1302
Konno, T, 936(ab)
Kooij, PPM, 768(ab)
Koper, JW, 768(ab)
Koppejan, H, 791(ab)
Koral, KF, 759(ab), 777(ab)
Kornguth, S, 935(ab)
Kosaka, N, 902(ab)
Kosterink, JGW, 1219
Kosuda, S, 853(ab)
Kotler, JA, 748(ab)
Kotler, TS, 729(ab), 837(ab)
Kotoura, H, 2050
Kotzerke, J, 1278(le)
Kouris, K, 842(ab), 857(ab), 876(ab), 942(ab)
Kouvelis, A, 890(ab)
Kowal, C, 905(ab)
Koyanagi, T, 2042
Kozuka, T, 868(ab), 881(ab)
Kramer, E, 835(ab)
Kramer, FM, 692
Krämer, M, 842(ab)
Kramer, PB, 385, 1095
Krasnow, AZ, 120, 754(ab)
Krawczynska, EG, 740(ab), 749(ab)
Krebs, D, 758(ab), 922(ab)
Kreidler, J, 835(ab)
Krenning, EP, 768(ab)
Kressel, HY, 328, 754(ab)
Kreuzer, H, 757(ab), 779(ab), 800(ab)
Krevsky, B, 764(ab)
Kriegel, H, 531
Kris, MG, 746(ab)
Krischek, O, 1278(le)
Krishnamurthy, GT, 873(ab), 905(ab)
Krishnamurthy, S, 905(ab)
Krishnan, L, 844(ab)
Krivokapich, J, 259, 838(ab)
Krohn, KA, 194, 342, 735(ab), 789(ab), 808(ab), 814(ab), 828(ab), 838(ab), 846(ab), 911(ab), 928(ab), 969(ab)
Kronauge, JF, 757(ab)
Krönke, C, 886(ab)
Kroon, BBR, 912(ab)
Kroon, DJ, 805(ab)
Kropp, J, 744(ab), 829(ab), 923(ab)
Kubo, A, 809(ab), 853(ab)
Kubo, S, 887(ab), 900(ab)
Kubo, Y, 738(ab)
Kubota, K, 739(ab), 788(ab), 1809, 1848, 2012
Kubota, R, 739(ab), 2012
Kuboto, K, 33
Kuczynski, BL, 1830
Kudo, M, 733(ab)
Küfferle, B, 731(ab)
Kuhl, DE, 829(ab), 837(ab), 873(ab), 895(ab)
Kuhn, W, 758(ab)
Kühnle, H, 758(ab)
Kuhns, LR, 799(ab)
Kulkarni, PV, 902(ab)
Kumagai, T, 830(ab)
Kumar, A, 771(ab), 899(ab)
Kumar, SJ, 799(ab)
Kung, HF, 88, 367, 731(ab), 761(ab), 762(ab), 773(ab), 803(ab), 830(ab), 834(ab), 926(ab), 939(ab)
Kung, M-P, 88, 731(ab), 762(ab), 773(ab), 803(ab), 834(ab), 926(ab)
Kung, S, 830(ab)
Kung HF, 803(ab)
Kuni, C, 961(ab), 967(ab)
Kuni, CC, 1881
Kunz, R, 813(ab)
Kuperus, JH, 38
Kupranick, D, 1902
Kurata, C, 70, 864(ab)
Kuroki, M, 747(ab)
Kurono, T, 892(ab)
Kursh, ED, 784(ab)
Kushner, M, 802(ab), 898(ab)
Kushner, MJ, 811(ab), 965(ab), 1607
Kusilek, LD, 918(ab)
Kusumoto, K, 965(ab)
Kuwabara, Y, 802(ab)
Kuwert, T, 771(ab), 895(ab)
Kwan, SYI, 918(ab)
Kwiatkowski, F, 295, 871(ab)
Kwok, CS, 777(ab), 1036
Laçon, JP, 825(ab)
Lagunas-Solar, MC, 849(ab), 968(ab), 1182
Lahiri, A, 773(ab), 818(ab), 868(ab)
Lake, RR, 1616
Lam, CF, 872(ab)
LaManna, MM, 867(ab)
Lambert, B, 904(ab)
Lambert, D, 916(ab)
Lambert, R, 759(ab), 790(ab), 865(ab), 944(ab)
Lamberts, SWJ, 768(ab)
Lambotte, L, 815(ab), 929(ab)
Lambrecht, RM, 922(ab), 1132
Lameris, JS, 768(ab)
Lamki, L, 130, 738(ab), 858(ab)
Lamki, LK, 905(ab)
Lamki, LM, 819(ab), 836(ab), 844(ab), 858(ab), T26C
Lammertsma, AA, 775(ab), 808(ab)
Lamoureux, F, 781(ab)
Lamoureux, G, 894(ab)
Lamoureux, J, 781(ab)
LaMuraglia, GM, 817(ab)
Lancaster, JL, 130
Landthaler, M, 907(ab)
Lane, WW, 737(ab)
Lang, L, 1205
Lange, HW, 771(ab)
Langen, K-J, 771(ab), 895(ab)
Langleben, D, 1297
Långström, B, 742(ab), 782(ab), 783(ab), 927(ab)
Lannoye, GS, 901(ab), 926(ab), 930(ab), 931(ab)
Lantto, T, 1332
Lanza, RC, 806(ab)
Laperrière, J, 944(ab)
Laperrière, L, 807(ab)
Lapointe, J, 1271
Lapointe, S, 944(ab)
Larcos, G, 754(ab), 1885
Larner, JM, 209
Larson, KB, 901(ab)
Larson, S, 320
Larson, SM, 581, 746(ab), 809(ab), 909(ab), 928(ab), 1311, 1693, 1966
Lasher, JC, 1737(le)
Lashford, L, 903(ab)
Lassen, NA, 775(ab), 796(ab), 896(ab)
Latham, IA, 773(ab), 818(ab)
Lattimer, JC, 966(ab)
Laurin, NR, 1627
Lau-Wong, MM, 918(ab)
LaVallee, DK, 936(ab)
Lavender, JP, 738(ab), 819(ab), 847(ab)
Lavender, PJ, 1636
Law, MP, 766(ab)
Lawrence, D, 934(ab)
Lawson, MS, 523
Lawson, WE, 165
Lawton, RG, 832(ab)
Lazarus, CR, 174
Lazewatsky, J, 870(ab)
Lazzari, S, 779(ab)
Lear, JL, 792(ab), 838(ab), 874(ab), 900(ab), 944(ab)
Leblanc, A, 1281
LeBlanc, A, 775(ab)
Leclef, B, 788(ab)
Leclerc, Y, 117
Lecloirec, J, 941(ab)
Lecomte, JL, 766(ab)
Lecomte, R, 766(ab)
Le Doussal, J-M, 907(ab), 1358
Lee, BI, 751(ab)
Lee, H-B, 666, 841(ab)
Lee, J, 747(ab)
Lee, KH, 886(ab)
Lee, KJ, 781(ab)
Lee, ME, 959(ab)
Lee, RE, 809(ab), 828(ab)
Lee, S-D, 1708
Lee, Y-CC, 763(ab), 935(ab)
Lefebvre, B, 759(ab)
Lefkowitz, DM, 876(ab)
Lefort, G, 904(ab)
Legaut, F, 897(ab)
Leichner, PK, 881(ab)
Leinsinger, G, 907(ab)
Lemaire, C, 752(ab)
Lemasson, P, 766(ab)
Lentle, BC, 961(ab)
Leon, JA, 936(ab)
Leon, M, 915(ab)
Leonard, JC, 890(ab)
Leoncini, M, 820(ab)
Lepp, EK, 853(ab)
Leppo, JA, 281, 730(ab),

756(ab), 833(ab), 1500
Lerner, CA, 834(ab)
Leroy, RF, 751(ab)
Lette, J, 1271
Leuven, KU, 871(ab)
Lévêille, J, 759(ab), 865(ab), 1902
Lever, J, 740(ab)
Lever, JR, 750(ab), 803(ab)
Leville, J, 1018
Levin, DR, 246
Levine, AH, 1111
Levine, G, 905(ab)
Levine, RL, 745(ab)
Levorato, M, 615
Levy, D, 901(ab)
Levy, R, 826(ab), 828(ab), 895(ab)
Levy, RD, 1297
Lew, AS, 729(ab), 837(ab)
Lewellen, TK, 789(ab), 797(ab), 825(ab), 846(ab), 852(ab), 879(ab), 893(ab), 1554
Lewis, CA, 891(ab)
Lewis, I, 903(ab)
Lewis, JP, 827(ab)
Leysen, J, 741(ab)
Leyssen, J, 926(ab)
Li, QS, 755(ab), 757(ab)
Li, S, 851(ab)
Liang, C-C, 960(ab)
Liang, Z, 755(ab)
Liberatore, FA, 787(ab)
Libson, K, 732(ab), 742(ab), 743(ab), 849(ab)
Libson, KF, 837(ab)
Lich, LL, 791(ab), 901(ab)
Licitra, G, 128
Liebert, M, 60, 777(ab), 912(ab)
Lietzenmayer, R, 813(ab)
Liewendahl, K, 1546
Likungu, J, 829(ab)
Limburg, M, 781(ab)
Lin, H-C, 1708
Lin, S, 901(ab)
Lin, W-C, 960(ab)
Linden, A, 842(ab), 843(ab), 903(ab)
Line, B, 934(ab)
Link, JM, 342, 789(ab), 808(ab), 846(ab), 852(ab), 911(ab), 928(ab)
Linkesch, W, 1005
Links, J, 731(ab)
Links, JM, 740(ab), 755(ab), 816(ab), 849(ab)
Lio, M, 902(ab)
Lisbona, R, 181, 1297
Lisic, EC, 925(ab)
Lister-James, J, 793(ab), 794(ab), 934(ab)
Liu, BL, 367, 939(ab)
Liu, CZ, 939(ab)
Liu, R-S, 871(ab), 1708
Livesey, JC, 814(ab)
Livni, E, 797(ab), 928(ab)
Llorens, V, 1277(le)
Lo, JM, 832(ab), 938(ab), 939(ab)
Loats, H, 750(ab), 838(ab)
Loats, HL, 816(ab)
Loats, S, 838(ab)
Loats, SE, 816(ab)
Loc'h, C, 731(ab), 762(ab), 825(ab), 898(ab)
Locke, E, 1095
Loeve, W, 768(ab)
Loewenstein, DA, 802(ab)
Logan, J, 730(ab), 761(ab), 801(ab), 898(ab)
Logan, KW, 964(ab)
Logothetis, C, 836(ab)
Logue, MB, 965(
Lohe, Evd, 739(a
Loken, MK, 1881
Lomeña, F, 1279(le)
Lomeña, FJ, 1470
London, J, 1117
Long, DT, 835(ab)
Longino, MA, 1088
Longo, D, 909(ab)
Lora, ME, 1311
Lorenz, WJ, 910(ab)
Lorre, JP, 742(ab), 877(ab)
Losinno, F, 615
Losse, B, 829(ab)
Lotke, PA, 733(ab)
Lötter, MG, 914(ab)
Lotze, MT, 1311
Lowe, JL, 742(ab)
Löwenhielm, P, 722
Lowenstein, E, 917(ab)
Lubin, E, 450, 538
Lubowksi, D, 764(ab), 887(ab)
Lubs, H, 802(ab)
Lucchesi, BR, 767(ab)
Lucignani, G, 792(ab), 831(ab), 869(ab)
Luckey, MM, 1875
Lucraft, H, 903(ab)
Ludwig, H, 1005
Lumia, FJ, 867(ab)
Lundell, G, 721
Lunghi, F, 742(ab)
Lurain, J, 827(ab)
Lusins, J, 1739(le)
Lusins, JO, 490
Lusson, J-R, 295
Lutz, RJ, 839(ab)
Luxen, A, 735(ab), 752(ab)
Lyle, FM, 871(ab)
Lynne, C, 841(ab)
Lyons, E, 749(ab), 820(ab)
Lyons, N, 754(ab), 764(ab), 851(ab), 887(ab)
Lyss, AP, 788(ab)
Lyster, DM, 925(ab)

Ma, GQ, 886(ab)
Maas, KW, 799(ab)
MacDonald, JR, 937(ab)
MacDonald, RN, 836(ab)
Macey, DJ, 778(ab), 827(ab), 884(ab)
MacFarlane, JK, 962(ab)
MacGregor, R, 761(ab), 898(ab)
MacGregor, RR, 741(ab)
Mach, J-P, 809(ab), 1646
Machac, J, 750(ab), 834(ab), 1445
Machida, K, 770(ab), 944(ab)
Machulla, HJ, 798(ab)
MacIntyre, WJ, 861(ab)
Mackay, BC, 782(ab)
Mackie, TR, 883(ab)
Maddahi, J, 301, 729(ab), 739(ab), 740(ab), 750(ab), 757(ab), 795(ab), 837(ab), 1718
Maddai, J, 780(ab)
Madden, J, 759(ab), 883(ab), 884(ab)
Madden, JA, 876(ab)
Maddox, A, 765(ab), 795(ab), 887(ab)
Madsen, JL, 402
Madsen, MT, 851(ab), 872(ab)
Madsen, SL, 848(ab)
Maecke, HR, 1235
Maeda, H, 897(ab)
Maeda, T, 738(ab)
Maffioli, L, 869(ab), 1415
Magata, Y, 803(ab), 866(ab), 887(ab), 900(ab)
Magill, CA, 923(ab)
Magnani, P, 888(ab)
Magoun, S, 918(ab)
Mahan, M, 961(ab)
Maheu, LJ, 773(ab)
Mahmarian, JJ, 749(ab), 760(ab), 780(ab)
Mahmoud, AH, 943(ab)
Mahoney, DK, 735(ab), 761(ab), 879(ab)
Maickel, RP, 920(ab)
Maier-Borst, W, 909(ab)
Maisey, MM, 174
Maisey, MN, 820(ab)
Makai, T, 150
Makler, PT, Jr, 1117
Makoroff, K, 920(ab)
Makrigiorgos, G, 826(ab), 883(ab), 1856
Malak, TA, 767(ab)
Malbrain, S, 2022
Maley, BL, 747(ab)
Malik, AB, 852(ab)
Mallette, S, 481
Malmin, RE, 852(ab)
Malmud, LS, 817(ab)
Maloney, P, 915(ab)
Maloney, PJ, 1311, 1693
Malov, AG, 1686
Mamiya, T, 770(ab), 944(ab)
Mamontova, AG, 66
Manco-Johnson, M, 874(ab)
Mandeli, JP, 1875
Mandelkern, M, 894(ab)
Mandell, GA, 799(ab)
Mangios, SH, 881(ab), 961(ab)
Mangner, T, 837(ab)
Mangner, TJ, 926(ab)
Mann, U, 896(ab)
Manning, R, 803(ab)
Manor, E, 804, 815(ab)
Manspeaker, P, 833(ab)
Manzel, L, 827(ab)
Maranhao, V, 867(ab)
Marchetta, F, 615
Marciano, D, 863(ab), 877(ab), 913(ab), 942(ab)
Marcus, CS, N1584
Marian, AJ, 760(ab)
Mariani, G, 749(ab)
Mariani, M, 908(ab)
Marin-Grez, M, 909(ab), 911(ab)
Marino, GG, 251
Markand, ON, 751(ab)
Markham, J, 825(ab)
Markusse, HM, 889(ab), 2017
Marmion, M, 773(ab)
Marmion, ME, 937(ab)
Marmor, A, 1657
Maron, BJ, 780(ab)
Marquis, J, 760(ab)
Marret, S, 776(ab)
Marrett, S, 839(ab), 875(ab)
Marrett, TS, 765(ab)
Marsano, L, 559
Marsch, S, 820(ab), 863(ab)
Marsden, PK, 766(ab)
Marsh, JD, 757(ab)
Martell, AE, 763(ab), 848(ab), 922(ab)
Martin, CC, 745(ab), 927(ab)
Martin, GL, 808(ab)
Martin, GV, 194, 798(ab), 846(ab)
Martin, JL, 732(ab)
Martin, M, 907(ab), 1358
Martin, NL, 843(ab)
Martin, P, 828(ab)
Martin, W, 818(ab)
Martin, WRW, 761(ab)
Martinez, F, 1113
Martinez, M, 863(ab)
Martinot, JL, 897(ab)
Martynov, AV, 1686
Marwick, TH, 759(ab)
Marwick, TH, 861(ab)
Masdeu, J, 811(ab)
Maseri, A, 808(ab)
Mash, D, 761(ab)
Mason, MD, 754(ab)
Massuger, L, 758(ab)
Masuda, K, 802(ab), 914(ab)
Masuda, Y, 865(ab), 866(ab)
Masui, H, 746(ab)
Masure, MC, 812(ab)
Matarrese, M, 742(ab), 831(ab), 869(ab)
Mather, SJ, 748(ab), 758(ab)
Mathias, CJ, 753(ab), 763(ab), 768(ab), 788(ab), 791(ab), 807(ab), 821(ab), 901(ab), 910(ab), 1205, 1843
Mathis, C, 822(ab)
Mathis, CA, 342
Mathog, RH, 967(ab)
Matinez, SJ, 398
Matsubara, N, 868(ab), 881(ab)
Matsuda, H, 897(ab), 939(ab)
Matsueda, GR, 785(ab)
Matsumori, A, 862(ab)
Matsumoto, K, 923(ab), 1838
Matsumoto, M, 508
Matsumoto, S, 760(ab)
Matsumoto, T, 885(ab)
Matsunaga, M, 858(ab)
Matsunari, I, 844(ab)
Matsuoka, K, 942(ab)
Matsuoka, Y, 747(ab)
Matsushima, H, 832(ab)
Matsuzawa, T, 33, 739(ab), 788(ab), 902(ab), 1809, 2012
Mattar, AG, 1627
Mattera, JA, 800(ab), 863(ab)
Matthiesen, S, 542
Matzku, S, 390
Maublant, JC, 295, 860(ab), 865(ab), 871(ab)
Maul, FD, 847(ab), 904(ab)
Maurer, AH, 764(ab), 782(ab), 794(ab), 817(ab)
Maurer, H, 849(ab)
Maurer, SB, 966(ab)
Mausner, L, 890(ab)
Mausner, LF, 921(ab), 923(ab), 935(ab)
Maxon, HR, 732(ab), 837(ab)
Mayaud, C, 746(ab)
Mayberg, HS, 740(ab), 750(ab)
Mayoral, G, 936(ab)
Mayoral, JL, 936(ab)
Mazière, B, 731(ab), 762(ab), 825(ab), 898(ab)
Mazière, M, 731(ab), 762(ab)
Mazoyer, B, 812(ab)
Mazoyer, BM, 766(ab), 825(ab), 877(ab), 897(ab)
Mazziotta, JC, 735(ab), 752(ab), 761(ab), 791(ab), 801(ab), 879(ab), 896(ab), 913(ab)
McAfee, JG, 659, 747(ab), 881(ab), 940(ab), 963(ab)
McCabe, RP, 909(ab)
McCall, MJ, 762(ab), 763(ab)
McCallum, RW, 764(ab), 882(ab)
McCandless, BK, 743(ab), 744(ab)
McCartney, WH, 497, 756(ab), 835(ab)
McClanahan, TB, 860(ab)
McConnell, DS, 1088
McConnell, TP, 776(ab)
McCready, VR, 813(ab)
McDiarmid, SA, 942(ab)
McDougall, IR, 255, 407, 2063(le)
McElwain, TJ, 474, 836(ab)
McEver, R, 787(ab)
McEwan, AJ, 812(ab), 836(ab), 914(ab), 961(ab)
McFalls, EO, 808(ab)
McFarland, WD, 964(ab)
McGhie, AI, 828(ab)
McGhie, I, 288, 770(ab), 801(ab), 810(ab), 871(ab)
McGrath, MA, 961(ab)
McGuire, AH, 788(ab), 791(ab)
McGuire, R, 819(ab)
McIndoe, DW, 1424
McIntyre, WJ, 759(ab)
McKay, DR, 683
McKay, WJ, 751(ab), 831(ab)
McKenzie, CG, 1636
McKnight, R, 834(ab)
McKusick, K, 301, 740(ab)

McLean, M, 866(ab)
McLean, R, 754(ab), 764(ab), 851(ab), 887(ab)
McNamara, M, 754(ab)
McNutt, K., 917(ab)
McPherson, DW, 848(ab), 925(ab)
McRae, T, 771(ab)
McSharry, B, 730(ab)
McSherry, B, 833(ab)
McTigue, M, 762(ab)
Meares, CF, 762(ab), 763(ab)
Mease, RC, 923(ab), 934(ab), 935(ab)
Meerdink, DJ, 756(ab), 1500
Meier, DE, 1875
Meignan, M, 734(ab), 746(ab)
Meijer, S, 1219
Meikle, SR, 872(ab), 964(ab)
Meinken, GE, 787(ab), 923(ab), 934(ab), 935(ab), 1848
Meldolesi, U, 820(ab)
Melega, WP, 735(ab), 752(ab), 761(ab)
Melin, JA, 788(ab), 797(ab)
Meller, ST, 474, 836(ab)
Melograna, J, 1079
Meltzer, CC, 750(ab)
Mena, FJ, 806(ab)
Mena, I, 599, 806(ab), 864(ab), 887(ab), 967(ab)
Mena, IG, 38, 1018
Mendelsohn, J, 746(ab)
Meneguetti, JC, 916(ab)
Meng, M, 367
Merbach, A, 743(ab)
Merchant, B, 748(ab), 906(ab)
Merhige, ME, 846(ab), 859(ab), 865(ab), 866(ab)
Merlet, P, 810(ab)
Mertens, J, 741(ab), 921(ab), 926(ab)
Mesa-Tesada, R, 936(ab)
Messa, C, 831(ab)
Messian, O, 820(ab)
Metz, JT, 899(ab)
Meury, V, 792(ab)
Meyer, E, 900(ab), 1069
Meyer, G-J, 880(ab), 910(ab)
Meyer, KL, 849(ab)
Meyne, NG, 780(ab)
Miceva, S, 823(ab)
Michael, RH, 843(ab)
Michaels, E, 942(ab)
Michalek, SM, 1464
Michel, C, 797(ab)
Michigishi, T, 844(ab)
Middelheim, AZ, 794(ab)
Midha, K, 731(ab)
Milhaud, G, 855(ab)
Miller, C, 542
Miller, DD, 787(ab), 860(ab)
Miller, DS, 827(ab)
Miller, JH, 799(ab), 857(ab)
Miller, KM, 937(ab)
Miller, LR, 764(ab)
Miller, PR, 967(ab)
Miller, R, 778(ab), 828(ab)
Miller, S, 855(ab)
Miller, TR, 781(ab), 808(ab), 834(ab), 2036
Milligan, T, 1032
Millin, J, 856(ab)
Mills, BJ, 754(ab)
Mills, SL, 827(ab), 907(ab)
Milo, TJ, 961(ab)
Min, CY, 1693
Minkin, E, 731(ab)
Minn, H, 912(ab)
Minnaar, P, 914(ab)
Minoshima, S, 738(ab), 858(ab), 910(ab)
Mintum, MA, 141
Mintun, MA, 788(ab), 901(ab)
Miraldi, F, 784(ab), 879(ab)
Mirelli, M, 615
Miron, SD, 734(ab)
Mirzadeh, S, 672, 968(ab)
Misaki, T, 786(ab)
Misra, HK, 793(ab)
Mistry, R, 174
Mitchell, DM, 901(ab)
Mitchell, M, 25
Mitsuka, S, 913(ab)
Miura, RS, 466, 784(ab)
Miura, S, 830(ab), 878(ab)
Miyagawa, M, 760(ab), 792(ab), 878(ab)
Miyagawa, N, 918(ab)
Miyake, M, 802(ab)
Miyaoka, RS, 893(ab)
Miyoshi, T, 150, 858(ab)
Mizuno, T, 258
Mochizuki, T, 760(ab), 805(ab), 864(ab), 878(ab), 943(ab)
Mock, BH, 920(ab)
Mock, BM, 799(ab)
Modell, HI, 789(ab)
Modell, JG, 895(ab)
Mody, FV, 846(ab), 867(ab)
Moeller, F, 805(ab)
Moeller, JR, 564, 839(ab), 1483
Moerlein, SM, 763(ab), 804(ab), 822(ab), 901(ab), 926(ab), 930, 931(ab)
Mogami, H, 792(ab), 805(ab), 864(ab), 878(ab), 943(ab)
Mohammed, MMJ, 864(ab), 959(ab)
Möhring, K, 784(ab)
Mohuiddin, S, 730(ab)
Moi, M, 763(ab)
Moins, N, 860(ab)
Moisan, A, 941(ab)
Mojiminiyi, OA, 1420(le)
Möllenstädt, S, 531
Möller, F, 856(ab)
Momose, T, 902(ab)
Monaghan, P, 754(ab)
Mondorf, UF, 495(ab)
Monetti, N, 615
Monroe, LA, 786(ab)
Montalescot, G, 917(ab)
Montemaggi, P., 769(ab)
Montilla, L, 826(ab)
Moolenaar, AJ, 769(ab)
Moore, DA, 922(ab)
Moore, RH, 913(ab)
Moore, SC, 806(ab)
Moore, WH, 786, 918(ab), 1741
Moragas, M, 1470
Moran, RD, 894(ab)
Morell, EM, 889(ab)
Moreno, AJ, 962(ab)
Moretti, J-L, 1018
Morgan, AC, 25, 216
Morgan, AC, Jr, 777(ab)
Morgan, C, 779(ab)
Morgan, JP, 870(ab)
Morgan, RA, 599, 1018, 1892, 1902
Morgan, WA, 782(ab)
Morguet, A, 757(ab), 779(ab), 800(ab)
Mori, A, 914(ab)
Mori, H, 897(ab), 939(ab)
Mori, K, 718
Mori, Y, 915(ab)
Morita, S, 942(ab)
Morozumi, R, 868(ab), 881(ab)
Morrel, EM, 1538
Morris, D, 923(ab)
Morris, JG, 683, 1865
Morris, JM, 905(ab)
Morrish, DW, 914(ab)
Morse, BS, 1550
Morser, J, 787(ab)
Mortelmans, L, 871(ab), 896(ab), 1992, 2022
Morton, T, 920(ab)
Moscatelli, G, 779(ab), 908(ab)
Moser, KM, 1531
Moses, WW, 745(ab)
Mosimann, F, 1646
Moskowitz, B, 246
Motekaitis, RJ, 922(ab)
Motta-Hennessy, C, 848(ab), 888(ab)
Moulton, JS, 837(ab)
Mountford, PJ, 562
Mountz, JM, 895(ab)
Moyes, JSE, 474, 836(ab)
Muecke, T, 765(ab)
Muehllehner, G, 766(ab)
Mueller, SP, 806(ab), 867(ab)
Mukai, T, 866(ab), 887(ab), 900(ab), 1775, 1977
Mukherjee, J, 924(ab), 930(ab)
Mulholland, CK, 932(ab)
Mulholland, GK, 822(ab), 926(ab), 930(ab)
Mullani, N, 775(ab), 865(ab), 909(ab), 966(ab), 1787
Mullani, NA, 707, 846, 880(ab), 964(ab)
Muller,Ch, 1005
Müller, H, 784(ab)
Müller, SP, 845(ab), 886(ab)
Müller-Suur, C, 1986
Müller-Suur, R, 1986
Mullholland, GK, 822(ab)
Mumper, RJ, 836(ab)
Munoz, L, 810(ab)
Munz, DL, 748(ab), 757(ab), 758(ab), 779(ab), 800(ab), 917(ab)
Murakami, M, 830(ab), 878(ab)
Murakawa, M, 718
Murase, K, 760(ab), 792(ab), 805(ab), 864(ab), 878(ab), 1192
Murata, H, 870(ab)
Murata, K, 916(ab)
Murayama, H, 746(ab), 892(ab)
Murphy, KA, 878(ab)
Murphy, P, 1136
Murphy, PH, 941(ab), 1741, 1918
Murphy, RA, 762(ab), 803(ab)
Murray, JL, 819(ab)
Murrell, M, 741(ab)
Musachio, JL, 803(ab)
Muschel, MJ, 312
Muto, MG, 904(ab), 933(ab)
Muz, J, 967(ab)
Muzi, M, 808(ab), 838(ab), 911(ab)
Muzik, O, 895(ab)
Muzykantov, VR, 1686
Myears, DW, 187
Mylonakis, T, 798(ab), 915(ab)

Naeem, M, 758(ab)
Nagle, CE, 736(ab), 959(ab)
Nair, M, 864(ab), 959(ab)
Najafi, A, 939(ab)
Najm, YC, 820(ab)
Nakahashi, H, 783(ab), 824(ab), 866(ab)
Nakai, T, 747(ab), 785(ab), 840(ab), 885(ab), 889(ab), 919(ab)
Nakajima, K, 825(ab), 844(ab), 870(ab), 997
Nakajima, S, 738(ab)
Nakamura, K, 809(ab)
Nakano, H, 811(ab)
Nakano, S, 157, 337, 1101
Nakata, S, 792(ab)
Nakatsuka, I, 803(ab)
Nanbu, I, 870(ab)
Narabayashi, I, 853(ab)
Narra, RK, 1830
Natale, RB, 25
Natarajan, TK, 731(ab), 741(ab)
Neben, T, 932(ab)
Neblock, D, 787(ab)
Nedelman, MA, 787(ab), 793(ab), 794(ab), 906(ab), 934(ab)
Need, JL, 968(ab)
Needleman, M, 385, 1095
Neely, H, 785(ab)
Nelp, WB, 25, 828(ab)
Nelson, AD, 784(ab), 879(ab)
Nelson, AH, 794(ab)
Nelson, CW, 1172
Nelson, DH, 966(ab)
Nelson, R, 963(ab)
Nenov, VI, 894(ab)
Neufang, KFR, 842(ab)
Neumann, PH, 852(ab)
Neumann, RD, 906(ab), 941(ab), 1311
Neumann, W, 773(ab)
Neumann, WL, 937(ab)
Newman, D, 810(ab)
Newton, RS, 768(ab)
Ng, AK, 819(ab)
Ng, CK, 1211
Nguyen, NTB, 733(ab), 767(ab)
Nichols, K, 757(ab), 795(ab)
Nickles, RJ, 745(ab), 927(ab), 930(ab), 935(ab), 965(ab)
Nickoloff, EL, 124
Nicol, PD, 785(ab)
Nicolas, JM, 788(ab)
Nicosia, S, 883(ab)
Niemann, H, 748(ab)
Nieminen, U, 1546
Nienaber, C, 729(ab), 837(ab)
Nienaber, CA, 359, 838(ab), 846(ab)
Niino, M, 760(ab)
Niklason, LT, 876(ab)
Nilson, TE, 943(ab)
Nimmon, C, 942(ab)
Nimmon, CC, 758(ab), 823(ab)
Nishihara, M, 830(ab)
Nishikawa, A, 919(ab)
Nishikawa, J, 813(ab), 902(ab)
Nishikimi, N, 458
Nishimura, K, 916(ab)
Nishimura, T, 591, 767(ab), 1713
Nishizasa, S, 150
Nishizawa, S, 900(ab), 1977
Nissen, HP, 923(ab)
Nitsch, J, 797(ab)
Niwa, H, 258
Niwayama, H, 865(ab), 866(ab)
Noda, H, 767(ab)
Noda, S, 942(ab)
Noël, P, 798(ab), 915(ab), 966(ab)
Nohara, N, 746(ab), 892(ab), 1337, 1825, 1982
Nohara, R, 866(ab)
Nohara, T, 863(ab)
Nolan, J, 963(ab)
Noon, GP, 780(ab), 1405
Nordberg, A, 742(ab)
Nordman, E, 912(ab)
Nordrehaug, JE, 1972
Normand, B, 865(ab)
Noronha, JG, 928(ab)
Norrgren, K, 1224
North, DL, 872(ab)
Northover, JMA, 748(ab)
Nosco, D, 773(ab)
Nosco, DL, 937(ab)
Nossiff, N, 762(ab), 859(ab)
Nossiff, ND, 1095
Noto, R, 731(ab), 834(ab)
Notohamiprodjo, G, 798(ab), 800(ab)
Noujaim, AA, 202
Novales-Diaz, JA, 181
Noz, ME, 835(ab)
Nunes, J, 1036
Nunn, AD, 1830
Nupnau, WA, 852(ab)
Nusynowitz, ML, 561
Nuyts, J, 871(ab), 1992

Nybäck, H, 742(ab)

Oates, E, 889(ab), 963(ab)
Oba, H, 897(ab)
Oberdorfer, F, 789(ab), 909(ab), 911(ab)
Obrador, D, 862(ab)
O'Connell, JW, 869(ab)
O'Connell, RA, 811(ab)
O'Connell, WC, 810(ab)
O'Connor, MK, 265, 1135, 1280(le)
Oda, Y, 866(ab)
Odano, I, 830(ab)
Odeh, N, 899(ab)
O'Donnell, S, 762(ab), 859(ab)
Oehr, P, 110, 758(ab), 879(ab)
Oei, HY, 785(ab)
Oepen, G, 812(ab)
Oettgen, HF, 809(ab)
O'Grady, LF, 738(ab), 827(ab), 907(ab)
Ohbayashi, K, 853(ab)
Ohno, K, 770(ab)
Ohta, H, 2050
Ohtake, H, 942(ab)
Ohtake, T, 902(ab)
Ohtani, H, 863(ab), 866(ab), 1775
Ojemann, GA, 838(ab)
Ojima, F, 917(ab)
Oka, H, 767(ab)
Okada, H, 892(ab)
Okada, J, 738(ab), 858(ab), 910(ab)
Okamoto, K, 936(ab)
Okazawa, H, 885(ab)
Olbrich, HG, 847(ab)
Old, LJ, 809(ab)
Oldfield, EH, 839(ab)
Olea, E, 816(ab), 942(ab)
O'Leary, DH, 1892
Oliverio, R, 889(ab)
Ollinger, JM, 736(ab)
Olson, DM, 896(ab)
Oluwoli, S, 890(ab)
Ong, RL, 813(ab)
Ono, S, 902(ab)
Ono, Y, 830(ab)
Oonuma, N, 858(ab)
Oosterlinck, A, 871(ab), 1992
O'Rear, J, 1616
Orellana, P, 942(ab), 963(ab)
Oria, R, 1424
Oriuchi, N, 895(ab)
Orlandi, C, 773(ab), 787(ab), 792(ab)
Ornish, D, 845(ab)
Orth, F, 910(ab)
Oshima, M, 458
Oster, ZH, 165, 831(ab)
Ostrzega, E, 780(ab), 837(ab)
Oswald, SG, 1321
Oswald, WM, 265, 1135
Otani, H, 859(ab)
Otsuka, M, 802(ab)
Otsuka, S, 866(ab)
Otsuki, H, 792(ab), 1676
Ott, RJ, 766, 813(ab)
Ottaviani, M, 898(ab)
Otto, CA, 930(ab), 932(ab)
O'Tuama, L, 838(ab)
Owens, ES, 1676
Owunwanne, A, 921(ab), 968(ab)
Ozzello, L, 819(ab)

Paakkinen, S, 1332
Paans, AMJ, 789(ab)
Paas, M, 845(ab)
Pablo, J, 761(ab)
Pabst, H-W, 531
Pace, L, 1966
Pacifici, R, 774(ab)
Paczolt, E, 817(ab)
Paczolt, EA, 782(ab), 794(ab)
Paik, CH, 832(ab), 940(ab), 1693
Pak, K, 787(ab)
Pak, KY, 793(ab), 859(ab), 901(ab), 906(ab), 934(ab)
Palac, RT, 1172, 1182
Palestro, C, 1445
Palestro, CJ, 737(ab), 754(ab), 785(ab), 804(ab), 815(ab)
Palevsky, HI, 733(ab)
Palinke, T, 935(ab)
Palmaz, J, 787(ab)
Palme, DF, 826(ab), 906(ab)
Palmer, E, 734(ab)
Palmer, EL, 556
Palmer, MR, 761(ab)
Pan, M, 924(ab)
Pan, M-L, 833(ab), 883(ab), 924(ab)
Pan, S, 88, 731(ab), 803(ab), 830(ab), 834(ab)
Papapoulos, SE, 775(ab)
Pappas, D, 886(ab)
Pappatta, S, 897(ab)
Paradise, AH, 892(ab)
Parikh, SR, 888(ab)
Paris, E, 909(ab)
Park, CH, 856(ab), 858(ab), 942(ab)
Park, HM, 751(ab)
Parker, BA, 778(ab)
Parker, JA, 855(ab), 870(ab), 874(ab)
Parker, RD, 731(ab)
Parkey, R, 770(ab)
Parkey, RW, 638, 902(ab)
Parkin, A, 45
Parkinson, D, 804(ab), 822(ab)
Parviainen, S, 892(ab)
Pascal, S, 772(ab), 802(ab)
Pascual, J, 967(ab)
Passeri, A, 880(ab)
Patel, BA, 827(ab), 888(ab), 933(ab)
Patel, D, 789(ab)
Patel, N, 754(ab)
Paterson, W, 812(ab)
Patlak, CS, 899(ab)
Patterson, J, 2063(le)
Patterson, RE, 796(ab)
Pauwels, EKJ, 769(ab), 775(ab), 889(ab), 2017
Pauwels, S, 815(ab), 929(ab)
Pavel, DG, 816(ab), 942(ab), 963(ab)
Pavia, D, 744(ab)
Pavia, J, 1470
Pavlosky, WF, 1627
Pawlak-Byczkowska, EJ, 828(ab)
Pawlikowska, TR, 1636
Pawlyk, D, 826(ab), 962(ab)
Payne, JK, 742(ab)
Peacock, WJ, 896(ab)
Peake, G, 772(ab)
Peake, J, 936(ab)
Pearlson, G, 731(ab)
Pearson, VD, 1737(le)
Pelizzari, CA, 777(ab)
Pellikka, PA, 801(ab)
Penney, BC, 755(ab), 756(ab), 816(ab), 835(ab), 876(ab), 881(ab), 1666
Pepys, MB, 847(ab)
Perentesis, P, 320
Perlman, SB, 745(ab), 965(ab)
Perlmutter, AD, 799(ab)
Perlmutter, M, 761(ab)
Perlmutter, MM, 752(ab)
Perri, JL, 794(ab)
Perry, DJ, 791(ab)
Perry, JR, 497, 755(ab), 756(ab), 835(ab)
Peters, AM, 738(ab), 784(ab), 841(ab), 842(ab)
Peters, T, 839(ab)
Petersen, M, 2063(le)
Petersen, RK, 796(ab)
Peterson, G, 925(ab)
Peterson, M, 255
Petry, NA, 895(ab)
Petry, NS, 860(ab)
Pettavel, J, 1646
Peyceion, P, 295
Phaneuf, DC, 759(ab)
Phelps, ME, 359, 735(ab), 752(ab), 761(ab), 791(ab), 801(ab), 824(ab), 838(ab), 846(ab), 863(ab), 867(ab), 879(ab), 896(ab), 1507
Philippe, L, 418
Phillips, P, 838(ab)
Phillips, RA, 1445
Phillips, RKS, 748(ab)
Phillips, SF, 764(ab)
Phillips, WJ, 764(ab)
Phillips, WT, 1737(le)
Philpot, M, 895(ab)
Philpott, GW, 763(ab)
Piager, B, 766(ab)
Picard, M, 301, 599
Pich, S, 757(ab)
Piepsz, A, 798(ab), 915(ab), 966(ab), 1337, 1825, 1982
Piera, C, 1470
Piers, DA, 605, 1219
Piketty, C, 855(ab)
Pilcher, G, 773(ab)
Pilcher, GD, 937(ab)
Pillai, MRA, 832(ab), 938(ab), 939(ab)
Pinney, KG, 928(ab)
Piotrowski, B, 886(ab)
Pippin, JJ, 288
Pisani, TL, 733(ab), 767(ab), 932(ab)
Pistocchi, E, 908(ab)
Piwnica-Worms, D, 757(ab), 938(ab)
Pizer, SM, 835(ab)
Pizzetti, G, 873(ab)
Pizzo, PA, 581
Plata, F, 746(ab)
Platsch, G, 751(ab)
Platts, SH, 792(ab)
Plenevaux, A, 753(ab), 821(ab)
Plott, CM, 960(ab)
Plunkett, ME, 1554
Pochis, R, 754(ab)
Podoloff, D, 738(ab), 819(ab), 858(ab), 909(ab), 966(ab)
Podoloff, DA, 844(ab), 858(ab), 905(ab)
Podreka, I, 731(ab)
Poels, L, 758(ab)
Poirier, JY, 941(ab)
Politano, V, 841(ab)
Pollack, WM, 165
Pollard, KR, 797(ab), 1554
Pollycove, M, 1702
Pomper, MG, 753(ab), 821(ab), 928(ab)
Ponce, YZ, 924(ab)
Pons, F, 1279(le), 1470
Ponto, J, 268
Ponto, JA, 416, 883(ab)
Ponto, R, 1559
Popma, JJ, 861(ab)
Port, S, 770(ab)
Porter, J, 909(ab)
Porter, WC, 265, 869(ab)
Posch, Ch, 922(ab)
Pounds, BK, 941(ab)
Powe, JE, 1113, 1627
Pozderac, RV, 799(ab)
Prasad, S, 873(ab), 905(ab)
Prasad, VMH, 940(ab)
Presant, CA, 813(ab)
Press, OW, 828(ab)
Preston, DF, 843(ab), 844(ab), 966(ab)
Prestwich, WV, 1036
Price, J, 740(ab)
Prigent, F, 729(ab), 750(ab), 780(ab), 1718
Prince, JR, 890(ab)
Proano, M, 764(ab)
Prosmanne, O, 944(ab)
Prudhomme, D, 886(ab)
Puccetti, DM, 799(ab)
Pupi, A, 820(ab), 880(ab)
Purut, CM, 420

Quadri, SM, 1693
Quarles, RP, 901(ab)
Quevedo, A, 734(ab)
Quint, RI, 1257

Rabinovitch, M, 810(ab)
Rabito, CA, 912(ab), 942(ab)
Radosevich, JA, 827(ab)
Radtke, RA, 752(ab)
Rafael, JA, 744(ab)
Raffel, D, 797(ab)
Raffel, DM, 1211
Raftery, EB, 868(ab)
Rahimtoola, SH, 821(ab)
Raichle, ME, 791(ab), 901(ab)
Rajagopalan, R, 937(ab)
Rajfer, J, 967(ab)
Rall, B, 739(ab)
Ram, S, 783(ab), 968(ab)
Ramanna, L, 734(ab), 844(ab), 853(ab), 915(ab)
Ramos-Gabatin, A, 1737(le)
Rancurel, G, 781(ab)
Ranganath, MV, 880(ab)
Ranger, NT, 1056
Rango, M, 811(ab), 898(ab)
Ransom, RW, 923(ab)
Rao, H, 564
Rao, S, 855(ab)
Rao, TN, 743(ab), 933(ab), 940(ab)
Rapoport, SI, 771(ab), 928(ab), 1386
Rasey, JS, 194, 342, 735(ab), 789(ab), 814(ab)
Ratib, O, 838(ab)
Ratliff, B, 779(ab)
Raubitshek, A, 672
Rauch, A, 731(ab), 834(ab)
Raval, B, 789(ab)
Ravert, H, 740(ab), 750(ab), 838(ab)
Ravert, HT, 731(ab), 741(ab), 849(ab), 929(ab), 930(ab), 931(ab)
Ray, DL, N1768
Raylman, RR, 892(ab)
Raymond, GM, 873(ab)
Raynaud, C, 731(ab), 781(ab), 810(ab), 812(ab), 877(ab)
Razumenic, N, 772(ab)
Rea, DW, 831(ab)
Real, FX, 746, 809(ab)
Reba, RC, 733(ab), 736(ab), 832(ab), 878(ab), 896(ab), 940(ab), 1079, 1693
Reddy, N, 887(ab)
Rees, M, 45
Regelmann, W, 967(ab)
Reggiani, P, 888(ab)
Rehm, PJ, 861(ab)
Rehm, PK, 759(ab)
Reiber, JHC, 806(ab)
Reiche, W, 841(ab)
Reichmann, K, 106
Reid, RC, 878(ab)
Reid, RH, 812(ab), 1621
Reidel, G, 531
Reifenrath, C, 829(ab)
Reijs, AEM, 806(ab)
Reilley, J, 88, 731(ab), 762(ab), 830(ab), 834(ab)
Reilly, J, 773(ab)
Reiner, BI, 412
Reiners, C, 845(ab), 886(ab)
Reiners, CHR, 867(ab)
Reinke, E, 935(ab)
Reisch, J, 771(ab)
Reitelman, C, 799(ab)
Reivich, M, 772(ab), 781(ab), 802(ab), 811(ab), 898(ab), 965(ab), 1607
Reker, DM, 840(ab)
Rembish, RA, 859(ab)
Reno, J, 793(ab), 933(ab)
Reno, JM, 25, 216
Reske, SN, 791(ab), 797(ab), 805(ab), 819(ab)
Respondek, M, 697
Resser, K, 740(ab)

Reubi, JC, 768(ab)
Reuland, P, 804(ab)
Reynolds, JC, 320, 903(ab), 906(ab), 909(ab), 915(ab), 1106, 1311, 1693
Rhamy, R, 841(ab)
Rhodes, CG, 808(ab)
Ricart, MJ, 1470
Richard, MD, 747(ab), 901(ab), 936(ab)
Riche, D, 762(ab)
Richman, P, 748(ab)
Richter, KY, 969(ab)
Riesen, A, 1235
Rifkin, MD, 901(ab)
Rigo, P, 791(ab), 1902
Rigo, PM, 1018
Rilinger, N, 748(ab)
Ritchie, J, 769(ab)
Ritter, W, 1235
Ritter-Hrncirik, CA, 747(ab), 963(ab)
Riva, P, 779(ab), 908(ab)
Rivera, J, 912(ab)
Rizzo, G, 869(ab)
Roa, PS, 741(ab)
Robb, SO, 918(ab)
Robb, T, 765(ab)
Robbins, MS, 937(ab)
Robbins, T, 850(ab)
Roberts, R, 749(ab)
Roberts, W, 759(ab), 883(ab), 884(ab), 918(ab)
Robertson, JM, 38
Robinson, D, 874(ab)
Robinson, DW, 917(ab)
Robinson, GD, 781(ab)
Robinson, R, 859(ab)
Robinson, RG, 843(ab), 844(ab), 966(ab)
Robinson, RP, 737(ab), 922(ab)
Robinson, WL, 251
Rocco, T, 740(ab)
Rocco, TP, 1149
Roddie, ME, 841(ab)
Rodman, MS, 794(ab)
Rodriguez, AA, 962(ab)
Roeske, J, 777(ab)
Roesler, H, 1960
Roger, P, 904(ab)
Rogers, L, 863(ab)
Rogers, PE, 374, 935(ab)
Rogers, VE, 873(ab)
Rogers, WL, 777(ab)
Rogic, M, 773(ab)
Roland, J, 794(ab)
Rollmann, O, 110
Romeral, LMD, 861(ab)
Rommer, P, 796(ab)
Rommney, B, 124
Roodt, A, 732(ab), 849(ab)
Roodt, JP, 914(ab)
Roosen, N, 895(ab)
Ropchan, J, 894(ab)
Rosa, C, 749(ab)
Rose, C, 810(ab)
Rose, P, 828(ab)
Rosebrough, SF, 747(ab), 963(ab)
Roselli, M, 320, 672
Rosen, CD, 857(ab)
Rosen, JM, 787(ab), 819(ab)
Rosen, M, 1607
Rosen, ST, 827(ab), 888(ab), 933(ab)
Rosenbaum, RC, 412
Rosenblum, M, 819(ab)
Rosenspire, KC, 735(ab), 752(ab), 767(ab), 783(ab)
Rosenstein, LM, 1574(le)
Rosenstein, N, 781(ab)
Rosenthal, MS, 875(ab)
Rosenthall, L, 810(ab)
Roskopf, M, 659
Ross, C, 731(ab)
Ross, PD, 1166, 1273
Rossetti, C, 792(ab), 831(ab)
Rossetti, E, 873(ab)
Rosso, J, 746(ab)
Roth, SC, 747(ab), 748(ab), 906(ab)
Rotmensch, J, 777(ab), 834(ab), 883(ab)
Rottenberg, DA, 564, 1483, 839(ab)
Rouleau, D, 766(ab)
Rovert, HT, 741(ab)
Rowe, CC, 751(ab), 831(ab)
Rowe, RW, 789(ab), 866(ab), 878(ab)
Rowell, N, 911(ab)
Roy, A, 181
Royston, I, 778(ab)
Rozanski, A, 729(ab), 740(ab), 750(ab), 1718
Rubin, RH, 385, 805(ab), 817(ab), 889(ab), 890(ab), 1095, 1538
Rubinstein,, M, 798(ab)
Rubinstein, M, 897(ab), 915(ab), 966(ab), 1337, 1982
Rubinstein, MI, 843(ab)
Ruch, J, 1079
Ruddy, T, 760(ab), 829(ab)
Ruether, W, 805(ab)
Rufini, V., 769(ab)
Ruhlmann, J, 805(ab), 856(ab)
Ruiz, M, 756(ab)
Rupich, R, 774(ab)
Rusckowski, M, 793(ab), 819(ab), 828(ab), 908(ab)
Rusinek, H, 835(ab)
Russell, CD, 823(ab), 943(ab), 1955, 2054
Russell, KJ, 814(ab)
Rust, M, 917(ab)
Ruth, TJ, 923(ab)
Rüther, W, 856(ab)
Ryan, JM, 868(ab)
Ryan, JP, 823(ab)
Ryan, JW, 883(ab)
Ryo, UY, 559, 836(ab), 918(ab)
Rysavy, JA, 876(ab)
Rytel, MW, 754(ab)

Sabha, M, 942(ab)
Sacker, DF, 831(ab), 1848
Sackett, JF, 965(ab)
Sadek, S, 921(ab), 968(ab)
Sadlo, HB, 749(ab)
Sadozt, B, 750(ab)
Sadzot, B, 740(ab), 849(ab)
Saga, T, 747(ab), 785(ab), 840(ab), 885(ab), 889(ab), 919(ab)
Sago, M, 767(ab)
Saha, G, 861(ab)
Saha, GB, 759(ab)
Said, J, 915(ab)
Saito, T, 739(ab), 762(ab)
Saji, H, 150, 803(ab), 863(ab), 866(ab), 900(ab), 1302, 1775
Sajjad, M, 922(ab), 1132
Sakahara, H, 747(ab), 1311
Sakai, K, 830(ab)
Sakamoto, J, 809(ab)
Sakata, K, 864(ab)
Sakata, S, 885(ab)
Sakharov, IY, 1686
Sakuma, S, 458
Salk, D, 818(ab), 819(ab)
Salvatore, M, 51, 941(ab), 1422(le)
Samaratunga, RC, 837(ab)
Samejima, N, 738(ab)
Sampathkumaran, KS, 2036
Samuels, LD, 267
Sanders, JA, 1412
Sanders, WE, Jr, 1405
Sanderson, J, 793(ab), 933(ab)
Sanderson, L, 833(ab)
Sandler, MP, 15, 563, 1917(le)
Sanger, JJ, 835(ab)
Santoro, GM, 820(ab)
Saris, SC, 839(ab), 899(ab)
Sarti, G, 779(ab)
Sartori, CG, 925(ab)
Sasaki, H, 878(ab), 917(ab)
Sasaki, Y, 895(ab)
Sato, N, 746(ab)
Sato, T, 739(ab), 2012
Sato, Y, 916(ab)
Savage, S, 756(ab)
Savi, A, 869(ab)
Savino, P, 772(ab), 802(ab)
Savoie, JC, 2063(le)
Savolainen, S, 1546
Savory, CG, 1321
Sax, FL, 780(ab)
Sayle, BA, 57
Scassellati, GA, 908(ab)
Schaible, TF, 787(ab)
Schapiro, MB, 771(ab)
Schatz, N, 772(ab)
Scheffel, UA, 803(ab)
Scheidler, J, 907(ab)
Schelberg, HR, 359
Schelbert, H, 729(ab)
Schelbert, HR, 735(ab), 824(ab), 837(ab), 838(ab), 846(ab), 867(ab)
Schicha, H, 842(ab), 843(ab), 903(ab)
Schiefelbein, M, 843(ab)
Schiepers, CW, 824(ab), 886(ab)
Schiepers, CWJ, 821(ab)
Schifelbein, M, 844(ab)
Schijf, Ch, 758(ab)
Schiyer, DJ, 893(ab), 898(ab), 932(ab)
Schlag, P, 789(ab), 910(ab), 911(ab)
Schlemper, EO, 938(ab)
Schlessel, JS, 1342
Schlom, J, 320, 672
Schlyer, D, 730(ab), 761(ab)
Schlyer, DJ, 741(ab), 776(ab)
Schmall, B, 928(ab)
Schmid, U, 390
Schmidt, RP, 836(ab)
Schmidt, U, 798(ab), 800(ab)
Schneidau, TA, 1079
Schneider, RF, 940(ab)
Schneider, V, 775(ab)
Schnur, G, 813(ab)
Schnur, W, 903(ab)
Schober, O, 856(ab), 880(ab)
Schoeps, K-O, 783(ab)
Schoser, K, 813(ab)
Schoukroun, C, 766(ab)
Schraube, P, 911(ab)
Schroder, LE, 837(ab)
Schroeder, KW, 764(ab)
Schroff, R, 779(ab), 933(ab)
Schroff, RW, 25
Schultheis, P, 847(ab)
Schwaiger, M, 359, 735(ab), 767(ab), 829(ab), 837(ab), 860(ab), 862(ab), 892(ab), 930(ab)
Schwartz, AN, 466, 784(ab)
Schwartz, C, 843(ab)
Schwarz, A, 904(ab)
Schwarzrock, R, 1278(le)
Schweighardt, S, 748(ab)
Schwender, SW, 849(ab), 1088
Schwendner, SW, 768(ab)
Schwesinger, WH, 815(ab)
Schyler, D, 801(ab)
Sciacca, B, 863(ab)
Sciagrà, R, 820(ab)
Sciammarella, M, 873(ab)
Sciuk, J, 856(ab)
Scott, JA, 556
Scott, PL, 832(ab)
Scrimger, J, 2063(le)
Scrimger, JW, 260
Seabold, J, 268
Seabold, JE, 754(ab), 1264
Sease, D, 859(ab), 866(ab)
Sease, DR, 865(ab)
Sebree, L, 797(ab)
Seccamani, E, 908(ab)
Sechtem, U, 903(ab)
Secter, B, 914(ab)
Sedvall, G, 742(ab)
Seeger, LL, 1136
Segall, GM, 548, 1738(le)
Sekel, R, 754(ab)
Sekela, ME, 780(ab)
Seki, H, 997
Seldin, DW, 312
Sell, TL, 420
Senda, M, 776(ab), 782(ab), 916(ab), 961(ab), 1302
Senekowitsch, R, 531
Seo, IS, 732(ab)
Seo, S, 1809
Sephton, RG, 913(ab)
Serafini, A, 798(ab), 841(ab), 859(ab), 915(ab), 944(ab)
Serafini, AN, 737(ab), 748(ab), 890(ab), 921(ab), 922(ab), 1935
Serafini, F, 911(ab)
Sergienko, VB, 1686
Sergott, R, 772(ab), 802(ab)
Ser. JB, 905(ab)
Servis, KL, 813(ab), 814(ab)
Seto, M, 844(ab)
Setoain, J, 1470
Severson, AR, 857(ab)
Sevrin, R, 1616
Sfakianakis, CN, 841(ab)
Sfakianakis, G, 859(ab), 890(ab), 963(ab)
Sfakianakis, GN, 737(ab), 798(ab), 886(ab), 893(ab), 915(ab), 922(ab)
Sfakinakis, GN, 944(ab)
Sgouros, G, 777(ab)
Shafer, RB, 918(ab)
Shafique, I, 885(ab)
Shah, A, 905(ab)
Shaheen, OH, 174
Sham, JST, 918(ab)
Shankland, EG, 814(ab)
Shankwiler, RA, 1577
Shapiro, B, 481, 833(ab), 836(ab), 850(ab), 1476
Sharir, T, 1657
Sharkey, RM, 809(ab), 826(ab), 828(ab), 848(ab), 888(ab), 962(ab)
Sharp, PF, 1134
Shatkin, B, 165
Shaw, SM, 920(ab)
Shealy, D, 833(ab)
Shearman, D, 765(ab), 795(ab), 887(ab)
Shefer, RE, 964(ab)
Sheldon, J, 849(ab)
Shelton, DK, 959(ab)
Shelton, ME, 351, 730(ab), 768(ab), 807(ab), 1843
Shen, W, 751(ab)
Shen, Y, 770(ab)
Shepherd, J, 758(ab)
Shepstone, BJ, 1420(le)
Sherman, CT, 838(ab)
Sherman, PS, 733(ab), 752(ab), 767(ab), 783(ab), 930(ab), 932(ab)
Sherwood, DF, 868(ab)
Shewmon, DA, 896(ab)
Shiba, K., 897(ab), 939(ab)
Shibasaki, T, 895(ab)
Shida, K, 802(ab)
Shields, AF, 789(ab)
Shih, W-J, 559, 918(ab)
Shihab-Eldeen, A, 921(ab)
Shimizu, K, 746(ab)
Shimoni, A, 450
Shin, SY, 1693
Shinohara, M, 2042
Shionoya, S, 358
Shishdo, F, 830(ab)
Shiue, C, 730(ab)
Shiue, C-Y, 753(ab), 898(ab), 932(ab)
Shlomo, IB, 1657
Shmerling, RH, 855(ab)
Shnyra, AA, 66
Shochat, D, 933(ab)
Shoop, JD, 567
Short, M, 808(ab), 809(ab), 908(ab)
Short, MD, 891(ab)
Shuke, N, 997, 844(ab), 903(ab), 909(ab), 915(ab)
Shuler, SE, 786(ab)

Shulgin, A, 822(ab)
Shulkin, BL, 843(ab), 1819
Sia, B, 751(ab), 831(ab)
Sicat, M, 749(ab), 862(ab)
Siccardi, AG, 749(ab)
Siddiqui, AR, 799(ab)
Siegel, BA, 788(ab)
Siegel, JA, 764(ab), 782(ab), 794(ab), 960(ab)
Siegel, ME, 821(ab), 824(ab), 886(ab)
Siegel, R, 750(ab)
Siffring, PA, 730(ab)
Sigal, SL, 863(ab)
Sigurdson, ER, 809(ab)
Silberstein, EB, 748(ab), 774(ab), 903(ab)
Silbiger, M, 759(ab), 883(ab), 884(ab), 918(ab)
Silbiger, ML, 876(ab)
Silverstein, EA, 874(ab), 888(ab)
Simon, H, 739(ab)
Simon, TR, 542, 861(ab)
Simonson, RB, 778(ab)
Simpfendorfer, CC, 759(ab)
Simpkin, DJ, 883(ab)
Simpson, NR, 928(ab)
Sindelar, W, 320
Singer, H., 731(ab)
Singh, A, 1814
Singh, M, 851(ab)
Singletary, E, 819(ab)
Sintsyn, VV, 66
Sinusas, AJ, 756(ab), 790(ab), 1456
Sinzinger, H, 1005
Sirr, SA, 858(ab), 1133, 1399
Sisson, JA, 481
Sisson, JC, 767(ab), 884(ab), 1476
Sivolapenko, GB, 1636
Sjögren, H-O, 1224
Skinner, RWS, 768(ab)
Skrade, B, 770(ab)
Slade, S, 778(ab)
Slater, JB, 894(ab)
Slichter, SJ, 629
Slinkin, MA, 1686
Slizofski, WJ, 1739(le)
Sloan, G, 799(ab)
Sloboda, R, 266
Sloboda, RS, 836(ab)
Smalling, RW, 846(ab)
Smart, R, 754(ab), 764(ab), 887(ab)
Smart, RC, 851(ab)
Smeltzer, SL, 845(ab)
Smith, AP, 796(ab)
Smith, GG, 967(ab)
Smith, GJW, 916(ab)
Smith, GS, 771(ab)
Smith, GT, 877(ab), 960(ab)
Smith, H, 873(ab)
Smith, HE, 803(ab)
Smith, J, 836(ab)
Smith, JJ, 941(ab)
Smith, KF, 312
Smith, L, 906(ab)
Smith, Q, 838(ab)
Smith, R, 917(ab)
Smith, RH, 832(ab)
Smith, T, 818(ab)
Smith, WH, 756(ab), 790(ab), 1456
Smitherman, TC, 542, 861(ab)
Smits, P, 861(ab), 1723
Smye, SW, 45
Snape, W, 887(ab)
Snook, D, 1636
Snyder, AL, 771(ab)
Soares, J, 841(ab)
Soares, J, Jr, 916(ab)
Sobel, BE, 837(ab), 1489, 1798
Sobnack, R, 748(ab)
Sobotka, PA, 1870
Soini, I, 1332
Sokoloff, L, 792(ab)
Solanki, K, 823(ab)
Solomon, H, 849(ab)
Solomon, HF, 741(ab), 923(ab), 930(ab), 931(ab)
Solomon, RW, 737(ab), 785(ab), 815(ab)
Solot, G, 757(ab)
Som, P, 831(ab), 1848
Sondel, J, 818(ab)
Sonnemaker, R, 786(ab)
Sood, A, 834(ab)
Sood, V, 1079
Sood, VK, 940(ab)
Soper, NDW, 1420(le)
Sorby, PJ, 683
Sorgentoni, K, 731(ab), 811(ab), 834(ab)
Sostre, S, 885(ab)
Soucy, JP, 781(ab)
Sowton, E, 820(ab)
Spaulding, M, 818(ab)
Spehl, M, 915(ab), 1337
Speller, RD, 891(ab)
Spence, AM, 838(ab), 911(ab)
Spencer, P, 760(ab)
Spencer, RP, 737(ab)
Spicer, JA, 843(ab), 844(ab), 1281
Spicer, KM, 872(ab)
Spies, SM, 827(ab), 888(ab), 933(ab), 874(ab)(ab)
Spies, WG, 827(ab), 874(ab), 888(ab), 933(ab)
Spinelli, A, 779(ab)
Spranzi, E, 908(ab)
Squicciarini, SA, 829(ab)
Srinivasan, A, 25, 793(ab), 933(ab), 940(ab)
Srivasatava, SC, 1848
Srivastava, PC, 925(ab)
Srivastava, SC, 787(ab), 811(ab), 890(ab), 921(ab), 923(ab), 934(ab), 935(ab)
Stabin, M, 415, 833(ab)
Stabin, MG, 599, 763(ab), 2002
Stadalnik, RC, 269, 733(ab), 814(ab), 879(ab), 1519
Stambler, BS, 870(ab)
Stanchfield, WR, 1399
Standke, RH, 295
Stanley, PC, 852(ab)
Stark, V, 833(ab), 883(ab)
Starling, MR, 1737(le)
Starr, CW, 872(ab)
Stathis, M, 803(ab)
Stauber, RE, 814(ab), 887(ab), 890(ab)
Staudacher, RS, 760(ab)
Stedman, RJ, 936(ab)
Stefan, H, 751(ab)
Stehlin, JS, 25
Stein, E, 845(ab)
Steinberg, ME, 733(ab)
Steiner, M, 731(ab)
Steis, RG, 909(ab)
Stella, A, 615
Stephens, R, 828(ab)
Steplewski, Z, 763(ab), 923(ab), 934(ab), 935(ab)
Stevens, S, 828(ab)
Stevenson, LW, 846(ab), 867(ab)
Stewart, CA, 824(ab), 857(ab), 886(ab)
Stewart, R, 793(ab)
Stewart, RE, 829(ab), 850(ab), 860(ab)
Stickney, DR, 905(ab)
Stochl, M, 908(ab)
Stöcklin, G, 110, 895(ab), 1367
Stokely, EM, 638
Stone-Elander, S, 927(ab)
Stoub, EW, 2029
Strand, S-E, 722, 1224
Strashun, A, 855(ab), 1445
Strashun, AM, 1563
Stratton, JR, 629
Straub, RF, 811(ab)
Strauss, A, 777(ab), 833(ab)
Strauss, EB, 1111
Strauss, HW, 301, 385, 729(ab), 734(ab), 739(ab), 740(ab), 762(ab), 797(ab), 805(ab), 817(ab), 859(ab), 868(ab), 869(ab), 889(ab), 890(ab), 901(ab), 913(ab), 917(ab), 1095, 1123, 1149, 1538, 1911
Strauss, J, 798(ab), 841(ab), 915(ab)
Strauss, LG, 784(ab), 789(ab), 909(ab), 910(ab), 911(ab)
Straw, J, 787(ab)
Stremmel, W, 798(ab)
Stringham, LM, 1814
Stritzke, P, 599, 785(ab)
Stritzke, PH, 1875
Strnat, MAP, 847(ab)
Stroble, MB, 781(ab)
Strother, SC, 564, 839(ab), 1483
Stroupe, SD, 908(ab)
Strubel, T, 773(ab)
Strubel, TW, 937(ab)
Stuart, DD, 1399
Stubbs, CC, 764(ab)
Stubbs, JB, 764(ab), 882(ab)
Studer, A, 1646
Stulzaft, O, 731(ab), 898(ab)
Stumpf, MJ, 816(ab)
Stunkard, AJ, 692
Stuttle, AWJ, 738(ab)
Stuyck, J, 2022
Styles, J, 808(ab), 809(ab)
Su, FM, 793, 849(ab)
Subramanian, G, 659, 940(ab)
Subramanian, K, 963(ab)
Subramanian, R, 797(ab)
Suehiro, M, 919(ab)
Suematsu, T, 853(ab)
Suess, E, 731(ab)
Suetens, P, 871(ab), 1992
Sugarbaker, P, 320
Sugimoto, H, 822(ab)
Sukalac, R, 817(ab)
Sullivan, MJ, 843(ab)
Sullivan, TJ, 959(ab)
Summers, D, 2063
Sumerdon, GA, 908(ab), 935(ab)
Sumida, R, 791(ab)
Summerville, DA, 1176
Sun, L, 794(ab)
Sun, LK, 934(ab)
Sun, TTH, 763(ab), 935(ab)
Sun, Y, 763(ab)
Sunderland, JJ, 745(ab), 927(ab), 930(ab)
Suneja, SK, 113
Surachno, J, 785(ab)
Susskind, H, 830(ab), 1342
Sutorik, A, 926(ab)
Suzuki, A, 770(ab)
Suzuki, N, 813(ab)
Suzuki, T, 914(ab)
Svensson, W, 813(ab)
Swanson, D, 797(ab)
Swanson, W, 789(ab)
Swayne, LC, 850(ab), 874(ab), 1408
Swinford, RD, 165
Swyer, AJ, 754(ab)
Sy, WM, N431, 734(ab), 1919
Sychra, JJ, 364(ab)
Syrjälä, MT, 1546
Syrota, A, 731(ab), 766(ab), 810(ab), 812(ab), 825(ab), 877(ab), 897(ab), 898(ab)
Szabò, Z, 829(ab)
Szilvasi, I, 748(ab)

Tabata, R, 914(ab)
Tada, M, 2012
Taddei, G, 735(ab)
Taegtmeyer, HT, 789(ab)
Taguchi, T, 864(ab)
Tahara, T, 802(ab)
Tai, K, 734(ab)
Taillefer, R, 759(ab), 790(ab), 865(ab), 1902
Tak, T, 821(ab)
Takada, Y, 853(ab)
Takagi, H, 743(ab)
Takahashi, A, 830(ab)
Takahashi, H, 858(ab)
Takahashi, K, 878(ab)
Takahashi, M, 258, 508
Takahashi, T, 739(ab), 917(ab), 944(ab), 2012
Takahasi, T, 33
Takano, H, 767(ab)
Takashashi, T, 770(ab)
Takayama, T, 997
Takehara, Y, 258
Takemura, Y, 923(ab)
Takeshita, G, 897(ab)
Takeuchi, A, 897(ab)
Taki, J, 844(ab), 870(ab)
Taki, S, 844(ab)
Takishima, T, 770(ab), 917(ab), 944(ab)
Tal, I, 874(ab)
Talbot, JN, 855(ab)
Tamaki, N, 718, 862(ab), 863(ab), 866(ab), 887(ab), 1302, 1775
Tamura, K, 853(ab)
Tan, P, 964(ab)
Tanabe, M, 858(ab)
Tanada, S, 150, 760(ab), 792(ab), 805(ab), 864(ab), 878(ab), 943(ab)
Tanaka, E, 746(ab), 870(ab), 892(ab)
Tanaka, T(ab), A811(ab)
Tani, A, 868(ab), 881(ab)
Tanigaki, S, 965(ab)
Taniguchi, M, 870(ab)
Taren, J, 833(ab)
Tashiro, K, 866(ab)
Tateno, M, 895(ab)
Tateno, Y, 866(ab), 885(ab)
Tattanelli, M, 908(ab)
Tatum, JL, 1257
Taupier, MA, 886(ab)
Tauxe, NW, 864(ab)
Tauxe, WN, 814(ab), 887(ab), 890(ab), 905(ab)
Tawk, TC, 761(ab)
Taylor, A, 943(ab), 1955
Taylor, A, Jr, 720, 823(ab)
Taylor, AT, 743(ab)
Taylor-Papadimitriou, J, 758(ab)
Teal, JS, 113
Teaster, B, 924(ab)
Tebbe, U, 800(ab)
Teixeira, JM, 867(ab)
Teixeira, LR, 916(ab)
Telepak, RJ, 1737(le)
Templeton, GH, 638
Temponi, M, 390, 936(ab)
Tenorio, L, 759(ab), 884(ab)
Tenorio, LE, 918(ab)
Terada, H, 897(ab)
Teran, JL, 800(ab)
Teras, M, 892(ab)
Terra-Filho, M, 916(ab)
Terui, S, 904(ab), 1198
Tewson, T, 909(ab), 966(ab)
Tewson, TJ, 789(ab), 928(ab)
Thakur, ML, 747(ab), 901(ab), 936(ab)
Theissen, P, 842(ab), 843(ab), 903(ab)
Théroux, P, 800(ab)
Thieme, AM, 821(ab)
Thien, T, 1723
Thomas, C, 879(ab)
Thomas, DGT, 1636
Thomas, FD, 659, 881(ab), 940(ab), 961(ab)
Thomas, SR, 732(ab), 1117
Thomas, WC, Jr, 842(ab)
Thomforde, GM, 764(ab)
Thompson, C, 806(ab)
Thompson, CJ, 765(ab), 1056
Thonnart, B, 820(ab)
Thonoor, CM, 1916(le)
Thoolen, M, 773(ab)
Thoolen, MJ, 787(ab)
Thornton, B, 780(ab)

Thorpe, H, 923(ab)
Thurber, M, 756(ab)
Ticheler, C, 885(ab)
Tikofsky, RS, 599
Tilbury, R, 909(ab), 928(ab), 966(ab)
Tilbury, RS, 1136
Tilyou, SM, N137, N139, N271, N279, N427, N435 N569, N987, N1139, N1141, N1435, N1579, N1761
Tilyou, T, N11
Timmis, AD, 820(ab)
Tindel, NL, 753(ab)
Tintner, R, 771(ab)
Tirindelli, D, 779(ab)
Titelbaum, DS, 1113
Tjoe, M, 886(ab)
Tobes, MC, 1476
Todd, CEC, 1318
Todd-Pokropek, A, 807(ab)
Todd-Pokropek, AE, 893(ab), 963(ab)
Togashi, M, 2042
Toita, T, 858(ab)
Tolman, GL, 1351
Toman, AS, 779(ab)
Tomitani, T, 746(ab), 776(ab)
Tomiyoshi, K, 895(ab)
Tompkins, RG, 889(ab), 1538
Tonami, N, 844(ab), 870(ab), 907(ab), 997
Tonan, AS, 758(ab)
Tondeur, M, 798(ab), 915(ab), 966(ab), 1337, 1825
Toney, MA, 962(ab)
Toorongian, S, 752(ab)
Toorongian, SA, 926(ab)
Topitz, A, 731(ab)
Topol, EJ, 862(ab)
Toporoff, SJ, 845(ab)
Toppet, V, 915(ab), 1337
Tor, Y, 106
Torchilin, V, 762(ab)
Torchilin, VP, 1686
Torizuka, K, 840(ab)
Torizuka, T, 718
Toyama, H, 870(ab), 897(ab)
Tracey, KP, 914(ab)
Treffert, JD, 2029
Tremaine, WJ, 764(ab)
Trentham, DE, 855(ab)
Tresgallo, M, 863(ab)
Treves, ST, 1176
Triebel, JG, 542
Troncone, L, 769(ab)
Trouet, A, 788(ab)
Troutner, DE, 832(ab), 938(ab), 939(ab)
Trudeau, WL, 733(ab), 879(ab)
Trumoer, J, 538
Trumper, J, 450
Tsai, D, 809(ab), 850(ab)
Tschudy, J, 797(ab)
Tse, JW, 202
Tsen, O, 833(ab)
Tsui, BMW, 497, 755(ab), 756(ab), 835(ab), 882(ab), 891(ab)
Tsuji, S, 897(ab)
Tudor, S, 1574(le)
Tulchinsky, M, 733(ab), 941(ab)
Tulip, TH, 773(ab)
Tumeh, SS, 821(ab), 842(ab)
Tune, L, 731(ab)
Tune, LE, 731(ab)
Tung, C, 755(ab)
Tupper, LK, 961(ab)
Turnbull, GL, 962(ab)
Turner, DA, 902(ab)
Turner, FE, 767(ab), 1182
Turner, JH, 683
Tweddel, AC, 818(ab)
Tyldesley, S, 923(ab)
Tyson, I, 759(ab), 883(ab), 884(ab)
Tyson, IB, 918(ab)
Tzourio, N, 781(ab), 812(ab), 877(ab)

Uchida, H, 892(ab)
Udelsman, R, 1420(ie)
Uebis, R, 791(ab)
Ueda, N, 918(ab)
Uehara, T, 591, 739(ab), 767(ab), 901(ab), 1713
Uematsu, S, 865(ab)
Uematu, S, 738(ab), 910(ab)
Uemura, K, 830(ab), 878(ab)
Ueno, T, 811(ab)
Uhland, W, 826(ab)
Ultee, ME, 778(ab), 831(ab)
Umbricht, G, 848(ab)
Umezaki, N, 942(ab)
Underwood, DA, 759(ab), 861(ab)
Unger, B, 906(ab)
Unger, EF, 807(ab)
Unger, M, 905(ab)
Unger, MW, 748(ab)
Uno, K, 738(ab), 858(ab), 910(ab)
Uno, Y, 838(ab)
Urbain, JL, 795(ab)

Vaalburg, W, 789(ab), 929(ab)
Vacher, J, 766(ab)
Vadhan, S, 738(ab)
Vahabzadeh, MR, 940(ab)
Valenzuela, GA, 764(ab)
Valette, H, 810(ab)
Valk, PE, 745(ab), 760(ab), 765(ab)
Valkema, R, 775(ab)
Vallabhajosula, S, 599, 785(ab), 856(ab), 1445
Valle, G, 917(ab), 965(ab)
Valois, JM, 825(ab), 877(ab)
VanBrocklin, HF, 753(ab), 821(ab), 910(ab), 928(ab)
van Buul, M, 780(ab)
van Buul, MMC, 785(ab)
Van den Abbeele, AD, 883(ab), 932(ab)
Vander Borght, T, 815(ab), 929(ab)
van der Hem, GK, 605, 1219
Vanderheyden, J-L, 743(ab), 779(ab), 793(ab), 849(ab), 933(ab)
van der Mey, AGL, 769(ab)
van der Schoot, J, 780(ab)
Vandevivere, J, 794(ab), 817(ab), 818(ab), 1025
Van Dort, M, 733(ab), 859(ab)
Van Dort, ME, 752(ab), 767(ab), 783(ab)
van Gils, APG, 769(ab)
Van Heertum, RL, 748(ab), 811(ab), 1018
van Kroonenburgh, MJPG, 769(ab), 889(ab), 2017
van Luijk, WHJ, 1219
Van Moffaert, G, 752(ab)
Van Nerom, C, 743(ab), 936(ab), 940(ab)
Van Nostrand, D, 1321
Vanoverschelde, JL, 797(ab)
VanPachterbeke, T, 915(ab), 1337, 1982
Vanregemorter, J, 875(ab)
van Royen, EA, 780(ab), 781(ab), 785(ab)
Van Thiel, DH, 814(ab), 887(ab), 890(ab)
Van Train, D, 729(ab)
Van Train, K, 739(ab), 750(ab), 757(ab), 795(ab), 1718
Van Train, KF, 780(ab)
Vantrappen, G, 795(ab)
van Vlies, B, 780(ab)
van Weeren, FH, 650
Vaquer, R, 855(ab), 1445
Vaquer, RA, 1563
Vargas, FS, 916(ab)
Varheyen, R, 758(ab)
Vassiliadis, J, 834(ab)
Vassos, A, 778(ab)
Vaughan, ATM, 843(ab), 933(ab)
Vaupel, P, 913(ab)
Vazquez, S, 741(ab)
Vecchietti, G, 779(ab)
Vedernikov, AY, 1686
Vega, A, 754, 804(ab)
Vekshtein, VI, 821(ab)
Vela, S, 2046
Velchik, MG, 328, 692, 731(ab), 754(ab), 834(ab), 884(ab), 1106
Ven, Hvd, 922(ab)
Venant, P, 810(ab)
Venkatesan, P, 779(ab), 793(ab)
Vera, DR, 733(ab), 814(ab), 879(ab), 1519
Verani, MS, 749(ab), 760(ab), 780(ab), 1405
Verba, J, 894(ab)
Verbeeten, B, 781(ab)
Verbruggen, A, 743(ab), 936(ab), 940(ab), 2022
Verhagen, A, 829(ab)
Verhoye, CM, 879(ab)
Verreault, J, 117
Verrey, B, 766(ab)
Verstraeten, F, 798(ab), 1825
Verweij, A, 806(ab)
Vessella, RL, 826(ab), 906(ab)
Vester, EG, 829(ab)
Veyre, A, 295, 865(ab), 871(ab)
Vieras, F, 941(ab)
Vigus, L, 760(ab)
Vik-Mo, H, 1972
Villablanca, JP, 906(ab)
Villanueva-Meyer, J, 806(ab), 864(ab), 887(ab), 967(ab)
Villemagne, V, 741(ab)
Vinitski, S, 901(ab)
Vinson, EL, 1456
Vinter, D, 883(ab)
Virzi, F, 793(ab)
Visser, TJ, 768(ab)
Vitti, RA, 764(ab), 782(ab), 794(ab)
Vogel, JM, 1166, 1273
Volkert, WA, 874(ab), 877(ab), 920(ab), 938(ab), 939(ab), 966(ab), 1814
Volkman, R, 858(ab)
Volkow, N, 741(ab), 771(ab), 898(ab)
Volkow, ND, 730(ab), 761(ab), 801(ab), 830(ab), 831(ab), 898(ab)
Volpe, M, 51, 941(ab)
von Eschenbach, A, 836(ab)
von Rensburg, AJ, 914(ab)
Voorhees, WD, 848(ab)
Vorne, M, 1332
Vorstman, B, 841(ab)
Vosberg, H, 829(ab)
Voth, E, 757(ab), 800(ab)
Vowden, P, 45
Vuletich, T, 765(ab)
Vyska, K, 798(ab), 800(ab)

Wackers, FJ, 770(ab), 800(ab), 863(ab)
Wackers, FJT, 301
Waddington, W, 808(ab), 809(ab), 908(ab)
Waddington, WA, 891(ab)
Wagner, H, Jr, 838(ab)
Wagner, HN, Jr, 731(ab), 740(ab), 741(ab), 750(ab), 803(ab), 816(ab), 849(ab), 885(ab), 929(ab), 930(ab), 931(ab), N1283
Wagner, JG, 815(ab)
Wagner, RH, 1577, 1870
Wahl, RL, 60, 759(ab), 777(ab), 793(ab), 815(ab), 832(ab), 847(ab), 850(ab), 884(ab), 912(ab)
Wahner, HW, 1918
Wakita, K, 783(ab), 866(ab)
Walker, BS, 542, 861(ab)
Walker, KZ, 683
Walker, MR, 933(ab)
Walker, PJ, 872(ab)
Walker-Andrews, S, 836(ab)
Wall, RM, 312
Wallace, S, 901(ab), 1012
Wallach, SM, 937(ab)
Wallis, JW, 781(ab), 808(ab), 834(ab), 2036
Walovitch, RC, 792(ab), 870(ab), 1892, 1902
Walroth, J, 873(ab)
Walsh, MN, 837(ab), 1489, 1798
Walsh, R, 860(ab)
Walsh, RA, 792(ab)
Waltman, A, 734(ab)
Wang, F, 700
Wang, L, 851(ab)
Wang, S-C, 840(ab)
Wang, SJ, 871(ab), 1708
Wang, TST, 787(ab), 819(ab), 936(ab)
Ware, RW, 1737(le)
Wasfie, T, 890(ab)
Washburn, LC, 763(ab), 935(ab)
Wasnich, RD, 1166, 1273
Watanabe, H, 824(ab)
Watanabe, K, 157, 337, 1101
Watanabe, M, 796(ab)
Watanabe, T, 737(ab)
Watanabe, Y, 747(ab), 785(ab), 840(ab), 885(ab), 889(ab), 919(ab)
, 997Watanuki, S, 33, 1809
Watanuki S, 788(ab)
Watkins, GL, 822(ab)
Watkinson, JC, 174
Watson, AD, 1892
Watson, DD, 301, 756(ab), 790(ab), 1456
Watson, EE, 1117, 2002
Watson, I, 911(ab)
Waxman, A, 1718
Waxman, AD, 734(ab), 844(ab), 853(ab), 915(ab)
Weadock, K, 904(ab)
Weadock, KS, 933(ab)
Webber, DI, 827(ab), 888(ab), 933(ab)
Webbon, P, 773(ab)
Weber, DA, 796(ab), 811(ab), 830(ab), 831(ab), 875(ab), 1117
Weber, KA, 756(ab)
Weber, P, 934(ab)
Weber, R, 793(ab), 934(ab)
Wedeking, P, 1830
Weiden, P, 779(ab)
Weiland, FL, 1737(le)
Weinberg, IN, 791(ab)
Weinberger, DR, 896(ab)
Weiner, MF, 771(ab)
Weiner, RE, 70
Weinheimer, CJ, 807(ab), 1798
Weiniger, J, 538
Weinmann, P, 810(ab)
Weinstein, JN, 903(ab)
Weise, S, 961(ab)
Weise, SB, 782(ab)
Welch, M, 1205
Welch, MJ, 351, 730(ab), 732(ab), 753(ab), 763(ab), 768(ab), 788(ab), 791(ab), 804(ab), 807(ab), 821(ab), 822(ab), 848(ab), 901(ab), 910(ab), 922(ab), 926(ab), 928(ab), 930(ab), 931(ab), 964(ab), 968(ab), 1843
Wellens, HJJ, 791(ab)
Weller, R, 835(ab), 1393
Weller, S, 804(ab)
Wellman, HN, 751(ab), 799(ab)
Welt, S, 746(ab), 809(ab)
Weltman, R, 765(ab)

Wernicke, PG, 843(ab)
Wernovsky, G, 1176
Wessels, BW, 777(ab), 826(ab), 827(ab)
Wester, DW, 940(ab)
Wetzel, E, 910(ab)
White, DL, 968(ab)
White, JA, 805(ab)
White, M, 760(ab)
White, TA, 892(ab)
White DL, 840(ab)
Widén, L, 927(ab)
Wiebe, LI, 202
Wieland, DM, 733(ab), 735(ab), 752(ab), 767(ab), 783(ab), 859(ab), 929(ab)
Wiens, L, 814(ab)
Wierenga, RA, 789(ab)
Wierzbinski, B, 918(ab)
Wiese, H, 1278(le)
Wijnhoven, GPJ, 650
Wijns, W, 797(ab)
Wilbur, DS, 25, 216, 793(ab), 832(ab), 924(ab), 932(ab)
Wilkening, D, 793(ab)
Wilkinson, D, 45
Wilkinson, R, 385, 1095
Wilkinson, RA, 805(ab), 889(ab), 890(ab), 913(ab), 917(ab), 1538
Willerson, JT, 770(ab), 810(ab)
Williams, A, 1814
Williams, CC, 837(ab)
Williams, CM, 842(ab), 1916(le)
Williams, JH, Jr, 1581
Williams, KA, 788(ab), 868(ab)
Williams, LE, 1373
Williams, SJ, 1892
Wilson, A, 838(ab)
Wilson, AA, 731(ab), 740(ab), 741(ab), 750(ab), 849(ab), 930(ab), 931(ab), 929
Wilson, AF, 1531
Wilson, DG, 914(ab)
Wilson, HH, 852(ab)
Wilson, MA, 965(ab)
Wilson, PD, 731(ab)
Wilson, RA, 767(ab), 1172
Winker, KH, 804(ab)
Winkler, C, N1765
Winzelberg, GC, 419
Wiseman, C, 813(ab)
Wishart, J, 765(ab), 795(ab), 887(ab)
Wissing, JR, 227
Witanowski, LS, 961(ab)
Witherspoon, LR, 786(ab), 1571
Withiam, M, 934(ab)
Witsenboer, TJ, 650
Wlodkowski, T, 748(ab)
Wolf, AP, 730(ab), 741(ab), 753(ab), 761(ab), 771(ab), 776(ab), 782(ab), 783(ab), 801(ab), 821(ab), 898(ab), 932(ab)
Wolf, F, 751(ab)
Wolf, W, 813(ab), 814(ab)
Wolfangel, RG, 811(ab)
Wolfstein, I, 768(ab)
Wollenhaupt, J, 842(ab)
Wong, C, 739(ab), 757(ab), 795(ab)
Wong, DF, 731(ab), 741(ab), 930(ab)
Wong, JYC, 1373
Wong, LF, 845(ab)
Wong, WH, 880(ab), 964(ab)
Wood, MJ, 968(ab)
Woodhouse, C, 793(ab)
Woodhouse, CS, 25
Woodle, ES, 1519
Woods, M, 793(ab)
Woods, SD, 735(ab), 789(ab), 873(ab)
Woodward, WR, 1182
Woolfenden, JM, 891(ab)
Wooten, WW, 720
Wootton, R, 847(ab)
Worth, RM, 751(ab)
Woulfe, S, 773(ab)
Woulfe, SR, 937(ab)
Wright, DC, 839(ab), 899(ab)
Wright, SD, 852(ab)
Wu, J-C, 1708
Wu, LC, 871(ab), 1708

Xia, N, 861(ab)

Yacoub, T, 968(ab)
Yagyu, T, 783(ab)
Yamada, K, 902(ab)
Yamada, L, 1616
Yamada, M, 792(ab), 805(ab), 878(ab), 943(ab)
Yamada, N, 921(ab)
Yamada, S, 902(ab)
Yamada, T, 862(ab)
Yamagishi, H, 866(ab)
Yamaguchi, K, 33
Yamamoto, H, 904(ab), 1198
Yamamoto, K, 887(ab)
Yamamoto, M, 746(ab)
Yamamoto, S, 1464
Yamamoto, YL, 913(ab)
Yamasaki, T, 866(ab), 892(ab)
Yamashita, K, 863(ab), 866(ab), 1302, 1775
Yamashita, M, 824(ab), 866(ab)
Yamashita, T, 746(ab), 892(ab)
Yamazaki, K, 738(ab)
Yamazaki, N, 70, 864(ab)
Yamazaki, S, 965(ab)
Yamazaki, T, 914(ab)
Yan, Y, 824(ab)
Yanai, K, 741(ab)
Yanai, M, 917(ab)
Yang, CJC, 1264
Yang, F, 759(ab)
Yang, FE, 777(ab)
Yang, L, 829(ab)
Yang, LD, 740(ab)
Yang, NC, 881(ab)
Yano, T, 458
Yano, Y, 849(ab), 932(ab)
Yaoita, H, 739(ab)
Yaouanq, J, 941(ab)
Yarchoan, R, 581
Yarmush, ML, 889(ab), 1538
Yasillo, NJ, 899(ab)
Yasuda, T, 739(ab), 868(ab), 869(ab)
Yeatman, L, 838(ab)
Yee, C, 796(ab)
Yeh, SDJ, 746(ab), 809(ab)
Yeh, SH, 871(ab), 1708
Yen, C-K, 1702
Yeoh, E, 765(ab)
Yester, MV, 823(ab), 876(ab)
Yeung, DWC, 774(ab), 918(ab)
Yew, WW, 918(ab)
Yokoyama, A, 803(ab), 832(ab), 923(ab), 1838
Yokoyama, K, 320, 844(ab), 907(ab), 997, 1693
Yonekura, Y, 150, 803(ab), 862(ab), 863(ab), 866(ab), 887(ab), 900(ab), 916(ab), 923(ab), 1302, 1775, 1838, 1977
Yorke, ED, 777(ab)
Yoshida, A, 862(ab)
Yoshida, H, 508
Yoshida, K, 865(ab), 866(ab)
Yoshii, F, 88, 93, 802(ab)
Yoshikawa, E, 892(ab)
Yoshikawa, K, 738(ab), 813(ab), 858(ab), 910(ab)
Yoshimoto, T, 1809
Yoshioka, S, 33
Yoshitake, A, 803(ab)
Young, D, 731(ab)
Young, H, 808(ab), 809(ab)
Young, LT, 731(ab)
Young, T, 741(ab)
Yu, MD, 920(ab)
Yuan, J, 732(ab), 965(ab)
Yudd, AP, 811(ab)
Yui, N, 885(ab)
Yung, B, 774(ab)

Zabel, PL, 1627
Zafrir, N, 450
Zalutsky, MR, 778(ab)
Zankowich, R, 843(ab)
Zanzi, I, 1342
Zanzonico, PB, 777(ab), 833(ab)
Zapol, WM, 917(ab)
Zaret, BL, 770(ab), 800(ab)
Zasler, ND, 1032
Zeeberg, BR, 736(ab), 878(ab)
Zeidler, H, 842(ab)
Zeller, JA, 733(ab)
Zemach, D, 538
Zhang, Y, 940(ab)
Zhao, XD, 756(ab)
Zhu, JB, 797(ab), 1554
Zhu, L, 367
Zielinski, CC, 1005
Zielinski, JE, 209
Ziessman, HA, 233
Zilbovicius, M, 812(ab)
Zilleruelo, G, 798(ab), 841(ab), 915(ab)
Zillkens, KM, 805(ab)
Zimmer, AM, 827(ab), 874(ab), 888(ab), 933(ab)
Zimmerman, H, 1960
Zimmerman, R, 802(ab)
Zimmerman, RA, 1607
Zimmerman, RE, 599, 806(ab)
Zinn, KR, 791(ab)
Zinsmeister, AR, 764(ab)
Zito, F, 831(ab)
Zlatkin, MB, 754(ab)
Zoghbi, SS, 916(ab)
Zuccalá, A, 615
Zupanc, ML, 965(ab)
Zurawski, VR, Jr, 904(ab)
Zwas, ST, 737(ab), 768(ab)

A

Abdomen, irradiation, gastrointestinal functional disturbances, 765ab(5)
Abscess
detection of focal inflammation
In-111 chemotactic peptide, 805ab(5)
scintigraphy, Ga-67 citrate and Tc-99m albumin, 385
distribution of cell-bound activity, leukocytes, In-111 oxine and Tc-99m HM-PAO, 804ab(5)
hemodialysis access site infection, radionuclide diagnosis, 804ab(5)
infection of lower extremity, white blood cell scan, MRI, 856ab(5)
infectious complications in orthopedic surgery, Tc-99m HM-PAO-labeled leukocytes, 804ab(5)
inflammation imaging, HM-PAO-labeled leukocytes, 805ab(5)
localization by Tc-99m monoclonal antibody, subacute and chronic inflammatory lesions, 805ab(5)
myocardial formation, detection, In-111 leukocyte scintigraphy, 703
potential agent for labeling leukocytes, positron-emitting copper, 920ab(5)
subperiosteal, "cold" spot on bone scan, 857ab(5)
Tc-99m-SnF_2 colloid kit, leukocyte labeling, preparation and evaluation, 1257
Absorptiometry
dual-photon: *see* Dual-photon absorptiometry
single-photon, reproducibility, clinical setting, 775ab(5)
Accelerator, SDIO awards, N580
Acetate, fluoroacetate uptake and, glucose metabolic rate, 900ab(5)
Acetazolamide, SPECT IMP imaging, regional ischemia, 782ab(5)
Acetylcholinesterase, inhibitor, C-11, simple preparation, 822ab(5)
Achalasia, assessment and follow-up, esophageal dilatation, 851ab(5)
Acid phosphatase, prostatic, prostatic carcinoma, 3ab(2)
Acquired immunodeficiency syndrome (AIDS)
apical pattern of Ga-67 lung uptake, aerosolized pentamidine, 744ab(5)
diagnostic role of nuclear medicine, 1935
HIV-positive encephalopathy, I-123 IMP SPECT brain scanning, 811ab(5)
HIV-related lymphocytic alveolitis, Tc-99m DTPA lung clearance, gallium scans, 746ab(5)
Tc-99m albumin and Ga-67 citrate, lung scanning, HIV-positive patients, 917ab(5)
treatment of dementia complex with AZT, reversal, brain metabolic abnormalities, 581
utility of 24-hour gallium iamges, acute pulmonary processes, 888ab(5)
Adenocarcinoma, radioimmunodetection, antibody cocktail development, 935ab(5)
Adenomata, low sensitivity of parathyroid scintigraphy, new subtraction method, detectability, 885ab(5)
Adenosine
infusion, comparative efficacy, dipyridamole-Tl-201 perfusion imaging, 730ab(5)
Tl-201 SPECT, ischemic heart disease, 1745ab(10)
Adrenal glands, occult lung metastasis of pheochromocytoma, I-131 MIBG scintigraphy, 885ab(5)
Aerosols
radioaerosol containment system, 1ab(2)
Tc-99m, lung ventilation scintigraphy, 744ab(5)
Tc-99m DTPA, scans, ventilator-dependent patients, 743ab(5)
Tc-99m HM-PAO, pulmonary clearance, new application, 743ab(5)
Aging
evaluation of neuropsychiatric disorders, PET, CT and MRi, 1589
normal
CT, MR and PET, 1607
longitudinal PET, CT scans, 772ab(5)
-related reduction, nutrient hepatic blood flow, 1748ab(10)
Alcohol
imaging of *in vivo* chemistry, N1286
intoxication, decreased brain metabolism, 801ab(5)
Klebsiella pneumoniae osteomyelitis, three-phase radionuclide bone imaging, 1412
Algorithms
application of stopping criteria, iterative maximum likelihood-EM reconstruction, SPECT, 882ab(5)
diagnostic role of nuclear medicine, acquired immunodeficiency syndrome, 1935
elimination of K_1 from least squares optimization, rate parameters, three-compartment model, 879ab(5)
iterative, filtered backprojection, cone beam tomography, 882ab(5)
iterative least squares reconstruction, regularization, emission tomography, 880ab(5)
myocardial perfusion tomography, 1746ab(10)
nature of background, radionuclide ventriculography, 872ab(5)
percent hypoperfused myocardium, Tl-201 SPECT, 750ab(5)
PET-MRI volume matching, evaluation, 875ab(5)
reconstruction
non-stationary SPECT image noise, 1746ab(10)
radial long-axis tomography, Tl-201 SPECT, 881ab(5)
Alkaline phosphatase
bone scintigraphy, stress fractures, military basic trainees, 3ab(2)
placental, antibody guided diagnosis, glioma, 1636
Allograft, renal, radionuclide scintigraphy, aspiration biopsy, 785ab(5)
Alzheimer's disease
cerebral blood flow, multi-infarct dementia and, 772ab(5)
cerebral glucose metabolism
effect, disease severity, 965ab(5)
F-18 FDG, PET, 771ab(5)
correlation of visual symptoms, regional cerebral glucose metabolism, 772ab(5)
dementia, CT, MR and PET, 1607
F-18 deoxyglucose PET and I-123 QNB SPECT, dementia, 896ab(5)
longitudinal PET and CT scans, 772ab(5)
one year follow-up of dementia, rCBF/PET correlations, 895ab(5)
parietal hypometabolism, tissue atrophy, PET studies, 895ab(5)
quantitative analysis, Tc-99m HM-PAO SPECT, 806ab(5)
regional cerebral blood flow, SPECT, 771ab(5)
Ambulatory cardiac monitoring device
cardiovascular nuclear medicine, the next step, 1123
continuous radionuclide ventricular function, coronary angioplasty, 770ab(5)
left ventricular diastolic filling, 868ab(5)
American College of Nuclear Physicians (ACNP)
market planning seminar, N440
petition to change 10 CFR 35, N1296
testimony on DOE 1990 budget, N1148
American College of Physicians (ACP), award to David E. Kuhl, N1148
American College of Radiology, RVS close to implementation, Harvard study, second phase, N271
Amino acids
cerebral uptake, C-11 L-methionine, PET, 838ab(5)
uptake in brain, kinetic modeling approaches, 880ab(5)
Amiodarone, pneumonitis, Tc-99m DTPA aerosol washout rates, 916ab(5)
Ammonia-13, kinetics in lung, positron emission computed tomography, smokers and nonsmokers, 866ab(5)
Amyloidosis
diagnostic imaging, 847ab(5)
plasma turnover studies, serum amyloid P component, 847ab(5)
Tc-99m (V) DMSA uptake, 2050
Angina
anti-anginal agents, effects with PET, 866ab(5)
left ventricular wall motion, stress myocardial perfusion, Tc-99m MIBI, 864ab(5)
prediction of future cardiac events, dipyridamole Tl-201 SPECT, 861ab(5)
silent ischemia, significance, positive thallium stress test, 863ab(5)
Angiocardiography, radionuclide
first-pass iridium-191m, evaluation, ventricular function, 450
Os-191/Ir-191m generator, silica gel, triidodecylmethylammonium chloride, 538
pulmonary uptake of thallium-201, exercise, 788ab(5)
Angiography, radionuclide
alternate R-wave, 1280(le)

Page numbers followed by ab(x) indicate abstracts and month.
Page numbers followed by (le) indicate letter.
Page numbers preceded by N indicate articles appearing in *Newsline*.

blood-pool, functional assessment, total artificial heart, 1405
diagnosis of coronary artery disease, left ventricular function, 1966
first-pass
bicycle exercise, silent myocardial ischemia, 868ab(5)
treadmill exercise, 770ab(5)
imaging thrombi, improved formulation, I-123 fragment E1, 817ab(5)
left ventricular function, assisted circulation, artificial heart, 780ab(5)
left ventricular pressure-volume analysis, 420(le)
quantification of amplitude images, gated radionuclide heart studies, 1393
simultaneous Tc-99m MIBI, myocardial perfusion imaging, 38
Tl-201 perfusion and, during exercise, coronary artery disease, 818ab(5)
ventriculography, percutaneous aortic balloon valvuloplasty, 867ab(5)

Angioplasty
coronary
coronary artery disease diagnosis, PET, 845ab(5)
detection of area at risk, Tc-99m RP-30, 791ab(5)
myocardial reperfusion assessment, Tc-99m isonitrile, 821ab(5)
PTCA, relief of chronic ischemia, 838ab(5)
renal artery stenosis, renal blood flow change, captopril, 841ab(5)

Angiotensin converting enzyme
diagnostic use of inhibitors, radioisotope evaluation, unilateral renal artery stenosis, 605
intrarenal plasma flow, essential hypertension, 6ab(4)
radioimmunoimaging of lung vessels, 1686

Antibodies
antigen-binding site protection, radiolabeling, higher immunoreactive fraction, 932ab(5)
anti-mouse, biodistribution, intact and Fab fragments of mAb, 847ab(5)
astatine-211-labeled, 832ab(5)
bifunctional, CEA as metabolic indicator, colon carcinoma, 905ab(5)
cocktail development, radioimmunodetection, adenocarcinoma, 935ab(5)
human anti-murine
complex formation and biodistribution, cancer patients, 1311
detection, murine mAb administration, 908ab(5)
immunoglobulin complex formation, 10ab(4)
In-111 ZCE 025 monoclonal antibody, colorectal carcinoma, 906ab(5)
patients not injected with murine mAb, 1749ab(10)
para-iodophenyl conjugates, synthesis, radioiodination, 924ab(5)
labeled with radioiodine atoms, full retention, immunoreactivity, 831ab(5)
labeling, Cu-64 *p*-carboxyalkylphenyldithiosemicarbazones, 848ab(5)
native and aglycosylated, comparison, *in vitro* behavior, 933ab(5)
radioiodinated iodobenzoyl conjugates, para and meta isomers, 932ab(5)
radiolabeled, kinetics, penetration into micrometastatic cell clusters, 777ab(5)
remote high level iodinations, 933ab(5)
tumor-specific mouse/human chimeric, Tc-99m labeling, human γ3 constant region, 934ab(5)

Antimony-118, tellerium-118 generator development, PET application, 849ab(5)

α_1-Antitrypsin, deficiency, comparison of V/Q and CT, 1755ab(10)

Anxiety, imaging of *in vivo* chemistry, N1288

Aorta
diagnosis of dissection, radionuclide imaging, 1727
pressure change, myocardial performance, radionuclide ventriculography, 1657

Arteriography
PET and
coronary artery disease severity, 846ab(5)
coronary artery stenosis reversal, cholesterol lowering, 845ab(5)
pulmonary, PIOPED study, N279

Artery
renal: *see* Renal artery
small vessels, NMR velocity measurements, 1753ab(10)

Arthritis
inflammatory, imaging with Tc-99m IgG, 2017
new agent for radiation synovectomy, holmium-166 FHMA, 856ab(5)
septic, lumbar facet joint, bone SPECT imaging, 1408

Arthroplasty
asymptomatic cementless hip, bone scanning, femoral component, 858ab(5)
porous coated hip, three-phase bone scan, indium white blood cell scintigraphy, 1321

Ascites, early, tumor model, 5-[I-123]iodo-2′-deoxyuridine, 882ab(5)

Asia and Oceania Congress 1988, scientific highlights, N431

Assays
noninvasive test, colonic transit in man, 764ab(5)
Whitaker test and diuresis renogram, position-dependent discrepanices, obstructive uropathy, 2ab(4)

Astatine-211
design and construction, radiochemistry facility, 968ab(5)
labeled antibodies, 832ab(5)
labeled F(ab′)$_2$ fragment, immunoreactivity, tumor uptake, 778ab(5)

Astatine-211 17-alpha-astatovinyl-11-beta-methoxy-estradiol, biological behavior, 925ab(5)

Atheromatous lesions, imaging with In-111 IgG, iliac and femoral vessels, 817ab(5)

Atherosclerosis
cardiovascular nuclear medicine, the next step, 1123
In-111 LDL imaging, 787ab(5), 788ab(5)
localization with monoclonal antibody, 859ab(5)
radionuclide imaging, nonspecific polyclonal immunoglobulin G, 1095
renal artery stenosis, outcome of treatment, quantitative renography, 1946

Atomic Energy Control Board (AECB), phase I of cancer cluster study, N1147

Atrial natriuretic peptide, glomerular filtration rate, essential hypertension, 941ab(5)

Attenuation correction
compensation for cone beam SPECT, maximum likelihood reconstruction, 881ab(5)
dual energy, optimum energies, SPECT, 5ab(2)
emission and transmission SPECT data combination, 835ab(5)
esophageal transit scintigraphy, effect of projection, 850ab(5)
left anterior oblique projection, peak-to-scatter ratio, gastric emptying, 233
multiresolution method, PET, 880ab(5)
nonuniform
cardiac SPECT imaging, 497
heart SPECT, iterated radial post correction method, 870ab(5)
PET, application, masked orbiting transmission source, 1056
spectral attenuation ciphers, Tl-201 paradigm, 1744ab(10)
thallium SPECT, differential attenuation, thallium photons, 1746ab(10)
three-dimensional coefficients, distribution for SPECT, chest, 128(le)
Tl-201 myocardial tomography, solution, inferior wall attenuation, 398
whole-body PET, adaptive filtering, transmission profiles, 1751ab(10)

Autoradiography
differential intratumor localization, two monoclonal antibodies, mice bearing transplantable human tumors, 1758ab(10)
dual-isotope, quantitative difference mapping, 874ab(5)
dual-tracer, Tl-201 and radioiodinated fatty acid, cardiomyopathy, 80
dynamic PET and, tracer arrival delay correction, cerebral blood flow, 1069
estimation of LDL catabolic sites, hypercholesterolemia, hyperlipidemic rabbits, 932ab(5)
[I-123]- and [I-125]-3-iodo-MK-801, NMDA receptor-ion channel complex, 923ab(5)
influence of antibody protein dose, antibody distribution, human tumor xenografts, 759ab(5)
L6 binding sites, 1754ab(10)
oxygen-15, realtime correction for deadtime, PET, 878ab(5)
quantitative
lesion to normal bone uptake ratios, skeletal radiopharmaceuticals, 920ab(5)
radiolabeled proteins, In-111, 889ab(5), 1538
radiolabeled monoclonal antibodies, variations in absorbed dose, murine-human xenografts, 777ab(5)
rate of valine incorporation into proteins, brain tumor model, 913ab(5)
Tc-99m D,L-HM-PAO comparison, I-125 IMP, 938ab(5)
Tl-201, estimation, tumor and normal organ flow, 913ab(5)
tumor-associated antigens, malignant melanoma, 906ab(5)

Avidin
biotin conjugation to antibody, amplification, tumor targeting, 832ab(5)
rapid blood clearance, biotinylated IgG, 66

3′-Azido-2′,3′-dideoxythymidine, reversal of brain metabolic abnormalities, treatment, AIDS dementia complex, 581

B

Basal ganglia, imaging, iodine-123 IBZM, 731ab(5)

Benzamides, iodine-substituted, high affinity, SPECT, 803ab(5)

Berson-Yalow Award, Robert C. Stadalnik, excellence, radioassay, N994

Bile
elimination, Tc-99m 1,1,1-tri(5-methylsalicylaldiminomethyl)ethane, 937ab(5)
salts, evaluation, blind loop syndrome, 962ab(5)
Bile duct, portasystemic shunt fraction quantification, I-123 IMP, 1702
Biotin
conjugation to antibody, amplification, tumor targeting, 832ab(5)
streptavidin and monoclonal antibody radiolabeling, 832ab(5)
radioimmunotargeting of tumor, 819ab(5)
Bismuth-212, labeled antibody, human cancer peritoneal xenografts, 778ab(5)
Bladder
artifact correction, hip SPECT, 857ab(5)
estimation of Bremsstrahlung radiation dose, 1373
permeability to water, assessment, tritiated water, 2ab(4)
radiation dose to wall, 2-[F-18]-fluoro-2-deoxy-D-glucose, 1747ab(10)
Blood
automated sampler, high count rate, 745ab(5)
levels of Tl-201, reversible myocardial defects, 1172
rapid clearance of biotinylated IgG, after avidin infusion, 66
whole, cyclosporine concentrations, radioimmunoassays, 786ab(5)
Blood-brain barrier, integrity under MRI conditions, Gd-DTPA and In-DTPA-IgG brain uptake, 839ab(5)
Blood flow
abnormal patterns in dementia, cerebral atrophy, Tc-99m HM-PAO SPECT, 896ab(5)
accelerated glucose utilization, ischemic myocardium, quantitative PET, 867ab(5)
brain
amino acid uptake, kinetic modeling approaches, 880ab(5)
congenital dysphasia, Tc-99m HM-PAO SPECT, 1825
realtime correction for deadtime, PET, 878ab(5)
Tc-99m ECD, kinetics and biodistribution, 599
Tc-99m *p*-halophenethyl diaminodithiol analogs, 939ab(5)
central area of cerebral infarcts, Xe-133, I-123 isopropyliodoamphetamine tomography, 781ab(5)
cerebral
activation studies, I-123 iodoamphetamine, 811ab(5)
acute ischemic stroke, SPECT, 781ab(5)
Alzheimer's disease, multi-infarct dementia, 772ab(5)
Alzheimer's disease, SPECT, 771ab(5)
Alzheimer-type dementia, PET correlations, 895ab(5)
arterial dispersion time constant, PET, 900ab(5)
comparative study, PET, 157
copper-labeled-PTSM, PET, 791ab(5)
critical thresholds, SPECT, 337
cytoarchitectural pattern, SQ 32097, 1751ab(10)
drug abusers, SPECT, 1ab(11)
dynamic SPECT, four-headed gamma camera, 792ab(5)
I-123 IMP, normal subjects, 1753ab(10)
interictal and ictal SPECT, seizure focus localization, 751ab(5)
O-15 and C-11 butanol, PET, 901ab(5)
on-line plasma separation, PET, 791ab(5)
Parkinson's disease, I-123 IMP SPECT, 830ab(5)
post-ictal, diagnostic patterns, 751ab(5)
Tc-99m ECD, microspheres, 792ab(5)
tracer arrival delay correction, autoradiography and dynamic PET, 1069
validity of microsophere model, I-123 IMP, 878ab(5)
volume comparison, capillary transit time, 792ab(5)
Xe-133 SPECT and Tc-99m HMPAO uptake, dedicated brain imaging device, 1752ab(10)
cerebral perfusion imaging with Tc-99m HM-PAO, brain death, central nervous system injury, 1627
cerebral perfusion studies, Tc-99m D,L-CB-PAO, 831ab(5)
combined CBF/CBV SPECT study, recent and old strokes, 897ab(5)
corpora cavernosa, radioisotope penile plethysmography, early tumescence, 466
effects of anti-anginal agents, PET, 866ab(5)
evaluation of cerebral perfusion, violent sexual aggression, 812ab(5)
focal cerebral ischemia, Tc-99m HM-PAO, 781ab(5)
following radiation, lung vascular permeability, 852ab(5)
forearm, Tc-99m human serum albumin, after brachial arteriotomy, 45
head trauma, panic attacks, Tc-99m D,L-HM-PAO, 965ab(5)
hepatic, nutrients, age-related reduction, 1748ab(10)
improved routine synthesis, O-15 butanol, PET, 927ab(5)
intrarenal, essential hypertension, angiotensin converting enzyme, 6ab(4)
kinetics of copper-PTSM in heart, 1843
localization of seizure foci, Tc-99m HM-PAO, interictal and immediate postictal SPECT, 831ab(5)
measurement of capillary permeability, small solutes, 842ab(5)
measurement of functional hepatic mass, Tc-99m galactosyl neoglycoalbumin, 814ab(5)
method to outline myocardium, single diffusible tracer, 775ab(5)
microsphere-like retention in heart, copper-PTSM, PET, 768ab(5)
microspheres, Cu(PTSM) localization, dog heart and kidney, 848ab(5)
myocardial
accuracy of quantitative measurements, rubidium-82 and PET, 807ab(5)
DMIP uptake, reperfused myocardium, 797ab(5)
isosorbide dinitrate, dynamic PET, 866ab(5)
myocardial infarction, dynamic PET, 945ab(5)
new quantitation method, 808ab(5)
O-15 water, novel mathematical approach, 825ab(5)
O-15 water, PET, 807ab(5)
penile
male impotence, non-invasive technique, 784ab(5)
radioisotope plethysmography, 784ab(5)
primate brain, single-pass extraction, I-123 amines, 901ab(5)
regional, copper-PTSM and PET measurements, 807ab(5)
regional cerebral, preliminary kinetics, SQ32097, 792ab(5)
regional pulmonary perfusion, heart-lung transplantation, 1297
renal
captopril, angioplasty in renal artery stenosis, 841ab(5)
hypertension, extracorporeal shock wave lithotripsy, 4ab(11)
hypertension, lithotripsy complications, 842ab(5)
oxygen-15 water, PET, 824ab(5)
renovascular hypertension, captopril, Tc-99m GHA and Tc-99m DMSA, 841ab(5)
right-to-left shunting, left superior vena cava, perfusion lung scintigraphy, 412
shunt size determination, atrial and ventricular levels, dynamic MRI, 903ab(5)
subcutaneous, dialysate sodium concentration, skeletal muscle, 4ab(4)
temporal lobe epilepsy, presurgical evaluation, Xe-133 SPECT and Tc-99m HM-PAO, 896ab(5)
tumor and normal organ, estimation, Tl-201 autoradiography, 913ab(5)
uptake of Tc-99m MIBI, coronary occlusion, reperfusion, 756ab(5)
visualization of pulsatile lung circulation, ECG gated acquisition, 744ab(5)
Blood-pool imaging
antibody and chelate, diester linkage, radioimmunodetection of tumor, 1693
blood-pool radionuclide angiography, functional assessment, total artificial heart, 1405
blood-pool subtraction, cardiac In-111 platelets, 1445
evaluation of ventricular function, coronary artery disease, 1149
gated cardiac, three-dimensional display, 2036
left ventricular diastolic filling patterns, hypertrophic cardiomyopathy, 868ab(5)
left ventricular function, assisted circulation, artificial heart, 780ab(5)
novel functionalized diphosphine complexes, Tc-99m, myocardial imaging, 818ab(5)
radionuclide blood pool venography, deep vein thrombosis, 1744ab(10)
scintigraphic LV volume calculations, technical aspects, 869ab(5)
Tc-99m red blood cell scanning
diagnosis, hepatic hemangioma, 815ab(5)
labeling interference, chronic renal failure, 869ab(5)
labeling kit, first human studies, 811ab(5)
soft-tissue hemangioma, vascular malformation, 799ab(5)
Bone
appearance of Paget's disease, In-111 leukocyte images, 754ab(5)
brown tumor, false-positive Tl-201 localization, 1264
cancer radiopharmaceutical, evolution, Sm-153 EDTMP, 966ab(5)
chronic complicated osteomyelitis, In-111 white blood cells, MRI, 754ab(5)
correlative pediatric imaging, 15
dental, orthopan-tomoscintigram, 835ab(5)
detection of infected orthopedic implants, Tc-99m MDP and WBC, Ga-67 scans, 754ab(5)
diagnostic accuracy of skeletal infection, blood-pool sign, gallium scintiscan, 774ab(5)

dual-energy radiography, comparison, quantitative computed tomography, 774ab(5)
extended x-ray absorption fine structure, technetium and rhenium diphosphonates, 732ab(5)
imaging agents, Tc-99m label, radiation absorbed dose, 1117
infectious complications in orthopedic surgery, Tc-99m HM-PAO-labeled leukocytes, 804ab(5)
inflammation imaging, HM-PAO labeled leukocytes, anti-granulocyte-antibody, 805ab(5)
In-111 white blood cell scintigraphy, three-phase bone scintigraphy, pedal osteomyelitis in diabetics, 753ab(5)
joint diseases and, Tc-99m granulocytes, 1743ab(10)
lesion to normal bone uptake ratios, skeletal radiopharmaceuticals, QARG, 920ab(5)
mandibular grafts, utility of SPECT, 843ab(5)
marrow doses, delivery in radioimmunotherapy, 778ab(5)
marrow imaging, Tc-99m sulfur colloid, GM-CSF, 738ab(5)
marrow imaging *vs.* blind biopsy, Hodgkin's and non-Hodgkin's lymphoma, 843ab(5)
marrow scintigraphy, Tc-99m NCA-antibodies, breast carcinoma and malignant lymphomas, 819ab(5)
marrow uptake and clearance, I-131 labeled antibody, 826ab(5)
mestastases, nuclear medicine in monitoring, response to cancer treatment, 1731
mineral content
  disease versus etiology, 1273
  lumbar spine vertebrae, uremic patients, 774ab(5)
  precision, whole-body scanning, 775ab(5)
  scintigraphic findings, Paget's disease, 855ab(5)
  single and multi-site measurements, spine fracture probability, 1166
mineral densitometry, HCFA's intention to deny Medicare coverage, N139
mineral density
  non-hormonal cyclic therapy, postmenopausal osteoporosis, 774ab(5)
  precision, total body scans, 2ab(2)
  x-ray analyzer, reproducibility, 1750ab(10)
mineral distribution, spinal cord injury, five years later, 857ab(5)
marrow, effect of Sn-117mDTPA, 1754ab(10)
nuclear magnetic imaging, systemic mastocytosis, 2046
painful metastases
  action of 186-Re(Sn)-HEDP, 732ab(5), 837ab(5)
  palliation, strontium-89, 2ab(2)
pain treatment, N1293
photopenia, clinical significance, In-111 leukocyte scintigraphy, 1749ab(10)
prediction of osteomyelitis cure, three-phase bone and Ga-67 scans, 754ab(5)
radionuclide scan
  detection, noncalcified splenic hemangioma, 1111
  early detection, hip fractures, 843ab(5)
  HIV-associated myositis, 556
routine imaging, occult metastases, advanced melanoma, 1ab(2)
scan
  acute myelofibrosis, 251
  asymptomatic cementless hip arthroplasty, 858ab(5)
  chemotherapy, hot skull, 858ab(5)
  "cold" spot, subperiosteal abscess, 857ab(5)
  hot kidney, cancer patients, 858ab(5)
  prostate specific antigen, prostate cancer follow-up, 9ab(4)
  significance of abnormalities, no underlying malignancy, 856ab(5)
scintigraphy
  diagnosis, sacral fractures, 959ab(5)
  MR and, early stage of Legg-Calve-Perthes disease, 1755ab(10)
  MRI and radiography, sacroilitis, 842ab(5)
  non-osseous subtalar coalitions, 799ab(5)
  reflex sympathetic dystrophy, lower extremities, 856ab(5)
  serum alkaline phosphatase, stress fractures, 3ab(2)
  serum osteocalcin, PSA and/or PAP, 918ab(5)
  serum osteocalcin levels, 1748ab(10)
  SPECT, 240
secondaries in breast cancer, 1318
-seeking radiotherapeutic agent, yttrium-90 EDTMP, 843ab(5)
sickle cell-related infarction, nonspecificity, gallium citrate localization, 855ab(5)
single photon absorptiometry, reproducibility, clinical setting, 775ab(5)
SPECT
  back pain, lumbar spine surgery, 490
  persistent back pain, lumbar spinal fusion, 1739(le)
  septic arthritis, lumbar facet joint, 1408
Tc-99m phosphonate, detection, infected hip prosthesis, 562(le)
three-phase scan
  indium white blood cell scintigraphy, porous coated hip arthroplasty, 1321
  Klebsiella pneumoniae, 1412
tumor response to chemotherapy, ^{31}P magnetic resonance spectroscopy, 813ab(5)

Book reviews

An Atlas of Clinical Nuclear Medicine, 1577
An Atlas of Planar and SPECT Bone Scans, 1424
Anatomy and MRI of the Joints: A Multiplanar Atlas, 1136
Avulsion and Stress Injuries of the Musculoskeletal System, 2064
Bone Mineral Measurements by Photon Absortiometry: Methodological Problems, 1281
Cardiovascular Nuclear Medicine, 422
Clinical Radioimmunomaging, 130
Computed Tomography, 130
Computed Tomography of the Head and Neck: Neuroradiology, Volume 3, 1424
Coronary Angioplasty, 1281
Correlative Imaging: Nuclear Medicine, Magnetic Resonance, Computed Tomography, Ultrasound, 1919
Data for Use in Protection against External Radiation, ICRP Publication 51, 566
Gastrointestinal Nuclear Imaging, 269
Handbooks in Radiology Vol 6: Nuclear Medicine, 270
Health Physics Annotated Bibliography, 1424
Imaging in Clinical Practice, 2065
Intermediate Physics for Medicine and Biology. 2nd Ed., 1136
Interventional Radiology, 1577
Living with Radiation: the Risk, the Promise, 566
Magnetic Resonance Imaging: Atlas of the Head, Neck and Spine, 725
Magnetic Resonance Imaging: Basic Principles, 422
Magnetic Resonance Imaging in Diseases of the Nervous System-An Introduction, 566
Magnetic Resonance of Myelin, Myelination, and Myelin Disorders, T26B
Modern Imaging of the Liver. Applications of Computerized Tomography, Ultrasound, Nuclear Medicine, and Magnetic Resonance Imaging, 1577
NCRP Report No. 100, Eposure of the U.S. Population from Diagnostic Medical Radiation, 1741
NCRP Report No. 101, Eposure of the U.S. Population from Occupational Radiation, 1918
Normal Anatomy for Multiplanar Imaging: the Trunk and Extremities, Vol. 1. Normal Anatomy for Multiplanar Imaging: Head, Neck, and Spine, Vol. 2, 725
Nuclear Analytical Techniques in Medicine, 1136
Nuclear Medicine Annual 1988, 2064
Principles of Radiopharmacology, 422
Quantitative Methods in Bone Densitometry, 1918
Radiobiology for the Radiologist, 269
Radiochemistry of Carbon, Nitrogen and Oxygen, 1741
Radiologic-Pathologic Correlation of Musculoskeletal Lesions, 423
Radiopharmacy & Radiopharmacology Yearbook, 1281
Ultrasonic Bioinstrumentation, 131
Would the Insects Inherit the Earth? And Other Subjects of Concern to Those Who Worry about Nuclear War, 725

Brain

acute cerebral damage, Tc-99m glucarate, marker, 901ab(5)
acute injury, early and delayed SPECT, I-123 IMP, 1751ab(10)
acute stroke, clinical and metabolic correlates, 898ab(5)
amino acid uptake, kinetic modeling approaches, 880ab(5)
basal ganglia imaging, 731ab(5)
"beam" mapping, SPECT iofetamine scans, 966ab(5)
benzodiazepine receptor, radioiodinated diazepam derivative, SPECT studies, 803ab(5)
blood-brain barrier integrity, MRI conditions, Gd-DTPA and In-DTPA-IgG uptake, 839ab(5)
blood flow
  congenital dysphasia, Tc-99m HM-PAO SPECT, 1825
  realtime correction for deadtime, PET, 878ab(5)
  Tc-99m *p*-halophenethyl diaminodithiol analogs, 939ab(5)
C-11 and F-18 labeled 4-fluorodeprenyl, probes, functional monoamine oxidase, 821ab(5)
central area of cerebral infarcts, Xe-133, I-123 isopropyliodoamphetamine tomography, 781ab(5)
cerebral acetate and fluoroacetate uptake, glucose metabolic rate, 900ab(5)
cerebral aerobic and anaerobic metabolism, simultaneous determination, 838ab(5)

cerebral atrophy, abnormal blood flow patterns, Tc-99m HM-PAO SPECT, 896ab(5)
cerebral blood flow
  activation studies, emission tomography, 811ab(5)
  acute ischemic stroke, SPECT, 781ab(5)
  Alzheimer-type dementia, PET correlations, 895ab(5)
  arterial dispersion time constant, PET, 900ab(5)
  comparative study, PET, 157
  critical thresholds, SPECT, 337
  cytoarchitectural pattern, SQ 32097, 1751ab(10)
  dynamic SPECT, four-headed gamma camera, 792ab(5)
  I-123 IMP, normal subjects, 1753ab(10)
  O-15 and C-11 butanol, PET, 901ab(5)
  Parkinson's disease, I-123 IMP SPECT, 830ab(5)
  preliminary kinetics, SQ32097, 792ab(5)
  tracer arrival delay correction, autoradiography and dynamic PET, 1069
  validity of microsphere model, I-123 IMP, 878ab(5)
  volume comparison, capillary transit time, 792ab(5)
cerebral dopamine D-1 receptors, non-carrier-added synthesis, F-18 fluoroethyl SCH-23390, 931ab(5)
cerebral glucose metabolism
  carbon monoxide poisoning, 802ab(5)
  correlation of visual symptoms, Alzheimer's disease, 772ab(5)
  F-18 FDG PET, Alzheimer's disease, 771ab(5)
  normals, patients with optic nerve damage, 802ab(5)
  quantitative comparison, two positron emission tomographs, 1386
  stress effect, N1288
  uptake, thirty *vs.* forty-five-minute period, 899ab(5)
cerebral ischemia, filling out phenomenon, Tc-99m HM-PAO SPECT, 591
cerebral metabolism of L-[2-F-18]fluorotyrosine, tracer of protein synthesis, 1367
cerebral regional metabolism, determination, radioligand binding parameters, 898ab(5)
cerebral tissues, compartmental model, 6-[F-18] fluoro-L-dopa, 735ab(5)
characterization of D-1 dopamine receptor ligand, I-123 FISCH, 830ab(5)
chronic cerebral infarction, biodistribution, Tc-99m ethyl cysteinate dimer, 1018
cocaine binding, carbon-11, human and baboon, 761ab(5)
cocaine effect, iodoamphetamine uptake, dog, 830ab(5)
combined CBF/CBV SPECT study, recent and old strokes, 897ab(5)
comparison of SPECT images, stereographic projection, 875ab(5)
complex partial seizures, pathologic findings, FDG-PET and MRI, 752ab(5)
correlative pediatric imaging, 15
cortical circumferential profiling, 816ab(5)
corticosteroid receptors, F-18, 821ab(5)
craniosynostosis, I-123 IMP SPECT, 916ab(5)
customizable volume of interest atlas, three-dimensional PET data analysis, 839ab(5)
cystic tumor, P-32 chromic phosphate colloid, distribution, 833ab(5)
death, determination, Tc-99m HM-PAO, 1621, 1627
decreased metabolism, alcohol intoxication, 801ab(5)
development
  plasticity, PET, 801ab(5)
  preliminary results, high-resolution PET scanner, 892ab(5)
dopamine D-2 receptors
  I-123 IBZM biodistribution, dosimetry, 834ab(5)
  I-123 IBZM evaluation, 88
  I-123 iodolisuride imaging agent, SPECT, 731ab(5)
  quantification, PET, 736ab(5)
  uptake of C-11 YM-09151-2, 515
dopamine neurons, quality control procedure, 6-[F-18]fluoro-L-DOPA, 1249
dual-energy SPECT, methods and applications, 1750ab(10)
enhanced tumor imaging with Gd-DTPA, T1 and T2 relaxation times, MRI, 902ab(5)
evaluation of cerebral perfusion, violent sexual aggression, 812ab(5)
focal cerebral ischemia, Tc-99m HM-PAO, 781ab(5)
focal epilepsy, ictal Tc-99m HM-PAO SPECT, 751ab(5)
F-18 pipamperone synthesis, PET studies, baboon, 932ab(5)
glioma, intravascular streaming, intracarotid infusion, 839ab(5)
glucose and deoxyglucose phosphorylation ratio, hexokinase Michaelis-Menten kinetics, 838ab(5)
glucose metabolism, psychiatric patients, summer affective disorders, 1752ab(10)
head trauma, panic attacks, Tc-99m D,L-HM-PAO, 965ab(5)
high spatial resolution time-of-flight positron tomograph, physical performances, clinical images, 766ab(5)
histamine H1 receptor imaging, PET, baboon, 741ab(5)
HIV-positive encephalopathy, I-123 IMP SPECT, 811ab(5)
HPLC injection, radiopharmaceutical purification, 923ab(5)
human neuroblastoma nude mouse xenograft, radiolabeled MIBG uptake, 884ab(5)
Huntington's disease
  glucose consumption, PET, 771ab(5)
  striatal functional impairment, PET, 762ab(5)
I-123 cerebral perfusion agents, no-carrier-added radiosynthesis, 926ab(5)
I-123 IMP SPECT, children, alternating hemiplegias, 965ab(5)
I-123 6-iododopa, potential SPECT imaging agent, 924ab(5)
imaging agent synthesis, 4-*O*-(*E*)-iodopropenyl glucose, 3ab(11)
N-(ω-iodoalkenyl)spiroperidol analogs, dopamine receptor imaging, SPECT, 925ab(5)
ischemia, redistribution phenomenon, IMP metabolism, 897ab(5)
least-squares optimization, reconstruction filters, high resolution PET, 745ab(5)
localization of seizure foci, Tc-99m HM-PAO, SPECT, 831ab(5)
mapping of cerebral sigma opiate receptors, no-carrier-added synthesis, F-18 fluoropropyl preclamol, 930ab(5)
maturation, imaging in human, I-123 IMP SPECT, 1982
measurement of post-synaptic dopamine receptors, cocaine abusers, 730ab(5)
measurement of tissue perfusion, Cu-64 PTSM, 1756ab(10)
mechanism of I-125 MHTP accumulation, dopaminergic radiotracer, 761ab(5)
metabolic and electrophysiologic manifestations, recognition memory, 894ab(5)
minor ischemic stroke, SPECT measurement, cerebral perfusion reserve, 897ab(5)
model for outcome-prediction, comparison, CT and HM-PAO SPECT, 895ab(5)
multiplanar PET, long-term performance, 1378
neural crest tumors, therapeutic potential, I-131 MIBG, 769ab(5)
neuroblastoma
  I-125 MIBG uptake, children, 474
  I-131 MIBG, therapeutic use, 903ab(5)
  SPECT bone studies, extremities, 858ab(5)
neurofibromatosis, re-evaluation of Tc-99m DTPA, 915ab(5)
neutral amino acid uptake, C-11 L-methionine PET, 838ab(5)
nicotine binding, PET, 742ab(5)
noninvasive functional mapping, O-15 water, PET, 141
novel Tc-N_2S_2 complex, synthesis, characterization, 773ab(5)
pediatric imaging, Tc-99m HM-PAO and SPECT, 1917(le)
perfusion
  I-123 IMP imaging, schizophrenia, 1616
  Tc-99m L,L-ECD, humans, 1902
  Tc-99m L,L-ECD, nonhuman primates, 1892
positioning of cortical region of interest, SPECT images, isocontour method, 877ab(5)
primate, single-pass extraction, I-123 amines, 901ab(5)
principal axis transformation, image registration, 776ab(5)
quantification of HM-PAO distribution, pediatric psychiatric patients, 812ab(5)
quantitative pH mapping, acute stroke, C-11 carbon dioxide and PET, 782ab(5)
rat glioma model, use of C1 *vs.* C2, C-11 glucose, 911ab(5)
refractory complex partial seizures, surgery candidates, I-123 HIPDM SPECT, 751ab(5)
regional cerebral distribution, microspheres, Tc-99m ECD, 792ab(5)
regional cerebral localization, SQ 32097, SPECT, 1ab(11)
regional cerebral metabolic rates, fixed dephosphorylation rate, 1483
regional comparison of lumped constants, fluorodeoxyglucose, deoxyglucose, 900ab(5)
regional dynamics, N-isopropyl-[I-123]*p*-iodoamphetamine, 150
regional ischemia, acetazolamide SPECT IMP imaging, 782ab(5)
residual or recurrent tumor detection, F-18 FDG PET, Posicam 6.5 camera, 909ab(5), 966ab(5)
reversal of metabolic abnormalities, AIDS dementia treatment, AZT, 581
right hemisphere involvement, mescaline-induced psychosis, 812ab(5)
seizure focus localization, interictal and ictal SPECT, cerebral blood flow, 751ab(5)
serotonin S-2 receptors
  mapping and SPECT, baboon, 741ab(5)
  no-carrier-added synthesis, F-18 fluoroethylketanserin, 822ab(5)

SPECT
3-[I-123]iodo-α-methyltyrosine, PET validation, 895ab(5)
imaging characteristics, ASPECT, 796ab(5)
neonates, 915ab(5)
Tc-99m HM-PAO, congenital dysphasia, 798ab(5)
SPECT in neonates, 1337
stage IV neuroblastoma, Tc-99m and I-131 monoclonal antibody, 904ab(5)
states, metabolic characterization, partial sensory limitation, 899ab(5)
stereotactic method, anatomical mapping, PET, 961ab(5)
structure-activity relationships, metal-labeled perfusion tracers, 742ab(5)
subacute cerebral infarct, discordance, I-123 IMP and Tc-99m HM-PAO, 1752ab(10)
synthesis and biodistribution, F-18 DFPA, 928ab(5)
synthesis and biological evaluation, Tc-99m bis(aminoethanethiol), 939ab(5)
Tc-99m D,L-CB-PAO, new tracer, cerebral perfusion studies, 831ab(5)
Tc-99m D,L-HM-PAO purity, diastereomeric mixtures, NMR techniques, 106
Tc-99m ECD
metabolism in rat, 743ab(5)
new imaging agent, kinetics and biodistribution, 599
Tc-99m HM-PAO SPECT
children, 966ab(5)
3D region of interest analysis, 961ab(5)
Tc-99m PAO, new cerebral perfusion agent, 742ab(5)
temporal changes in accumulation, *N*-isopropyl-*p*-iodoamphetamine, lung clearance, 1977
temporal lobe epilepsy
diagnostic patterns, post-ictal cerebral blood flow, 751ab(5)
presurgical evaulation, Xe-133 SPECT and Tc-99m HMPAO, 896ab(5)
theoretical effects of radioligand diffusional gradients, neuroreceptor distribution, 878ab(5)
three-dimensional imaging
brain phantom, ECT applications, 851ab(5)
high-resolution PET scanner, 765ab(5)
I-123 IMP, CT and MRI comparisons, 961ab(5)
MR image data, 902ab(5)
three-dimensional visualization, structure-function relationships, 1747ab(10)
tissue atrophy and parietal hypometabolism, Alzheimer's disease, PET studies, 895ab(5)
tomographic mapping of kinetic rate constants, I-123 IMP, dynamic SPECT, 805ab(5)
traumatic injury, visual cortex metabolism, affected arm movement, 965ab(5)
tumor model, valine incorporation into proteins, autoradiography, 913ab(5)
tumors
dexamethasone effect, extracellular space, 899ab(5)
FDG-PET, 2ab(11)
I-123 iodo-α-methyl tyrosine, SPECT, 110
kinetic rate constants, F-18 fluorodeoxyglucose, 900ab(5)
monitoring of response to cancer treatment, 1731
neuropsychiatric disorders evaluation, PET, CT and MRI, 1589
protein synthesis, C-11 L-methionine, 910ab(5)
Tl-201 and I-123 IMP SPECT, F-18 FDG PET, 895ab(5)
Tl-201 SPECT, 913ab(5)
two-compartment Rb-82/PET model, 839ab(5)
volume, tomography of Tc-99m D,L-HMPAO, 1752ab(10)
whole-body multidetector SPECT, variable aperture, 796ab(5)
Breast
carcinoma: *see* Carcinoma, breast
bone metastases
improved clinical response, strontium-89, 843ab(5)
palliative therapy, strontium-89, 836ab(5)
cancer
bone secondaries, solitary metastasis, 1318
detection, imageable estradiol, 844ab(5)
detection, In-111 GYK-DTPA-B72.3 monoclonal antibody, 819ab(5)
detection, In-111 monoclonal antibody B72.3, 2ab(2)
epirubicin application schemes, radionuclide ventriculography, 867ab(5)
simplified lymphoscintigraphic technique, 1198, 904ab(5)
milk, excretion of radioiodine, 124, 127(le)
16α-substituted 21-[F-18]fluoro-(19-nor)-progesterones, receptor binding ligands, PET, 929ab(5)
Bremsstrahlung, radiation dose, measurement and estimation, 1375
BrφHBED, improved bifunctional chelate, radiolabeling of antibodies, 763ab(5)
Bromine-76 bromolisuride, cerebral regional metabolism, determination, radioligand binding parameters, 898ab(5)
Bromine-75 6-bromo-m-tyrosine, tracer for CNS dopamine, synthesis, evaluation, 924ab(5)
Bromine-80m halodeoxyuridines, Auger electron radiotherapy, intraperitoneal cancer, 833ab(5)
Bronchitis, pulmonary mucociliary transport, FDG powder inhalation, PET, 917ab(5)
Budinger, Thomas F., honors for outstanding contributions, basic science, N576

C

CA 125
co-expression of sialyl SSEA-1 antigen, variability of expression, 919ab(5)
radioimmunoassay, I-131 HMFG1 monoclonal antibody, ovarian cancer, 918ab(5)
ultrasensitive assay for measuring serum values, monoclonal antibodies, different antigenic determinants, 785ab(5)
Caffeine, reduction, dipyridamole-induced myocardial ischemia, 1723, 861ab(5)
Calcium
channel blocker, synthesis, [F-18] fluorocinnarizine, 753ab(5)
ion sequestrants, inhibition, platelet thrombosis, 859ab(5)
renal tubular reabsorption, primary hyperthyroidism, 2ab(4)
Cameras
Anger, quantitative quality control program, SPECT, 851ab(5)
single-crystal ring, imaging characteristics, brain SPECT, 796ab(5)
Tc-99m DTPA images, quantitative calculations, GFR, 1747ab(10)
Cancer
chemotherapy and hot skull, radionuclide bone scans, 858ab(5)
imaging, F-18 FDG uptake, human tumor xenografts, 912ab(5)
imaging in multicenter trial, fragments of CEA monoclonal antibodies, 748ab(5)
intraperitoneal, I-123 and Br-80m halodeoxyuridines, Auger electron radiotherapy, 833ab(5)
metastatic, human pharmacokinetics, Sm-153 EDTMP, 1814
radiotherapy, radioiodinating reagent development, monoclonal antibodies, 216
treatment, nuclear medicine in monitoring response, 1731
Capillary
permeability
regional flows, heart, 798ab(5)
small solutes, 842ab(5)
transit time, cerebral blood flow, volume comparison, 792ab(5)
Captopril
differing responses after Tc-99m GHA and Tc-99m DMSA, renovascular hypertension, 841ab(5)
effect on glucoheptonate scintirenogram, renal artery stenosis, 1759ab(10)
-enhanced renal scintigraphy, hypertension evaluation, Tc-99m DTPA, 615
renal blood flow change, angioplasty, renal artery stenosis, 841ab(5)
renal scinitgraphy, pitfall, bilateral renal artery stenosis, 2042
renography
duplexsonography, renovascular hypertension, 6ab(4)
renal artery stenosis, Tc-99m DTPA, 6ab(4)
scintigraphy
diagnosis, renovascular hypertension, 944ab(5)
neonatal hypertension, 798ab(5)
-stimulated renography, renal vein renins, hypertension, 5ab(4)
test in hypertensive patients, renal artery stenosis detection, Gates' technique, 51
test in screening hypertensive patients, 1422(le)
Carbidopa, importance in 6-[F-18]fluoro-L-dopa PET studies, 761ab(5)
Carbon-11
acetylcholinesterase inhibitor, simple preparation, 822ab(5)
cocaine binding in human and baboon brain, 761ab(5)
resin-supported methylation approach, phenols, amides and acidic precursors, 822ab(5)
Carbon-11 acetate
kinetics, dietary state, human heart, 837ab(5)
PET
myocardial oxidative metabolism, substrate utilization, 187
myocardial oxidative metabolic reserve, 1489
regional myocardial oxygen consumption, 1798
quantification of myocardial metabolic reserve, PET, dobutamine, 837ab(5)
regional myocardial oxidative metabolism, serial PET imaging, 867ab(5)
tracer for myocardial metabolism, 1743ab(10)
Carbon-11 amino acids
preparation, automated microprocessor-controlled reaction system, 4ab(11)
preparation from C-11 nitroalkanes, 783ab(5)
Carbon-11 ammonium cyanide, method for routine production, C-11 D-glucose, 927ab(5)
Carbon-11 benztropine, possible muscarinic

cholinergic receptor ligand, PET, 741ab(5)
Carbon-11 betamethylheptadecanoic acid
myocardial fatty acid metabolism, 797ab(5)
synthesis and biodistribution in rats, 928ab(5)
Carbon-11 butanol, O-15 water and, cerebral blood flow, PET, 901ab(5)
Carbon-11 carbon dioxide
C-11 pyruvic acid synthesis, 928ab(5)
PET, quantitative brain pH mapping, acute stroke, 782ab(5)
Carbon-11 carfentanil, opiate receptor regulation, temporal lobe epilepsy, PET, 750ab(5)
Carbon-11 citalopram, facile synthesis, PET, serotonin uptake sites, 1757ab(10)
Carbon-11 cocaine, PET studies, kinetic analysis, baboon brain, 898ab(5)
Carbon-11 diprenorphine
opiate receptor density and ligand affinity, 740ab(5)
opiate receptor regulation, temporal lobe epilepsy, PET, 750ab(5)
Carbon-11 fatty acids, synthesis and biodistribution, C-11 betamethylheptadecanoic acid, 928ab(5)
Carbon-11 4-fluorodeprenyl, synthesis, probe, functional monoamine oxidase, 821ab(5)
Carbon-11 D-glucose
method for radiosynthesis, 1756ab(10)
method for routine production, C-11 ammonium cyanide, 927ab(5)
remote automated synthesis, PET, 928ab(5)
use of C1 *vs.* C2, rat glioma model, 911ab(5)
Carbon-11 glycine, preparation of C-11 amino acids, C-11 nitroalkanes, 783ab(5)
Carbon-11 HECNU, "no-carrier-added" synthesis, 783ab(5)
Carbon-11 hydroxyephedrine
alternative to 6-[F-18]fluorometaraminol, heart neuronal imaging, 767ab(5)
synthesis, neuronal cardiac imaging, 783ab(5)
Carbon-11 methionine
compared to F-18 fluorodeoxyglucose, differential diagnosis, lung tumor, 788ab(5)
PET, cerebral neutral amino acid uptake, 838ab(5)
protein synthesis in brain tumors, 910ab(5)
radiation effects on tumor, 739ab(5)
tumor uptake, response to irradiation, 2012
uptake in tumor, quantitative evaluation, PET, 1809
uptake with PET
histologic type, primary lung cancer, 33
prognosis, bronchogenic carcinoma, 1420(le)
Carbon-11 methoxy-MK-801, imaging of NMDA receptors by PET, 741ab(5)
Carbon-11 8-methoxy-MK-801, synthesis and preliminary evaluation, 930ab(5)
Carbon-11 methyl acyclovir, synthesis, 929ab(5)
Carbon-11 methyl iodide, simplified solid-phase synthesis, 927ab(5)
Carbon-11 MK-329, synthesis, cholecystokinin receptors, PET, 931ab(5)
Carbon-11 MTRB, pituitary imaging agent, 932ab(5)
Carbon-11 nitroalkanes, preparation of C-11 amino acids, 783ab(5)
Carbon-11 *N*-Me-paroxetine, central serotonin re-uptake sites, PET, 1753ab(10)
Carbon-11 NMSP, PET D-2 dopamine receptor quantification, schizophrenia, 731ab(5)
Carbon-11 ornithine, no-carrier-added synthesis, 782(ab), 783ab(5)
Carbon-11 phorbol esters, specific binding to protein kinase C, PET, 783ab(5)
Carbon-11 pyruvic acid, synthesis, 928ab(5)
Carbon-11 thymidine, liver regeneration measurement by PET, 929ab(5)
Carbon-11 tropanyl benzilate methiodide, synthesis and animal studies, promising ligand, peripheral muscarinic receptors, 930ab(5)
Carbon-11 tyrosine, effect of radiotherapy, tumor metabolism, PET, 789ab(5)
Carbon-11 YM-09151-2, brain uptake, D-2 dopamine receptor, 515
Carbon-13, nuclear magnetic resonance, cellular redox, 814ab(5)
Carbon-14 cocaine, whole body distribution and kinetics, 831ab(5)
Carbon-14 deoxyglucose
deposition, ischemia, reperfusion, 797ab(5)
fluorodeoxyglucose and, regional comparison, lumped constants, 900ab(5)
Carbon-14 6-glucose, cerebral aerobic and anaerobic metabolism, simultaneous determination, 838ab(5)
Carbon monoxide, poisoning, regional cerebral glucose metabolism, 802ab(5)
Carcinoembryonic antigen (CEA)
anti-CEA imaging
I-123 Fab′ and F(ab′)2 fragments, 903ab(5)
pharmacokinetics and imaging, colorectal carcinoma, 908ab(5)
chimeric mouse-human anti-CEA antibody of IgG4, immunoscintigraphy, colorectal carcinoma, 809ab(5)
I-123 anti-CEA monoclonal antibody, evaluation, colorectal carcinoma, 890ab(5)
I-131 anti-CEA/CA 19-9, immunoscintigraphy efficacy, colorectal cancer, 907ab(5)
I-131 anti-colon specific antigen-p, monoclonal antibody, therapeutic efficacy, 826ab(5)
In-111 monoclonal antibody
detection, recurrent colorectal carcinoma, 748ab(5)
metabolism, nude mouse tissues, 888ab(5)
monoclonal antibody fragments, cancer imaging, multicenter trial, 748ab(5)
monoclonal anti-CEA antigen I-123 $F(ab')_2$ fragments, pretherapy dosimetry, 962ab(5)
new Tc-99m antibody labeling method, initial clinical imaging, 809ab(5)
preparation and characterization, Re-186 NR-CO-02 $F(ab')_2$, 793ab(5)
role as metabolic indicator, bifunctional antibody system, colon carcinoma, 905ab(5)
size-related diagnostic sensitivity, tumor radioimmunoscintigraphy, standard X-rays, 749ab(5)
tumor localization of anti-CEA monoclonal antibodies, epitope specificity, 747ab(5)
yttrium-labeled anti-CEA monoclonal antibodies, IgG and fragments, radioimmunotherapy, 848ab(5)
Carcinoid tumor, metastatic, I-131 MIBG treatment, 836ab(5)
Carcinoma, effects of interferon-αA, monoclonal antibody targeting, 809ab(5)
Carcinoma, breast
axillary metastasis and, Tl-201 scintigraphy, 844ab(5)
bone marrow scintigraphy, Tc-99m NCA-antibodies, 819ab(5)
metastatic, 16-α-[F-18]fluoroestradiol uptake, PET, 788ab(5)
xenografts, localization, In-111 tumor necrosis factor, 819ab(5)
Carcinoma, bronchial, Tc-99m MIBI and Tl-201 uptake, 845ab(5)
Carcinoma, bronchogenic, C-11-L-methionine uptake with PET, predictor of prognosis, 1420(le)
Carcinoma, colonic
role of CEA as metabolic indicator, bifunctional antibody system, 905ab(5)
xenografts, comparative biodistribution, Yt- and In-labeled monoclonal antibody B72.3, 672
Carcinoma, colorectal
anti-CEA antibody, pharmacokinetics, imaging, 908ab(5)
biodistribution and tumor localization, In-111 monoclonal antibody, 747ab(5)
chimeric mouse-human anti-CEA antibody of IgG4, immunoscintigraphy, 809ab(5)
clinical value of immunoscintigraphy, 1646
differentiation from scar, PET, 789ab(5)
evaluation, early and delayed radioimmunoscintigrams, 890ab(5)
HAMA responses
intraperitoneal radioimmunotherapy infusions, 827ab(5)
patterns, In-111 ZCE 025 monoclonal antibody, 906ab(5)
liver metastases
immunoscintigraphy, Tc-99m monoclonal anti-CEA antibody, 748ab(5)
I-131 monoclonal antibody, 809ab(5)
perfusion and shunting, F-18 uracil, N-13 glutamate, 910ab(5)
recurrent, detection, In-111 monoclonal antibody, 748ab(5)
xenografts, radioimmunotherapy, Y-90 CO17-1A, 935ab(5)
Carcinoma, hepatocellular, diagnosis with Tc-99m DISIDA, adenoma, focal nodular hyperplasia, 1278(le)
Carcinoma, lung
Tc-99m α-D-glucose 1-phosphate, compared to Ga-67 imaging, 913ab(5)
Tc-99m NR-LU-10 monoclonal antibody, 1ab(11)
Carcinoma, mammary, xenografts, curative radioimmunotherapy, I-131 monoclonal antibodies, 531
Carcinoma, ovarian
anti-CA 12.5 radioimmunodetection, 758ab(5)
human antimurine antibody responses, intraperitoneal radioimmunotherapy infusions, 827ab(5)
I-131 HMFG1 trial, 759ab(5)
I-131 HMKG1 monoclonal antibody, kinetics, nude mice and patients, 883ab(5)
immunoscintigraphy, In-111 monoclonal antibody, 758ab(5)
influence of antibody protein dose, antibody distribution, autoradiography, 759ab(5)
prospective immunoscintigraphic study, 758ab(5)
radioimmunoscintigraphy, monoclonal antibody SM3, 758ab(5)
Carcinoma, prostatic
bone scintigram, serum osteocalcin, PSA and/or PAP, 918ab(5)
prostatic acid phosphatase, prostatic specific antigen, 3ab(2)
Carcinoma, renal cell
xenografts
external beam irradiation, radioimmunotherapy, 826ab(5)
I-131 and In-111 monoclonal antibody, 906ab(5)
Carcinoma, small cell, F-18 deoxyglucose PET,

1754ab(10)
Carcinoma, squamous cell
head and neck, Tc-99m DMSA uptake, 174
lung
monoclonal antibody radioimmunoassay, 918ab(5)
serum TA-4 level, localization, 918ab(5)
radiolabeled anti-EGF receptor, phase I, imaging trial, 746ab(5)
Carcinoma, thyroid
detection, cervical magnetic resonance imaging, 841ab(5)
differentiated, Tc-99m MIBI imaging, follow-up, 904ab(5)
improved determination, 24-hour I-131 uptake, 737ab(5)
medullary, Tc-99m DMSA scintigraphy, 1420(le)
Tl-201 and I-131 scintigraphy comparison, follow-up, 914ab(5)
Carcinomatosis, intraperitoneal, lavage, improved monoclonal antibody uptake, 60
Cardiolite: *see* Technetium-99m HEXAMIBI
Cardiomyopathy
damage delineated by In-111 monoclonal anti-myosin, 779ab(5)
dual-tracer autoradiography, Tl-201, radioiodinated fatty acid, 80
hypertrophic, left ventricular diastolic filling patterns, 868ab(5)
idiopathic congestive, I-125 MIBG imaging, 1182
primary hypertrophic, I-123 MIBG myocardial uptake, 810ab(5)
visual analysis of PET images, reproducibility, reliability, 846ab(5)
Cardiopulmonary resuscitation, back-flow testing of CPR airway valves, radioactive gas, 1755ab(10)
Cardiovascular system, European Association of Nuclear Medicine Congress, 1989, N1921
Carotid artery, extraction and kinetics, Tc-99m ECD and HM-PAO, 742ab(5)
Catecholamines
analog behavior, compartmental analysis, myocardial tissue, 735ab(5)
depletion of myocardial stores, detection with I-123 MIBG, acute myocardial infarction, 810ab(5)
dopamine infusion, myocardial glucose uptake, regional ischemia, 859ab(5)
Catheter
indwelling, radionuclide evaluation, chemotherapy, 845ab(5)
therapeutic transcatheter embolization, improved radiolabeling technique, ivalon, 1399
Cations, complexes of technetium, myocardial imaging, 1415
Caudate nucleus, quantification of dopamine D-2 receptor, PET, 736ab(5)
Central nervous system
brain death, cerebral perfusion imaging, Tc-99m HM-PAO, 1627
correlative pediatric imaging, 15
Cerebrospinal fluid, fistulae, diagnosis, radionuclide cisternography, 120
CGP 12177, β-adrenergic receptors, PET, 766ab(5), 825ab(5)
Chelate, antibody and, diester linkage, radioimmunodetection of tumor, 1693
Chelating agents
antibody-bifunctional chelator conjugates, ester-linker Tc-99m, whole-body clearance, 934ab(5)
BrøHBED, radiolabeling of antibodies, 763ab(5)
chemical modification, Tc-99m antibody, accelerated background clearance, 940ab(5)
comparison of five techniques for radiolabeling, monoclonal antibody with Y-90, 763ab(5)
endotoxin testing, limulus amoebocyte lysate, radiopharmaceuticals, 921ab(5)
hexadentate bifunctional, radiolabeling of antibodies, 1758ab(10)
macrocyclic bifunctional, Y-90 monoclonal antibodies, 763ab(5)
N_3S, Tc-99m and Re-186/-188 immunoconjugates, kit preparation, 933ab(5)
porphyrin bifunctional chelator, monoclonal antibody labeling, radioactive manganese, 935ab(5)
preparation of new agents, immunoscintigraphy, 936ab(5)
radiolabeled antibody imaging, gastrointestinal cancer, 909ab(5)
Tc-99m-labeled antibody-bifunctional chelator conjugates, 793ab(5)
Tc-99m tetradentate amine-phenols, radiopharmaceutical cell labeling, 938ab(5)
Chemodectoma, I-123 MIBG uptake, 769ab(5)
Chemotaxis, neutrophil function, after monoclonal antibody interaction, 747ab(5)
Chemotherapy
bone and soft tissue response, ^{31}P magnetic resonance spectroscopy, 813ab(5)
F-18 uracil uptake, changes in tumor volume, colorectal carcinoma, 911ab(5)
hot kidney or skull on radionuclide bone scans, cancer patients, 858ab(5)
radionuclide evaluation, indwelling catheters, 845ab(5)
synthesis of "no-carrier-added,cQ C-11 HECNU, 783ab(5)
Chernobyl, Swedish thyroid cancer risk, 721(le)
Chervu, Lakshman Rao, In Memoriam, 723
Chervu, Shanta, In Memoriam, 723
Chest
correlative pediatric imaging, 15
three-dimensional attenuation coefficients, distribution for SPECT, 128(le)
Child abuse, unusual and subtle scintigraphic findings, 967ab(5)
evaluation, 4ab(2)
Cholecystokinin, receptor localization, MK 329, 849ab(5)
Cholescintigraphy
morphine-augmented, 8ab(4), 850ab(5)
reflux sign, administration, gallbladder contracting agent, 1192
sensitivity, sonography, gallbladder perforation, 850ab(5)
Cholesterol, lowering, coronary artery stenosis reversal, PET, 845ab(5)
Chromatography
HPLC
injection, radiopharmaceutical purification, 923ab(5)
Tc-99m radiopharmaceuticals, quality control, 940ab(5)
Tc-99m radiopharmaceuticals, structural identification, 1240
internal surface-reverse phase, plasma metabolite analysis, radiopharmaceuticals, 920ab(5)
Cirrhosis, portasystemic shunt fraction quantification, I-123 IMP, 1702
Cisplatin, -induced tubular toxicity, comparison, radioactive renal agents, 659
Cisternography, radionuclide, diagnosis, pleural cerebrospinal fluid fistulae, 120
Clonidine, pre-treatment for early detection, mechanical-overload heart failure, I-123 MIBG SPECT, 810ab(5)
Cobalt-55, development as an antibody label, PET imaging studies, 923ab(5)
Cobalt-57 cyanobalamin, content uniformity of capsules, 265(le)
Cocaine
abusers, measurement, post-synaptic dopamine receptors, 730ab(5)
carbon-11, binding, human and baboon brain, 761ab(5)
effect on brain uptake, iodoamphetamine, dog, 830ab(5)
imaging *in vivo* chemistry, N1285
whole-body distribution and kinetics, 831ab(5)
Colchicine, -induced thyroidal radioiodide retention, iodine-deficient male rats, 737ab(5)
Collimator
angulation error, effect on SPECT, 852ab(5)
diverging, glomerular filtration rate inaccuracies, 941ab(5)
electronically collimated SPECT, first experimental study, 851ab(5)
influence on SPECT center of rotation, measurements, 265(le)
performance
penetration effects, 891ab(5)
use, hotelling trace, 892ab(5)
restoration filter and, quantitative imaging, I-131 antibody, 876ab(5)
rotating slanthole, SPECT, 1737(le)
scatter, novel Monte Carlo simulation, 806ab(5)
technique for evaluation of anisotropy, SPECT, 894ab(5)
Colon
cancer, In-111 monoclonal antibodies, 905ab(5)
carcinoma: *see* Carcinoma, colonic
coverage by mesalamine enema, active distal ulcerative colitis, 764ab(5)
scintigraphy, chronic constipation, 887ab(5)
transit
clinical assessment, In-111 DTPA, 887ab(5)
development, noninvasive test, 764ab(5)
non-invasive radionuclide assessment, 746ab(5)
oral I-131 cellulose, health and constipation, 764ab(5)
Colony-stimulating factor, granulocyte-macrophage, bone marrow imaging, Tc-99 sulfur colloid, 738ab(5)
Colorectal cancer
cold antibody administration, In-111 monoclonal antibody, 809ab(5)
diagnostic efficacy of immunoscintigraphy, SPECT and I-131 anti-CEA/CA 19-9, 907ab(5)
epithelial membrane antigen, target antigen, radiolabeled monoclonal antibody, 808ab(5)
F-18 uracil uptake, changes in tumor volume, chemotherapy, 911ab(5)
In-111 and I-131 monoclonal antibody, B72.3, 320
inflammation-related mAb localization, 3ab(11)
intra-operative localization, metastases, radiation detection probe, 908ab(5)
metastatic, F-18 uracil and O-15 water, 910ab(5)
radioimmunoscintigraphy, Tc-99m monoclonal

antibody, 748ab(5)
Complex, formation and biodistribution, mouse antitumor monoclonal antibody, cancer patients, 1311
Computed tomography
constraining SPECT reconstruction to body volume, 835ab(5)
correlative pediatric imaging, 15
3D brain imaging, I-123 IMP, 961ab(5)
effect of radioiodination, protein charge, electrophoretic mobility, 933ab(5)
Ga-67 SPECT, evaluation, recurrent lymphoma, 874ab(5)
HM-PAO SPECT comparison, model for outcome-prediction, after stroke, 895ab(5)
localization of pheochromocytoma, correlation with MIBG and MRI, 328
longitudinal PET and, normal aging, Alzheimer's disease, 772ab(5)
metabolic PET correlates, anatomic lesions, head trauma, 802ab(5)
MR and PET, Alzheimer's dementia, normal aging, 1607
MRI and PET, evaluation, neuropsychiatric disorders, 1589
quantitative
comparison, dual energy radiography, 774ab(5)
image registration system, 894ab(5)
transmission computerized tomography, utility of Ga-67, lymphoma, 914ab(5)
Computers
all-digital nuclear medicine department, display stations, 874ab(5)
identifiability analysis, ligand-receptor model influence, injection protocol, 877ab(5)
implementation of nuclear medicine computer hardware, software quality control program, 874ab(5)
Macintosh, PET data analysis, 873ab(5)
microcomputer-based molecular modeling, radiopharmaceuticals, structure/activity relationships, 877ab(5)
ultra-high speed nuclear medicine image telecommunications, ISDN, 874ab(5)
Computers, software
analysis of cardiac perfusion tomography, 871ab(5)
analysis of scatter and quantum noise, camera non-uniformity, holospectral imaging, 807ab(5)
application of machine intelligence, diagnosis, coronary stenosis, 816ab(5)
automatic program for long axis, left ventricular myocardium, Tl-201, 806ab(5)
automatic superposition of cardiac SPECT images, 871ab(5)
composite gallium SPECT-CT images, evaluation, recurrent lymphoma, 874ab(5)
computer-aided radiopharmaceutical design, 732ab(5)
correction of bladder artifact, hip SPECT, 857ab(5)
cortical circumferential profiling, emission tomography, 816ab(5)
dental bone scans, orthopan-tomoscintigram, 835ab(5)
development of image display, analysis workstation, 873ab(5)
development of treatment planning program, radioimmunotherapy, 884ab(5)
3D non-stationary simulation of SPECT imaging, 881ab(5)
effect of attenuation weighted backprojection, 3D MTF, SPECT, 816ab(5)
effect of differential washout, reconstructed SPECT images, 870ab(5)
efficient attenuation reprojection algorithm, SPECT, 817ab(5)
elimination of K_1 from least squares optimization, rate parameters, three-compartment model, 879ab(5)
experimental information directory, international computer network, 815ab(5)
gamma camera image restoration and applications, 876ab(5)
I-123 MIBG uptake by chemodectomas, 769ab(5)
maximum likelihood image reconstruction, PET, 776ab(5)
miniature scintillation detector system, 891ab(5)
model for fluoromisonidazole retention, PET image interpretation, 735ab(5)
Monte Carlo simulation, collimator scatter, 806ab(5)
new reconstruction algorithm, radial long-axis tomography, Tl-201 SPECT, 881ab(5)
operation, picture archiving and communication system, 873ab(5)
optimal experimental design for tissue data, fluorodeoxyglucose, 879ab(5)
practical use of full relational model, dynamic management, nuclear and cardiological data, 873ab(5)
quality control program, implementation, nuclear medicine computer hardware, 874ab(5)
quantification of amplitude images, gated radionuclide heart studies, 1393
quantification of myocardial perfusion and thickness, tomographic phantom studies, 871ab(5)
quantitative difference mapping, dual isotope autoradiography, 874ab(5)
quantitative measurement, In-111 anti-melanoma monoclonal antibody, 885ab(5)
robustness of dynamic D-2 receptor models, 736ab(5)
scintigraphic display and processing software, personal computer, 969ab(5)
simple positron imaging, time-of-flight, iterative deblurring, 746ab(5)
simplified analysis of gastric emptying, PC-based system, weighted-least-squares regression, 794ab(5)
simulation of scintigrams, 879ab(5)
synthetic classification images, cardiac RWMA, 816ab(5)
three-dimensional display
cardiac metabolism, PET, 808ab(5)
SPECT images, 834ab(5)
validation of Bayesian reconstruction, Monte Carlo simulations, real data, 755ab(5)
validity of microsphere model, cerebral blood flow,, I-123 IMP, 878ab(5)
Constipation, chronic, colonic scintigraphy, 887ab(5)
Copper
metal-labeled perfusion tracers, structure-activity relationships, 742ab(5)
positron-emitting, potential agent, leukocyte labeling, 920ab(5)
Copper-18, monoclonal antibody conjugation, desferrioxamine In-111, oligosaccharide moiety, 936ab(5)
Copper-62, Zn-62 Cu-62 generator, PET radiopharmaceuticals, 1838
Copper-64, *p*-carboxyalkylphenyldithiosemicarbazones, antibody labeling, 848ab(5)
Copper-64 PTSM, measurement of tissue perfusion, 1756ab(10)
Copper-67, improved separation procedure, radiotherapy, 921ab(5)
Copper-67 beta dose point kernels, potential use in radioimmunotherapy, 1036
Copper-PTSM
cerebral blood flow, PET, 791ab(5)
correlation of localization, microsphere blood flow, dog heart and kidney, 848ab(5)
kinetics in heart, PET, 1843
measurement of regional blood flow, PET, 807ab(5)
microsphere-like retention in heart, blood flow, PET, 768ab(5)
subcellular distribution, tissue radiocopper, 920ab(5)
Coronary artery
flow and distribution, response to stress, 818ab(5)
normal, causes, abnormal stress Tl-201 SPECT, 750ab(5)
Coronary artery disease (CAD)
automatic superposition of cardiac SPECT images, 871ab(5)
bicycle exercise first-pass radionuclide angiography, frequency, silent myocardial ischemia, 868ab(5)
cardiac transplant patients, 3ab(2)
comparison of severity, PET, arteriography, 846ab(5)
comparison of SPECT and Tl-201, I-123 fatty acids, 739ab(5)
continuous radionuclide ventricular function, coronary angioplasty, 770ab(5)
detection of area at risk, angioplasty, Tc-99m RP-30, 791ab(5)
diagnosis by radionuclide angiography, left ventricular function, 1966
diagnosis with PET, correlation, coronary angioplasty, 845ab(5)
diagnostic utility of Tc-99m SQ 30217, rapid imaging protocol, 730ab(5)
differences, Tl-201, Tc-99m MIBI, 865ab(5)
dipyridamole effects, cardiac MRI, 840ab(5)
dipyridamole-thallium imaging, lazy man's stress test, 281
effects of anti-anginal agents, PET, 866ab(5)
evaluation of ventricular function, 1149
identification of high-risk patients, oral dipyridamole Tl-201 SPECT, 862ab(5)
In-111 neutrophils, myocardial infarction, reperfusion injury, 859ab(5)
I-123 phenylpentadecanoic acid tomography, dipyridamole infusion, 760ab(5)
left ventricular dilation, exercise SPECT thallium imaging, three-vessel disease, 749ab(5)
low risk patients, quantitative Tl-201 SPECT, 863ab(5)
myocardial fatty acid utilization, tomographic assessment, recurrent chest pain, 828ab(5)
myocardial perfusion and Tc-99m RP-30A, coronary arteriography, exercise Tl-201 SPECT, 820ab(5)
myocardial perfusion abnormality, exercise, Tl-201 SPECT, 749ab(5)
myocardial perfusion imaging, Tc-99m HEXAMIBI, Tl-201, 301
myocardial scintigraphy, I-123 phenylpentadecanoic acid, 829ab(5)
optimal specificity of Tl-201 SPECT,

recognition, imaging artifacts, 441
radionuclide angiography and Tl-201 perfusion, during exercise, 818ab(5)
redistribution after thallium reinjection, relationship, coronary anatomy and regional wall motion, 740ab(5)
regional left ventricular filling, diastolic abnormalities, myocardium, 165
regional wall motion, gated myocardial PET, 1775
right ventricular uptake, Tc-99m MIBI and Tl-201, 820ab(5)
rubidium-82 and Tl-201 myocardial perfusion imaging, coronary artery disease, 759ab(5)
rubidium-82 PET and Tl-201 SPECT, comparisons, 829ab(5)
Tc-99m HEXAMIBI and Tl-201 SPECT, diagnosis, 4ab(2)
Tc-99m monoclonal antibody, after balloon arterial injury, atherosclerotic model, 787ab(5)
three-dimensional cardiac PET, automated quantitation, routine clinical use, 1787
three-dimensional SPECT Tl-201 images, accuracy of detection, 834ab(5)
Tl-201 myocardial tomography, analysis, polar probability map, 871ab(5)
Tl-201 scintigraphy, maximal coronary vasodilation, adenosine, 760ab(5)
Tl-201 SPECT
myocardial imaging, prone position, 750ab(5)
left bundle branch block, 419(le)
treadmill stress test and intravenous dipyridamole, myocardial perfusion imaging, Tc-99m MIBI, 759ab(5)
ventricular function and perfusion, myocardial infarction, Tc-99m MIBI, 801ab(5)

Corrections, table correction, 268

Creatinine, measurement of renal function, radionuclides, 2054

Crohn's transit, gallbladder and gastrointestinal transit, 764ab(5)

Cryptand 2.2.2, tritiated, synthesis and biodistribution, 1756ab(10)

CsI-photodiode detector, patient-borne, left ventricular function, ST segment, 868ab(5)

Cyclohexylpolyaminocarboxylates, improved In-111 immunoconjugates, tumor imaging, 934ab(5)

Cyclosporine
comparison of INCSTAR CYCLOTRAC and SANDOZ SANDIMMUNE, whole blood assays, 3ab(2)
concentrations in whole blood, H-3 and I-125 radioimmunoassays, monoclonal antibody, 786ab(5)
nephrotoxicity, pathophysiology, 784ab(5)

Cyclosporine A, toxicity, hepatobiliary dysfunction, Tc-99m EHIDA, 921ab(5)

Cyclotron
essentials of design and operation, corrections to lecture notes, 129(le)
first products, nuclear medicine history, St. Louis, N569
-produced radiopharmaceuticals, IAEA report, N1443
proton only, automated radiopharmaceutical production, 965ab(5)
small proton, electrophilic F-18, 927ab(5)
solution to current radioisotope shortage, N438

Cyst, choledochal, scintigraphic features, 622

Cystic fibrosis, pulmonary function testing, Tc-99m DTPA aerosol ventilation studies, 967ab(5)

Cystography
nuclear, Tc-99m pertechnetate absorption, bladder augmentation, 2ab(2)
radionuclide, two-stage, early results, 10ab(4)
radionuclide voiding, vesico-ureter reflux, expert system, 5ab(2)

D

Dehdashti, Farrokh, Mallinckrodt Fellowship, N1444

Dementia
abnormal blood flow patterns, cerebral atrophy, Tc-99m HM-PAO SPECT, 896ab(5)
AIDS, reversal, brain metabolic abnormalities, 581
Alzheimer's
CT, MR and PET, 1607
one year follow-up, rCBF/PET correlations, 895ab(5)
Alzheimer's disease, regional cerebral blood flow, SPECT, 771ab(5)
brain tumor and, kinetic rate constants, F-18 fluorodeoxyglucose, 900ab(5)
evaluation of neuropsychiatric disorders, PET, CT and MRI, 1589
F-18 deoxyglucose PET and I-123 QNB SPECT, 896ab(5)
HIV-positive encephalopathy, I-123 IMP SPECT brain scanning, 811ab(5)
multi-infarct, Alzheimer's disease and, cerebral blood flow, 772ab(5)

Deoxyglucose, glucose phosphorylation ratio, hexokinase Michaelis-Menten kinetics, 838ab(5)

Department of Energy (DOE)
isotope production and distribution office, N1933
nuclear medicine research grants, N1148
SNM/ACNP testimony on 1990 budget, N1148
suspension of enriched uranium shipments, jeopardized Mo-99/Tc-99m supply, N1139

Dermatomyositis, P-31 MR spectroscopy and MRI, 5ab(11)

Desferrioxamine, In-111, MoAb-CU-18 conjugation, oligosaccharide moiety, 936ab(5)

Dexamethasone, effect on extracellular space, influx and plasma volume, human brain tumors, 899ab(5)

Diabetes, *Klebsiella pneumoniae* osteomyelitis, three-phase radionuclide bone imaging, 1412

Diabetes mellitus
nephropathy, early detection, Tc-99m DTPA and I-131 hippuran, 941ab(5)
pedal osteomyelitis, three-phase bone scintigraphy, In-111 leukocytes, 753ab(5)
type 1, modulation of gastric emptying, blood glucose concentrations, 795ab(5)
type 2, esophageal and gastric emptying, 795ab(5)

Dialysate sodium, concentration, skeletal muscle and subcutaneous blood flow, 4ab(4)

Diazepam, radioiodinated derivative, SPECT studies, benzodiazepine receptor, 803ab(5)

Diet
nutrient hepatic blood flow, age-related reduction, 1748ab(10)
protein, radionuclide assessment, glomerular filtration rate, 785ab(5)

Diethylenetriamine, labeling of human IgG, Rh-105 complexes, 832ab(5)

Digoxin, radioiodinated derivative, Na,K-ATPase binding, myocardial imaging agent, 923ab(5)

3,3-Dimethyl(p-I-123 phenyl-)pentadecanoic acid, uptake in excess to rMBF, reperfused myocardium, 797ab(5)

Dipyridamole
effects on cadiac MRI, coronary artery disease, 840ab(5)
-induced myocardial ischemia, reduction by caffeine, 861ab(5), 1723
infusion for CAD detection, I-123 phenylpentadecanoic acid tomography, 760ab(5)
Rb-82 PET and Tl-201 SPECT disparities, myocardial perfusion imaging, 861ab(5)
-redistribution Tl-201 ECT, children, Kawasaki disease, 760ab(5)
"stress", dynamic exercise, ambulatory ST changes and perfusion, 861ab(5)
Tl-201 imaging
comparative efficacy, adenosine infusion, 730ab(5)
lazy man's stress test, 281
transient mitral regurgitation, myocardial ischemia, 1271
Tl-201 SPECT
left bundle branch block, 2ab(11)
compared to exercise RNV, jeopardized myocardium detection, 862ab(5)
future cardiac events, angina pectoris, 861ab(5)
high-risk patient identification, coronary artery disease , 862ab(5)

Distinguished Scientist Award, David A. Goodwin, N14

DMSA, studies in infants under one year old, 5ab(4)

Dobutamine, quantification of myocardial metabolic reserve, C-11 acetate, PET, 837ab(5)

Dopamine
asymmetric synthesis, 6-[F-18]fluoro-L-dopa, NCA nucleophilic fluorination, 752ab(5)
Br-75 6-bromo-*m*-tyrosine as tracer, synthesis, evaluation, 924ab(5)
central norepinephrine protracer, synthesis, F-19/F-18 MOPS, 929ab(5)
D-2 imaging agent, I-123 IBF, 762ab(5)
dopaminergic radiotracer, I-125 MHTP, mechanism of accumulation, 761ab(5)
imaging of *in vivo* chemistry, N1287
infusion, myocardial glucose uptake, regional ischemia, 859ab(5)
neurons, quality control procedure, 6-[F-18] fluoro-L-DOPA, 1249
presynaptic dopaminergic function, probe, 4[F-18]fluoro-L-*m*-tyrosine, 752ab(5)
protracers for neuron mapping, [H-3]-L-*m*-tyrosine, [H-3] α-methyl-L-*m*-tyrosine, 752ab(5)
receptors: *see* Receptors

Dosimetry
conventional internal, limitations, cellular levels, 826ab(5)
distributions for alpha and beta particle emitters, intraperitoneal radioimmunotherapy, 777ab(5)
EGS4 Monte Carlo determination, beta dose kernel in water, 883ab(5)
encapsulated nondigestible In-111 source, human gastrointestinal tract, 882ab(5)
estimation of bone marrow doses, delivery, radioimmunotherapy, 778ab(5)
gastrointestinal cancer radioimmunotherapy, administration, monoclonal antibodies,

779ab(5)
heterogeneity of monoclonal antibody uptake, human tumor xenografts, Sprint tomographic scanner, 777ab(5)
human radioimmunotherapy estimates, mouse data basis, antibody carrier/radionuclide combinations, 777ab(5)
hyperthyroidism radioiodine treatment, extra-thyroidal absorbed doses, 833ab(5)
I-123 IBZM biodistribution, 834ab(5)
I-125 seed implants using SPECT, 1748ab(10)
I-131 anti-idiotype monoclonal antibody, B cell lymphoma, 826ab(5)
I-131 HMFG1 monoclonal antibody, whole body profile scanning, 884ab(5)
inhomogenous deposition of radiopharmaceuticals, cellular level, 883ab(5)
internal, model, peritoneal cavity, 2002
iodoantipyrine labeled with radioactive iodine, 1ab(2)
kinetics of radiolabeled antibody penetration, micrometastatic cell clusters, 777ab(5)
new coated-bead dosage form, I-131 sodium iodide, 886ab(5)
pretherapy, monoclonal anti-CEA antigen I-123 $F(ab')_2$ fragments, 962ab(5)
radiation
exposure and risk, performance of radiologic studies, 884ab(5)
In-111 antimyosin pharmacokinetics, 833ab(5)
radionuclide hysterosalpingography, Tc-99m, 415(le)
splenectomy, intraarterial P-32 chromic phosphate, 884ab(5)
radiobiological efficacy, clinical radioimmunotherapy, 827ab(5)
"S" factors for self-dose to large tumors, selected therapeutic radionuclides, 883ab(5)
Tc-99m ethyl cysteinate dimer, biodistribution, chronic cerebral infarction, 1018
variations in absorbed dose, radiolabeled monoclonal antibodies, murine-human xenografts, 777ab(5)
Drug abusers, regional cerebral blood flow, SPECT, 1ab(11)
Drug targeting, F-19 nuclear magnetic resonance, animal tumor models, 814ab(5)
Dual-photon absorptiometry (DPA)
bone mineral content, lumbar spine vertebrae, uremic patients, 774ab(5)
bone mineral density response, non-hormonal cyclic therapy, postmenopausal osteoporosis, 774ab(5)
nuclear magnetic imaging, systemic mastocytosis, 2046
scintigraphic findings and bone mineral content, Paget's disease, 855ab(5)
Duplexsonography, captopril renography and, renovascular hypertension, 6ab(4)
DuPont Nuclear Medicine Technologist Advisory Board, Professional Development Program, N1588
Dyslexia, PET studies, 802ab(5)
Dysphasia
congenital, brain blood flow, Tc-99m HM-PAO SPECT, 798ab(5), 1825
developmental, abnormal regional response, SPECT and xenon-133, 812ab(5)

E

Echocardiography, radial shortening and myocardial thickening, Tc-99m MIBI, 821ab(5)
Editorials
Cardiovascular nuclear medicine: the next step, 1123
Disease versus etiology, 1273
Excretion of radioiodine in breast milk, 124
Education and Research Foundation (E&R), student fellowships, N1441
EHPG complexes, behavior with metal ions, 848ab(5)
Ejection fraction
continuous radionuclide ventricular function, coronary angioplasty, 770ab(5)
evaluation of ventricular function, coronary artery disease, 1149
first pass left ventricular, iridium-191m, new generator system, 817ab(5)
left ventricular diastolic filling, left ventricular systolic dysfunction, 868ab(5)
nature of background, radionuclide ventriculography, 872ab(5)
patient-borne CsI-photodiode detector, left ventricular function, ST segment, 868ab(5)
percutaneous aortic balloon valvuloplasty, radionuclide ventriculography, 867ab(5)
pulmonary uptake of thallium-201, exercise, 788ab(5)
Electrocardiogram (ECG) gating
Tl-201 myocardial SPECT, clinical evaluation, 864ab(5)
whole body multidetector SPECT, variable aperture, 796ab(5)
Electrocorticography, PET and, epilepsy surgery, children, 896ab(5)
Embolization, therapeutic transcatheter, improved radiolabeling technique, ivalon, 1399
Emission computed tomography
analysis of cardiac perfusion tomography, new quantitative method, 871ab(5)
commercially available SPECT systems
assessment, 893ab(5)
assessment, progress report, 963ab(5)
cortical circumferential profiling, 816ab(5)
3-D brain phantom, 851ab(5)
dipyridamole-redistribution Tl-201, children, Kawasaki disease, 760ab(5)
high spatial resolution time-of-flight positron tomograph, physical performances, clinical images, 766ab(5)
image reconstruction, Bayesian methods, planar image processing, 880ab(5)
interpolating shape and intensity, 960ab(5)
new Genesys center of rotation, radius of orbit, 893ab(5)
quantitative cerebral blood flow activation, I-123 iodoamphetamine, 811ab(5)
validation of Bayesian reconstruction, Monte Carlo simulations, real data, 755ab(5)
Emphysema, comparison of V/Q and CT, *alpha*-1 antitrypsin deficiency, 1755ab(10)
Encephalopathy, HIV-positive, I-123 IMP SPECT brain scanning, 811ab(5)
Endotoxemia, pulmonary localization, In-111 neutrophils, monoclonal antibodies, 852ab(5)
Endotoxins, testing with limulus amoebocyte lysate, radiopharmaceuticals, chelating agents, 921ab(5)
Enema, mesalamine, colonic coverage, ulcerative coverage, 764ab(5)
Environmental Protection Agency (EPA)
continuing debate over radon, N987
med-waste regulations, N1431
radionuclide emission standards, N1435
Epilepsy
evaluation of neuropsychiatric disorders, PET, CT and MRI, 1589
focal, ictal Tc-99m HM-PAO SPECT, 751ab(5)
localization of epileptogenic foci, PET, 2ab(11)
postictal studies and SPECT, N1289
seizure focus localization, interictal and ictal SPECT, cerebral blood flow, 751ab(5)
surgery in children, PET, intraoperative electrocorticography, 896ab(5)
temporal lobe
diagnostic patterns, post-ictal cerebral blood flow, 751ab(5)
opiate receptor regulation, C-11 diprenorphine and PET, 750ab(5)
presurgical evaluation, Xe-133 SPECT and Tc-99m HM-PAO, 896ab(5)
Epirubicin, different application schemes, radionuclide ventriculography, breast cancer, 867ab(5)
Epithelial membrane antigen, radiolabeled monoclonal antibody as target antigen, colorectal cancer, 808ab(5)
Erythromycin, abolition of gastric emptying discrimination, solids and liquids, 795ab(5)
Erythropoietin, radioimmunoassay, recombinant human erythropoietin, 918ab(5)
Escherichia coil, short-term ethanol consumption, R-E cell function of liver, Tc-99m sulfur colloid, 1ab(2), 815ab(5)
Esophagus
dilatation, assessment and follow-up, achalasia, 851ab(5)
gastric emptying and, type 2 diabetes mellitus, 795ab(5)
transit scintigraphy, effect of projection, 850ab(5)
Ethanol, short-term consumption, R-E cell function of liver, Tc-99m sulfur colloid, 1ab(2), 815ab(5)
European Association of Nuclear Medicine Congress, 1989, N1921
European Economic Community, symposium, N1588
Europium-153, dual radionuclide SPECT, flood radionuclide choice, Tc-99m base, 872ab(5)
EXAFS spectroscopy, structural studies on technetium, rhenium diphosphonates, 732ab(5)
Exercise
bicycle, silent myocardial ischemia, first pass radionuclide angiography, 868ab(5)
dynamic, ambulatory ST changes and perfusion, dipyridamole "stress", 861ab(5)
effects on myocardial kinetics, I-123 phenylpentadecanoic acid, 829ab(5)
-induced myocardial ischemia, iodine-123 fatty acid, compared to thallium-201, 729ab(5)
one and two day rest and treadmill tests, comparison, Tc-99m HEXAMIBI, 790ab(5)
peak, anaerobic threshold, left ventricular function, 1744ab(10)
pulmonary uptake of thallium-201, 788ab(5)
right ventricular uptake, Tc-99m MIBI and Tl-201, 820ab(5)
RNV, compared to dipyridamole Tl-201 SPECT, jeopardized myocardium detection, 862ab(5)
Tl-201 SPECT
false positive, men, 749ab(5)
myocardial perfusion abnormality, 749ab(5)
treadmill, first-pass radionuclide angiography, 770ab(5)

vigorous, response, splenic platelet pool, 738ab(5)

F

Fab fragments
diagnosis of acute heart transplant rejection, In-111 antimyosin Fab mAb imaging, 847ab(5)
monoclonal antibodies, biodistribution, anti-mouse antibody effects, 847ab(5)
non-specific lymph node background, monoclonal antibody lymphoscintigraphy, 847ab(5)
radiolabeled monovalent and divalent haptens, dual specificity monoclonal antibody conjugates, 1358
Tc-99m labeled antibody-bifunctional chelator conjugates, 793ab(5)
Tc-99m monoclonal antibody, small cell lung carcinoma, 819ab(5)
Fat, Xe-133 hepatic retention ratio, 1708
Fatty acids
altered myocardial perfusion, small-vessel disease, 829ab(5)
characterization of carrier, human myocardium, 798ab(5)
I-123 phenylpentadecanoic acid, myocardial scintigraphy, 829ab(5)
myocardial metabolism, 1-[C-11] betamethylheptadecanoic acid, 797ab(5)
radioiodinated, dual tracer autoradiography, cardiomyopathy, 80
radioiodinated IPPA and BMIPP, HPLC analysis, 923ab(5)
Feet, scintigraphic evaluation, 959ab(5)
Ferritin, transfer of In-111 and Ga-67, transferrin, phosphate-containing compounds, 70
Fibrin, -specific monoclonal antibodies, thrombus imaging, 747ab(5)
Fibrinopeptide, urinary, evaluation, pulmonary embolism, 733ab(5)
Filters
finite spatial, scintigraphic images, energy weighted acquisition, 2029
restoration, collimator, quantitative imaging with I-131 antibody, 876ab(5)
Wiener
combined conjugate views in SPECT, 756ab(5)
improved SPECT quantification, myocardial ischemia, 755ab(5)
Fistulae
hemodialysis, In-111 WBC enhancement, Tc-99m RBC subtraction, 10ab(4)
pleural cerebrospinal fluid, diagnosis, radionuclide cisternography, 120
tracheoesophageal, gastrointestinal visualization, Xe-133 ventilation study, 258
Fluorine, -substituted progestins, uptake selectivity, 928ab(5)
Fluorine-15, modified diuresis renography, uses and interpretation, 3ab(4)
Fluorine-18
automated blood sampler, high count rate, 745ab(5)
brain corticosteroid receptors, 821ab(5)
electrophilic, small proton cyclotron, 927ab(5)
fluorinated U-50488 analogs, characterization, PET studies, 931ab(5)
high-resolution positron emission tomography, clinical efficacy, 765ab(5)
least-squares optimization, reconstruction filters, high resolution PET, 745ab(5)
NO_2 aromatic nucleophilic substitution reactions, no-carrier-added, nitrocinnamic acid derivatives, 1757ab(10)
PET and SPECT detection of residual viable tissue, myocardial infarctions, different ages, 869ab(5)
progesterone receptor binding ligands, PET, 929ab(5)
receptor imaging agents, direct analysis, binding assays, 931ab(5)
Fluorine-18 aromatic compounds, nucleophilic aromatic substitution, electron-rich aromatic rings, 753ab(5)
Fluorine-18 benzamide analogs, potential ligands, imaging dopamine D-2 receptors, PET, 899ab(5)
Fluorine-18 2-deoxy-2-fluoro-D-glucose
evaluation as imaging agent, malignant melanoma, 738ab(5)
PET, therapeutic effect, malignant lymphoma, 910ab(5)
Fluorine-18 deoxyglucose
cortical and thalamic glucose consumption, Huntington's disease, PET, 771ab(5)
PET
I-123 QNB SPECT, dementia, 896ab(5)
myocardial glucose utilization, 359
radiotherapy effect, tumor metabolism, 789ab(5)
relief of chronic ischemia, recovery of myocardial metabolism, 838ab(5)
visual analysis of PET images, reproducibility, reliability, 846ab(5)
Fluorine-18 DFPA, synthesis and biodistribution studies, 928ab(5)
Fluorine-18 estrogens, 17α-ethynyl-11β-substituted, improved PET imaging agent, 753ab(5)
Fluorine-18 FES, estrogen receptor concentration, tamoxifen, 910ab(5)
Fluorine-18 fluoride
extraction from O-18 water, fibrous ion exchange resin, 926ab(5)
fluorination of heteroaromatic compounds, nucleophilic displacement, halide, 925ab(5)
new radiotracer for PET, dopamine D2 receptors, 1757αD(10)
Fluorine-18 fluorocinnarizine, synthesis, calcium channel blocker, 753ab(5)
Fluorine-18 fluorodeoxyglucose
automated radiopharmaceutical production, proton only cyclotron, 965ab(5)
automated synthesis, 2ab(11)
cerebral aerobic and anaerobic metabolism, simultaneous determination, 838ab(5)
cerebral glucose metabolism, PET, Alzheimer's disease, 771ab(5)
compared to C-11 methionine, differential diagnosis, lung tumor, 788ab(5)
deoxyglucose and, regional comparison, lumped constants, 900ab(5)
"first session" effects in PET studies, 899ab(5)
kinetic rate constants, brain tumor and dementia, 900ab(5)
O-15 water PET, colorectal carcinoma, radiation therapy, 909ab(5)
PET
detection, residual or recurrent brain and liver tumors, 909ab(5), 966ab(5)
pancreas cancer, chronic pancreatitis differentiation, 887ab(5)
powder inhalation, pulmonary mucociliary transport, 917ab(5)
Tl-201 and I-123 IMP SPECT, brain tumor, 895ab(5)
two behavioral states, single procedure, 93
production, computer-controlled synthesis unit, 968ab(5)
radiation dose to bladder wall, dynamic bladder model, 1747ab(10)
radiotherapy, imaging of noncerebral tumors, 912ab(5)
regional cerebral metabolic rates, fixed dephosphorylation rate, 1483
reversal of brain metabolic abnormalities, AIDS dementia treatment, AZT, 581
routine production, direct nucleophilic exchange, quaternary ammonium resin, 1758ab(10)
uptake in benign and malignant musculoskeletal tumors, 1753ab(10)
uptake in human tumor xenografts, feasibility studies, cancer imaging, 912ab(5)
Fluorine-18 4-fluorodeprenyl, synthesis, probe, functional monoamine oxidase, 821ab(5)
Fluorine-18 fluoro-L-dopa
asymmetric synthesis, NCA nucleophilic fluorination, 752ab(5)
compartmental model, kinetics, cerebral tissues, 735ab(5)
importance of carbidopa, PET studies, 761ab(5)
pharmacokinetics, 1757ab(10)
presynaptic nigrostriatal function, Parkinson's disease, 761ab(5)
quality control procedure, brain dopamine neurons, 1249
Fluorine-18 fluoroestradiol, PET assessment of uptake, metastatic breast carcinoma, 788ab(5)
Fluorine-18 fluoroethylketanserin, no-carrier-added synthesis, cerebral serotonin S-2 binding ligand, 822ab(5)
Fluorine-18 fluoroethyl SCH-23390, no-carrier-added synthesis, mapping, cerebral dopamine D-1 receptors, 931ab(5)
Fluorine-18 fluorometaraminol, C-11 hydroxyephedrine alternative, heart neuronal imaging, 767ab(5)
Fluorine-18 fluoromisonidazole
detection of viable hypoxic myocardium, PET, 846ab(5)
enhanced extraction in jeopardized myocardium, PET assessment, 730ab(5)
hypoxia imaging of tumors, 789ab(5)
radiosynthesis, 343
retention, model, PET image interpretation, 735ab(5)
Fluorine-18 fluorotyrosine, cerebral metabolism, PET tracer of protein synthesis, 1367
Fluorine-18 fluoro-L-*m*-tyrosine, probe, presynaptic dopaminergic function, 752ab(5)
Fluorine-18 fluoro-D,L-*m*-tyrosine, protracer for dopamine neuron mapping, 752ab(5)
Fluorine-18 fluoropropyl preclamol, no-carrier-added synthesis, mapping, cerebral sigma opiate receptors, 930ab(5)
Fluorine-18 fluoropropylputrescine, potential PET imaging agent, prostate and prostate-derived tumors, 1205
Fluorine-18 haloperidol, binding in baboon and human brain, kinetic analysis, 898ab(5)
Fluorine-18 *m*-hydroxyphenylserine, synthesis, central norepinephrine protracer, 929ab(5)
Fluorine-18 misonidazole, myocardial kinetics, marker of hypoxia, 351
Fluorine-18 N-3-propyldiprenorphine, sex-dependent differences, distribution and metabolism, 732ab(5)

Fluorine-18 pipamperone, synthesis and PET studies, baboon, 932ab(5)
Fluorine-18 uracil
changes in tumor volume, chemotherapy, colorectal carcinoma, 911ab(5)
N-13 glutamate and, perfusion and shunting, colorectal carcinoma, 910ab(5)
O-15 water and, PET, regional chemotherapy of liver metastases, 1754ab(10)
PET, metastatic colorectal cancer, 910ab(5)
Fluorine-19
magnetic resonance spectroscopy, 5-fluorouracil pharmacokinetics, 813ab(5)
nuclear magnetic resonance
drug targeting, animal tumor models, 814ab(5)
5-fluorouracil trapping, therapeutic effectiveness, 813ab(5)
Fluoroacetate, acetate uptake and, glucose metabolic rate, 900ab(5)
Fluoroalkyl amphetamine analogs, synthesis and evaluation, serotonin 5-HT2 agonists, PET, 822ab(5)
Fluorodeoxyglucose
causes of variability in studies, N1288
imaging and Tl-201 redistribution, value of quantitative Tl-201 SPECT, 863ab(5)
kinetic determination of model parameters, high-resolution PET, 879ab(5)
optimal experimental design, tissue data, 879ab(5)
parametric images of myocardial glucose utilization, dynamic cardiac FDG-PET studies, 735ab(5)
-PET, evaluation of seizures, primary brain tumors, 2ab(11)
PET and MRI, pathologic findings, complex partial seizures, 752 ab(5)
relationship between Q-wave and circulation metabolism, threshold determination, 830ab(5)
whole body imaging technique for PET, 1750ab(10)
5-Fluorouracil
pharmacokinetics, F-19 magnetic resonance spectroscopy, 813ab(5)
therapeutic effectiveness, F-19 nuclear magnetic resonance, 813ab(5)
Follicle-stimulating hormone, specificity of radioimmunoassay, polyclonal and monoclonal antibodies, 919ab(5)
Food and Drug Administration (FDA), pilot drug review division, N1147
Furosemide
diuretic renography, 841ab(5)
serial renography, asymptomatic hydronephrosis, ultrasound, 4ab(4)
standard method *vs.* direct intrapelvic infusion, diuretic renography, 7ab(4)

G

Gadolinium, -labeled microspheres and liposomes, MRI, lung parenchyma, 901ab(5)
Gadolinium-153
clearance and organ distribution, MRI contrast agent, 840ab(5)
simultaneous transmission/emission SPECT, moving line source, 964ab(5)
Gadolinium-155, dual radionuclide SPECT, flood radionuclide choice, Tc-99m base, 872ab(5)
Gadolinium-DTPA
brain uptake, blood-brain barrier integrity, MRI conditions, 839ab(5)
enhanced brain tumor imaging, T1 and T2 relaxation times, MRI, 902ab(5)
evaluation of musculoskeletal sarcomas, 901ab(5)
Gallbladder
administration of contracting agent, reflux sign, cholescintigraphy, 1192
gastrointestinal transit, Crohn's disease, 764ab(5)
morphine hepatobiliary scintigraphy, potential pitfalls, 850ab(5)
perforation, sensitivity, cholescintigraphy and sonography, 850ab(5)
Gallium, new amino-thiol ligand, radiopharmaceutical use, 922ab(5)
Gallium-67
apical pattern of lung uptake, AIDS, aerosolized pentamidine, 744ab(5)
"delayed" localization, clinical significance, 969ab(5)
detection of infected orthopedic implants, 754ab(5)
diagnostic accuracy of skeletal infection, blood pool sign, 774ab(5)
labeled bivalent haptens, improved tumor uptake, immunoscintigraphy, 762ab(5)
new generation scintillation camera system, 855ab(5)
radionuclide evaluation, acute pulmonary emboli, right ventricular function, 853ab(5)
relationship, Tl-201 scintigraphy, lymphoma, 915ab(5)
SPECT, evaluation, recurrent lymphoma, 874ab(5)
Tc-99m DTPA lung clearance, HIV-related lymphocytic alveolitis, 746ab(5)
Tc-99m α-D-glucose 1-phosphate, lung carcinoma imaging, 913ab(5)
three-phase bone scans and, prediction, osteomyelitis cure, 754ab(5)
transfer from transferrin to ferritin, phosphate-containing compounds, 70
tumor accumulation, lysosomal role, dual-tracer studies, 921ab(5)
uptake
rejecting and nonrejecting cardiac implants, 1464
tumors, whole body irradiated mice, 913ab(5)
utility
24-hour images in acute pulmonary processes, AIDS, 888ab(5)
transmission computerized tomography, lymphoma, 914ab(5)
Gallium-67 citrate
detection of focal inflammation, scintigraphy, 385
detection of inflammatory lesions, Tc-99m HM-PAO leukocytes, 1332
diagnostic role of nuclear medicine, acquired immunodeficiency syndrome, 1935
nonspecificity of localization, sickle cell-related marrow infarction, 855ab(5)
scintigraphy, salmonella-infected thrombus, left ventricular aneurysm, 1277(le)
Tc-99m albumin comparison, lung scanning, HIV-positive patients, 917ab(5)
Gallium-67 DAS-DFO-fibrinogen, pitfalls in detection of thrombi, transplanted grafts, 914ab(5)
Gallium-67 deferoxamine, labeled antibody, spacer, maleimidoethyl succinimyl succinate, 832ab(5)
Gallium-67 MDP, distribution in rats, 857ab(5)
Gallium-67 monoclonal antibody, development of antibody cocktail, radioimmunodetection, adenocarcinoma, 935ab(5)
Gallium-68, labeled bivalent haptens, improved tumor uptake, immunoscintigraphy, 762ab(5)
Gallium-68 DTPA-VLDL, PET quantification, tissue low-density lipoprotein receptor activity, 763ab(5)
Gallium-69 transferrin, iron-59 and In-111, vascular permeability, transferrin receptor, 1676
Gamma cameras
camera- and well-counting techniques, portal systemic shunting, 890ab(5)
commercially available SPECT systems assessment, 893ab(5)
assessment, progress report, 963ab(5)
four-headed, dynamic SPECT, regional cerebral blood flow, 792ab(5)
glomerular filtration rate inaccuracies, diverging collimator, 941ab(5)
high spatial resolution SPECT, small-animal resolution, 796ab(5)
image restoration and applications, 876ab(5)
line resolution pattern, new intrinsic resolution test pattern, 1134(le)
modern, comparison, imaging parameters, 3ab(2)
multiple-energy, dynamic transport studies, 852ab(5)
phantom feet on digital radionuclide images, 1559
renography, renal vein renin *vs.* peripheral plasma renin, renovascular hypertension, 6ab(4)
surgical imaging probe for tumor detection, 891ab(5)
technique for evaluation of anisotropy, collimators used for SPECT, 894ab(5)
Gangliosides, antigenic, radioimmunoassay, monoclonal antibodies, 919ab(5)
Gastric emptying
abolition of discrimination between solids and liquids, erythromycin, 795ab(5)
esophageal and, type 2 diabetes mellitus, 795ab(5)
Garren-Edwards gastric bubble effect, 692
improved analytical method, 794ab(5)
influence of stress, 794ab(5)
left anterior oblique projection, peak-to-scatter ratio, attenuation compensation, 233
meal energy content effect, 1106
metoclopramide-induced patient restlessness, radionuclide imaging, 3ab(11)
modulation by blood glucose concentrations, type 1 diabetes mellitus, 795ab(5)
regulation of PET radiopharmaceuticals, N137
simplified analysis with PC-based system, weighted-least-squares regression, 794ab(5)
solid and caloric liquid meals, relationships, 887ab(5)
solid phase, reduced acquisition time, 1749ab(10)
Gastric function
colonic scintigraphy, chronic constipation, 887ab(5)
gastroesophageal scintigraphy and barium exams, pH probe studies, pediatric patients, 2ab(2)
Gastrointestinal tract
cancer
radioimmunotherapy, monoclonal antibody administration, 779ab(5)
radiolabeled antibody imaging, chelating agents, 909ab(5)

two probe systems, In-111 monoclonal antibody, 891ab(5)
complete duodenogastric reflux, scintigraphic sign, 1568
correlative pediatric imaging, 15
dosimetric calculations, encapsulated nondigestible In-111 source, 882ab(5)
evaluation of blind loop syndrome, bile salts, 962ab(5)
functional disturbances, after abdominal irradiation, 765ab(5)
gallbladder and, Crohn's transit, 764ab(5)
inflammatory bowel disease
autologous labeled In-111 leukocytes, 1ab(2)
In-111 white blood cells, 963ab(5)
transit, Tc-99m cellulose fiber, In-111 plastic particles, 402
visualization during Xe-133 ventilation study, tracheoesophageal fistula, 258

Gated blood-pool studies
equilibrium gated radionuclide ventriculography, post extra systolic potentiation, 870ab(5)
evaluation of ventricular function parameters, sampling requirements, corrections, 872ab(5)
Fourier-gated PET, wall motion analysis, 771ab(5)
gated SPECT, aortic and mitral valve regurgitation, 870ab(5)
left ventricular function, assisted circulation, artificial heart, 780ab(5)
myocardial perfusion and regional wall motion, coronary anatomy, anterior infarction, 739ab(5)
regional ejection fraction, definition, normal limits, 769ab(5)
Tc-99m RBC labeling interference, chronic renal failure patients, 869ab(5)
three dimensional cinematic display, SPECT, 770ab(5)
visualization of pulsatile lung circulation, 744ab(5)

Gated heart studies
detection of subendocardial ischemia, gated positron tomography, left ventricular hypertrophy, 866ab(5)
evaluation of ventricular function, coronary artery disease, 1149
quantification of amplitude images, 1393
quantification of 3D lef. ventricular segmental wall motion, radionuclide ventriculograms, 638
radial shortening and myocardial thickening, Tc-99m MIBI, echocardiography, 821ab(5)
realistic dynamic cardiac phantom, evaluation, radionuclide ventriculography, 542

Gates' technique
glomerular filtration rate, factors affecting measurement, 842ab(5)
renal artery stenosis detection, captopril test, hypertensives, 51
validation in children, 2ab(2)

Generators, isotope
carbon-based system, ultrashort-lived Ir-191m, left ventricular function, 1025
development, tellerium-118/antimony-118, 849ab(5)
iridium-99m left ventricular first pass angiocardiography, exercise, coronary artery disease, 818ab(5)
Krypton-81m gas, long-lived radioactive contaminant, 1574(le)
zirconium-tungsten gel, 849ab(5)

Glioma
antibody guided diagnosis, epidermal growth factor receptor, placental alkaline phosphatase, 1636
glucose and deoxyglucose phosphorylation ratio, hexokinase Michaelis-Menten kinetics, 838ab(5)
intracarotid infusion, intravascular streaming, PET, 839ab(5)
rat model, use of C1 *vs.* C2, C-11 glucose, 911ab(5)

Glomerular filtration rate (GFR)
Gates methodology, children, 1755ab(10)
quantitative calculations, Tc-99m DTPA camera images, 1747ab(10)
tubular secretion of MAG-3 and, rat kidney, 1936

Glucoheptonate
increased uptake, renovascular hypertension, 5ab(4)
scintirenogram, captopril effect, renal artery stenosis, 1759ab(10)

Glucose
cerebral metabolism
Alzheimer's disease, correlation of visual symptoms, 772ab(5)
Alzheimer's disease, disease severity, 965ab(5)
carbon monoxide poisoning, 802ab(5)
imaging of *in vivo* chemistry, N1288
normals, patients with optic nerve damage, 802ab(5)
quantitative comparison, two positron emission tomographs, 1386
thirty *vs.* forty-five-minute period, 899ab(5)
deoxyglucose phosphorylation ratio, hexokinase Michaelis-Menten kinetics, 838ab(5)
metabolism
cerebral acetate, fluoroacetate uptake, 900ab(5)
IBG as potential tracer, 921ab(5)
psychiatric patients, summer affective disorders, 1752ab(10)
modulation of gastric emptying, blood concentrations, type 1 diabetes mellitus, 795ab(5)
myocardial uptake, dopamine infusion, regional ischemia, 859ab(5)
myocardial utilization, PET, F-18 deoxyglucose, 359
regional cerebral metabolic rates, fixed dephosphorylation rate, 1483
three-dimensional visualization of brain, structure-function relationships, 1747ab(10)

Goodwin, David A., Distinguished Scientist Award, N14

Granulocytes, evaluation of labeling, Tc-99m D,L-HM-PAO, 2022

Grave's disease, anti-thyroid medications, thyroid scan, 1748ab(10)

H

Halide, nucleophilic displacement, fluorination, heteroaromatic compounds, 925ab(5)

HAMA response: *see* Antibodies, human anti-murine

Haptens, radiolabeled monovalent and divalent, dual specificity monoclonal antibody conjugates, 1358

Haynie, Thomas P, "Last Thoughts from the Editor to a Future Trust", T21

Head
irradiation for Hodgkin's disease, hyperthyroidism, low radioiodine uptake, 255
trauma, metabolic PET correlates, anatomic lesions, 802ab(5)

Health Care Financing Administration (HCFA)
ACR RVS close to implementation, Harvard study, second phase, N271
implementation of ICD-9-CM codes, N580
intention to deny Medicare coverage, bone mineral densitometry, N139
PET coverage, N580

Heart
acute coronary occlusion, critically ischemic myocardial mass, PET, 866ab(5)
180° and 360° reconstructions, Tl-201 and Tc-99m SPECT, 756ab(5)
angina pectoris, sympathetic nervous function, I-123 MIBG SPECT, 811ab(5)
aortic and mitral valve regurgitation, gated SPECT, 870ab(5)
artificial, left ventricular function, assisted circulation, 780ab(5)
blood-pool scintigraphy, Tc-99m DTPA-HSA, 1713
canine, myocardial retention, Tc-99m SQ30217, 860ab(5)
cardiac MRI, dipyridamole effects, coronary artery disease, 840ab(5)
cardiac RWMA, synthetic classification images, 816ab(5)
cardiac wall motion abnormalities, automated detection, 961ab(5)
cardiovascular nuclear medicine
European Association of Nuclear Medicine Congress, N1921
new Young Investigator Award, N14
the next step, 1123
characterization of *beta*-adrenergic receptors, CGP-12177, PET, 766ab(5)
competition between palmitate and ketone bodies, fuels, 797ab(5)
computer subtracted thallium cardiac images, 4ab(2)
coronary bypass surgery, In-111 anti-myocin scintigraphy, 780ab(5)
coronary insufficiency, cardiac events predictor, exercise radionuclide ventriculography, 1745ab(10)
correlative pediatric imaging, 15
cultured cardiac cells, Tl-201 and Tc-99m MIBI uptake, 860ab(5)
Cu(PTSM) localization, microsphere blood flow, 848ab(5)
detection of acute cardiac injury, Tc-99m glucaric acid, 1743ab(10)
detection of myocardial abscess, In-111 leukocyte scintigraphy, endocarditis, 703
diagnosis of coronary stenosis, application, machine intelligence, 816ab(5)
dynamic management of cardiological data, practical use, full relational model, 873ab(5)
early detection of mechanical-overload failure, clonidine pre-treatment, I-123 MIBG SPECT, 810ab(5)
economic analysis of clinical PET, Rb-82, 707
effect of stereochemistry, Tc-99m isonitrile, 773ab(5)
evaluation, renal imaging, thallium-201, 2ab(4)
gated cardiac blood-pool studies, three-dimensional display, 2036
high spatial resolution time-of-flight positron tomograph, physical performances, clinical images, 766ab(5)
human organ transplants, evaluation of viability, magnetic resonance spectroscopy,

813ab(5)
imaging agent synthesis, 4-*O*-(*E*)-iodopropenyl glucose, 3ab(11)
I-125 MIBG imaging, idiopathic congestive cardiomyopathy, cardiac transplants, 1182
impaired diastolic function, hypertensive patients, no left ventricular hypertrophy, 780ab(5)
importance of timing, Rb-82 PET, 871ab(5)
In-111 antimyosin pharmacokinetics, radiation dosimetry, 833ab(5)
independence of C-11 acetate kinetics, dietary state, 837ab(5)
ischemic disease, adenosine infusion, Tl-201 SPECT, 1745ab(10)
kinetics of copper-PTSM, PET, 1843
left ventricular diastolic filling patterns, hypertrophic cardiomyopathy, 868ab(5)
-lung transplantation, regional pulmonary perfusion, 1297
microsphere-like retention, copper-PTSM, blood flow and PET, 768ab(5)
myocardial imaging agents, synthesis, technetium-nitride cations, 773ab(5)
myocardial kinetics and exercise, I-123 phenylpentadecanoic acid, 829ab(5)
myocardial perfusion imaging
percholate, failure to inhibit Tc-99m isonitrile thyroid binding, 885ab(5)
simultaneous Tc-99m MIBI angiography, 38
neuronal imaging
C-11 hydroxyephedrine, 6-[F-18] fluorometaraminol, 767ab(5)
C-11 *m*-hydroxyephedrine synthesis, 783ab(5)
neuronal markers, H-3 phenylephrine, H-3 epinephrine, 733ab(5)
neutral and cationic myocardial perfusion agents, mechanistic comparison, 757ab(5)
no-carrier-added I-123 iodocyanopindolol, rapid high yield synthesis, 859ab(5)
noninvasive detection of left-to-right shunts, carbon-15 oxygen, cardiac PET study, 865ab(5)
non-uniform attenuation correction, SPECT, iterated radial post correction method, 870ab(5)
novel Tc-N_2S_2 complex, synthesis, characterization, 773ab(5)
parametric images of myocardial glucose utilization, dynamic cardiac FDG-PET studies, 735ab(5)
percutaneous aortic balloon valvuloplasty, radionuclide ventriculography, 867ab(5)
percutaneous transluminal coronary angioplasty, scintigraphy, myocardial reperfusion, 821ab(5)
perfusion imaging. Tc-99m MIBI, 790ab(5)
PET scans, partial volume and spillover correction, 824ab(5)
PET studies, N1289
postexercise lung Tl-201 uptake, SPECT, 288
pulse sequence of cine NMR imaging, 4ab(2)
radioiodinated IPPA and BMIPP fatty acid, HPLC analysis, 923ab(5)
rate, myocardial Tl-201 uptake and clearance, 1972
realistic dynamic cardiac phantom, radionuclide ventriculography, 542
reconstruction of truncated fan beam data, 755ab(5)
regional flows, capillary permeability, 798ab(5)
regional myocardial oxygen consumption, C-11 acetate PET, 1798
shunt size determination, atrial and ventricular levels, dynamic MRI, 903ab(5)
SPECT imaging, correction, nonuniform attenuation, 497
synthesis of aqueous N-13 ammonia, proton irradiation of water, hydrogen pressure, 926ab(5)
Tc-99m complexes with ester analogues, biological characteristics, 937ab(5)
three-dimensional cardiac PET, automated quantitation, routine clinical use, 775ab(5)
three-dimensional characterization of metabolism, PET, 808ab(5)
three-dimensional PET, automated quantitation, routine clinical use, 1787
total artifical, functional assessment. blood-pool radionuclide angiography, 1405
transplantation
clinical utility, radionuclide ventriculography, 781ab(5)
noninvasive follow-up, In-111 antimyosin scintigraphy, 862ab(5)
transplant rejection, diagnosis, In-111 antimyosin Fab mAb imaging, 847ab(5)
"upward creep", false-positive reversible defects, Tl-201 stress-redistribution SPECT, 1718
use of mercury-thiol resin, preparation, I-123 IPPA, 925ab(5)
value of blood-pool subtraction, In-111 platelets, 1445
whole body distribution and kinetics, cocaine, 831ab(5)

Hemangioma
hepatic, early blood pool phases, Tc-99m red blood cells, 815ab(5)
liver, scintigraphic and ultrasound features, 181
noncalcified splenic, detection, radionuclide bone scan, 1111
soft tissue, Tc-99m RBC scanning, 799ab(5)

Hemodialysis
access site infection, radionuclide diagnosis, 804ab(5)
fistulas, In-111 WBC enhancement, Tc-99m RBC subtraction, 10ab(4)

Heparin, -protamine reaction, In-111 protamine scanning, sheep, 917ab(5)

Hepatobiliary imaging
cholescintigraphy and sonography, sensitivity, gallbladder perforation, 850ab(5)
deconvolutional analysis of scans, jaundiced infant, 9ab(4)
early tumor response to therapy, PET, 789ab(5)
hepatobiliary dysfunction, cyclosporine A toxicity, Tc-99m EHIDA, 921ab(5)
morphine-augmented cholescintigraphy, 850ab(5)
scintigraphic features, choledochal cyst, 622
scintigraphy, morphine, potential pitfalls, 850ab(5)
semiquantitative scintigraphy, functional parameters, orthotopic liver transplant, 888ab(5)

Hevesy Nuclear Medicine Pioneer Award, John G. McAfee, N577

Hexadentate, bifunctional chelating agents, radiolabeling of antibodies, 1758ab(10)

Hexokinase, Michaelis-Menten kinetics, glucose and deoxyglucose phosphorylation ratio, brain and gliomas, 838ab(5)

Hip
arthroplasty, three-phase bone scan, indium white blood cell scintigraphy, 1321
asymptomatic cementless arthroplasty, bone scanning, femoral component, 858ab(5)
detection of infected prosthesis, Tc-99m phosphonate bone and In-111 leukocyte scanning, 562(le)
fractures, radionuclide bone imaging, early detection, 843ab(5)
SPECT, correction, bladder artifact, 857ab(5)

Hippurate, post-transplant renograms, long-term graft development, 784ab(5)

Hodgkin's disease, hyperthyroidism with low radioiodine uptake, head and neck irradiation, 255

Holmium-165, activation in biodegradeable microspheres, 836ab(5)

Holmium-166 FHMA, new agent for radiation synovectomy, 856ab(5)

Holospectral imaging, analysis of scatter, quantum noise, camera non-uniformity, 807ab(5)

Human immunodeficiency virus (HIV)
-associated myositis, detection, radionuclide bone scanning, 556
-positive encephalopathy, I-123 IMP SPECT brain scanning, 811ab(5)
-positive patients, Tc-99m albumin and Ga-67 citrate, lung scanning, 917ab(5)
-related lymphocytic alveolitis, Tc-99m DTPA lung clearance, gallium scans, 746ab(5)

Huntington's disease
cortical and thalamic glucose consumption, reduction, PET, 771ab(5)
detection of striatal functional impairment, primate model, PET, 762ab(5)
evaluation of neuropsychiatric disorders, PET, CT and MRI, 1589

Hydrogen-3, radioimmunoassay, cyclosporine concentrations, whole blood, 786ab(5)

Hydrogen-3 epinephrine, neuronal marker for heart, 733ab(5)

Hydrogen-3 fluoromisonidazole, binding of hypoxic cell marker, ischemic myocardium, 194

Hydrogen-3 α-methyl-L-*m*-tyrosine, protracer for dopamine neuron mapping, 752ab(5)

Hydrogen-3 *m*-hydroxyephedrine, neuronal marker for heart, 733ab(5)

Hydrogen-3 MK 329, cholecystokinin receptor localization, 849ab(5)

Hydrogen-3 L-*m*-tyrosine, protracer for dopamine neuron mapping, 752ab(5)

Hydrogen-3 phenylephrine, neuronal marker for heart, 733ab(5)

Hydronephrosis
antenatal, diuretic renography, 799ab(5)
asymptomatic, serial furosemide renography, ultrasound, 4ab(4)
lasix renal scintigraphy, pressure-perfusion test, 944ab(5)
renal parenchymal transit time of Tc-99m MAG_3, factor analysis, ROI selection, 3ab(4)

Hyperemia, forearm blood flow measurements, Tc-99m serum albumin, after brachial arteriotomy, 45

Hyperplasia, focal nodular, hepatocellular carcinoma diagnosis, Tc-99m DISIDA, 1278(le)

Hypertension
captopril-enhanced renal scintigraphy, Tc-99m DTPA, 615
captopril test, 1422(le)
decreased renal blood flow, extracorporeal shock wave lithotripsy, 4ab(11)
essential, intrarenal plasma flow, angiotensin converting enzyme, 6ab(4)
glomerular filtration rate, atrial natriuretic peptide, 941ab(5)

impaired diastolic function, without left ventricular hypertrophy, 780ab(5)
neonatal, captopril scintigraphy, 798ab(5)
renal artery stenosis detection, Gates' technique, captopril test, 51
renovascular
captopril, Tc-99m GHA and Tc-99m DMSA, 841ab(5)
captopril renography, duplexsonography, 6ab(4)
diagnosis, captopril scintigraphy, 944ab(5)
increased glucoheptonate uptake, 5ab(4)
parametric imaging, renal function, 5ab(4)
primary parenchymal disease *vs.* secondary disease, 942ab(5)
renal vein renin *vs.* peripheral plasma renin, gamma camera renography, 6ab(4)
Tc-99m MAG_3 clearances, captopril, 666
two-kidney/two-clip, captopril-stimulated renography, renal vein renins, 5ab(4)
Hyperthermia, malignant, Tc-99m pyrophosphate scintigraphy, 718(le)
Hyperthyroidism
head and neck irradiation, 2063(le)
low radioiodine uptake, head and neck irradiation, Hodgkin's disease, 255
nonimmunogenic, radioiodine, surgical treatment, 1960
primary, renal tubular reabsorption, 2ab(4)
TSH-receptor antibody measurements, clinical significance, 786ab(5)
Hypoxia
F-18 fluoromisonidazole tumor imaging, 789ab(5)
marker, myocardial kinetics, F-18 misonidazole, 351
myocardial extraction of Tc-99m sestamibi, flow effects, thallium-201, 756ab(5)
ouabain and, myocardial uptake kinetics, Tc-99m HEXAMIBI and Tl-201, 1500
regions of low myocardial flow, 808ab(5)
Hysterosalpingography, radionuclide, radiation dosimetry, Tc-99m, 415(le)

I

Ibuprofen, In-111 neutrophils, myocardial infarction, reperfusion injury, 859ab(5)
Image processing
image restoration and, gamma camera, 876ab(5)
planar, Bayesian methods, ECT image reconstruction, 880ab(5)
principal axis transformation, image registration, 776ab(5)
Image reconstruction
accuracy of contour detection, small objects, scintigraphic images, 806ab(5)
maximum likelihood, PET, 776ab(5)
Immune complexes, Tc-99m metallothionein-conjugated mouse mAb B72.3, pharmacokinetic evaluation, monkeys, 1351
Immunogens, synthetic peptide, cardiac myosin light chain 1 mAb, radioimmunoassay, 785ab(5)
Immunoglobulin
complex formation, murine monoclonal antibodies, 10ab(4), 888ab(5)
detection of focal inflammation, scintigraphy, Ga-67 citrate and Tc-99m albumin, 385
Immunoglobulin G
antibody labeling, rapid and efficient method, Tc-99m, 793ab(5)
biotinylated, rapid blood clearance, avidin infusion, 66
conjugation of MoAb-CU-18, desferrioxamine In-111, oligosaccharide moiety, 936ab(5)
In-111-labeled, monitoring response, antimicrobial therapy, 890ab(5)
In-111 radiolabeled proteins, autoradiographic method, quantitation, 889ab(5)
labeling with Rh-105 complexes, diethylenetriamine derivatives, 832ab(5)
polyclonal, radionuclide imaging, atherosclerosis, 1095
radioimmunotherapy of colorectal carcinoma xenografts, Y-90 CO17-1A, 935ab(5)
Tc-99m-labeled, imaging, inflammatory arthritis, 2017
yttrium-labeled anti-CEA monoclonal antibodies, radioimmunotherapy, 848ab(5)
Immunoglobulin M, monoclonal antibodies, pharmacokinetics, 909ab(5)
Immunoreactivity
higher immunoreactive fraction, antigen-binding site protection, radiolabeling, 932ab(5)
monoclonal antibody, Lindmo double reciprocal analysis, 903ab(5)
Immunoscintigraphy
charge modification of monoclonal antibodies, enhanced target localization, 762ab(5)
colorectal carcinoma, clinical value, 1646
diagnosis of acute heart transplant rejection, In-111 antimyosin Fab mAb imaging, 847ab(5)
diagnostic efficacy, SPECT and I-131 anti-CEA/CA 19-9, colorectal cancer, 907ab(5)
effect of human anti-mouse antibodies, 786ab(5)
follow-up of cutaneous melanoma, 907ab(5)
human leukemia xenografts, radiolabel and antigen modulation, 889ab(5)
improved tumor uptake, In-111, Ga-67 and Ga-68, 762ab(5)
In-111 monoclonal antibody, ovarian carcinoma, 758ab(5)
liver metastases, Tc-99m monoclonal anti-CEA antibody, colorectal carcinoma, 748ab(5)
melanoma targeting, monoclonal antibody cocktail, human HMW-MAA, 390
preparation of new agents, 936ab(5)
prospective study, ovarian carcinoma, 758ab(5)
Tc-99m and I-131 monoclonal antibody, stage IV neuroblastoma, 904ab(5)
Tc-99m genetically engineered chimeric metallothionein antibody, 794ab(5)
Immunospheres, Tc-99m albumin, intravascular targeting, 934ab(5)
Immunosuppression
Ga-67 uptake in tumors, whole body irradiated mice, 913ab(5)
local lymphoid irradiation, palladium-190, 890ab(5)
Impotence
male
non-invasive technique, 784ab(5)
radioisotope penile plethysmography, 784ab(5)
Indium-111
accumulation in liver, administration, B72.3 antibody, 1575(le)
anti-EGF receptor monoclonal antibody, phase I, imaging trial, 746ab(5)
clinically practical quantitative SPECT, 881ab(5)
desferrioxamine, MoAb-CU-18 conjugation, oligosaccharide moiety, 936ab(5)
development of noninvasive test, colonic transit in man, 764ab(5)
encapsulated nondigestible source, dosimetry, human gastrointestinal tract, 882ab(5)
GYK-DTPA-B72.3 monoclonal antibody, breast cancer detection, 819ab(5)
inhibition of platelet thrombosis, biomaterials, calcium ion sequestrants, 859ab(5)
iron-59 and Ga-69 transferrin, vascular permeability, transferrin receptor, 1676
labeled bivalent haptens, improved tumor uptake, immunoscintigraphy, 762ab(5)
new amino-thiol ligand, radiopharmaceutical use, 922ab(5)
non-invasive radionuclide assessment, colonic transit, 764ab(5)
preparation of new agents, immunoscintigraphy, 936ab(5)
radiolabeled proteins in tissues, autoradiographic method, quantitation, 889ab(5), 1538
stationarity of modulation transfer function, scatter fraction, conjugate view SPECT imaging, 755ab(5)
thrombus imaging, fibrin-specific monoclonal antibodies, 747ab(5)
transfer from transferrin to ferritin, phosphate-containing compounds, 70
Indium-111 antibodies
anti-CEA antibody, colorectal carcinoma, 908ab(5)
I-125 antibody and, dual isotope study, athymic mice, 374
Indium-111 antimelanoma monoclonal antibody, ZME-018, quantitative measurement, 885ab(5)
Indium-111 antimyosin
delineation of myocardial damage, cardiomyopathy, 779ab(5)
pharmacokinetics, radiation dosimetry, 833ab(5)
scintigraphy, noninvasive follow-up, heart transplant, 862ab(5)
scintigraphy after coronary bypass surgery, 780ab(5)
Tc-99m MIBI and, post-infarction myocardial viability, 800ab(5)
Tc-99m pyrophosphate and, detection of different stages, myocardial infarction, 862ab(5)
Indium-111 antimyosin Fab
monoclonal antibody imaging, diagnosis, acute heart transplant rejection, 847ab(5)
Tc-99m for anatomical landmarking, myocardial infarction, 800ab(5)
Tc-99m MIBI and, myocardial infarction, reperfusion, 757ab(5)
Indium-111 chemotactic peptide, rapid detection, focal sites of infection, 805ab(5)
Indium-111 chloride, joint imaging, rheumatoid arthritis, 855ab(5)
Indium-111 DTPA
clinical assessment of colon transit, 887ab(5)
low-density lipoprotein imaging, receptor activity, 768ab(5)
molecular structure, 1235
plasma clearance in liver and kidney transplants, measurement, glomerular filtration rate, 942ab(5)
Indium-111 DTPA-IgG, brain uptake, blood-brain barrier integrity, MRI conditions, 839ab(5)
Indium-111 granulocytes, sequestration in lungs, 1531
Indium-111 IgG
antimicrobial therapy, monitoring response,

890ab(5)
imaging of atheromatous lesions, iliac and femoral vessels, 817ab(5)
Indium-111 immunoconjugates, improved tumor imaging, cyclohexylpolyaminocarboxylates, 934ab(5)
Indium-111 leukocytes
appearance of Paget's disease, 754ab(5)
autologous label, inflammatory bowel disease, 1ab(2)
compared to three-phase bone scintigraphy, pedal osteomyelitis, diabetics, 753ab(5)
hemodialysis site infection, radionuclide diagnosis, 804ab(5)
scintigraphy, bone photopenia, clinical significance, 1749ab(10)
Tc-99m MDP images, false-positive, noninfected Charcot joints, 754ab(5)
Tc-99m phosphonate bone scanning, detection, infected hip prosthesis, 562(le)
urinary tract activity, 889ab(5)
Indium-111 low-density lipoproteins, imaging of atherosclerotic lesions, 787ab(5), 788ab(5)
Indium-111 metalloporphyrin, tumor imaging, 738ab(5)
Indium-111 monoclonal antibody
anti-laminin, detection, irradiation lung injury, 916ab(5)
B72.3
breast cancer detection, 2ab(2)
colorectal cancer, 320
biodistribution and tumor localization, colorectal carcinoma, 747ab(5)
cold antibody administration, colorectal cancer, 809ab(5)
colon cancer, 905ab(5)
compared to Y-88 monoclonal antibody, biodistribution, colon carcinoma xenografts, 672
detection of recurrent colorectal carcinoma, 748ab(5)
development of antibody cocktail, radioimmunodetection, adenocarcinoma, 935ab(5)
epithelial membrane antigen, target antigen, colorectal cancer, 808ab(5)
evaluation of two probe systems, gastrointestinal cancer, 891ab(5)
I-131 and, renal cell carcinoma xenografts, 906ab(5)
immunoscintigraphy, ovarian carcinoma, 758ab(5)
metabolism in nude mouse tissues, 888ab(5)
subcellular kinetics, liver and tumor, 907ab(5)
TAG-72 and, tumor expression, relationship, 908ab(5)
ZCE 025
concentration, primary lung cancer, 905ab(5)
HAMA development patterns, colorectal carcinoma, 906ab(5)
Indium-111 neutrophils
myocardial infarction, reperfusion injury, 859ab(5)
pulmonary localization, endotoxemia, monoclonal antibodies, 852ab(5)
Indium-111 oxine
distribution of cell-bound activity, human leukocytes, 804ab(5)
-labeled peripheral blood mononuclear cells, lymphatic malignancies, 1005
platelet scintigraphy, thrombocytopenia, children, 1819
Indium-111 plastic particles, gastrointestinal transit, 402
Indium-111 platelets
human pancreatic transplants, 1470
scintigraphy, false-positive, 267(le)
splenic dynamics, idiopathic thrombocytopenic purpura, 1546
value of blood-pool subtraction, cardiac imaging, 1445
Indium-111 protamine, scanning during heparin-protamine reaction, sheep, 917ab(5)
Indium-111 TE-BAT, new myocardial imaging agent, 367
Indium-111 tropolone, whole body and depth-independent build-up factor, platelet uptake, liver and spleen, 914ab(5)
Indium-111 tumor necrosis factor, breast carcinoma xenografts, 819ab(5)
Indium-111 white blood cells
diagnostic role of nuclear medicine, acquired immunodeficiency syndrome, 1935
enhancement of hemodialysis fistulas, Tc-99m RBC subtraction, 10ab(4)
evaluation of granulocyte labeling, Tc-99m D,L-HM-PAO, 2022
inflammatory bowel disease, 963ab(5)
vs. MRI, chronic complicated osteomyelitis, 754ab(5)
Inflammation, detection of lesions with Tc-99m HM-PAO leukocytes, compared to Ga-67 citrate, 1332
Inflammatory diseases, vertebral column, new scintigraphic technique, 856ab(5)
In Memoriam
Lakshman Rao Chervu, 723
Shanta Chervu, 723
William Graydon Myers, 1129
Interferon, response to therapy, hairy-cell leukemia, Tc-99m colloid liver/spleen scans, 2ab(2)
Interferon-αA, effect on monoclonal antibody targeting, carcinoma, 809ab(5)
Iodine
antigen-binding site protection, radiolabeling, higher immunoreactive fraction, 932ab(5)
-substituted benzamides, high affinity, SPECT, 803ab(5)
Iodine-123
chimeric mouse-human anti-CEA antibody of IgG4, immunoscintigraphy, colorectal carcinoma, 809ab(5)
diagnostic imaging of amyloidosis, 847ab(5)
diazepam derivative, benzodiazepine receptor, SPECT studies, 803ab(5)
N-(ω-iodoalkenyl)spiroperidol analogs, dopamine receptor imaging, SPECT, 925ab(5)
3-iodo-MK-801, NMDA receptor-ion channel complex, SPECT, 923ab(5)
iodovinylestrogens, steroidal and triphenylethylene-based, 924ab(5)
labeled SPECT cerebral perfusion agents, no-carrier-added radiosynthesis, 926ab(5)
octreotide, metabolism, clinical applications, 768ab(5)
radioiodinated digoxin derivative, myocardial imaging agent, Na,K-ATPase binding, 923ab(5)
radionuclide evaluation, acute pulmonary emboli, right ventricular function, 853ab(5)
scintigraphy of adrenergic receptors and neurons, myocardial infarcts, 767ab(5)
thyroid uptake, techniques for measurement, 886ab(5)
Iodine-123 amines
cerebral perfusion agents, no-carrier-added radiosynthesis, 926ab(5)
single-pass extraction, primate brain, 901ab(5)
Iodine-123 anti-CEA monoclonal antibody, early and delayed radioimmunoscintigrams, evaluation, colorectal carcinoma, 890ab(5)
Iodine-123 estradiol, breast cancer detection, 844ab(5)
Iodine-123 Fab fragments
anti-CEA imaging, 903ab(5)
monoclonal anti-CEA antigen, pretherapy dosimetry, 962ab(5)
Iodine-123 fatty acid
compared to thallium-201, exercise-induced myocardial ischemia, 729ab(5)
comparison of SPECT and Tl-201, coronary artery disease, 739ab(5)
Iodine-123 FISCH, characterization, D-1 dopamine receptor imaging ligand, 830ab(5)
Iodine-123 fragment E1, imaging thrombi with improved formulation, 817ab(5)
Iodine-123 halodeoxyuridines, Auger electron radiotherapy, intraperitoneal cancer, 833ab(5)
Iodine-123 HEAT, use of carrier, 1916(le)
Iodine-123 HIPDM
cerebral perfusion agents, no-carrier-added radiosynthesis, 926ab(5)
SPECT, surgery candidates, refractory complex partial seizures, 751ab(5)
Iodine-123 hippuran, renal allograft evaluation, radionuclide scintigraphy, aspiration biopsy, 785ab(5)
Iodine-123 hippurate, Tc-99m MAG_3 clearance and, renal scintigraphy, 2ab(4)
Iodine-123 IBF, potential CNS D-2 dopamine imaging agent, 762ab(5)
Iodine-123 IBHPE, biodistribution studies, novel non-steroidal estrogen, 883ab(5)
Iodine-123 IBZ, potential D-2 dopamine receptor imaging agent, 88
Iodine-123 IBZM
D2 receptor agent, biodistribution, dosimetry, 834ab(5)
imaging of basal ganglia, 731ab(5)
preparation, peracetic acid, superior oxidant, 926ab(5)
Iodine-123 IMP
aerosol, assessment, inhalation lung imaging, 853ab(5)
brain perfusion imaging, schizophrenia, 1616
brain SPECT in neonates, 1337
cerebral perfusion agents, no-carrier-added radiosynthesis, 926ab(5)
3D brain imaging, CT and MRI comparisons, 961ab(5)
dynamic SPECT and, tomographic mapping, kinetic rate constants, 805ab(5)
dynamic SPECT with Tc-99m HM-PAO, meningiomas, 1101
early and delayed SPECT, acute brain injury, 1751ab(10)
effect on brain uptake, iodoamphetamine, 830ab(5)
local cerebral blood flow, Parkinson's disease, 830ab(5)
PET, regional cerebral blood flow, 157
portasystemic shunt fraction quantification, 1702
quantitative cerebral blood flow activation, emission tomography, 811ab(5)
redistribution and metabolism, brain ischemia, 897ab(5)
regional cerebral blood flow, normal subjects,

1753ab(10)
regional dynamics in human brain, 150
SPECT
brain tumor usefulness, F-18 FDG PET, 895ab(5)
children, alternating hemiplegias, 965ab(5)
craniosynostosis, 916ab(5)
critical cerebral blood flow thresholds, 337
functional imaging, brain maturation, 1982
HIV-positive encephalopathy, 811ab(5)
Tc-99m HM-PAO and, discordance, subacute cerebral infarct, 1752ab(10)
temporal changes in brain accumulation, lung clearance, 1977
validity of microsphere model, cerebral blood flow, 878ab(5)
Iodine-123 *N*-iodoallylspiperone, synthesis, dopamine D-2 receptor studies, 803ab(5)
Iodine-123 iodobenzamide, dopamine D2 receptor imaging, SPECT, 731ab(5)
Iodine-123 iodocyanopindolol, no-carrier-added, rapid high yield synthesis, 859ab(5)
Iodine-123 iodo-2′-deoxyuridine, early ascites tumor model, 882ab(5)
Iodine-123 6-iododopa, potential SPECT brain imaging agent, 924ab(5)
Iodine-123 iodoestradiol, interaction with estrogen receptor, 209
Iodine-123 iodolisuride, new SPECT imaging agent, brain dopamine D-2 receptors, 731ab(5)
Iodine-123 iodo-α-methyltyrosine
brain SPECT, validation with PET, 895ab(5)
brain tumor imaging, SPECT, 110
Iodine-123 IPPA, use of mercury-thiol resin for preparation, 925ab(5)
Iodine-123 isopropyliodoamphetamine, central area of cerebral infarcts, spontaneous evolution, 781ab(5)
Iodine-123 low-density lipoprotein, hypercholesterolemia, hyperlipidemic rabbits, 932ab(5)
Iodine-123 MIBG
detection of depleted myocardial catecholamine stores, acute myocardial infarction, 810ab(5)
early detection of mechanical-overload heart failure, clonidine pre-treatment, SPECT, 810ab(5)
first pass extraction fraction, swine heart, 767ab(5)
myocardial sympathetic nervous function, angina pectoris, SPECT, 811ab(5)
scintigraphy
children with neuroblastoma, 799ab(5)
myocardial sympathetic nerve development, 810ab(5)
uptake by chemodectomas, 769ab(5)
Iodine-123 phenylpentadecanoic acid
exercise effects, myocardial kinetics, 829ab(5)
myocardial fatty acid utilization, recurrent chest pain, SPECT, 828ab(5)
tomography, CAD detection, dipyridamole infusion, 760ab(5)
Iodine-123 QNB, SPECT, F-18 deoxyglucose PET, dementia, 896ab(5)
Iodine-123 SCH-23982, D-1 receptor-based SPECT studies, 804ab(5)
Iodine-123 spiperone, tracer for D-2 receptor studies, SPECT, 926ab(5)
Iodine-123 tyramine-cellobiose, low-density lipoprotein estimation, hypercholesterolemia, hyperlipidemic rabbits, 932ab(5)
Iodine-124, PET applications, immunotherapeutic radiopharmaceuticals, 922ab(5)
Iodine-124 2-iodoisonicotinic acid hydrazide, radiotracer for tuberculoma, 1756ab(10)
Iodine-125
effects of interferon-αA, monoclonal antibody targeting, carcinoma, 809ab(5)
full retention of immunoreactivity, antibody labeling, site-specific methods, 831ab(5)
high spatial resolution SPECT, small-animal resolution, 796ab(5)
3-iodo-MK-801, NMDA receptor-ion channel complex, SPECT, 923ab(5)
iodovinylestrogens, steroidal and triphenylethylene-based, 924ab(5)
new radioimmunoassay, simultaneous measurement, serum T3 and T4, 919ab(5)
non-specific lymph node background, monoclonal antibody lymphoscintigraphy, 847ab(5)
plasma turnover studies, serum amyloid P component, 847ab(5)
radioimmunoassay, cyclosporine concentrations, whole blood, 786ab(5)
seed implants, dosimetry, SPECT, 1748ab(10)
serum osteocalcin, bone scintigram, prostate carcinoma, 918ab(5)
specificity of radioimmunoassay for LH and FSH, monoclonal and polyclonal antibodies, 919ab(5)
Iodine-125 antibody, In-111 antibody and, dual isotope study, athymic mice, 374
Iodine-125 cholesteryl iopanoate, uptake into steroid hormone-secreting tissues, enhancement, lipoprotein, 1088
Iodine-125 cyclosporine, comparison of INCSTAR CYCLOTRAC and SANDOZ SANDIMMUNE, whole blood assays, 3ab(2)
Iodine-125 FISCH, improved imaging ligand, dopamine D-1 receptors, 803ab(5)
Iodine-125 IMP, compared to Tc-99m D,L-HM-PAO, autoradiographic analysis, 938ab(5)
Iodine-125 iodophenyl-6-selenapentadecanoic acid, preparation and evaluation, 968ab(5)
Iodine-125 iothalamate
I-131 OIH and Tc-99m MAG_3 comparisons, renal ischemia, 1ab(4)
renal ischemia, 823ab(5)
Iodine-125 IPPA, myocardial kinetics, quantitative analysis, 1211
Iodine-125 low-density lipoprotein, hypercholesterolemia, hyperlipidemic rabbits, 932ab(5)
Iodine-125 MHTP, mechanism of accumulation, dopaminergic radiotracer, 761ab(5)
Iodine-125 MIBG
denervated but viable canine myocardium, acute myocardial infarction, thallium SPECT, 767ab(5)
heart imaging, idiopathic congestive cardiomyopathy, cardiac transplants, 1182
uptake, human neuroblastoma nude mode xenograft, 884ab(5)
uptake and histopathology, neuroblastoma, 836ab(5)
uptake in children, neuroblastoma, tumor histopathology, 474
Iodine-125 monoclonal antibody, isotype switch variant anti-idiotype mAb, comparative radiolabeling, 227
Iodine-125 *N*-iodoallylspiperone, synthesis, dopamine D2 receptor studies, 803ab(5)
Iodine-125 phospholipid ether, tumor imaging agents, 849ab(5)
Iodine-125 3-(R)-quinuclidinyl (S)-4-iodobenzilate, *in vitro* and *in vivo* characteristics, 1079
Iodine-125 tyramine-cellobiose, low-density lipoprotein estimation, hypercholesterolemia, hyperlipidemic rabbits, 932ab(5)
Iodine-131
anti-CA 12.5 radioimmunodetection, follow-up ovarian carcinoma, 758ab(5)
anti-colon specific antigen-p, therapeutic efficacy, monoclonal antibody, 826ab(5)
anti-pan-B cell antibodies, radioimmunotherapy, non-Hodgkin's lymphoma, 828ab(5)
diffuse hepatic uptake, total body scans, thyroid cancer, 4ab(2)
effectiveness of radionuclide treatment, differentiated thyroid cancer, 737ab(5)
excretion in breast milk, 124, 127(le)
heavy activity radioiodination, monoclonal antibodies, iodogen particle suspensions, 933ab(5)
hyperthyroidism treatment, extra-thyroidal absorbed doses, 833ab(5)
improved determination of uptake, metastatic thyroid carcinoma, 737ab(5)
new generation scintillation camera system, 855ab(5)
new radioimmunoassay, simultaneous measurement, serum T3 and T4, 919ab(5)
para-iodophenyl conjugates of antibodies, synthesis, radioiodination, 924ab(5)
prospective immunoscintigraphic study, ovarian carcinoma, 758ab(5)
quantitation of therapeutic concentration, SPECT, 737ab(5)
radiolabeled conjugates of monoclonal antibodies, fragments, urinary metabolites, 793ab(5)
scintigraphy, Tl-201 comparison, thyroid carcinoma follow-up, 914ab(5)
solitary autonomous thyroid nodules, long-term follow-up, 736ab(5)
toluidine blue, mediastinal parathyroid adenoma, 768ab(5)
Iodine-131 antibody
importance of collimator and restoration filter, quantitative imaging, 876ab(5)
uptake and clearance, bone marrow, 826ab(5)
Iodine-131 anti-CEA/CA 19-9, diagnostic efficacy of immunoscintigraphy, colorectal cancer, 907ab(5)
Iodine-131 anti-idiotype monoclonal antibody, B cell lymphoma therapy, external beam irradiation, 826ab(5)
Iodine-131 beta dose point kernels, potential use in radioimmunotherapy, 1036
Iodine-131 cellulose, oral, colonic transit, health and constipation, 764ab(5)
Iodine-131 hippuran
Tc-99m DTPA and, early detection, diabetic nephropathy, 941ab(5)
Tc-99m MAG_3 and, clearances, renal plasma flow, 823ab(5)
Iodine-131 HMFG1, trial diagnostic distribution and dose-controlled therapy, otherwise incurable ovarian carcinoma, 759ab(5)
Iodine-131 immunoglobulin G, pretherapy dosimetry, comparison, I-123 Fab fragments, 962ab(5)
Iodine-131 iym-1, chronic lymphocytic leukemia, 827ab(5)
Iodine-131 MIBG

alterations of biodistribution, impaired renal function, 6ab(4)
biodistribution alterations, anephritic patient, 1476
localization of pheochromocytoma, correlation with CT and MRI, 328
reduction of uptake by labetalol, pheochromocytoma, normal tissues, 481
scintigraphy, occult lung metastasis, pheochromocytoma, 885ab(5)
therapeutic use
neural crest tumors, 769ab(5)
treatment, resistant neuroblastoma, 903ab(5)
treatment of metastatic carcinoid tumor, 836ab(5)
uptake, human neuroblastoma nude mouse xenograft, 884ab(5)
Iodine-131 monoclonal antibody
B72.3, colorectal cancer, 320
curative radioimmunotherapy, mammary carcinoma xenografts, 531
estimating dosimetry, whole body profile scanning, 884ab(5)
HMFG1, CA 125 RIA, ovarian cancer, 918ab(5)
imaging of hepatic metastases, colorectal carcinoma, 809ab(5)
In-111 and, renal cell carcinoma xenografts, 906ab(5)
ovarian cancer, kinetics, nude mice and patients, 883ab(5)
stage IV neuroblastoma, 904ab(5)
successful serial radioimmunotherapy, HAMA response, 827ab(5)
Iodine-131 OC 125, intraperitoneal, advanced ovarian cancer, 904ab(5)
Iodine-131 OIH
renal ischemia, 823ab(5)
Tc-99m MAG_3 clearances
captopril, renovascular hypertension, 666
iothalamate comparisons, renal ischemia, 1ab(4)
renal plasma flow, 823ab(5)
renal plasma flow, renal artery stenosis, 1ab(4)
Tc-99m DTPA comparison, follow-up renal transplants, 4ab(4)
Iodine-131 ortho iodo hippurate, renal transplant and lymphoceles, 3ab(11)
Iodine-131 sodium iodide, new coated-bead dosage form, 886ab(5)
Iodine-137 MIBG, myocardial uptake, primary hypertrophic cardiomyopathy, 810ab(5)
Iodoantipyrine, labeled with radioactive iodine, dosimetry, 1ab(2)
Iodobenzamide, new analogs, potential D-2 dopamine imaging agents, 803ab(5)
***para*-Iodo-benzyl alcohol ester,** antibody conjugate, synthesis, radioiodination, 924ab(5)
Iodophenyl pentadecanoic acid, noninvasive testing, hypoxic myocyte metabolism, 860ab(5)
4-*O*-(*E*)-Iodopropenyl glucose, synthesis, brain and heart imaging agent, 3ab(11)
Iodovinylestrogens, steroidal and triphenylethylene-based, biodistribution, metabolism, 924ab(5)
Iofetamine, SPECT, child psychiatry, "beam" brain mapping, 966ab(5)
Iridium-191m
clinical usefulness, carbon-based generator system, left ventricular function, 1025
first pass left ventricular ejection fraction, 817ab(5)
left ventricular first pass angiocardiography, Tl-201 perfusion during exercise, coronary artery disease, 818ab(5)
-Os-191 generator based on silica gel, impregnation, tridodecylmethylammonium chloride, 538
radionuclide angiocardiography, evaluation, ventricular function, 450
Iron-59, In-111 and Ga-69 transferrin, vascular permeability, transferrin receptor, 1676
Irradiation
abdominal, gastrointestinal functional disturbances, 765ab(5)
external beam
combined with radioimmunotherapy, renal cell carcinoma xenografts, 826ab(5)
I-131 anti-idiotype mAb, B cell lymphoma, 826ab(5)
head and neck, hyperthyroidism, 2063(le)
rapid and sensitive response, carbon-11-L-methionine tumor uptake, 2012
volunteers in nuclear medicine, 260, 2062(le)
Ischemia, preoperative prediction of reversible asynergy, rest-stress myocardial positron tomography, 1302
Isotopes, production and distribution office, DOE, N1933
Ivalon, improved radiolabeling technique, monitoring, therapeutic transcatheter embolization, 1399

J

Jaudice, infant, deconvolutional analysis, hepatobiliary scans, 9ab(4)
Joint
bone diseases and, Tc-99m granulocytes, 1743ab(10)
Charcot, false-positive, In-111 leukocyte/Tc-99m MDP images, 754ab(5)
In-111 chloride imaging, rheumatoid arthritis, 855ab(5)
radiation synovectomy, radiopharmaceuticals, Y-90 particulate agents, 1047
reflex sympathetic dystrophy, lower extremities, bone scintigraphy, 856ab(5)
sacroilitis, MRI and radiography, bone scinitgraphy, 842ab(5)
scintigraphy, Tc-99m IgG, inflammation, 889ab(5)
subtalar, non-osseous coalitions, bone scintigraphy, 799ab(5)

K

Kawasaki disease, dipyridamole-redistribution Tl-201 ECT, children, 760ab(5)
Ketone bodies, palmitate and, competition as fuels, heart, 797ab(5)
Kidney
abnormal mobility, radionuclide features, clinical relevance, 3ab(4)
anephritic patient, alterations, I-131 MIBG, 1476
antenatally diagnosed pelviureteric junction obstruction, conservative management, 5ab(4)
atherosclerotic renal artery stenosis, outcome of treatment, quantitative renography, 1946
bilateral renal artery stenosis, pitfall, captopril renal scintigraphy, 2042
blood flow, captopril, angioplasty in renal artery stenosis, 841ab(5)
captopril-enhanced renal scintigraphy, hypertension evaluation, Tc-99m DTPA, 615
captopril-stimulated renography, renal vein renins, hypertension, 5ab(4)
chronic renal failure patients, Tc-99m RBC labeling interference, 869ab(5)
clearance of Tc-99m MAG_3, simplified methods, 943ab(5)
comparison of radioactive agents, cisplatin-induced tubular toxicity, 659
correlative pediatric imaging, 15
cyclosporine nephrotoxicity, pathophysiology, 784ab(5)
decreased blood flow and hypertension, complications, renal lithotripsy, 842ab(5)
"delayed" Ga-67 localization, clinical significance, 969ab(5)
depth, radionuclide renal studies, 1745ab(10)
diuretic renography
antenatal hydronephrosis, 799ab(5)
standard furosemide method, direct infusion comparison, 7ab(4)
DMSA studies, infants under one year of age, 5ab(4)
estimated differential renal clearance, dynamic Tc-99m DTPA imaging, compartmental model analysis, 877ab(5)
evaluation of MAG_3-like compounds, 937ab(5)
factors affecting Gates' GFR measurement, 842ab(5)
functional changes, extra-corporeal piezoelectric lithotripsy, 943ab(5)
functional renal imaging post lithotripsy, 942ab(5)
glomerular filtration rate
atrial natriuretic peptide, essential hypertension, 941ab(5)
diverging collimator, SFOV gamma camera, 941ab(5)
In-111 DTPA plasma clearance, liver and kidney transplants, 942ab(5)
partial obstruction, long-term follow-up, 4ab(4)
radionuclide assessment, protein diet, 785ab(5)
tubular secretion of MAG-3, 1986
handling of Tc-99m and Re-186 CO_2DADS, pair applications, 743ab(5)
handling of Tc-99m DMSA, glomerular filtration, peritubular uptake, 1219
handling of Tc-99m MAG_3, 1ab(4)
high-resolution Tc-99m DMSA SPECT imaging, 1759ab(10)
hot, radionuclide bone scans, cancer patients, 858ab(5)
imaging of Tl-201, cardiac thallium evaluation, 2ab(4)
impaired renal function, alterations, I-131 MIBG biodistribution, 6ab(4)
importance of Tc-99m glucoheptonate scintigraphy, first UTI, infants, 915ab(5)
ischemia, I-131 OIH, Tc-99m MAG_3 and I-125 iothalamate, 1ab(4), 823ab(5)
lasix renal scintigraphy, hydronephrosis, pressure-perfusion test, 944ab(5)
measurement of renal function, radionuclides, 2054
microsphere blood flow, Cu(PTSM) localization, 848ab(5)
modified diuresis renography, uses and interpretation, 3ab(4)
neonatal hypertension, captopril scintigraphy, 798ab(5)
obstructive renal disease, scintigraphy, sonography, 944ab(5)

parametric imaging of function, renovascular hypertension, 5ab(4)
parenchymal transit time of Tc-99m MAG_3, factor analysis, hydronephrosis, 3ab(4)
percutaneous nephroureterolithotomy, therapeutic effect, Tc-99m DTPA renal scintigraphy, 942ab(5)
plasma flow
clearances, Tc-99m MAG_3 and I-131 OIH, 823ab(5)
errors, single plasma sample-based values, 944ab(5)
oxygen-15 water, PET, 824ab(5)
plasma flow and renal artery stenosis, I-131 OIH and Tc-99m MAG_3 clearances, 1ab(4)
primary parenchymal disease *vs.* secondary disease, renovascular hypertension, 942ab(5)
prototype total performance kinetic phantom, 1750ab(10)
quantitation of renal uptake, Tc-99m DMSA, SPECT, 246
radioiodinated iodobenzoyl conjugates, para and meta isomers, 932ab(5)
radioisotopic evaluation, spinal cord injury, 944ab(5)
radiopharmaceutical evaluation, 823ab(5)
relative renal function estimation, early and delay Tc-99m MDP scintigraphy, 941ab(5)
renal artery stenosis
captopril effect, glucoheptonate scintirenogram, 1759ab(10)
diagnostic use, angiotensin converting enzyme inhibitor, 605
Gates' technique, captopril test, 51
renal cell carcinoma
external beam irradiation, radioimmunotherapy, 826ab(5)
xenografts, I-131 and In-111 monoclonal antibody, 906ab(5)
renal transplant and lymphoceles, Tc-99m DTPA, I-131 ortho iodo hippurate, 3ab(11)
renovascular hypertension
captopril, Tc-99m GHA and Tc-99m DMSA, 841ab(5)
captopril, Tc-99m MAG_3 clearance, 656
increased glucoheptonate uptake, 5ab(4)
scintigraphy
special chair, upright position, 963ab(5)
Tc-99m MAG_3 and I-123 hippurate clearances, 2ab(4)
Tc-99m MAG_3, 1ab(4)
Tc-99m MDP scintigraphy, functional assessment, 945ab(5)
Tc-99m methylene diphosphate uptake, therapeutic radiation, vertebral metastases, 1113
Tc-99m MSG and Tc-99m MAG_3, comparative pharmacokinetics, dogs, 937ab(5)
thallium distribution, stress/delayed renal scintigraphy, 824ab(5)
transplants
allograft evaluation, radionuclide scintigraphy and aspiration biopsy, 785ab(5)
bone mineral content, lumbar spine vertebrae, 774ab(5)
evaluation, radionuclide monitoring, 3ab(4)
evaluation, Tc-99m MAG_3, 823ab(5)
evaluation of viability, magnetic resonance spectroscopy, 813ab(5)
hippurate renograms, long-term graft development, 784ab(5)
measurements, Tc-99m MAG_3 uptake, 3ab(4)
Tc-99m MAG_3, I-131 OIH and Tc-99m DTPA comparisons, 4ab(4)
tubular reabsorption of calcium, primary hyperthyroidism, 2ab(4)
tumor cells, transport mechanism, Tc-99m glucoheptonate, 912ab(5)
validation of Gates GFR methodology, 1755ab(10)
children, 2ab(2)
Krypton-81m
gas generator, long-lived radioactive contaminant, 1574(le)
reservoir administration systems, evaluation methods, 650
Kuhl, David E., ACP award, N1148

L

Labetalol, reduction of I-131 MIBG uptake, pheochromocytoma, normal tissues, 481
Lead-203 immunoconjugates, tumor imaging agents, 935ab(5)
Left bundle branch block, dipyridamole-thallium 201 SPECT, 2ab(11)
Leg, muscle perfusion, quantification, Tl-201 SPECT, 458
Legg-Calve-Perthes disease, early stage, bone scintigraphy and MR, 1755ab(10)
Leukemia
chronic lymphocytic, I-131 lym-1, 827ab(5)
diffuse nonuniformity on SPECT, liver studies, 905ab(5)
hairy-cell, interferon therapy, Tc-99m colloid liver/spleen scans, 2ab(2)
phase I of cancer cluster study, N1147
SPECT liver/spleen scans, 3ab(2)
xenografts, immunoscintigraphy, radiolabel and antigen modulation, 889ab(5)
Leukocytes
chemotactic peptide labeled with In-111, rapid detection, focal infection sites, 805ab(5)
labeled with In-111 oxine and Tc-99m HM-PAO, 804ab(5)
potential agent for labeling, positron-emitting copper, 920ab(5)
Tc-99m HM-PAO-labeled
detection of inflammatory lesions, 1332
infectious complications, orthopedic surgery, 804ab(5)
Tc-99m-SnF_2 colloid kit, preparation, evaluation, 1257
Levothyroxin, triiodothyroacetic acid and, TSH suppressive treatment, thyroid cancer, 886ab(5)
Ligands
bifunctional, Tc-99m complex, protein labeling, 940ab(5)
C-11 tropanyl benzilate methiodide, peripheral muscarinic receptors, 930ab(5)
exchange, Tc-99m glucoheptonate, BPA-BAT, 939ab(5)
hexadentate Schiff base, preparation, Tc-99m, 773ab(5)
mixed, technetium(III/II) complexes, inorganic chemistry, 936ab(5)
new amino-thiol, use with indium and gallium, 922ab(5)
-receptor model influence, injection protocol, identifiability analysis, 877ab(5)
substitution, comparative rates, technetium(V) and rhenium(V), 743
Limb, forearm blood flow measurements, Tc-99m serum albumin, after brachial arteriotomy, 45
Lipids, -soluble Sn(II)MPO, platelet labeling, Tc-99m pertechnetate, 922ab(5)
Lipoproteins
low density
estimation of catabolic sites, hypercholesterolemia, 932ab(5)
In-111 imaging, atherosclerotic lesions, 787ab(5)
paramagnetic label, localization in tumor model, 902ab(5)
receptor activity, Ga-68 DTPA-VLDL, 763ab(5)
radioiodinated cholesteryl ester uptake, steroid hormone-secreting tissues, 1088
Lithotripsy
extracorporeal piezoelectric, renal functional changes, 943ab(5)
extracorporeal shock wave, decreased renal blood flow, hypertension, 4ab(11)
functional renal imaging, 942ab(5)
long-term complications, renal blood flow, hypertension, 842ab(5)
Liver
correlative pediatric imaging, 15
diffuse hepatic uptake of I-131, total body scans, thyroid cancer, 4ab(2)
diffuse nonuniformity on SPECT, leukemia, 905ab(5)
giant hemangiomas, scintigraphic and ultrasound features, 181
hepatic retention ratio, Xe-133, 1708
human organ transplants, evaluation of viability, magnetic resonance spectroscopy, 813ab(5)
immunoscintigraphy, Tc-99m monoclonal anti-CEA antibody, colorectal carcinoma, 748ab(5)
In-111 accumulation, administration, B72.3 antibody, 1575(le)
magnetite particles as MR contrast agent, 840ab(5)
measurement of functional hepatic mass, Tc-99m galactosyl neoglycoalbumin, 814ab(5)
metastases
detection, hepatic arterial perfusion scintigraphy, 4ab(11)
I-131 monoclonal antibody, colorectal carcinoma, 809ab(5)
metastases from colorectal cancer, F-18 uracil uptake and tumor volume changes, chemotherapy, 911ab(5)
morphine hepatobiliary scintigraphy, potential pitfalls, 850ab(5)
orthotopic transplant, semiquantitative hepatobiliary scintigraphy, 888ab(5)
perfusion system, R-E cell function, Tc-99m sulfur colloid, 4ab(2)
peritoneo-pleural fluid communication, mediastinal lymph nodes, Tc-99m albumin colloid, 559(le)
planar scintigraphy, worth of SPECT, 57
platelet uptake, whole body, depth-independent build-up factor, 914ab(5)
portal systemic shunting
portal hypertensive rats, 887ab(5)
portal hypertensive rats, portal vein stenosis, 814ab(5)
radioparticle uptake, discrepant sulfur colloid, superior vena cava obstruction, 113
radiopharmaceutical receptor binding, discriminant analysis, Tc-99m NGA, 879ab(5)
R-E cell function, short-term ethanol consumption, Tc-99m sulfur colloid, 1ab(2)
regeneration, determination, radiothymidine labeled in carbon 2 position, 815ab(5)

regeneration measurement by PET, C-11 thymidine, 929ab(5)
residual or recurrent tumor detection, F-18 FDG PET, posicam 6.5 camera, 909ab(5), 966ab(5)
routine imaging, occult metastases, advanced melanoma, 1ab(2)
short-term ethanol consumption, R-E cell function, liver, 815ab(5)
SPECT
automated body contour, 266(le)
leukemia, 3ab(2)
splenic uptake and, monoclonal antibody study, 5ab(11)
subcellular kinetics, In-111 monoclonal antibody, 907ab(5)
Tc-99m colloid, interferon therapy, hairy-cell leukemia, 2ab(2)
Tc-99m complexes with ester analogues, biological characteristics, 937ab(5)
Tc-99m ECD metabolism in rat, 743ab(5)
therapeutically embolized, variable perfusion patterns, Tc-99m MAA, 1012
tracer kinetic modeling approaches, quantification, Tc-99m DISIDA and scintigraphy, 1507
transplant, In-111 DTPA plasma clearance, glomerular filtration rate, 942ab(5)
tumor, metabolic PET images, 878ab(5)

Lung
acute pulmonary emboli, radionuclide evaluation, right ventricular function, 853ab(5)
acute pulmonary processes, 24-hour gallium images, AIDS, 888ab(5)
aminodarone pneumonitis, Tc-99m DTPA aerosol washout rates, 916ab(5)
ammonia-13 kinetics, positron emission computed tomography, smokers and nonsmokers, 866ab(5)
assessment of inhalation imaging, I-123 IMP aerosol, 853ab(5)
biventricular forward and regurgitant flows, radioangiography, 560(le)
cancer
In-111 anti-CEA ZCE 025 monoclonal antibody, 905ab(5)
radon, information for practicing physician, 961ab(5)
radon debate, N987
central pulmonary emboli, perfusion distribution patterns, 734ab(5)
characterization of *beta*-adrenergic receptors, CGP-12177, PET, 766ab(5)
clearance of I-123 IMP, temporal changes, brain accumulation, 1977
clearance of Tc-99m HM-PAO aerosols, new application, 743ab(5)
correlative pediatric imaging, 15
decreased clearance of Tc-99m imidodiphosphate, Tc-99m DTPA, 853ab(5)
detection of irradiation injury, In-111 monoclonal anti-laminin antibody, 916ab(5)
detection of pulmonary aspiration in children, radionuclide "salivagram", 697
diffuse uptake of Tc-99m sulfur colloid, malaria, 117
disease, N1292
Ga-67 uptake, AIDS, aerosolized pentamidine, 744ab(5)
-heart transplantation, regional pulmonary perfusion, 1297
inhalation scintigraphy in newborns, 744ab(5)
krypton-81m reservoir administration systems, evaluation methods, 650
localization of In-111 neutrophils, endotoxemia, monoclonal antibodies, 852ab(5)
malignant lesion differentiation, SPECT, 844ab(5)
mucociliary transport, FDG powder inhalation, PET, 917ab(5)
myocardial-to-lung ratio, perfusion tracers and techniques, comparison, 959ab(5)
non-thromboembolic disease, reversed mismatch, ventilation-perfusion ratio, 734ab(5)
obstructive pulmonary disease, Xe-133, dynamic SPECT, 916ab(5)
occult metastasis of pheochromocytoma, I-131 MIBG scintigraphy, 885ab(5)
parenchyma, gadolinium-labeled microspheres, MRI, 901ab(5)
perfusion scans, hot spots, 734ab(5)
perfusion scintigraphy, right-to-left shunting, persistent left superior vena cava, 412
postexercise Tl-201 uptake, SPECT, 288
pre-operative ventilation and perfusion scans, pulmonary embolism assessment, 733ab(5)
primary cancer, histologic type, C-11 L-methionine uptake with PET, 33
pulmonary aspiration, scintigraphy, videofluoroscopy, 967ab(5)
pulmonary function testing, Tc-99m DTPA aerosol ventilation studies, cystic fibrosis, 967ab(5)
pulsatile, visualization of circulation, ECG gated acquisition, 744ab(5)
reversed V/Q mismatch, clinical significance, 734ab(5)
reversible uptake, pulmonary osteoarthropathic distribution, Tc-99m methylene diphosphonate, 1563
scans and pulmonary arteriography, PIOPED study, N279
sequestration of In-111 granulocytes, organ specificity, 1531
small cell carcinoma
Tc-99m monoclonal antibody Fab fragment, 819ab(5)
Tc-99m monoclonal antibody, 818ab(5)
squamous cell carcinoma, serum TA-4 level, localization, 918ab(5)
suspected cancer, evaluation, Tl-201 SPECT, 997
Tc-99m aerosol scans, performance, ventilator patients, 9ab(4)
Tc-99m albumin and Ga-67 citrate, HIV-positive patients, 917ab(5)
Tc-99m HEXAMIBI isonitrile uptake, discordant hemodynamic disturbances, 860ab(5)
tumor
C-11 methionine, F-18 fluorodeoxyglucose, 788ab(5)
small cell, Tc-99m NR-Lu-10 monoclonal antibody, 1749ab(10)
transport mechanism, Tc-99m glucoheptonate, 912ab(5)
uptake of Tl-201 during exercise, 788ab(5)
vascular permeability, blood flow following radiation, 852ab(5)
ventilation/perfusion mismatch, positive pressure ventilatory support, 1268
ventilation scintigraphy, Tc-99m Technegas, 744ab(5)
vessels, radioimmunoimaging, 1686

Luteinizing hormone, specificity of radioimmunoassay, polyclonal and monoclonal antibodies, 919ab(5)

Lymph node
contralateral metastasis, melanoma, lower extremity, 912ab(5)
malignancies, tracing, In-111 oxine-labeled mononuclear cells, 1005
mediastinal, peritoneo-pleural fluid communication, 559(le)
non-specific background, monoclonal antibody lymphoscintigraphy, Fab fragments, 847ab(5)
uptake, Tc-99m hydroxyethyl starch, 969ab(5)

Lymphoceles, renal transplant and, Tc-99m DTPA, I-131 ortho iodo hippurate, 3ab(11)

Lymphoma
Hodgkin's and non-Hodgkin's, bone marrow imaging, blind biopsy, 843ab(5)
malignant
bone marrow scintigraphy, Tc-99m NCA-antibodies, 819ab(5)
therapeutic effect, F-18 FDG PET, 910ab(5)
non-Hodgkin's
radioimmunotherapy, I-131 anti-pan-B cell antibodies, 828ab(5)
Y-90 anti-idiotype monoclonal antibody, 778ab(5)
nuclear medicine in monitoring, response to cancer treatment, 1731
recurrent, composite gallium SPECT-CT images, 874ab(5)
Tl-201 scintigraphy, relationship, Ga-67, 915ab(5)
utility of Ga-67, transmission computerized tomography, 914ab(5)

Lymphoma, B cell
I-131 anti-idiotype monoclonal antibody, external beam irradiation, 826ab(5)
radioimmunodetection and radioimmunotherapy, monoclonal antibody, 828ab(5)

Lymphoscintigraphy
contralateral lymph node metastasis, melanoma, lower extremity, 912ab(5)
simplified technique, breast cancer, 904ab(5), 1198
surgical management, truncal melanoma, Tc-99m sulfur colloid and serum albumin, 844ab(5)

Lysosomes, role in tumor accumulation, Ga-67, dual-tracer studies, 921ab(5)

M

Magnetic resonance imaging: *see* Nuclear magnetic resonance

Magnetite particles, MR contrast agent for liver, 840ab(5)

Malaria, diffuse lung uptake, Tc-99m sulfur colloid, 117

Maleimidoethyl succinimyl succinate, spacer for Ga-67 deferoxamine labeled antibody, 832ab(5)

Malformation
therapeutic transcather embolization, improved radiolabeling technique, ivalon, 1399
vascular, Tc-99m RBC scanning, 799ab(5)

Mallinckrodt Fellowship
applications, N1933
award to Farrokh Dehdashti, N1444

Manganese, radioactive, monoclonal antibody labeling, porphyrin bifunctional chelator, 935ab(5)

Mastocytosis, systemic, nuclear medicine imaging,

2046
McAfee, John G., SNM Hevesy Nuclear Medicine Pioneer Award, N577
Medicare
Catastrophic Coverage Act of 1988, implementation of ICD-9-CM codes, N580
radiology fee schedule, effect on a practice, N1143
Melanoma
affinity enhanced targeting, radiolabeled divalent haptens, mice, 907ab(5)
cutaneous, follow-up, immunoscintigraphy, 907ab(5)
heterotransplanted nude rats, biokinetics, radiolabeled monoclonal antibodies, 1224
lower extremity, contralateral lymph node metastasis, 912ab(5)
malignant
evaluation, F-18 2-deoxy-2-fluoro-D-glucose, 738ab(5)
successful imaging, Tc-99m monoclonal antibodies, 25
tumor-associated antigens, autoradiography, 906ab(5)
mouse antitumor monoclonal antibody, complex formation and biodistribution, cancer patients, 1311
radioimmunoscintigraphy *vs.* X-rays, size-related diagnostic sensitivity, 749ab(5)
routine bone and liver imaging, occult metastases, 1ab(2)
targeting, monoclonal antibody cocktail, human HMW-MAA, 390
truncal, lymphoscintigraphy, Tc-99m sulfur colloid and serum albumin, 844ab(5)
Memory, recognition, metabolic and electrophysiologic manifestations, 894ab(5)
Mesalamine, enema, colonic coverage, active distal ulcerative colitis, 764ab(5)
Mescaline, -induced psychosis, right hemisphere involvement, 812ab(5)
Metabolite, analysis, internal surface-reverse phase chromatography, 920ab(5)
Metaiodobenzylguanidine, use in neurocardiology, N1291
Metal, -labeled perfusion tracers, structure-activity relationships, 742ab(5)
Metallothionein, genetically engineered chimeric antibody, Tc-99m, 794ab(5)
Metastasis
axillary, primary breast carcinoma, Tl-201 scintigraphy, 844ab(5)
bone
nuclear medicine in monitoring response to cancer treatment, 1731
palliation, strontium-89, 2ab(2), 836ab(5)
bone scintigram, serum osteocalcin, PSA and/or PAP, 918ab(5)
contralateral lymph node, melanoma, lower extremity, 912ab(5)
hepatic
detection, hepatic arterial perfusion scintigraphy, 4ab(11)
I-131 monoclonal antibody, colorectal carcinoma, 809ab(5)
intra-operative localization, radiation detection probe, colorectal cancer, 908ab(5)
lung, pheochromocytoma, I-131 MIBG scintigraphy, 885ab(5)
micrometastatic cell clusters, kinetics, radiolabeled antibody penetration, 777ab(5)
occult, routine bone and liver imaging, melanoma, 1ab(2)
skeletal, action of 186-Re(Sn)-HEDP, 732ab(5)
solitary, bone secondaries, breast cancer, 1318
spinal, malignant struma ovarii, 407
vertebral, renal uptake, Tc-99m methylene diphosphate, 1113
Methylene diphosphate, Ga-67 distribution, 857ab(5)
Methyl iodide, carbon-11, simplified solid-phase synthesis, 927ab(5)
Metoclopramide, -induced patient restlessness, radionuclide gastric empyting imaging, 3ab(11)
Michaelis-Menten kinetics, hexokinase, glucose and deoxyglucose phosphorylation ratio, brain and gliomas, 838ab(5)
Microspheres
biodegradeable, Ho-165 activation, 836ab(5)
blood flow, Cu(PTSM) localization, dog heart and kidney, 848ab(5)
gadolinium-labeled, MRI, lung parenchyma, 901ab(5)
-like retention in heart, copper-PTSM, blood flow and PET, 768ab(5)
regional cerebral distribution, Tc-99m ECD, non-human primates, 792ab(5)
validity of model in cerebral blood flow, I-123 IMP, 878ab(5)
yttrium-90, therapy, hepatic metastasis, 836ab(5)
Mintun, Mark A., Tetalman Memorial Award, N1141
MIRD "S" factor, disparity in organ masses, 416(le)
MK 329, cholecystokinin receptor localization, 849ab(5)
Molybdenum-99, suspension of uranium shipments, Department of Energy, N1139
Monoamine oxidase, probes, C-11 and F-18 labeled 4-fluorodeprenyl, 821ab(5)
Monoclonal antibodies
anti-CEA, epitope specificity, tumor localization, 747ab(5)
anti-fibrin T2G1S, thrombus imaging, 963ab(5)
anti-idiotype, I-131, B cell lymphoma, 826ab(5)
anti-melanoma, variation in labeling efficiency, different Tc-99m generators, 1759ab(10)
astatine-211 labeled $F(ab')_2$ fragment, immunoreactivity, tumor uptake, 778ab(5)
B72.3, accumulation of In-111, liver, 1575(le)
cardiac myosin light chain 1, synthetic peptide immunogens, radioimmunoassay, 785ab(5)
charge modification, enhanced target localization, 762ab(5)
chelate and, diester linkage, radioimmunodetection of tumor, 1693
clinical value of immunoscintigraphy, colorectal carcinoma, 1646
cocktails
localization, tumor xenografts, 747ab(5)
melanoma targeting, human HMW-MAA, 390
copper-18 conjugation, desferrioxamine In-111, oligosaccharide moiety, 936ab(5)
detection of human anti-murine antibody response, 908ab(5)
diagnosis of acute heart transplant rejection, In-111 antimyosin Fab mAb imaging, 847ab(5)
differential intratumor localization, mice bearing transplantable human tumors, autoradiography, 1758ab(10)
dual specificity conjugates, radiolabeled monovalent and divalent haptens, 1358
effect of interferon-αA on targeting, carcinoma, 809ab(5)
enhanced regional delivery, peritoneal cavity, transdiaphragmatic blockade, 815ab(5)
epidermal growth factor receptor, placental alkaline phosphatase, glioma, 1636
estimate of immunoreactive fraction, curve fitting method, 915ab(5)
fibrin-specific, thrombus imaging, 747ab(5)
fragments of CEA, cancer imaging, multicenter trial, 748ab(5)
heterogeneity of uptake, human tumor xenografts, Sprint tomographic scanner, 777ab(5)
high activity radioiodination, iodogen particle suspensions, 933ab(5)
human anti-mouse, immunoscintigraphy effect, 786ab(5)
human antimurine antibody responses, intraperitoneal radioimmunotherapy infusions, 827ab(5)
I-131 and Re-186 radiolabeled conjugates, urinary metabolites, 793ab(5)
I-131 HMFG1, ovarian cancer, nude mice and patients, 883ab(5)
immunoglobulin complex formation, 10ab(4), 888ab(5)
immunoglobulin M, pharmacokinetics, 909ab(5)
immunoreactivity, Lindmo double reciprocal analysis, 903ab(5)
improved labeling with BrϕHBED, bifunctional chelate, 763ab(5)
improved uptake, lavage, intraperitoneal carcinomatosis, 60
inflammation-related localization, colorectal cancer, 3ab(11)
influence of antibody protein dose, antibody distribution, human tumor xenografts, 759ab(5)
In-111 GYK-DTPA-B72.3, breast cancer detection, 819ab(5)
In-111-labeled, two probe systems, gastrointestinal cancer, 891ab(5)
intact and Fab fragments, biodistribution, anti-mouse antibody effects, 847ab(5)
interaction, evaluation, neutrophil function, 747ab(5)
isotype switch variant anti-idiotype, comparative radiolabeling, 227
L-6, dose-dependent human biokinetics, 907ab(5)
labeling, combined radioimmunoscintigraphy, radioimmunotherapy, 683
labeling with radioactive manganese, porphyrin bifunctional chelator, 935ab(5)
liver and splenic uptake, comparative analysis, 5ab(11)
localization of atherosclerotic lesions, 859ab(5)
lymphoscintigraphy, non-specific lymph node background, Fab fragments, 847ab(5)
mouse antitumor, complex formation and biodistribution, cancer patients, 1311
mouse B72.3, conjugated to Tc-99m metallothionein, Rhesus monkeys, 1351
patients not injected with murine mAb, characterization, human anti-murine antibody, 1749ab(10)
percolation through tumors, modeling analysis, 903ab(5)
preparation of new agents, immunoscintigraphy, 936ab(5)
pulmonary localization of In-111 neutrophils, endotoxemia, 852ab(5)
quo vadis radioimmune imaging, 1911
radioimmunoassay, diagnosis, squamous cell

carcinoma of lung, 918ab(5)
radioimmunoimaging of lung vessels, 1686
radioimmunotherapy of colorectal carcinoma xenografts, Y-90 CO17-1A, mouse IgG coinjection, 935ab(5)
radioiodinated and yttrium-labeled anti-CEA, IgG and fragments, radioimmunotherapy, 848ab(5)
radiolabeled
epithelial membrane antigen, colorectal cancer target antigen, 808ab(5)
heterotransplanted nude rats, biokinetics, 1224
variations in absorbed dose, murine-human tumor xenograft, 777ab(5)
radiolabeled anti-EGF receptor, phase I, imaging trial, 746ab(5)
radiolabeling, hexadentate bifunctional chelating agents, 1758ab(10)
radiolabeling with Y-90, comparison, five bifunctional chelate techniques, 763ab(5)
SM3, radioimmunoscintigraphy, ovarian tumors, 758ab(5)
specificity of radioimmunoassay for LH and FSH, compared to polyclonal antibodies, 919ab(5)
stable radioiodinating reagent development, cancer radiotherapy, 216
sulfhydryl site-specific radiolabeling, biotin/streptavidin methodology, 832ab(5)
systemic and locoregional administration, gastrointestinal cancer radioimmunotherapy, 779ab(5)
Tc-99m, successful imaging, malignant melanoma, 25
Tc-99m and platelet activation, after balloon arterial injury, arteriosclerotic model, 787ab(5)
ultrasensitive assay for measuring serum CA125 values, different antigenic determinants, 785ab(5)
use in cancer, N1293
Y-90
effect of carrier IGG, biodistribution, 4ab(11)
macrocyclic bifunctional chelating agents, 763ab(5)
Mononuclear cells, In-111 oxine-labeled, tracing, lymphatic malignancies, 1005
Morphine
-augmented cholescintigraphy, 8ab(4), 850ab(5)
hepatobiliary scintigraphy, potential pitfalls, 850ab(5)
Muscle
perfusion in leg, quantification, Tl-201 SPECT, 458
skeletal, dialysate sodium concentration, subcutaneous blood flow, 4ab(4)
Musculoskeletal neoplasms, benign and malignant, F-18 FDG uptake, 1753ab(10)
Myelofibrosis, acute, correlation of findings, 251
Myers, William Graydon, In Memoriam, 1129
Myocardial, uptake kinetics, hypoxia and ouabain effects, Tc-99m HEXAMIBI and Tl-201, 1500
Myocardial infarction
analysis of cardiac perfusion tomography, new quantitative method, 871ab(5)
assessment of myocardial salvage, Tc-99m MIBI, 801ab(5)
assessment of ventricular topography, gated tomographic radionuclide ventriculography, 770ab(5)
denervated but viable canine myocardium, I-123 MIBG, thallium SPECT, 767ab(5)
depletion of myocardial catecholamine stores, detection with I-123 MIBG, 810ab(5)
detection of different stages, In-111 antimyosin, Tc-99m pyrophosphate, 862ab(5)
detection of residual viable tissue, PET and SPECT, different ages, 869ab(5)
development of cardiac myosin light chain 1 mAb, synthetic peptide immunogens, radioimmunoassay, 785ab(5)
dipyridamole Tl-201 SPECT, compared to exercise RNV, jeopardized myocardium detection, 862ab(5)
enhanced F-18 fluoromisonidazole extraction, PET assessment, 730ab(5)
evaluation of ventricular function, coronary artery disease, 1149
flow and distribution response to stress, normal coronary arteries, 818ab(5)
identification of viable myocardium, automated 3D cardiac PET, Rb-82, 865ab(5)
In-111 antimyosin Fab and Tc-99m MIBI, reperfusion, 757ab(5)
myocardial viability, rest-redistribution thallium scintigraphy, early post-thrombosis, 729ab(5)
neuronal markers, H-3 phenylephrine, H-3 epinephrine, 733ab(5)
pre- and post-thrombolysis, Tc-99m MIBI SPECT, 820ab(5)
quantitative stress-redistribution Tl-201 SPECT, 780ab(5)
regional wall motion and coronary anatomy, myocardial perfusion relationship, 739ab(5)
reperfusion injury, In-111 neutrophils, 859ab(5)
scintigraphy of adrenergic receptors and neurons, 767ab(5)
serial Tc-99m MIBI myocardial SPECT studies, reperfusion, 800ab(5)
silent myocardial ischemia, evaluation, exercise Tl-201 SPECT, 864ab(5)
stress myocardial perfusion, left ventricular wall motion, Tc-99m MIBI, 864ab(5)
Tc-99m MIBI for anatomical landmarking, In-111 antimyosin Fab, 800ab(5)
Tc-99m MIBI uptake, coronary occlusion, reperfusion, 756ab(5)
variability of response to reperfusion, thrombolysis, MIBI-SPECT, 820ab(5)
ventricular function and perfusion, gated tomographic imaging, Tc-99m MIBI, 801ab(5)
Myocardial ischemia
accelerated glucose utilization, quantitative PET, 867ab(5)
ambulatory ST changes and perfusion imaging, dynamic exercise, dipyridamole "stress", 861ab(5)
binding of hypoxic cell marker, H-3 fluoromisonidazole, 194
C-14 deoxyglucose deposition, reperfusion, 797ab(5)
cultured cardiac cells, Tl-201 and Tc-99m MIBI uptake, 860ab(5)
detection of area at risk, coronary angioplasty, Tc-99m RP-30, 791ab(5)
detection of subendocardial ischemia, gated positron tomography, left ventricular hypertrophy, 866ab(5)
diagnosis of coronary artery disease, coronary angioplasty, PET, 845ab(5)
diagnosis of coronary stenosis, application, machine intelligence, 816ab(5)
dipyridamole-induced, reduction by caffeine, 1723, 861ab(5)
enhanced F-18 fluoromisonidazole extraction, PET assessment, 730ab(5)
exercise-induced, iodine-123 fatty acid, compared to thallium-201, 729ab(5)
exercise/rest Tc-99m MIBI-SPECT, regional quantitation, coronary heart disease, 791ab(5)
fatty acid utilization, tomographic assessment, recurrent chest pain, 828ab(5)
improved Tc-99m isonitrile uptake, myocardial salvage, compared to Tl-201, 800ab(5)
left ventricular dilation, exercise SPECT thallium imaging, three-vessel disease, 749ab(5)
mechanisms of RP-30 redistribution, post-ischemia, 757ab(5)
myocardial glucose uptake, dopamine infusion, PET, 859ab(5)
planar Tl-201 perfusion defects, 863ab(5)
quantitation of mass, acute coronary occlusion, PET, 866ab(5)
Rb-82 PET and Tl-201 SPECT disparities, dipyridamole stress, 861ab(5)
redistribution after thallium reinjection, relationship, coronary anatomy and regional wall motion, 740ab(5)
relief by PTCA, recovery, myocardial metabolism, 838ab(5)
reversible, dipyridamole perfusion PET, 760ab(5)
scintigraphic assessment of myocardial reperfusion, percutaneous transluminal coronary angioplasty, 821ab(5)
significance of absence or presence of angina, positive thallium Tl-201 stress test, 863ab(5)
silent
after myocardial infarction, exercise Tl-201 SPECT, 864ab(5)
bicycle exercise, first pass radionuclide angiography, 868ab(5)
three-dimensional cardiac PET, automated quantitation, routine clinical use, 1787
Tl-201 imaging and FDG imaging, redistribution, metabolic activity, 863ab(5)
transient mitral regurgitation, dipyridamole-thallium imaging, 1271
treadmill stress test and intravenous dipyridamole, myocardial perfusion imaging, Tc-99m MIBI, 759ab(5)
unstable angina patients, coronary stenosis, resting/redistribution Tl-201, 740ab(5)
whole body multidetector SPECT, variable aperture, 796ab(5)
Wiener filtering, SPECT quantification, 755ab(5)
Myocardium
altered perfusion, free fatty acid utilization, small-vessel disease, 829ab(5)
behavior of catecholamine analogs, compartmental analysis, 735ab(5)
blood flow
isosorbide dinitrate, dynamic PET, 866ab(5)
myocardial infarction, dynamic PET, 945ab(5)
O-15 water, novel mathematical approach, 825ab(5)
O-15 water, PET, 807ab(5)
quantitative measurements, rubidium-82 and PET, 807ab(5)
cationic complexes of technetium for imaging, 1415
characterization of fatty acid carrier, 798ab(5)
delineation of damage, In-111 monoclonal anti-

myosin, cardiomyopathy, 779ab(5)
differentiation of viable from scarred, delayed SPECT Tl-201 images, 864ab(5)
3,3-dimethyl(p-I-123 phenyl-)pentadecanoic acid uptake, reperfusion, 797ab(5)
3D quantification of defects, axial sampling and motion, PET, 892ab(5)
extraction of Tc-99m sestamibi, flow effects, thallium-201, 756ab(5)
false positive exercise Tl-201 SPECT in men, 749ab(5)
fatty acid metabolism, 1-[C-11] betamethylheptadecanoic acid, 797ab(5)
glucose utilization, PET, F-18 deoxyglucose, 359
human, thallium kinetics, 863ab(5)
imaging, neutral Tc-99m complex, 1830
I-123 MIBG uptake, primary hypertrophic cardiomyopathy, 810ab(5)
I-123 phenylpentadecanoic acid tomography, dipyridamole infusion, CAD detection, 760ab(5)
jeopardized, dipyridamole Tl-201 SPECT, exercise RNV, 862ab(5)
kinetics and exercise, I-123 phenylpentadecanoic acid, 829ab(5)
kinetics of F-18 misonidazole, marker of hypoxia, 351
kinetics of 15-*p*-[I-125]iodophenylpentadecanoic acid, quantitative analysis, 1211
left ventricular, automatic program for long axis, Tl-201, 806ab(5)
measurement of regional blood flow, copper-PTSM, PET, 807ab(5)
metabolic and functional abnormalities, coronary thrombolysis, 837ab(5)
metabolism tracer, C-11 acetate, 1743ab(10)
method to outline, single diffusible tracer, 775ab(5)
neuronal markers, H-3 phenylephrine, H-3 epinephrine, 733ab(5)
neutral and cationic perfusion agents, mechanistic comparison, 757ab(5)
new imaging agent, In-111 TE-BAT, 367
noninvasive assessment of performance, radionuclide ventriculography, aorta pressure change, 1657
novel functionalized diphosphine complexes, Tc-99m, 818ab(5)
optimal specificity of Tl-201 SPECT, recognition, imaging artifacts, 441
optimization of Tc-99m MIBI SPECT acquisition, processing parameters, 757ab(5)
oxidative metabolic reserve, PET, C-11 acetate, 1489
oxidative metabolism, C-11 acetate and PET, substrate utilization, 187
percent hypoperfused, algorithm, Tl-201 SPECT, 750ab(5)
perfusion abnormality, exercise, Tl-201 SPECT, 749ab(5)
perfusion agent Tc-99m SQ 30217, diagnostic utility, rapid imaging protocol, 730ab(5)
perfusion images from SPECT, model based quantification, 1992
perfusion imaging
functionalized diphosphine complexes, Tc-99m, 773ab(5)
simultaneous Tc-99m MIBI angiography, 38
Tc-99m HEXAMIBI, Tl-201, 301
Tc-99m SQ30217, Tl-201, 312
perfusion safety and efficacy, Tc-99m CDO-MEB, 959ab(5)
perfusion scans, limitations in LV wall thickness, SPECT, 796ab(5)
perfusion tomography, quantitative algorithm, 1746ab(10)
perfusion tracers and techniques, comparison, myocardial-to-lung ratio, 959ab(5)
PET compared to arteriography, coronary artery disease severity, 846ab(5)
post-infarction viability, In-111 antimyosin antibodies, Tc-99m MIBI, 800ab(5)
quantification of metabolic reserve, C-11 acetate, PET, 837ab(5)
quantitative standards for HEXAMIBI, 790ab(5)
radial shortening and myocardial thickening, Tc-99m MIBI, echocardiography, 821ab(5)
radioiodinated digoxin derivative, Na,K-ATPase binding, 923ab(5)
radioiodinated IPPA and BMIPP fatty acid, HPLC analysis, 923ab(5)
regional blood flow, new quantitation method, 808ab(5)
regional left ventricular filling, diastolic abnormalities, contiguous areas, 165
regional oxidative metabolism, C-11 acetate, serial PET imaging, 867ab(5)
regional perfusion, Tc-99m teboroxime, dynamic SPECT, 1744ab(10), 1ab(11)
regions of low flow, not necessarily hypoxic, 808ab(5)
rejecting and nonrejecting cardiac implants, imaging agent uptake, 1464
retention and clearance of Tc-99m SQ30217, dog, 860ab(5)
reversible defects, Tl-201 blood levels, 1172
rubidium-82 and Tl-201 perfusion imaging, coronary artery disease, 759ab(5)
scintigraphy, I-123 phenylpentadecanoic acid, 829ab(5)
simultaneous transmission/emission SPECT, moving line source, 964ab(5)
SPECT
color-coded surface image display, 872ab(5)
sectional images, rotating patient chair, 1ab(2)
swine, first pass extraction fraction, 767ab(5)
sympathetic nerve development, scintigraphic assessment, MIBG, 810ab(5)
sympathetic nervous function, angina pectoris, I-123 MIBG SPECT, 811ab(5)
synthesis and biodistribution, C-11 betamethylheptadecanoic acid, 928ab(5)
Tc-99m cardiac phantom, attenuation correction, SPECT quantitation, 894ab(5)
Tc-MIBI SPECT acquisition parameters, 795ab(5)
Tc-99m MIBI SPECT, 180° and 360° data collection, 295
Tl-201 ECG-gated myocardial SPECT, clinical evaluation, 864ab(5)
Tl-201 SPECT, prone *vs.* supine, 548
Tl-201 tomography
analysis, polar probability map, 871ab(5)
solution, inferior wall attenuation, 398
Tl-201 uptake and clearance, effects of heart rate, 1972
value of rest-stress positron tomography, nitrogen-13 ammonia, reversible asynergy, 1302
viable hypoxic, detection by PET, F-18 fluoromisonidazole, 846ab(5)
viable *vs.* infarcted, automated 3D cardiac PET, Rb-82, 865ab(5)
Myocytes, hypoxic metabolism, noninvasive testing, iodophenyl pentadecanoic acid, 860ab(5)
Myositis, HIV-associated, radionuclide bone scanning, 556

N

Nanocolloid, inflammation imaging, HM-PAO labeled leukocytes, 805ab(5)
National Cancer Institute (NCI), Canadian energy agency release, phase I, cancer cluster study, N1147
NCRP, Radiation Protection Award, N1934
Neck, irradiation for Hodgkin's disease, hyperthyroidism, low radioiodine uptake, 255
Neonates
brain SPECT, 915ab(5), 1337
effect on PEEP on regional ventilation, mechanically ventilated preterm lamb, 1342
importance of Tc-99m glucoheptonate scintigraphy, first UTI, 915ab(5)
Nephropathy, diabetic, early detection, Tc-99m DTPA and I-131 hippuran, 941ab(5)
Nephrotoxicity
cisplatin-induced tubular toxicity, comparison, radioactive renal agents, 659
cyclosporine nephrotoxicity, pathophysiology, 784ab(5)
Nephroureterolithotomy, percutaneous, therapeutic effect, Tc-99m DTPA renal scintigraphy, 942ab(5)
Neural crest tumors, therapeutic potential, I-131 MIBG, 769ab(5)
Neuroblastoma
children, I-123 metaiodobenzylguanidine scintigraphy, 799ab(5)
I-125 MIBG uptake
correlation, tumor histopathology, 474
histopathology, 836ab(5)
nude mouse xenograft, radiolabeled MIBG uptake, 884ab(5)
resistant, therapeutic use, I-131 MIBG, 903ab(5)
SPECT bone studies of extremities, 858ab(5)
stage IV, Tc-99m and I-131 monoclonal antibody, 904ab(5)
Neurocardiology, use of MIBG, N1291
Neurofibromatosis, re-evaluation of Tc-99m DTPA, tumor-seeking agent, 915ab(5)
Neuropsychiatric disorders
D-2 dopamine receptor densities, PET, 731ab(5)
evaluation, PET, CT and MRI, 1589
Neuroreceptors
imaging histamine H1 receptors, PET, baboon brain, 741ab(5)
imaging *in vivo* chemistry, N1283
theoretical effects, radioligand diffusional gradients, kinetic studies, 878ab(5)
Neutrophils, function, after monoclonal antibody interaction, 747ab(5)
Newsline
addendum, Pennsylvania certification, N14
Commentary
developments in RVSs/10CFR35/PET, N992
lines from the President, N1440, N1931
magnitude estimation, N1294
NRC workshop participants, N1584
nuclear medicine, procedural and cognitive, N276
radioimmunoassay, N12
RVSs and PET reimbursement, budget, N277
solution, radioisotope shortage, N438
radwaste revisited-1989, N133
survey of nuclear medicine physicians, scientists, facilities, N1
Nicotine, binding in brain, PET, 742ab(5)
Nifedipine, effects with PET, 866ab(5)

Nitride, -technetium cations, synthesis, myocardial imaging agents, 773ab(5)
Nitrocinnamic acid, no-carrier-added F-18-for-NO_2 aromatic nucleophilic substitution, 1757ab(10)
Nitrogen-13
ammonia-13 kinetics in lung, positron emission computed tomography, smokers and nonsmokers, 866ab(5)
effects of anti-anginal agents, PET, 866ab(5)
Nitrogen-13 ammonia
aqueous, proton irradiation of water, hydrogen pressure, 926ab(5)
PET, rest-stress value, preoperative prediction of reversible asynergy, 1302
relief of chronic ischemia, recovery of myocardial metabolism, 838ab(5)
visual analysis of PET images, reproducibility, reliability, 846ab(5)
Nitrogen-13 glutamate, F-18 uracil and, perfusion and shunting, colorectal carcinoma, 910ab(5)
Nitroglycerin, effects with PET, 866ab(5)
Norepinephrine, protracer, synthesis, F-19/F-18-*m*-hydroxyphenylserine, 929ab(5)
Nuclear magnetic resonance
behavior of EHPG complexes, metal ions, 848ab(5)
blind biopsy and, Hodgkin's and non-Hodgkin's lymphoma, 843ab(5)
blood-brain barrier integrity, Gd-DTPA and In-DTPA-IgG brain uptake, 839ab(5)
bone scintigraphy and, early stage, Legg-Calve-Perthes disease, 1755ab(10)
carbon-13, cellular redox, 814ab(5)
cardiac, dipyridamole effects, coronary artery disease, 840ab(5)
cervical, detection, recurrent thyroid carcinomas, 841ab(5)
cine, pulse sequence, heart, 4ab(2)
constraining SPECT reconstruction to body volume, 835ab(5)
correction of spatial distortions, MR and PET, structure-function registration, 1746ab(10)
correlative pediatric imaging, 15
CT and PET, Alzheimer's dementia, normal aging, 1607
3D brain imaging, I-123 IMP, 961ab(5)
dynamic MRI, shunt size determination, atrial and ventricular levels, 903ab(5)
evaluation of viability, human organ transplants, 813ab(5)
F-19
drug targeting, animal tumor models, 814ab(5)
5-fluorouracil pharmacokinetics, 813ab(5)
5-fluorouracil trapping, therapeutic effectiveness, 813ab(5)
FDG-PET and, pathologic findings, complex partial seizures, 752ab(5)
gadolinium-labeled microspheres and liposomes, lung parenchyma, 901ab(5)
global uniformity index, 1.5 tesla imager, 5ab(2)
localization of pheochromocytoma, correlation with CT and MIBG, 328
metabolic PET correlates, anatomic lesions, head trauma, 802ab(5)
MR contract agent, magnetite particles, liver, 840ab(5)
MRI contrast agent, Gd-153 clearance and organ distribution, 840ab(5)
observer reliability, 840ab(5)
PET and CT, evaluation, neuropsychiatric disorders, 1589
PET-MRI volume matching algorithm, evaluation, 875ab(5)
P-31 MR spectroscopy and, dermatomyositis, 5ab(11)
prinicipal axis transformation, image registration, 776ab(5)
quantitative imaging, image registration system, 894ab(5)
radiography and bone scintigraphy, sacroilitis, 842ab(5)
superimposed PET and MR images, simple and precise method, 876ab(5)
T1 and T2 relaxation times, Gd-DTPA enhanced brain tumor imaging, 902ab(5)
T1 and T2 weighted, multi-weighted linear combination, 902ab(5)
Tc-99m D,L-HM-PAO purity, diastereomeric mixtures, 106
three-dimensional brain surface image, 902ab(5)
tumor response to chemotherapy, bone and soft tissue, 813ab(5)
velocity measurements, small arterial vessels, 1753ab(10)
volumetric PET/MRI image matching and displays, 776ab(5)
vs. In-111 white blood cells, chronic complicated osteomyelitis, 754ab(5)
white blood cell scan, infection, lower extremity, 856ab(5)
Nuclear medicine
diagnostic role, acquired immunodeficiency syndrome, 1935
facilities, survey, N1
history, St. Louis, N569
procedural and cognitive, N276
Nuclear Medicine Week, 1989, N574
Nuclear Regulatory Commission (NRC)
issuance of final rules, emergency access, LLRW sites, N1143
SNM/ACNP petition to change 10 CFR 35, N1296
Nuclear stethoscope, computer-controlled miniature scintillation detector system, 891ab(5)

O

Obsessive-compulsive disorder, neuropsychological and PET study, 897ab(5)
Octreotide, I-123 labeling, metabolism, clinical applications, 768ab(5)
Oncology, PET studies, N1292
Opioids, sex-dependent differences in distribution, N-3-[F-18]propyldiprenorphine, 732ab(5)
Optic nerve, damage, regional cerebral glucose metabolism, 802ab(5)
Osmium-191, -Ir-191m generator based on silica gel, impregnation, tridodecylmethylammonium chloride, 538
Osteitis fibrosa cystica, false-positive Tl-201 localization, 1264
Osteocalcin
serum
bone scintigram, prostate carcinoma, 918ab(5)
concurrent bone scintigraphic findings, 1748ab(10)
Osteomyelitis
chronic complicated, In-111 white blood cells, MRI, 754ab(5)
diagnostic accuracy of skeletal infection, blood pool sign, gallium scintiscan, 774ab(5)
In-111 white blood cell scintigraphy, three-phase bone scintigraphy, diabetics, 753ab(5)
Klebsiella pneumoniae, three-phase radionuclide bone imaging, 1412
prediction of cure, three-phase bone and Ga-67 scans, 754ab(5)
subperiosteal abscess, "cold" spot, bone scan, 857ab(5)
Osteoporosis
dual energy radiography, comparison, quantitative computed tomography, 774ab(5)
postmenopausal, bone mineral density, non-hormonal cyclic therapy, 774ab(5)
regional migratory, scintigraphic findings, 858ab(5)
Ouabain, hypoxia and, myocarial uptake kinetics, Tc-99m HEXAMIBI and Tl-201, 1500
Ovarian cancer
I-131 HMFG1 monoclonal antibody
CA 125 radioimmunoassay, 918ab(5)
kinetics, nude mice and patients, 883ab(5)
intraperitoneal radioiodinated OC 125, 904ab(5)
intraperitoneal yttrium-90 immunotherapy, 828ab(5)
remote high level iodinations of antibodies, 932ab(5)
Ovary, metastatic malignant struma ovarii, spinal metastasis, 407
Oxygen, myocardial consumption, PET, C-11 acetate, 1798
Oxygen-2, LCMRO2 and LCBF measurements, on-line plasma separation, PET, 791ab(5)
Oxygen-15
amino acid uptake in brain, kinetic modeling approaches, 880ab(5)
autoradiography, realtime correction for dead-time, PET, 878ab(5)
high spatial resolution time-of-flight positron tomograph, physical performances, clinical images, 766ab(5)
Oxygen-15 butanol, improved routine synthesis, positron tomography, 927ab(5)
Oxygen-15 water
arterial dispersion time contant, direct estimation, PET CBF data, 900ab(5)
autoradiography and dynamic PET, tracer arrival delay correction, cerebral blood flow, 1069
C-11 butanol and, cerebral blood flow, PET, 901ab(5)
F-18 uracil and, PET, regional chemotherapy of liver metastases, 1754ab(10)
FDG PET, colorectal carcinoma, radiation therapy, 909ab(5)
noninvasive functional brain mapping, change-distribution analysis, PET, 141
PET
metastatic colorectal cancer, 910ab(5)
myocardial blood flow, 807ab(5)
myocardial blood flow, novel mathematical approach, 825ab(5)
relationship between Q-wave and circulation metabolism, threshold determination, 830ab(5)
renal plasma flow, PET, 824ab(5)
Oxygen-18 water, extraction of F-18 fluoride, fibrous ion exchange resin, 926ab(5)

P

PACS, operation of, 873ab(5)
Paget's disease
appearance on In-111 leukocyte images, 754ab(5)
scintigraphic findings, bone mineral content, 855ab(5)
Palladium-109, immunosuppression, local lymphoid irradiation, 890ab(5)
Palmitate, ketone bodies and, competition as fuels, heart, 797ab(5)
Pan-American Development Foundation, donations, N1587
Pancreas
cancer, chronic pancreatitis differentiation, F-18

FDG PET, 887ab(5)
human organ transplants, evaluation of viability, magnetic resonance spectroscopy, 813ab(5)
transplant monitoring, In-111 platelets, 1470
Parathyroid
adenoma, radioiodinated toluidine blue, scintigraphy, 768ab(5)
detection of abnormalities, Tc-99m/Tl-201 subtraction technique, scintigraphy, 3ab(2)
I-123 MIBG uptake by chemodectomas, 769ab(5)
scintigraphy, low sensitivity, upper pole adenomata, 885ab(5)
thallium-technetium subtraction, global *vs.* regional image normalization, 769ab(5)
Tl-201 uptake, enhancement, thyroxine pretreatment, 886ab(5)
Parenchyma, transit time index, surgery evaluation, obstructive uropathy, 942ab(5)
Parkinson's disease
dopamine D-2 receptor imaging, I-123 iodobenzamide, SPECT, 731ab(5)
local cerebral blood flow, I-123 IMP SPECT, 830ab(5)
presynaptic nigrostriatal function, 761ab(5)
PB-212 macroaggregate, toxicity in dogs, 834ab(5)
PEEP: *see* Positive end-expiratory pressure
Penis
blood flow, Xe-133 washout, 1032
blood flow during early erection, radioisotope penile plethysmography, 784ab(5)
evaluation of male impotence, non-invasive technique, 784ab(5)
radioisotope plethsmography, corpora cavernosa blood flow, early tumescence, 466
Pentamidine, apical pattern of Ga-67 lung uptake, AIDS, 744ab(5)
Peracetic acid, superior oxidant, I-123 IBZM preparation, 926ab(5)
Perfusion
effect on PEEP on regional ventilation, mechanically ventilated preterm lamb, 1342
lung scan hot spots, 734ab(5)
metal-labeled tracers, structure-activity relationships, 742ab(5)
myocardial
functionalized diphosphine complexes, Tc-99m, 773ab(5)
late reversibility, Tl-201 stress studies, 740ab(5)
Peritoneal cavity, model for use in internal dosimetry, 2002
PET: *see* Positron emission tomography (PET)
Phantom, realistic dynamic cardiac, evaluation, radionuclide ventriculography, 542
Pharmaceuticals, research centers, N1295
Phenols, resin-supported C-11 methylation approach, 822ab(5)
Pheochromocytoma
localization with MIBG, CT and MRI correlation, 328
occult lung metastasis, detection, I-131 MIBG scintigraphy, 885ab(5)
reduction of I-131 MIBG uptake, labetalol, 481
Phosphate, -containing compounds, In-111 and Ga-67 transfer, transferrin to ferritin, 70
Phosphines
new class of mixed ligand radiopharmaceuticals, Tc-99m, 772ab(5)
technetium-nitride cations, synthesis, myocardial imaging agents, 773ab(5)
Phospholipid ethers, radioiodinated, tumor imaging agents, 849ab(5)
Phosphorus-31, MR spectroscopy and MRI, dermatomyositis, 5ab(11)
Phosphorus-32 beta dose point kernels, potential use in radioimmunotherapy, 1036
Phosphorus-32 chromic phosphate colloid
intraarterial, radiation splenectomy, 884ab(5)
treatment of cystic brain tumor, 833ab(5)
Photopenia, bone, clinical significance, In-111 leukocyte scintigraphy, 1749ab(10)
Physicians, nuclear medicine, survey, N1
Pituitary, imaging agent, C-11 MTRB, 932ab(5)
Planar imaging
Bayesian methods, ECT image reconstruction, 880ab(5)
liver scintigraphy, worth of SPECT, 57
new Tc-99m antibody labeling method, initial clinical imaging, 809ab(5)
quantitative, Tc-99m MIBI, compared to Tl-201, 1456
Tl-201, perfusion defects, extent and severity, 863ab(5)
Plasma
clearance, Tc-99m MAG_3, one or two blood samples, 943ab(5)
clearance of Tc-99m MAG_3, estimation, one or two blood samples, 1955
metabolite analysis, internal surface-reverse phase chromatography, 920ab(5)
single sample value errors, renal plasma flow, distribution volume, 944ab(5)
Tc-99m RBC labeling interference, chronic renal failure patients, 869ab(5)
volume, dexamethasone effect, human brain tumors, 899ab(5)
Plasminogen activator, rapid clot uptake, animal model, deep vein thrombosis, 787ab(5)
Platelets
activation after balloon arterial injury, Tc-99m monoclonal antibody, atherosclerotic model, 787ab(5)
destruction in autoimmune thrombocytopenic purpura, clearance, In-111 autologous platelets, 629
efficient labeling method, Tc-99m, 737ab(5)
estimation of mean survival time, rapid method, 1550
inhibition of thrombosis on biomaterials, calcium ion sequestrants, 859ab(5)
labeling with Tc-99m pertechnetate, Sn(II)MPO, 922ab(5)
reaction with Tc-99m monoclonal antibody, monitoring thrombolysis, 1743ab(10)
scintigraphy, use of In-111 oxine, thrombocytopenia in children, 1819
splenic pool, response, vigorous exercise, 738ab(5)
uptake in liver and spleen, whole body, depth-independent build-up factor, 914ab(5)
Plethysmography
radioisotope penile
blood flow, early erection, 784ab(5)
corpora cavernosa blood flow, early tumescence, 466
Pneumocystis carinii
reversible pulmonary uptake, osteoarthropathic distribution, Tc-99m methylene diphosphonate, 1563
Tc-99m albumin and Ga-67 lung scanning, HIV-positive patients, 917ab(5)
Pneumonitis, amiodarone, Tc-99m DTPA aerosol washout rates, 916ab(5)
Poisoning, carbon monoxide, regional cerebral glucose metabolism, 802ab(5)
Porphyrin, bifunctional chelator, monoclonal antibody labeling, radioactive manganese, 935ab(5)
Positive end-expiratory pressure, effect on regional ventilation and perfusion, mechanically ventilated preterm lamb, 1342
Positron emission tomography (PET)
accuracy of quantitative measurements, myocardial blood flow, rubidium-82, 807ab(5)
β-adrenergic receptors, CGP 12177, 766ab(5), 825ab(5)
Alzheimer-type dementia, regional cerebral blood flow, 895ab(5)
amino acid uptake in brain, kinetic modeling approaches, 880ab(5)
ammonia-13 kinetics in lung, smokers and nonsmokers, 866ab(5)
anti-anginal agents, 866ab(5)
arterial dispersion time constant, 900ab(5)
assessment of myocardial viability, rest-redistribution thallium scintigraphy, 729ab(5)
attenuation correction, application, masked orbiting transmission source, 1056
automated three-dimensional, Rb-82, viable *vs.* infarcted myocardium, 865ab(5)
axial acceptance angle, effect, energy threshold, 766ab(5)
axial sampling and motion, 3D quantification, myocardial defects, 892ab(5)
brain glucose metabolism, psychiatric patients, summer affective disorders, 1752ab(10)
C-11 acetate
independence in dietary state, human heart, 837ab(5)
myocardial oxidative metabolism, substrate utilization, 187
regional myocardial oxygen consumption, 1798
serial imaging, regional myocardial oxidative metabolism, 867ab(5)
C-11 acetate and dobutamine, quantification, myocardial metabolic reserve, 837ab(5)
N-[C-11-methyl]acyclovir synthesis, 929ab(5)
C-11 amino acids
preparation, automated microprocessor-controlled reaction system, 4ab(11)
preparation, C-11 nitroalkanes, 783ab(5)
C-11 and F-18 labeled 4-fluorodeprenyl, probes, functional monoamine oxidase, 821ab(5)
C-11 benztropine, possible muscarinic cholinergic receptor ligand, 741ab(5)
C-11 carbon dioxide, quantitative brain pH mapping, acute stroke, 782ab(5)
C-11 citalopram, facile synthesis, serotonin uptake sites, 1757ab(10)
C-11 cocaine
binding in human and baboon brain, 761ab(5)
kinetic analysis, baboon brain, 898ab(5)
C-11 diprenorphine, opiate receptor density, ligand affinity, 740ab(5)
C-11 D-glucose
remote automated synthesis, 928ab(5)
routine preparation method, C-11 ammonium cyanide, 927ab(5)
C-11 L-methionine
cerebral neutral amino acid uptake, 838ab(5)
F-18 fluorodeoxyglucose comparison, lung tumor diagnosis, 788ab(5)
histologic type, primary lung cancer, 33
tumor uptake, response to irradiation, 2012
uptake as a predictor of prognosis, bronchogenic carcinoma, 1420(le)
L-[methyl-C-11] methionine, uptake in tumor, 1809
C-11 8-methoxy-MK-801
design, synthesis and evaluation, 930ab(5)
NMDA receptor imaging, 741ab(5)

C-11 MK-329, cholecystokinin receptors, 931ab(5)
C-11 phorbol ester, specific binding, protein kinase C, 783ab(5)
C-11 thymidine, liver regeneration measurement, 929ab(5)
C-15 oxygen, noninvasive detection, left-to-right shunts, 865ab(5)
cardiovascular nuclear medicine, the next step, 1123
central serotonin re-uptake sites, C-11 *N*-Me-paroxetine, 1753ab(10)
cerebral glucose metabolism
  Alzheimer's disease, 771ab(5)
  thirty *vs.* forty-five-minute period, 899ab(5)
cerebral regional metabolism, determination, radioligand binding parameters, 898ab(5)
characterization of fluorinated U-50488 analogs, 931ab(5)
clinical
  economic analysis, Rb-82 and heart, 707
  manpower requirements, 1132(le)
  reduction of radiation exposure, 962ab(5)
  study scheduling and coordination, 2ab(11)
clinical and metabolic correlates, acute stroke, 898ab(5)
clinical practice, 960ab(5)
comparative study, regional cerebral blood flow, 157
copper-PTSM
  cerebral blood flow, 791ab(5)
  microsphere-like retention in heart, blood flow, 768ab(5)
  regional blood flow, 807ab(5)
coronary artery disease severity, comparison, quantitative arteriography, 846ab(5)
coronary artery stenosis reversal, cholesterol lowering, arteriography, 845ab(5)
cortical and thalamic glucose consumption, reduction, Huntington's disease, 771ab(5)
CT and MR, Alzheimer's dementia, normal aging, 1607
CT and MRI, evaluation, neuropsychiatric disorders, 1589
data analysis with Macintosh computer, 873ab(5)
defense of quantitative techniques, 564(le)
detection
  residual or recurrent brain and liver tumors, 909ab(5)
  residual viable tissue, myocardial infarctions of different ages, 869ab(5)
  striatal functional impairment, Huntington's disease, 762ab(5)
  viable hypoxic myocardium, F-18 fluoromisonidazole, 846ab(5)
determination of liver regeneration, radiothymidine, 815ab(5)
development
  Co-55 as an antibody label, 923ab(5)
  image display, analysis workstation, 873ab(5)
  nuclear medicine history, St. Louis, N569
developmental brain plasticity, 801ab(5)
diagnosis of coronary artery disease, correlation, coronary angioplasty, 845ab(5)
diagnostic role of nuclear medicine, acquired immunodeficiency syndrome, 1935
differentiation of recurrent colorectal carcinoma, scar, 789ab(5)
dipyridamole perfusion, assessment, myocardial ischemia, 760ab(5)
dopamine D-2 receptors
  densities, neuropsychiatric disorders, 731ab(5)
  imaging, F-18 benzamide analogs, 899ab(5)
  quantification, caudate nucleus, 736ab(5)
  quantification, C-11 NMSP and schizophrenia, 731ab(5)
dopamine receptors, post-synaptic, cocaine abusers, 730ab(5)
dynamic
  isosorbide dinitrate, myocardial blood flow, 866ab(5)
  O-15 water and C-11 butanol, cerebral blood flow, 901ab(5)
early tumor response to therapy, 789ab(5)
evaluation of F-18 2-deoxy-2-fluoro-D-glucose, malignant melanoma, 738ab(5)
event pileup, 2-D modular detector systems, multiplane, 745ab(5)
F-18 2-deoxy-2-fluoro-D-glucose, therapeutic effect, malignant lymphoma, 910ab(5)
F-18 deoxyglucose
  myocardial glucose utilization, 359
  small cell carcinoma, 1754ab(10)
F-18 estrogens, 17α-ethynyl-11β-substitution, 753ab(5)
F-18 fluoride radiotracer, dopamine D2 receptors, 1757ab(10)
F-18 fluorodeoxyglucose
  kinetic rate constants, brain tumor and dementia, 900ab(5)
  pancreas cancer, chronic pancreatitis differentiation, 887ab(5)
  residual or recurrent brain and liver tumors, 966ab(5)
  Tl-201 and I-123 IMP SPECT, brain tumor, 895ab(5)
6-[F-18]fluoro-L-DOPA
  importance of carbidopa, 761ab(5)
  quality control procedure, brain dopamine neurons, 1249
16-α-[F-18]fluoroestradiol, uptake, metastatic breast carcinoma, 788ab(5)
F-18 fluoromisonidazole, enhanced extraction, jeopardized myocardium, 730ab(5)
16α-substituted 21-[F-18]fluoro-(19-nor)-progesterones, receptor binding ligands, 929ab(5)
N-3-[F-18]fluoropropylputrescine, prostate and prostate-derived tumors, 1205
L-[2-F-18]fluorotyrosine, cerebral metabolism, protein synthesis, 1367
F-18 pipamperone synthesis, baboon, 932ab(5)
F-18 uracil and O-15 water
  metastatic colorectal cancer, 910ab(5)
  regional chemotherapy, liver metastases, 1754ab(10)
finite tomograph resolution, tracer kinetics, compartmental modeling, 825ab(5)
"first session" effects, 899ab(5)
fluoroalkyl amphetamine analogs, synthesis, serotonin 5-HT2 agonists, 822ab(5)
fluorodeoxyglucose
  evaluation of seizures, primary brain tumors, 2ab(11)
  optimal experimental design, tissue data, 879ab(5)
  pathologic findings, complex partial seizures, 752ab(5)
  two behavioral states, single procedure, 93
fluorodeoxyglucose and O-15 water, colorectal carcinoma, radiation therapy, 909ab(5)
focus on the heart, N1289
Fourier-gated, wall motion analysis, 771ab(5)
gated, subendocardial ischemia detection, left ventricular hypertrophy, 866ab(5)
gated myocardial, quantitative analysis, regional wall motion, 1775
HCFA coverage, N580
high current electrostatic accelerator, 964ab(5)
high-resolution
  clinical efficacy, 765ab(5)
  kinetic determination, FDG model parameters, 879ab(5)
high-resolution multi-plane animal tomograph, modular detector system, 892ab(5)
high-resolution scanner
  brain imaging, three dimensions, 765ab(5)
  development, preliminary results, 892ab(5)
high spatial resolution time-of-flight, physical performances, clinical images, 766ab(5)
HPLC injection, radiopharmaceutical purification, 923ab(5)
I-124, immunotherapeutic radiopharmaceuticals, 922ab(5)
imaging histamine H1 receptors, baboon brain, 741ab(5)
imaging *in vivo* chemistry, N1283
imaging positron emitting radionuclides, radiation therapy, 911ab(5)
initial results from prototype tomograph, solid-state scintillation detectors, 766ab(5)
intraoperative electrocorticography and, epilepsy surgery, children, 896ab(5)
intravascular streaming, intracarotid infusion, glioma, 839ab(5)
kinetics of copper-PTSM in heart, 1843
LCMRO2 and LCBF measurements, on-line plasma separation, 791ab(5)
least-squares optimization, reconstruction filters, brain imaging, 745ab(5)
lesion detectability, axial resolution and sampling, 746ab(5)
ligand-receptor model influence, injection protocol, identifiability analysis, 877ab(5)
localization of epileptogenic foci, 2ab(11)
longitudinal, CT studies and, normal aging and Alzheimer's disease, 772ab(5)
maximum likelihood image reconstruction, 776ab(5)
metabolic and electrophysiologic manifestations, recognition memory, 894ab(5)
metabolic characterization of brain states, partial sensory limitation, 899ab(5)
metabolic correlates, anatomic lesions, head trauma, 802ab(5)
metabolic liver tumor image analysis, 878ab(5)
metal-labeled perfusion tracers, structure-activity relationships, 742ab(5)
MR and, correction of spatial distortions, structure-function registration, 1746ab(10)
-MRI volume matching algorithm, evaluation, 875ab(5)
multiplanar, long-term performance, 1378
multiresolution method, attenuation correction, 880ab(5)
multi-slice, axial positioning, recovery coefficient, 893ab(5)
myocardial blood flow
  myocardial infarction, 945ab(5)
  new quantitation method, 808ab(5)
  O-15 water, novel mathematical approach, 825ab(5)
  O-15 water, without bloodpool scan, 807ab(5)
myocardial glucose uptake, dopamine infusion, regional ischemia, 859ab(5)
myocardial oxidative metabolic reserve, C-11 acetate, 1489
Newsline Commentary, developments, RVSs and 10CFR35, N992
nicotine binding in brain, 742ab(5)
nitrogen-13 ammonia, rest-stress value, preoperative prediction of reversible asynergy, 1302
no-carrier-added synthesis

aryl [F-18]fluorides, nucleophilic aromatic substitution, 753ab(5)
C-11 HECNU, 783ab(5)
L-[5-C-11]ornithine, 782(ab), 783ab(5)
F-18 fluoroethylketanserin, serotonin S-2 receptors, 822ab(5)
obsessive-compulsive disorder, 897ab(5)
O-15 butanol, improved routine synthesis, 927ab(5)
O-15 water
brain mapping, change-distribution analysis, 141
renal plasma flow, 824ab(5)
oncology, N1292
parametric images of myocardial glucose utilization, dynamic cardiac FDG-PET studies, 735ab(5)
partial volume and spillover correction, cardiac scans, 824ab(5)
potential L-dopa tracers, radiofluorinated *m*-tyrosine analogs, 930ab(5)
presynaptic nigrostriatal function, Parkinson's disease, 761ab(5)
prinicipal axis transformation, image registration, 776ab(5)
procedure protocols, 960ab(5)
quantitative
correction, blessing and curse, 129(le)
critically ischemic myocardial mass, acute coronary occlusion, 866ab(5)
glucose utilization, ischemic myocardium, 867ab(5)
relative maximum flow, stenosis, 846ab(5)
quantitative 3-D, multiwire proportional chamber positron camera, 766ab(5)
radiation exposure reduction, 4ab(11)
radiopharmaceuticals
regulation, N137
routine, laboratory robotics, 968ab(5)
Zn-62 Cu-62 generator, Cu-62 source, 1838
Rb-81, quantitative tumor perfusion measurement, 911ab(5)
Rb-82
importance of timing, heart, 871ab(5)
Tl-201 SPECT, coronary artery diseasc detection, 829ab(5)
Tl-201 SPECT disparities, myocardial perfusion imaging, 861ab(5)
two-compartment model, brain tumor patient data, 839ab(5)
realtime correction for deadtime and decay, cerebral blood flow, O-15 water autoradiography, 878ab(5)
reimbursement, N1931
reimbursement and budget, N277
relationship between Q-wave and circulation metabolism, threshold determination, 830ab(5)
reversal of brain metabolic abnormalities, treatment, AIDS dementia complex, 581
rotating pin transmission sources, physical effects, 745ab(5)
scatter effects, model parameter estimation, 824ab(5)
semi-quantitative incorporation quotient images, simple method for creation, 776ab(5)
set-up in major cities, Mallinckrodt and CSI plan, N1147
simple positron imaging, time-of-flight, iterative deblurring, 746ab(5)
simultaneous emission and transmission scans, masked orbiting transmission source, 1751ab(10)
SP3000 TOFPET, characterization, multiple coincidences, 893ab(5)
stereotactic method, anatomical mapping, brain, 961ab(5)
Strategic Defense Initiative and, N14
studies during reading, dyslexics and controls, 802ab(5)
superimposed MR images, simple and precise method, 876ab(5)
synthesis of aqueous N-13 ammonia, proton irradiation of water, hydrogen pressure, 926ab(5)
tellerium-118/antimony-118 generator development, 849ab(5)
three-dimensional cardiac
automated quantitation, routine clinical use, 775ab(5), 1787
cardiac metabolism and function, 808ab(5)
three-dimensional data analysis, customizable volume of interest atlas, 839ab(5)
tissue atrophy and parietal hypometabolism, Alzheimer's disease, 895ab(5)
two tomographs, quantitative comparison, cerebral glucose metabolic rates, 1386
United States Pharmacopeial Convention, N1587
validation
brain SPECT, 3-[I-123]iodo-α-methyltyrosine, 895ab(5)
post-injection transmission measurements, 825ab(5)
visual analysis, reproducibility, reliability, 846ab(5)
visual cortex metabolism, affected arm movement, traumatic brain injury, 965ab(5)
volumetric, MRI image matching, displays, 776ab(5)
whole-body
attenuation correction, adaptive filtering, 1751ab(10)
imaging technique, 1750ab(10)
Zr-89, production, purification, 935ab(5)

Positron imaging
C-11 betamethylheptadccanoic acid, synthesis, biodistribution, 928ab(5)
C-11 MTRB, pituitary imaging agent, 932ab(5)
Cu-64 *p*-carboxyalkylphenyldithiosemicarbazones, antibody labeling, 848ab(5)
decreased brain metabolism, alcohol intoxication, 801ab(5)
quantitative accuracy of scanner, 892ab(5)
whole-body staggered detector positron camera, design and performance, 964ab(5)

Probes, novel approaches, N1293

Progestins, fluorine-substituted, uptake selectivity, 928ab(5)

Propranolol, portasystemic shunt fraction quantification, I-123 IMP, 1702

Prostate
cancer
PAP and PSA as markers of disease, 786ab(5)
186-Re(Sn)-HEDP palliation, painful skeletal metastases, 837ab(5)
painful bone metastases
improved clinical response, strontium-89, 843ab(5)
palliative therapy, strontium-89, 836ab(5)
potential PET imaging agent, N-3-[F-18]fluoropropylputrescine, 1205
prostatic specific antigen, bone scanning, prostate cancer follow-up, 9ab(4)

Prostheses, porous coated hip arthroplasty, three-phase bone scan, indium white blood cell scintigraphy, 1321

Protein
labeling, Tc-99m complex, bifunctional ligand, 940ab(5)
radioiodinated iodobenzoyl conjugates, para and meta isomers, 932ab(5)
radiolabeled, autoradiographic quantitation, In-111, 1538
rate of valine incorporation, brain tumor model, autoradiography, 913ab(5)
synthesis
brain tumors, C-11 L-methionine, 910ab(5)
cerebral metabolism, L-[2-F-18]fluorotyrosine, 1367

Protein kinase C, C-11 phorbol ester binding, PET, 783ab(5)

Psychiatric disorders, pediatric, quantification, HMPAO distribution, 812ab(5)

Psychiatry
"beam" brain mapping, SPECT iofetamine scans, 966ab(5)
obsessive-compulsive disorder and PET, 897ab(5)
schizophrenia, F-18 haloperidol binding, kinetic analysis, 898ab(5)

Psychology, panic attacks, head trauma patients, Tc-99m D,L-HM-PAO, 965ab(5)

Psychosis, mescaline-induced, right hemisphere involvement, 812ab(5)

Pulmonary embolism
central, perfusion distribution patterns, 734ab(5)
clearance of Tc-99m HM-PAO aerosols, new application, 743ab(5)
evaluation, urinary fibrinopeptide, 733ab(5)
lung parenchyma, gadolinium-labeled microspheres, MRI, 901ab(5)
non-thromboembolic lung disease, reversed mismatch, ventilation-perfusion ratio, 734ab(5)
PIOPED study, lung scans, pulmonary arteriography, N279
pre-operative ventilation and perfusion scans, relative value, 733ab(5)
ventilation/perfusion mismatch, positive pressure ventilatory support, 1268

Purpura, idiopathic thrombocytopenic, splenic dynamics, In-111 platelets, 1546

R

Radiation
blood flow, lung vascular permeability, 852ab(5)
exposure reduction, clinical PET, 4ab(11)
Protection Award announced by NCRP, N1934
reduction of exposure, clinical PET, 962ab(5)
scatter and background suppression, nuclear medicine imaging, 1747ab(10)
synovectomy, new agent, holmium-166 FHMA, 856ab(5)
therapy, FDG and O-15 water PET, colorectal carcinoma, 909ab(5)

Radiation dose
beta dose kernel in water, EGS4 Monte Carlo determination, 883ab(5)
bladder wall, 2-[F-18]-fluoro-2-deoxy-D-glucose, dynamic bladder model, 1747ab(10)
Bremsstrahlung, estimation in organs, 1373
development of treatment planning program, radioimmunotherapy, 884ab(5)
exposure and risk, performance of radiologic studies, radioactive patients, 884ab(5)
exposure from Tc-99m MAG_3, 720(le)
failure of percholate to inhibit Tc-99m isonitrile binding, myocardial perfusion studies, 885ab(5)
quantitative measurement, In-111 anti-melanoma monoclonal antibody, 885ab(5)
Tc-99m-labeled bone imaging agents, 1117

Radiation therapy, imaging positron emitting radio-

nuclides, 911ab(5)
Radioactive waste, low-level compacts, N133
Radioaerosol, containment system, 1ab(2)
Radioangiography, biventricular forward and regurgitant flows, 560(le)
Radioassay, receptor biochemistry, Tc-99m galatosyl-neoglycoalbumin, 733ab(5)
Radiocolloids, PB-212 macroaggregate toxicity in dogs, 834ab(5)
Radiography
acute myelofibrosis, 251
dual energy, comparison, quantitative computed tomography, 774ab(5)
magnetic resonance imaging and bone scintigraphy, sacroiliitis, 842ab(5)
Radioimmunoassay
CA125
co-expression of sialyl SSEA-1 antigen, variability, 919ab(5)
I-131 HMFG1 monoclonal antibody, ovarian cancer, 918ab(5)
monoclonal antibodies, different antigenic determinants, 785ab(5)
development of cardiac myosin light chain 1 mAb, synthetic peptide immunogens, 785ab(5)
effect on immunoscintigraphy, human anti-mouse antibodies, 786ab(5)
excellence in, Berson-Yalow Award, Robert C. Stadalnik, N994
imaging of lung vessels, 1686
immunotherapeutic radiopharmaceuticals, I-124, PET applications, 922ab(5)
monoclonal antibodies
diagnosis, squamous cell carcinoma of lung, 918ab(5)
LH and FSH specificity, polyclonal antibodies, 919ab(5)
recognition, antigenic gangliosides, 919ab(5)
PAP and PSA as markers of disease, prostate cancer, 786ab(5)
preparation and characterization, Re-186 NR-CO-02 F(ab')$_2$, 793ab(5)
quo vadis imaging, 1911
recombinant human erythropoietin, 918ab(5)
simultaneous measurement of serum T3 and T4, 919ab(5)
valuable laboratory technique, N12
Radioimmunoassayists, new technology, 1571
Radioimmunodetection
adenocarcinoma, antibody cocktail development, 935ab(5)
anti-CA 12.5, follow-up, ovarian carcinoma, 758ab(5)
radioimmunotherapy and, B-cell lymphoma, monoclonal antibody, 828ab(5)
tumor, diester linkage, antibody and chelate, 1693
Radioimmunoimaging
maleimidoethyl succinimidyl succinate, spacer, Ga-67 deferoxamine labeled antibody, 832ab(5)
rapid blood clearance, biotinylated IgG, avidin infusion, 66
Radioimmunoscintigraphy
chimeric mouse-human anti-CEA antibody of IgG4, colorectal carcinoma, 809ab(5)
early and delayed, colorectal carcinoma evaluation, 890ab(5)
monoclonal antibody SM3, ovarian tumors, 758ab(5)
radioimmunotherapy and, monoclonal antibody labeling, Sm-153, 683
radiolabeled monovalent and divalent haptens, dual specificity monoclonal antibody conjugates, 1358
Tc-99m monoclonal antibody, colorectal cancer, 748ab(5)
Tc-99m monoclonal antibody Fab fragment, small cell lung carcinoma, 819ab(5)
vs. standard X-rays, size-related diagnostic sensitivity, 749ab(5)
Radioimmunotherapy
astatine-211 labeled antibodies, 832ab(5)
clinical, dosimetry, radiobiological efficacy, 827ab(5)
colorectal carcinoma xenografts, Y-90 CO17-1A, mouse IgG, 935ab(5)
combined with external beam irradiation, renal cell carcinoma xenografts, 826ab(5)
curative, mammary carcinoma xenografts, I-131 monoclonal antibodies, 531
Curie level iodinations, 969ab(5)
development of treatment planning program, 884ab(5)
estimation of bone marrow doses, 778ab(5)
gastrointestinal cancer, administration, monoclonal antibodies, 779ab(5)
human cancer peritoneal xenografts, bismuth-212 labeled antibody, 778ab(5)
human estimates based on mouse data, antibody carrier/radionuclide combinations, 777ab(5)
I-131 and Re-186 radiolabeled conjugates, monoclonal antibodies, urinary metabolites, 793ab(5)
I-131 anti-colon specific antigen-p, therapeutic efficacy, monoclonal antibody, 826ab(5)
immunoglobulin complex formation, murine monoclonal antibodies, 888ab(5)
intraperitoneal, dose distributions, alpha and beta particle emitters, 777ab(5)
non-Hodgkin's lymphoma, I-131 anti-pan-B cell antibodies, 828ab(5)
potential use, beta dose point kernels, radionuclides, 1036, 1739(le)
radioimmunodetection and, B-cell lymphoma, monoclonal antibody, 828ab(5)
radioimmunoscintigraphy and, monoclonal antibody labeling, Sm-153, 683
Re-186, nude mouse model relevant to man, 779ab(5)
Re-186 NR-CO-02 anti-CEA F(ab')$_2$ fragment, preliminary clinical evaluation, 779ab(5)
remote high level iodinations of antibodies, 932ab(5)
serial, HAMA response, 827ab(5)
stage IV neuroblastoma, Tc-99m and I-131 monoclonal antibody, 904ab(5)
Radioiodide, colchicine-induced retention, iodine-deficient male rats, 737ab(5)
Radioiodination
comparative radiolabeling, isotype switch variant anti-idiotype mAb, 227
effect on protein charge, electrophoretic mobility, 933ab(5)
iodoantipyrine labeled with radioactive iodine, dosimetry, 1ab(2)
monoclonal antibodies, iodogen particle suspensions, 933ab(5)
remote high level, antibodies, 932ab(5)
use of mercury-thiol resin, preparation, I-123 IPPA, 925ab(5)
Radioiodine, nonimmunogenic hyperthyroidism, 1960
Radioisotopes, solution to current shortage, N438
Radioligands
cerebral regional metabolism, determination, binding parameters, 898ab(5)
diffusional gradients, theoretical effects, neuroreceptors, 878ab(5)
Radiology, fully networked department, 2ab(11)
Radionuclides
assessment of protein diet effect, glomerular filtration rate, 785ab(5)
beta dose point kernels, potential use, radioimmunotherapy, 1739(le)
cardiovascular nuclear medicine, the next step, 1123
detection of duodenal ulcer, 700
effectiveness of treatment, differentiated thyroid cancer, 737ab(5)
emission standards proposed by EPA, N1435
features and clinical relevance, abnormal renal mobility, 3ab(4)
imaging in diagnosis, aortic dissection, 1727
measurement of renal function, 2054
monitoring, renal transplantation, 3ab(4)
positron emitting, generation during radiation therapy, 911ab(5)
renal studies of kidney depth, 1745ab(10)
'salivagram', detection, pulmonary aspiration in children, 697
short-lived, nuclear medicine history, St. Louis, N569
therapeutic, "S" factors, self-dose to large tumors, 883ab(5)
Radiopharmaceuticals
amine-phenol complexes, Tc-99m, 938ab(5)
automated production system, proton only cyclotron, 965ab(5)
behavior of EHPG complexes, metal ions, 848ab(5)
bone cancer, evolution, Sm-153 EDTMP, 966ab(5)
cell labeling, Tc-99m tetradentate amine-phenols, 938ab(5)
comparison, cisplatin-induced tubular toxicity, 659
computer-aided design, 732ab(5)
cyclotron-produced, IAEA report, N1443
endotoxin testing with limulus amoebocyte lysate, chelated metallic radionuclides, chelating agents, 921ab(5)
F-18 fluoropropyl preclamol, mapping, cerebral sigma opiate receptors, 930ab(5)
HPLC injection for purification, remotely operated evaporation, 923ab(5)
I-124 2-iodoisonicotinic acid hydrazide, radiotracer for tuberculoma, 1756ab(10)
immunotherapeutic, I-124, PET applications, 922ab(5)
inhomogenous deposition, cellular level, dosimetry, 883ab(5)
internal surface-reverse phase chromatography, plasma metabolite analysis, 920ab(5)
irradiation of volunteers, nuclear medicine, 260
metal-labeled perfusion tracers, structure-activity relationships, 742ab(5)
mixed ligand technetium complexes
inorganic chemistry, 936ab(5)
new class, Tc-99m, 772ab(5)
no indemnification for licensees, N1444
PET
laboratory robotics, 968ab(5)
regulation, N137
Zn-62 Cu-62 generator, Cu-62 source, 1838
radiation synovectomy, Y-90 particulate agents, 1047
receptor binding, discriminant analysis, Tc-99m NGA, 879ab(5)
renal, evaluation, 823ab(5)
skeletal, lesion to normal bone uptake ratios,

QARG, 920ab(5)
structure/activity relationships, microcomputer-based molecular modeling, 877ab(5)
Tc-99m
in situ formation, redox chemistry, 937ab(5)
practical HPLC method, quality control, 940ab(5)
structural identification, HPLC, 1240
Tc-99m galactosyl-neoglycoalbumin, kinetic sensitivity, receptor binding, 1519
Tc-99m HM-PAO and SPECT, pediatric brain imaging, 1917(le)
Radioscintigraphy, effect of film selection, lesion detectability curves, 890ab(5)
Radiosynthesis
6-[C-11]-D-glucose, 1756ab(10)
fluorine-18 fluoromisonidazole, 343
Radiotherapy
Auger electron, I-123 and Br-80m halodeoxyuridines, intraperitoneal cancer, 833ab(5)
cancer, radioiodinating reagent development, monoclonal antibodies, 216
C-11 L-methionine tumor uptake, response to irradiation, 2012
effect on L-[1-11C]tyrosine, 18FDG metabolism, PET, 789ab(5)
gastrointestinal functional disturbances, after abdominal irradiation, 765ab(5)
imaging of noncerebral tumors, F-18 fluorodeoxyglucose, Tc-99m HM-PAO, 912ab(5)
I-125 MIBG uptake in children, neuroblastoma, tumor histopathology, 474
improved separation procedure of Cu-67, 921ab(5)
radiation effects on tumor, L-[methyl C-11] methionine uptake, 739ab(5)
Radiothymidine, labeled in carbon 2 position, determination, liver regeneration, 815ab(5)
Radioventriculography, first-pass, model, evaluation of ventricular insufficiency, 417(le)
Radon
continuing debate, N987
information for practicing physician, 961ab(5)
Reading, PET studies, dyslexics and controls, 802ab(5)
Receiver operating characteristic (ROC) analysis, collimator performance, use, hotelling trace, 892ab(5)
Receptors
adrenergic, scintigraphy, myocardial infarcts, 767ab(5)
β-adrenergic
CGP 12177, PET, 766ab(5), 825ab(5)
high yield synthesis, I-123 iodocyanopindalol, 859ab(5)
anti-EGF, phase I, imaging trial, 746ab(5)
benzodiazepine, radioiodinated diazepam derivative, SPECT studies, 803ab(5)
binding of Tc-99m galactosyl-neoglycoalbumin, kinetic sensitivity, 1519
binding radiopharmaceuticals, discriminant analysis, Tc-99m NGA, 879ab(5)
biochemistry, Tc-99m galactosyl-neoglycoalbumin, 733ab(5)
cardiovascular nuclear medicine, the next step, 1123
cholecystokinin
C-11 MK-329 synthesis, PET, 931ab(5)
localization, MK 329, 849ab(5)
corticosteroid, F-18, 821ab(5)
dopamine
measurement, cocaine abusers, 730ab(5)
N-(ω-iodoalkenyl)spiroperidol analogs, SPECT, 925ab(5)
dopamine D-1
F-18 fluoroethyl SCH-23390, no-carrier-added synthesis, 931ab(5)
I-123 FISCH, characterization, 830ab(5)
I-125 FISCH, improved imaging ligand, 803ab(5)
I-123 SCH-23982, SPECT studies, 804ab(5)
dopamine D-2
brain uptake, C-11 YM-09151-2, 515
density, neuropsychiatric disorders and PET, 731ab(5)
F-18 benzamide analogs, PET, 899ab(5)
F-18 haloperidol binding, kinetic analysis, 898ab(5)
I-123 IBZM, evaluation, 88
I-123 IBZM biodistribution, dosimetry, 834ab(5)
I-123 IBZM preparation, peracetic acid, 926ab(5)
I-123 iodobenzamide imaging, SPECT, 731ab(5)
I-123 iodolisuride imaging agent, SPECT, 731ab(5)
I-123 spiperone, tracer for SPECT, 926ab(5)
new analogs of iodobenzamide, 803ab(5)
new [F-18]fluoride radiotracer, PET, 1757ab(10)
quantification, caudate nucleus and PET, 736ab(5)
quantification, PET C-11 NMSP in schizophrenia, 731ab(5)
robustness of models, 736ab(5)
synthesis, I-125/123 *N*-iodoallylspiperone, 803ab(5)
epidermal growth factor, antibody guided diagnosis, glioma, 1636
estradiol, imaging, breast cancer detection, 844ab(5)
estrogen
astatine-211, biological behavior, 925ab(5)
biodistribution studies, I-123 IBHPE, 883ab(5)
concentration, tamoxifen and F-18 FES, 910ab(5)
16-α-[F-18]fluoroestradiol uptake, metastatic breast carcinoma, 788ab(5)
11β-methoxy-[16α-I-123]iodoestradiol interaction, 209
histamine H1, PET imaging, baboon brain, 741ab(5)
imaging agents, F-18, binding assays, 931ab(5)
-ligand model influence, injection protocol, identifiability analysis, 877ab(5)
lipoprotein
low-density, In-111 DTPA, 768ab(5)
PET quantification, Ga-68 DTPA-VLDL, 763ab(5)
muscarinic
C-11 MTRB, pituitary imaging agent, 932ab(5)
synthesis, C-11 tropanyl benzilate methiodide, 930ab(5)
muscarinic acetylcholine, I-125 3-(R)-quinuclidinyl (S)-4-iodobenzilate, 1079
muscarinic cholinergic, C-11 benztropine, PET, 741ab(5)
NMDA
C-11 8-methoxy-MK-801, synthesis, 930ab(5)
[I-123]- and [I-125]-3-iodo-MK-801, SPECT, 923ab(5)
PET imaging, 8-[C-11] methoxy-MK-801, 741ab(5)
opiate
density and ligand affinity, PET and C-11 diprenorphine, 740ab(5)
mapping, F-18 fluoropropyl preclamol, 930ab(5)
temporal lobe epilepsy, C-11 diprenorphine and PET, 750ab(5)
progesterone, binding ligands, PET, 929ab(5)
serotonin S-2
non-carrier-added synthesis, F-18 fluoroethylketanserin, 822ab(5)
SPECT, baboon brain, 741ab(5)
transferrin, vascular permeability, iron-59/In-111/Ga-69 transferrin, 1676
TSH, antibody measurements, hyperthyroidism, 786ab(5)
Reconstruction
algorithms, non-stationary SPECT image noise, 1746ab(10)
efficient attenuated reprojection algorithm, SPECT, 817ab(5)
Red blood cells
new bifunctional synthon, Tc-99m carbonic anhydrase, 940ab(5)
Tc-99m-labeled
early blood pool phases, hepatic hemangioma, 815ab(5)
first human studies, new kit, 811ab(5)
Redox, cellular, C-13 nuclear magnetic resonance, 814ab(5)
Reflex, sympathetic dystrophy, 959ab(5)
Reflux, duodenogastric, scintigraphic sign, 1568
Regional wall motion
assessment of ventricular topography, after acute myocardial infarction, 770ab(5)
automated detection of abnormalities, 961ab(5)
cardiac, synthetic classification images, 816ab(5)
evaluation of ventricular function, coronary artery disease, 1149
Fourier-gated PET, 771ab(5)
left ventricular, quantification, radionuclide ventriculograms, 638
quantitative analysis, gated myocardial PET, compared to left ventriculography, 1775
regional ejection fraction, definition, normal limits, 769ab(5)
Relative value scales, Resource Based, N1294
Renal artery, bilateral stenosis, captopril renal scintigraphy, 2042
Renins
renal vein
captopril-stimulated renography, hypertension, 5ab(4)
peripheral plasma, gamma camera renography, 6ab(4)
Renography
diuretic
antenatal hydronephrosis, 799ab(5)
early injection of furosemide, 841ab(5)
standard furosemide method, direct infusion comparison, 7ab(4)
quantitative, outcome of treatment, atherosclerotic renal artery stenosis, 1946
Reperfusion
C-14 deoxyglucose deposition, ischemia, 797ab(5)
myocardial, scintigraphy, percutaneous transluminal coronary angioplasty, 821ab(5)
serial Tc-99m MIBI myocardial SPECT studies, acute myocardial infarction, 800ab(5)
variability of response, thrombolysis, acute myocardial infarction, 820ab(5)
Resin, -supported C-11 methylation approach, phenols, amides and acidic precursors, 822ab(5)
Rhenium-186
labeled NR-CO-02 anti-CEA $F(ab')_2$ fragment, potential radioimmunotherapeutic agent,

779ab(5)
radioimmunotherapy, nude mouse model relevant to man, 779ab(5)
radiolabeled conjugates of monoclonal antibodies, fragments, urinary metabolites, 793ab(5)
Tc-99m and, comparative renal handling, CO_2DADS, 743ab(5)
Rhenium-186 beta dose point kernels, potential use in radioimmunotherapy, 1036
Rhenium-186 HEDP, palliation of painful skeletal metastases, prostate cancer, 837ab(5)
Rhenium-186 N_3S antibody, immunoconjugates, N_3S chelating agents, kit preparation, 933ab(5)
Rhenium-186 NR-CO-02 F(ab')$_2$, preparation and characterization, 793ab(5)
Rhenium-186 (Sn)-HEDP
mechanism of action, painful skeletal metastases, 732ab(5)
palliation of painful skeletal metastases, prostate cancer, 837ab(5)
Rhenium-188, zirconium-tunsten gel generators, 849ab(5)
Rhenium-188 beta dose point kernels, potential use in radioimmunotherapy, 1036
Rhenium diphosphonates, extended X-ray absorption fine structure, 732ab(5)
Rhenium(V), compared to technetium(V), ligand substitution, 743ab(5)
Rheumatoid arthritis
In-111 chloride joint imaging, 855ab(5)
radiopharmaceuticals, radiation synovectomy, Y-90 particulate agents, 1047
Rhodamine, sulfhydryl site-specific radiolabeling, monoclonal antibodies, 832ab(5)
Rhodium-105, labeling of human IgG, diethylenetriamine derivatives, 832ab(5)
RP-30, mechanisms of redistribution, post-ischemic myocardium, 757ab(5)
Rubidium-81, PET, quantitative tumor perfusion measurement, 911ab(5)
Rubidium-82
accuracy of quantitative measurements, myocardial blood flow, 807ab(5)
assessment of reversible myocardial ischemia, dipyridamole perfusion PET, 760ab(5)
automated 3D cardiac PET, viable *vs.* infarcted myocardium, 865ab(5)
diagnosis of coronary artery disease, coronary angioplasty, PET, 845ab(5)
economic analysis, clinical PET, heart, 707
PET
arteriography and, coronary artery disease severity, 846ab(5)
importance of timing, heart, 871ab(5)
Tl-201 SPECT and, coronary artery disease, 829ab(5)
Tl-201 SPECT disparities, myocardial perfusion imaging, 861ab(5)
two-compartment model, brain tumor patient data, 839ab(5)
thallium-201 and, myocardial perfusion imaging, coronary artery disease, 759ab(5)

S

Sacroilitis, MRI and radiography, bone scintigraphy, 842ab(5)
Salmonella, -infected thrombus, left ventricular aneurysm, Ga-67 citrate scintigraphy, 1277(le)
Samarium-153 EDTA, high specific activity, experimental tumor models, 202
Samarium-153 EDTMP
evolution, bone cancer radiopharmaceutical, 966ab(5)
human pharmacokinetics, metastatic cancer, 1814
Samarium-153 monoclonal antibody, combined radioimmunoscintigraphy, radioimmunotherapy and, 683
Sarcoma, musculoskeletal, evaluation, use of Gd-DTPA, 901ab(5)
Scatter
background suppression and, nuclear medicine imaging, 1747ab(10)
collimator, novel Monte Carlo simulation, 806ab(5)
Compton, distribution function, nonuniform attenuation media, 875ab(5)
fraction measurement, SPECT imaging, 876ab(5)
model parameter estimation, PET data, 824ab(5)
Monte Carlo simulation, non-uniform attenuating media, 875ab(5)
quantum noise and camera non-uniformity, analysis, holospectral imaging, 807ab(5)
-to-primary ratios, measurement, scintillation cameras, 876ab(5)
Schizophrenia
evaluation of neuropsychiatric disorders, PET, CT and MRI, 1589
F-18 haloperidol binding, kinetic analysis, baboon and human brain, 898ab(5)
I-123 IMP imaging, brain perfusion, 1616
PET D2 dopamine receptor quantification, C-11 NMSP, 731ab(5)
Scintigraphy
accuracy of contour detection, small objects, 806ab(5)
adrenergic receptors and neurons, myocardial infarcts, 767ab(5)
bone
diagnosis, sacral fractures, 959ab(5)
non-osseous subtalar coalitions, 799ab(5)
serum osteocalcin levels, 1748ab(10)
brain perfusion imaging, Tc-99m L,L-ECD, nonhuman primates, 1892
captopril
diagnosis, renovascular hypertension, 944ab(5)
neonatal hypertension, 798ab(5)
cardiac blood-pool, Tc-99m DTPA-HSA, 1713
complete duodenogastric reflux, 1568
computer simulation of scintigrams, 879ab(5)
detection of focal inflammation, polyclonal human immunoglobulin, 385
detection of parathyroid abnormalities, Tc-99m/Tl-201 subtraction technique, 3ab(2)
display and processing software, personal computer, 969ab(5)
energy weighted acquisition, finite spatial filters, 2029
evaluation of feet, 959ab(5)
features of choledochal cyst, 622
Ga-67 citrate, salmonella-infected thrombus, left ventricular aneurysm, 1277(le)
gastroesophageal, barium exams, pH probe studies in children, 2ab(2)
hepatic arterial perfusion, detection of hepatic metastases, 4ab(11)
identification, inflammatory diseases, vertebral column, 856ab(5)
I-123 metaiodobenzylguanidine, children with neuroblastoma, 799ab(5)
In-111 anti-myosin, after coronary bypass surgery, 780ab(5)
In-111 leukocyte
bone photopenia, clinical significance, 1749ab(10)
detection, myocardial abscess formation, 703
In-111 platelets, false-positive, 267(le)
indium white blood cell, three-phase bone scan, porous coated hip arthroplasty, 1321
intraperitoneal, monoclonal antibody delivery, transdiaphragmatic blockade, 815ab(5)
kidney, special chair, upright position, 963ab(5)
L6 binding sites, autoradiography, 1754ab(10)
lung perfusion, right-to-left shunting, persistent left superior vena cava, 412
LV volume calculations, technical aspects, 869ab(5)
lymphoceles associated with renal transplant, Tc-99m DTPA, I-131 ortho iodo hippurate, 3ab(11)
myocardial, Tl-201 chloride compared to Tc-99m MIBI, infants, 1176
myocardial sympathetic nerve development, I-123 MIBG, 810ab(5)
platelet, use of In-111 oxine, thrombocytopenia in children, 1819
pulmonary aspiration, evaluation, 967ab(5)
regional migratory osteoporosis, 858ab(5)
renal
captopril, Tc-99m DTPA and hypertension, 615
captopril pitfall, bilateral renal artery stenosis, 2042
Tc-99m MAG_3 and I-123 hippurate clearances, 2ab(4)
scrotal, variocele, physical exam and renal venography, 943ab(5)
sonography correlation, obstructive renal disease, 944ab(5)
Tc-99m DISIDA and, quantification, tracer kinetic modeling approaches, 1507
Tc-99m MDP, relative renal function estimation, 941ab(5)
Tc-99m pyrophosphate, malignant hyperthermia, 718(le)
Tc-99m (V) DMSA uptake, amyloidosis, 2050
Tl-201 and I-131, thyroid carcinoma follow-up, 914ab(5)
ultrasound features and, giant hemangiomas, liver, 181
unusual and subtle findings, evaluation, battered child, 4ab(2), 967ab(5)
ventilation/perfusion, CT comparison, emphysema in alpha-1 antitrypsin deficiency, 1755ab(10)
Scintillation cameras
clinical
evaluation, pulse tail extrapolation electronics, 1554
pulse tail extrapolation electronics, 797ab(5)
discrepant sulfur colloid, radioparticle liver uptake, superior vena cava obstruction, 113
dual-headed extra wide field-of-view, 855ab(5)
electronically collimated SPECT, first experimental study, 851ab(5)
measurement of scatter-to-primary ratios, 876ab(5)
multiple-energy gamma camera system, dynamic transport studies, 852ab(5)
non-uniformity, analysis, holospectral imaging, 807ab(5)
quantitative quality control program, SPECT, 851ab(5)
solid-state detectors, initial results, prototype PET tomograph, 766ab(5)
stationarity of modulation transfer function, scatter fraction, conjugate view SPECT imaging, 755ab(5)
technique for evaluation of anisotropy, collima-

tors used for SPECT, 894ab(5)
Seizures, utility of FDG-PET, 2ab(11)
Serotonin
5-HT2 agonists, synthesis, fluoroalkyl amphetamine analogs, 822ab(5)
uptake sites, PET, facile synthesis of C-11 citalopram, 1757ab(10)
Serum amyloid P component
diagnostic imaging of amyloidosis, 847ab(5)
plasma turnover studies, quantitative test, 847ab(5)
Sex differences, N-3-(F-18)-propyldiprenorphine distribution, 732ab(5)
Sexual aggression, violent, evaluation of cerebral perfusion, 812ab(5)
Shunt
colorectal carcinoma, F-18 uracil, N-13 glutamate, 910ab(5)
left-to-right, noninvasive detection, C-15 oxygen cardiac PET study, 865ab(5)
portal systemic
camera- and well-counting techniques, 890ab(5)
portal hypertensive rats, 887ab(5)
portasystemic, fraction quantification, I-123 IMP, 1702
right-to-left, persistent left superior vena cava, perfusion lung scintigraphy, 412
size determination, atrial and ventricular levels, dynamic MRI, 903ab(5)
Sialyl SSEA-1 antigen, co-expression on CA125, variability of expression, 919ab(5)
Sickle cell, -related marrow infarction, nonspecificity, gallium citrate localization, 855ab(5)
Single photon emission computed tomography (SPECT)
abnormal regional response to verbal stimulation, developmental dysphasia, Xe-133, 812ab(5)
acetazolamide IMP imaging, regional ischemia, 782ab(5)
acquisition parameters, Tc-99m MIBI, 795
application of stopping criteria, iterative maximum likelihood-EM reconstruction, 882ab(5)
assessment of ventricular topography, after acute myocardial infarction, 770ab(5)
attenuation correction, Tc-99m cardiac phantom, 894ab(5)
attenuation correction of thallium, differential attenuation, thallium photons, 1746ab(10)
bone
back pain, lumbar spine surgery, 490
evaluation of persistent back pain, lumbar spinal fusion, 1739(le)
studies of extremities, neuroblastoma, 858ab(5)
bone imaging, lumbar facet joint, septic arthritis, 1408
brain
I-123 IMP scanning, HIV-positive encephalopathy, 811ab(5)
imaging characteristics, ASPECT, 796ab(5)
neonates, 915ab(5)
Tc-99m HM-PAO, congenital dysphasia, 798ab(5)
cardiac
automatic superposition of images, 871ab(5)
correction, nonuniform attenuation, 497
causes of abnormal stress Tl-201 SPECT, normal coronary arteries, 750ab(5)
causes of geometric distortion, 180° and 360° angular sampling, 1666
collimator angulation error, 852ab(5)
combined CBF/CBV, recent and old strokes, 897ab(5)
combined conjugate views, Wiener restoration, 756ab(5)
commercially available systems
assessment, 893ab(5)
assessment, progress report, 963ab(5)
comparison of images, stereographic projection, brain, 875ab(5)
comparison of one and two day rest and treadmill tests, Cardiolite, 790ab(5)
Compton scatter distribution function, non-uniform attenuation media, 875ab(5)
cone beam, attenuation compensation, maximum likelihood reconstruction, 881ab(5)
constraining reconstruction to body volume, CT or MR scans, 835ab(5)
correction of bladder artifact, hip SPECT, 857ab(5)
3D attenuation coefficients, distribution, chest, 128(le)
dental bone scans, orthopan-tomoscintigram, 835ab(5)
detection of breast cancer, imageable estradiol, 844ab(5)
detection of residual viable tissue, myocardial infarctions, different ages, 869ab(5)
development of MUMPI, 964ab(5)
diagnostic patterns of post-ictal cerebral blood flow, temporal lobe epilepsy, Tc-99m HM-PAO, 751ab(5)
diagnostic role of nuclear medicine, acquired immunodeficiency syndrome, 1935
differentiation, suspected malignant pulmonary lesions, 844ab(5)
diffuse nonuniformity, liver studies, leukemia, 905ab(5)
dipyridamole-thallium 201, left bundle branch block, 2ab(11)
3D non-stationary simulation, 881ab(5)
dopamine D2 receptor imaging, I-123 iodobenzamide, 731ab(5)
dosimetry of I-125 seed implants, 1748ab(10)
dual energy
attenuation correction, optimum energies, 5ab(2)
methods and applications, brain, 1750ab(10)
dual radionuclide, flood radionuclide choice, Tc-99m based cardiac agent, 872ab(5)
dynamic
four-headed gamma camera, RCBF, 792ab(5)
lung ventilation study, Xe-133, 916ab(5)
myocardial perfusion imaging, Tc-99m teboroxime, 1ab(11)
Tc-99m HM-PAO, meningiomas, 1101
Tc-99m teboroxime, regional myocardial perfusion, 1744ab(10)
early and delayed, I-123 IMP, acute brain injury, 1751ab(10)
early detection of mechanical-overload heart failure, I-123 MIBG, clonidine pre-treatment, 810ab(5)
effect of attenuation weighted backprojection, 3D MTF, 816ab(5)
efficient attenuated reprojection algorithm, 817ab(5)
electronically collimated, first experimental study, 851ab(5)
emission and transmission data combination, interactive 3D image presentation, 835ab(5)
exercise/rest Tc-99m MIBI, regional quantitation, coronary heart disease, 791ab(5)
follow-up of cutaneous melanoma, immunoscintigraphy, 907ab(5)
Ga-67, evaluation, recurrent lymphoma, 874ab(5)
gated, aortic and mitral valve regurgitation, 870ab(5)
'Harlequin' artifact, cause and correction, 1133(le)
high-resolution renal imaging, Tc-99m DMSA, 1759ab(10)
high spatial resolution, small-animal resolution, 796ab(5)
HM-PAO, model for outcome-prediction, after stroke, 895ab(5)
I-123 cerebral perfusion agents, no-carrier-added radiosynthesis, 926ab(5)
I-123 HIPDM, surgery candidates, refractory complex partial seizures, 751ab(5)
I-123 IMP
brain imaging in children, alternating hemiplegias, 965ab(5)
craniosynostosis, 916ab(5)
functional imaging, brain maturation, 1982
validity of microsphere model, cerebral blood flow, 878ab(5)
Xe-133 and, critical cerebral blood flow thresholds, 337
I-123 6-iododopa, potential brain imaging agent, 924ab(5)
I-123 iodolisuride imaging agent, brain dopamine D-2 receptors, 731ab(5)
I-123 iodo-α-methyl tyrosine
brain tumor imaging, 110
validation with PET, brain, 895ab(5)
I-123- and I-125- 3-iodo-MK-801, NMDA receptor-ion channel complex, 923ab(5)
I-123 SCH-23982, dopamine D1 receptors, 804ab(5)
I-123 spiperone, dopamine D-2 receptor studies, 926ab(5)
I-131 anti-CEA/CA 19-9, immunoscintigraphy efficacy, colorectal cancer, 907ab(5)
IBG as improbable potential tracer, glucose metabolism, 921ab(5)
imaging *in vivo* chemistry, N1283
improved quantification, Wiener filtering, myocardial ischemia, 755ab(5)
influence of collimators, center of rotation measurements, 265(le)
inherent limitations in LV wall thickness, mass measurements, myocardial perfusion scans, 796ab(5)
interictal and ictal, cerebral blood flow, seizure focus localization, 751ab(5)
interictal and immediate postictal, Tc-99m HM-PAO, localization of seizure foci, 831ab(5)
iodine-substituted benzamides, high affinity, 803ab(5)
N-(ω-iodoalkenyl)spiroperidol analogs, dopamine receptor imaging, 925ab(5)
iofetamine scans, child psychiatry, "beam" brain mapping, 966ab(5)
iterated radial post correction method, non-uniform attenuation correction, 870ab(5)
liver, automated body contour, 266(le)
liver/spleen scans, leukemia, 3ab(2)
measurement of cerebral perfusion reserve, minor ischemic stroke, 897ab(5)
methods of scatter fraction measurement, 876ab(5)
MIBI, reperfusion response, myocardial infarction, 820ab(5)
modern gamma camera systems, comparison, imaging parameters, 3ab(2)
Monte Carlo simulation, non-uniform attenuating media, 875ab(5)

multi-crystal cylindrical detector designs, 851ab(5)
myocardial, color-coded surface image display, 872ab(5)
myocardial fatty acid utilization, recurrent chest pain, normal coronary arteriography, 828ab(5)
myocardial perfusion images, model based quantification, 1992
myocardial sectional images, rotating patient chair, 1ab(2)
myocardial sympathetic nervous function, angina pectoris, I-123 MIBG, 811ab(5)
neonatal brain, 1337
new Tc-99m antibody labeling method, initial clinical imaging, 809ab(5)
new tracer for cerebral perfusion studies, Tc-99m D,L-CB-PAO, 831ab(5)
non-osseous subtalar coalitions, bone scintigraphy, 799ab(5)
non-stationary, image noise, reconstruction algorithms, 1746ab(10)
optimization of Tc-MIBI acquisition, processing parameters, 757ab(5)
positioning of cortical region of interest, isocontour method, 877ab(5)
postexercise lung Tl-201 uptake, 288
potential CNS D-2 dopamine imaging agent, I-123 IBF, 762ab(5)
prinicipal axis transformation, image registration, 776ab(5)
quantification
  3D left ventricular segmental wall motion, 638
  HM-PAO distribution, pediatric psychiatric patients, 812ab(5)
  myocardial perfusion and thickness, tomographic phantom studies, 871ab(5)
quantitative
  bone scintigraphy, 240
  clinical use, Tc-99m and In-111, 881ab(5)
  image registration system, 894ab(5)
  quality control program, 851ab(5)
  therapeutic radioiodine concentration, 737ab(5)
quantitative stress-redistribution Tl-201, myocardial infarction, 780ab(5)
radial long-axis tomography, new reconstruction algorithm, 881ab(5)
radioiodinated diazepam derivative, benzodiazepine recep.or, 803ab(5)
reconstructed, effect, differential washout, 870ab(5)
reconstruction of truncated fan beam data, heart, 755ab(5)
regional cerebral blood flow
  acute ischemic stroke, 781ab(5)
  Alzheimer's disease, 771ab(5)
regional cerebral blood flow, drug abusers, 1ab(11)
regional ejection fraction, definition, normal limits, 769ab(5)
regularization, iterative least squares reconstruction algorithms, 880ab(5)
reimbursement for studies, SNM/ACNP statement, N995
reviewing projection displays, 963ab(5)
rotating slanthole collimator, 1737(le)
serial Tc-99m MIBI myocardial studies, acute myocardial infarction, reperfusion, 800ab(5)
serotonin S_2 receptor mapping, baboon brain, 741ab(5)
simultaneous transmission/emission, moving line source, 964ab(5)
slant-hole, Tl-201, 1ab(2)
SQ 32097, regional cerebral localization, 1ab(11)
stationarity of modulation transfer function, scatter fraction, conjugate view SPECT imaging, 755ab(5)
stress-redistribution thallium-201 studies, reproducibility, quantitative indices, 729ab(5)
symposium, SNM 8th Annual Winter Meeting, N11
Tc-99m, spatial resolution, quantification values, 508
Tc-99m D,L-HM-PAO purity, diastereomeric mixtures, NMR techniques, 106
Tc-99m DMSA, quantitation, renal uptake, 246
Tc-99m ethyl cysteinate dimer, chronic cerebral infarction, 1018
Tc-99m HM-PAO
  abnormal blood flow patterns, cerebral atrophy, 896ab(5)
  brain, children, 966ab(5)
  brain blood flow, congenital dysphasia, 1825
  3D region of interest analysis, brain, 961ab(5)
  filling out phenomenon, cerebral ischemia, 591
  focal cerebral ischemia, 781ab(5)
  pediatric brain imaging, 1917(le)
  quantitative analysis, Alzheimer's disease, 806ab(5)
Tc-99m MIBI
  180° and 360° data collection, myocardium, 295
  pre- and post-thrombolysis, myocardial infarction, 820ab(5)
technique for evaluation of anisotropy, collimators used for SPECT, 894ab(5)
thallium myocardial, prone *vs.* supine, 548
three-dimensional display, 834ab(5)
  accuracy, coronary disease detection, 834ab(5)
  gated blood-pool studies, 770ab(5)
Tl-201
  adenosine infusion, ischemic heart disease, 1745ab(10)
  brain tumors, 913ab(5)
  compared to exercise RNV, jeopardized myocardium detection, 861ab(5)
  coronary artery disease, left bundle branch block, 419(le)
  delayed images, viable or scarred myocardium, 864ab(5)
  denervated but viable canine myocardium, myocardial infarction, 767ab(5)
  evaluation, suspected lung cancer, 997
  exercise, myocardial perfusion abnormality, 749ab(5)
  false positive, exercise, 749ab(5)
  FDG imaging and, redistribution and metabolic activity, 863ab(5)
  flood field correction, reconstruction, 3ab(2)
  future cardiac events, angina pectoris, 861ab(5)
  high-risk patient identification, coronary artery disease, 862ab(5)
  kinetics, human myocardium, 863ab(5)
  left ventricular wall motion, Tc-99m MIBI, 864ab(5)
  low risk patients, coronary artery disease, 863ab(5)
  myocardium, polar probability map, 871ab(5)
  optimal specificity, imaging artifact recognition, 441
  percent hypoperfused myocardium, algorithm, 750ab(5)
  quantification, leg muscle perfusion, 458
  Rb-82 PET, coronary artery disease detection, 829ab(5)
  Rb-82 PET disparities, myocardial perfusion imaging, 861ab(5)
  silent myocardial ischemia, after myocardial infarction, 864ab(5)
  Tc-99m HEXAMIBI, coronary artery disease, 4ab(2)
Tl-201 and I-123 IMP, brain tumor usefulness, F-18 FDG PET, 895ab(5)
Tl-201 and Tc-99m, 180° and 360° reconstructions, heart, 756ab(5)
Tl-201 ECG-gated myocardial, clinical evaluation, 864ab(5)
Tl-201 exercise, myocardial perfusion, Tc-99m RP-30A, 820ab(5)
Tl-201 myocardial imaging
  prone position, 750ab(5)
  prone *vs.* supine position, 1738(le)
Tl-201 reversibility, quantitative analysis, 739ab(5)
Tl-201 scintigraphy, maximal coronary vasodilation, adenosine, 760ab(5)
Tl-201 stress-redistribution, false-positive reversible defects, "upward creep" of heart, 1718
Tl-201 stress studies, frequency, late reversibility, 740ab(5)
tomographic mapping of kinetic rate constants, I-123 IMP, 805ab(5)
unstable angina patients, coronary stenosis, resting/redistribution Tl-201, 740ab(5)
utility in evaluation of mandibular bone grafts, 843ab(5)
validation of Bayesian reconstruction, Monte Carlo simulations, real data, 755ab(5)
ventricular function and perfusion, gated tomographic imaging, Tc-99m MIBI, 801ab(5)
volume quantitation, 2D *vs.* 3D image segmentation, 835(ab
vs. planar liver scintigraphy, 57
whole body multidetector, variable aperture, 796ab(5)
workstation development, AT personal computer, 960ab(5)
Xe-133 and Tc-99m HMPAO
  cerebral blood flow, 1752ab(10)
  presurgical evaluation, temporal lobe epilepsy, 896ab(5)
Skull, hot, chemotherapy, radionuclide bone scans, 858ab(5)
Small-vessel disease, altered myocardial perfusion, free fatty acid utilization, 829ab(5)
Smoking
  imaging of *in vivo* chemistry, N1286
  lung cancer, radon debate, N987
Sn-117mDTPA, effect on marrow and tumor, 1754ab(10)
Society of Nuclear Medicine (SNM)
  Board of Trustees, relative value scale survey, N435
  HFCA and PET coverage, N580
  origin and The Journal, St. Louis, N569
  petition to change 10 CFR 35, N1296
  resignation of Henry Ernstthal, Executive Director, Education Post, N993
  SNM Awards for young cardiovascular investigators, N1434
  SNM 36th Annual Meeting, St. Louis, N572
  imaging *in vivo* chemistry, N1283
  SNM 8th Annual Winter Meeting, SPECT symposium, N11
  testimony on DOE 1990 budget, N1148
Sodium-potassium-ATPase, myocardial imaging agent, radioiodinated digoxin derivative, 923ab(5)
Somatostatin, octreotide, I-123 labeling, metabolism, 768ab(5)
Sonography

scintigraphy correlation, obstructive renal disease, 944ab(5)
sensitivity, cholescinitgraphy, gallbladder perforation, 850ab(5)
Spermatozoa, Tc-99m HM-PAO labeling agent, 922ab(5)
Spinal cord
injury
bone mineral distribution, five years later, 857ab(5)
radioisotopic evaluation, kidney, 944ab(5)
Spine
fracture probability, single and multi-site bone mineral content measurements, 1166
lumbar, back pain after surgery, bone SPECT, 490
lumbar spinal fusion, evaluation of persistent back pain, bone SPECT, 1739(le)
Spiroperidol, D-2 dopamine receptor, brain uptake, C-11 YM-09151-2, 515
Spleen
correlative pediatric imaging, 15
dynamics of In-111 labeled platelets, idiopathic thrombocytopenic purpura, 1546
liver uptake and, monoclonal antibody study, 5ab(11)
noncalcified hemangioma, detection, radionuclide bone scan, 1111
platelet uptake, whole body, depth-independent build-up factor, 914ab(5)
radiation splenectomy, intraarterial P-32 chromic phosphate, 884ab(5)
response of platelet pool, vigorous exercise, 738ab(5)
SPECT, leukemia, 3ab(2)
Tc-99m colloid, interferon therapy, hairy-cell leukemia, 2ab(2)
SQ 30217, Tc-99m labeled, myocardial retention, canine heart, 860ab(5)
SQ 32097
cerebral blood flow, cytoarchitectural pattern, 1751ab(10)
preliminary kinetics, regional cerebral blood flow, 792ab(5)
regional cerebral localization, SPECT, normal volunteers, 1ab(11)
Stadalnik, Robert C., Berson-Yalow Award recipient, excellence, radioassay, N994
Stark Referrals Bill, Newsline article, N1579
Stenosis
bilateral renal artery, pitfall, captopril renal scintigraphy, 2042
coronary artery, cholesterol lowering, arteriography and PET, 845ab(5)
portal vein, portal systemic shunting, 887ab(5)
relative maximum flow, quantitative PET, 846ab(5)
renal artery
captopril effect, glucoheptonate scintirenogram, 1759ab(10)
captopril renography, Tc-99m DTPA, 6ab(4)
diagnostic use, angiotensin converting enzyme inhibitor, 605
Gates' technique, captopril test in hypertensives, 51
I-131 OIH and Tc-99m MAG_3 clearances, 1ab(4)
outcome of treatment, quantitative renography, 1946
Steroid hormone, -secreting tissues, radioiodinated cholestryl ester uptake, lipoprotein, 1088
St. Louis
city of nuclear medicine landmarks, innovators, N569
36th Annual Meeting of SNM, N572
Strategic Defense Initiative
accelerator projects awarded, N580
PET and, N14
Strauss, H. William, election as editor, *The Journal of Nuclear Medicine*, N1146
Streptavidin
biotin and
radioimmunotargeting of tumor, 819ab(5)
sulfhydryl site-specific radiolabeling, monoclonal antibodies, 832ab(5)
Stress
flow and distribution response, normal coronary arteries, 818ab(5)
imaging of *in vivo* chemistry, N1288
influence on gastric emptying, 794ab(5)
Stroke
acute, clinical and metabolic correlates, 898ab(5)
evaluation of neuropsychiatric disorders, PET, CT and MRI, 1589
ischemic, regional cerebral blood flow, SPECT, 781ab(5)
occult deep vein thrombosis, radioparticle venography, 917ab(5)
quantitative brain pH mapping, C-11 carbon dioxide, PET, 782ab(5)
recent and old, combined CBF/CBV SPECT study, 897ab(5)
Strontium-89
improved clinical response, increasing dose, metastatic prostate and breast cancer in bone, 843ab(5)
palliation of painful bone metastases, phase II study, 2ab(2), 836ab(5)
Struma ovarii, metastatic malignant, paraparesis, spinal metastasis, 407
Sulcralfate, chemical aspects of labeling, Tc-99m, 523
Sulfhydryl, site-specific radiolabeling, monoclonal antibodies, 832ab(5)
Summer affective disorders, psychiatric patients, glucose metabolism in brain, 1752ab(10)
Surveys
manpower, history and methodology, N1
nuclear medicine physicians, scientists, facilities, N1
Sweden, thyroid cancer risk from Chernobyl, 721(le)
Sympathetic nerve
development in myocardium, scintigraphic assessment, I-123 MIBG, 810ab(5)
first pass extraction fraction, swine heart, 767ab(5)
myocardial function, angina pectoris, I-123 MIBG SPECT, 811ab(5)
Sympatho-adrenal system, correlative pediatric imaging, 15
Synovectomy
radiation
new agent, holmium-166 FHMA, 856ab(5)
radiopharmaceuticals, Y-90 particulate agents, 1047
Syringes, aluminum-hubbed needles, degradation, Tc-99m pertechnetate, 1758ab(10)

T

TA-4, serum level, localization, squamous cell carcinoma of lung, 918ab(5)
TAG-72, In-111 monoclonal antibody and, tumor expression, relationship, 908ab(5)
Tamoxifen, estrogen receptor concentration, F-18 FES, 910ab(5)
Technegas
lung inhalation scintigraphy, newborns, 744ab(5)
lung ventilation scintigraphy, ultra-fine aerosol, 744ab(5)
Technetium
-nitride cations, synthesis, myocardial imaging agents, 773ab(5)
-thallium parathyroid subtraction, global *vs.* regional image normalization, 769ab(5)
Technetium(III/II), new class of mixed ligand complexes, inorganic chemistry, 936ab(5)
Technetium(V)
amine-phenol complexes, synthesis, X-ray structures, 938ab(5)
compared to rhenium(V), ligand substitution, 743ab(5)
Technetium-99m
antibody-bifunctional chelator conjugates, 793ab(5)
-based cardiac agent, flood radionuclide choice, dual radionuclide SPECT, 872ab(5)
bifunctional ligand, protein labeling, synthesis, 940ab(5)
cardiac phantom, attenuation correction, SPECT quantitation, 894ab(5)
cationic complexes for myocardial imaging, 1415
D,L-CB-PAO, cerebral perfusion studies, 831ab(5)
clinically practical quantitative SPECT, 881ab(5)
complexes with ester analogues, 1,1,1-tris(4-methoxysalicylaldiminomethyl)ethane, 937ab(5)
device to automate elution and dispensing, 5ab(11)
diphosphine complexes, myocardial imaging, 818ab(5)
efficient platelet labeling method, 737ab(5)
ester-linker, antibody-bifunctional chelator conjugates, whole-body clearance, 934ab(5)
evaluation of indwelling catheters, chemotherapy, 845ab(5)
extended X-ray absorption fine structure, 732ab(5)
generators, variations in labeling efficiency, anti-melanoma mAb, 1759ab(10)
genetically engineered chimeric metallothionein antibody, 794ab(5)
-labeled bone imaging agents, radiation absorbed dose, 1117
labeling of IgG antibodies, rapid and efficient method, 793ab(5)
low sensitivity of parathyroid scintigraphy, adenomata, new subtraction method, 885ab(5)
N-donor ligands, synthesis, low-oxidation state cations, 939ab(5)
neutral and cationic myocardial perfusion agents, mechanistic comparison, 757ab(5)
new antibody labeling method, initial clinical imaging, 809ab(5)
new class of mixed ligand radiopharmaceuticals, 772ab(5)
new functionalized diphosphine complexes, myocardial perfusion imaging, 773ab(5)
new labeled compound, visualization, experimental tumor model, 906ab(5)
novel Tc-N_2S_2 complex, synthesis, characterization, 773ab(5)
preparation and biodistribution, hexadentate Schiff base ligands, 773ab(5)
radiation dosimetry, radionuclide hysterosalpingography, 415(le)
radiopharmaceuticals
in situ formation, redox chemistry, 937ab(5)
practical HPLC method, quality control, 940ab(5)
structural identification, HPLC, 1240

Re-186 and, comparative renal handling, CO_2DADS, 743ab(5)
SPECT
180° and 360° reconstructions, heart, 756ab(5)
spatial resolution, quantification values, 508
suspension of uranium shipments, Department of Energy, N1139
tetradentate amine-phenols
cell labeling radiopharmaceuticals, 938ab(5)
radiochemical studies, 938ab(5)
Tl-201 subtraction technique, scintigraphic detection, parathyroid abnormalities, 3ab(2)
1,1,1-tris(5-methylsalicylaldiminomethyl)ethane, biliary elimination, rat and guinea pig, 937ab(5)
tumor-specific mouse/human chimeric antibody, human γ3 constant region, 934ab(5)
uptake, rejecting and nonrejecting cardiac implants, 1464

Technetium-99m albumin
compared to Ga-67 citrate, lung scanning, HIV-positive patients, 917ab(5)
detection of focal inflammation, scintigraphy, 385
forearm blood flow measurements, after brachial arteriotomy, 45
immunospheres, intravascular targeting, 934ab(5)
surgical management, truncal melanoma, 844ab(5)

Technetium-99m albumin colloid
peritoneo-pleural fluid communication, mediastinal lymph nodes, 559(le)
rapid filtration, particle size and radiochemical purity, 3ab(11)

Technetium-99m antibody
chemical modification, accelerated background clearance, 940ab(5)
labeling, use of thiocarbohydrazine, 793ab(5)

Technetium-99m antifibrin, uptake in acute venous thrombosis model, 787ab(5)

Technetium-99m bis(aminoethanethiol), synthesis and biological evaluation, 939ab(5)

Technetium-99m carbonic anhydrase, new bifunctional synthon, 940ab(5)

Technetium-99m CDO-MEB
myocardial perfusion safety and efficacy, 959ab(5)
neutral complex for myocardial imaging, 1830

Technetium-99m cellulose fiber, gastrointestinal transit, 402

Technetium-99m colloid, liver/spleen scans, interferon therapy, hairy-cell leukemia, 2ab(2)

Technetium-99m dimercaptosuccinic acid, uptake, head and neck squamous carcinoma, 174

Technetium-99m DISIDA
diagnosis of hepatocellular carcinoma, adenoma, focal nodular hyperplasia, 1278(le)
scintigraphy and, quantification, tracer kinetic modeling approaches, 1507

Technetium-99m disofenin, morphine hepatobiliary scintigraphy, potential pitfalls, 850ab(5)

Technetium-99m DMSA
high-resolution SPECT renal imaging, 1759ab(10)
renal handling, glomerular filtration, peritubular uptake, 1219
scintigraphy, medullary carcinoma of thyroid, 1420(le)
SPECT, quantitation, renal uptake, 246
Tc-99m GHA and, differing responses, renovascular hypertension after captopril, 841ab(5)
unilateral renal artery stenosis, diagnostic use, angiotensin converting enzyme inhibitor, 605

Technetium-99m (V) DMSA, uptake in amyloidosis, 2050

Technetium-99m DTPA
aerosol lung scans, performance, ventilator patients, 9ab(4)
aerosol ventilation studies, pulmonary function testing, cystic fibrosis, 967ab(5)
aerosol washout rates, amiodarone pneumonitis, 916ab(5)
antenatally diagnosed pelviureteric junction obstruction, conservative management, 5ab(4)
assessment of inhalation lung imaging, I-123 IMP aerosol, 853ab(5)
camera images, quantitative calculations, GFR, 1747ab(10)
captopril-enhanced renal scintigraphy, hypertension evaluation, 615
decreased pulmonary clearance, comparison, Tc-99m imidodiphosphate, 853ab(5)
estimated differential renal clearance, compartmental model analysis, 877ab(5)
I-131 hippuran and, early detection, diabetic nephropathy, 941ab(5)
lung clearance and gallium scanning, HIV-related lymphocytic alveolitis, 746ab(5)
radioisotopic evaluation of kidney, spinal cord injury, 944ab(5)
re-evaluation as tumor-seeking agent, neurofibromatosis, 915ab(5)
renal artery stenosis, captopril renography, 6ab(4)
renal scintigraphy, therapeutic effect, percutaneous nephroureterolithotomy, 942ab(5)
renal transplant and lymphoceles, 3ab(11)
Tc-99m MAG_3 and I-131 OIH comparisons, follow-up renal transplants, 4ab(4)
unilateral renal artery stenosis, diagnostic use, angiotensin converting enzyme inhibitor, 605

Technetium-99m DTPA aerosol, scans of ventilator-dependent patients, 743ab(5)

Technetium-99m DTPA-HSA, cardiac blood-pool scintigraphy, 1713

Technetium-99m ECD
extraction and kinetics, intracarotid injection, 742ab(5)
metabolism in isolated rat organs, 743ab(5)
new brain imaging agent, kinetics, biodistribution, 599
regional cerebral distribution, microspheres, nonhuman primates, 792ab(5)
TLC and HPLC analysis, 936ab(5)

Technetium-99m L,L-ECD
brain perfusion imaging
biodistribution, humans, 1902
nonhuman primates, 1892

Technetium-99m EHIDA, hepatobiliary dysfunction, cyclosporine A toxicity, 921ab(5)

Technetium-99m ethyl cysteinate dimer, biodistribution and dosimetry, chronic cerebral infarction, 1018

Technetium-99m galactosyl neoglycoalbumin
measurement of functional hepatic mass, after hepatic irradiation, 814ab(5)
receptor binding, kinetic sensitivity, 1519
receptor biochemistry, measurement validation, 733ab(5)
utility of discriminant analysis, receptor binding radiopharmaceuticals, 879ab(5)

Technetium-99m GHA, Tc-99m DMSA and, differing responses, renovascular hypertension after captopril, 841ab(5)

Technetium-99m glucarate, marker of acute cerebral damage, 901ab(5)

Technetium-99m glucaric acid, detection of acute cardiac injury, 1743ab(10)

Technetium-99m glucoheptonate
importance in infants, first UTI, 915ab(5)
increased uptake, renovascular hypertension, 5ab(4)
N-benzyl-N-methyl-piperidinyl-bis(aminoethanethiol) and, kinetic study, ligand exchange, 939ab(5)
transport mechanism, renal and lung tumor cells, 912ab(5)

Technetium-99m α-D-glucose 1-phosphate, lung carcinoma imaging, compared to Ga-67, 913ab(5)

Technetium-99m granulocytes, bone and joint diseases, 1743ab(10)

Technetium-99m p-halophenethyl diaminodithiol analogs, brain blood flow imaging, 939ab(5)

Technetium-99m HDP, bone scan, detection, noncalcified splenic hemangioma, 1111

Technetium-99m HEXAMIBI
comparison, one and two day rest and treadmill tests, 790ab(5)
comparison to Tl-201, myocardial perfusion imaging, 301
labeling procedure and stability, Tc-99m MIBI, 865ab(5)
quantitative standards, 790ab(5)
Tl-201 and, hypoxia and ouabain effects, myocardial uptake kinetics, 1500
Tl-201 SPECT and, diagnosis, coronary artery disease, 4ab(2)

Technetium-99m HEXAMIBI isonitrile, increased lung uptake, discordant hemodynamic disturbances, 860ab(5)

Technetium-99m HM-PAO
agent for human spermatozoans, 922ab(5)
brain SPECT
children, 966ab(5)
congenital dysphasia, 798ab(5)
3D region of interest analysis, 961ab(5)
brain SPECT in neonates, 1337
clinical use, determination of brain death, 1621, 1627
compared to CT, model for outcome-prediction, after stroke, 895ab(5)
diagnostic patterns of post-ictal cerebral blood flow, temporal lobe epilepsy, SPECT, 751ab(5)
distribution of cell-bound activity, human leukocytes, 804ab(5)
dynamic SPECT, meningiomas, compared with I-123 IMP, 1101
extraction and kinetics, intracarotid injection, 742ab(5)
ictal SPECT, focal epilepsy, 751ab(5)
I-123 IMP and, discordance, subacute cerebral infarct, 1752ab(10)
interictal and immediate postictal SPECT, localization, seizure foci, 831ab(5)
-labeled leukocytes
infectious complications, orthopedic surgery, 804ab(5)
inflammation imaging, 805ab(5)
PET, regional cerebral blood flow, 157
pulmonary clearance of aerosols, new application, 743ab(5)
quantitative analysis of SPECT studies, Alzheimer's disease, 806ab(5)
quantitative blood flow tracer, focal cerebral ischemia, 781ab(5)
radiotherapy, imaging of noncerebral tumors, 912ab(5)
regulation of PET radiopharmaceuticals, N137
SPECT

abnormal blood flow patterns, cerebral atrophy, 896ab(5)
brain blood flow, congenital dysphasia, 1825
filling out phenomenon, cerebral ischemia, 591
pediatric brain imaging, 1917(le)
Xe-133 SPECT and
cerebral blood flow, 1752ab(10)
presurgical evaluation, temporal lobe epilepsy, 896ab(5)
Technetium-99m D,L-HM-PAO
assessment of purity, diastereomeric mixtures, NMR techniques, 106
evaluation of granulocyte labeling, 2022
panic attacks, head trauma patients, 965ab(5)
tomography, brain volume, neuroanatomy, 1752ab(10)
Technetium-99m HM-PAO leukocytes, detection of inflammatory lesions, compared to Ga-67 citrate, 1332
Technetium-99m hydroxyethyl starch, effect on lymph node uptake, 969ab(5)
Technetium-99m IgG, imaging of inflammatory arthritis, 2017
Technetium-99m non-specific IgG, inflammatory joint scintigraphy, 889ab(5)
Technetium-99m imidodiphosphate, decreased pulmonary clearance, comparison, Tc-99m DTPA, 853ab(5)
Technetium-99m isonitrile: *see also* Technetium-99m RP-30A
comparison of one and two day rest and treadmill tests, Cardiolite, 790ab(5)
effect of stereochemistry, 773ab(5)
failure of percholate to inhibit binding, thyroid, myocardial perfusion studies, 885ab(5)
improved uptake after thrombolysis, myocardial salvage, compared to Tl-201, 800ab(5)
scintigraphic assessment of myocardial reperfusion, percutaneous transluminal coronary angioplasty, 821ab(5)
Technetium-99m MAA
camera- and well-counting techniques, portal systemic shunting, 890ab(5)
portal systemic shunting, portal hypertensive rats, portal vein stenosis, 814ab(5)
right-to-left shunting, left superior vena cava, perfusion lung scintigraphy, 412
variable perfusion patterns, therapeutically embolized liver, 1012
Technetium-99m MAG_3
chemistry and biokinetics, by-products, 1ab(4)
clearance after captopril, renovascular hypertension, 656
clearance determined by simplified methods, 943ab(5)
estimation of plasma clearance, 1955
estimation of plasma clearance, adults, one or two blood samples, 943ab(5)
evaluation as routine renal radiopharmaceutical, 823ab(5)
evaluation of MAG_3-like compounds, renal agents, 937ab(5)
glomerular filtration rate, tubular secretion, rat kidney, 1986
handling by kidney, 1ab(4)
I-123 hippurate clearance and, renal scintigraphy, 2ab(4)
I-131 OIH and, clearances, renal plasma flow, 823ab(5)
I-131 OIH and iothalamate comparisons, renal ischemia, 1ab(4)
I-131 OIH and Tc-99m DTPA comparisons, follow-up renal transplants, 4ab(4)
I-131 OIH clearances, renal plasma flow, renal artery stenosis, 1ab(4)
radiation exposure, 720(le)
renal ischemia, 823ab(5)
renal parenchymal transit time, factor analysis, hydronephrosis, 3ab(4)
renal transplant evaluation, 823ab(5)
routine renal radiopharmaceutical, 1ab(4)
Tc-99m MSG and, renal imaging, dogs, 937ab(5)
uptake in renal transplant, measurements, 3ab(4)
Technetium-99m MDP
detection of infected orthopedic implants, 754ab(5)
In-111 leukocytes, false-positive, noninfected Charcot joints, 754ab(5)
renal scintigraphy, functional assessment, 945ab(5)
scintigraphy, relative renal function estimation, 941ab(5)
utility of SPECT, evaluation, mandibular bone grafts, 843ab(5)
Technetium-99m metallothionein, -conjugated mouse monoclonal antibody B72.3, Rhesus monkeys, 1351
Technetium-99m methylene diphosphate, renal uptake, therapeutic radiation, vertebral metastases, 1113
Technetium-99m methylene diphosphonate
diagnostic role of nuclear medicine, acquired immunodeficiency syndrome, 1935
reversible pulmonary uptake, hypertrophic pulmonary osteoarthropathic distribution, 1563
Technetium-99m MIBI
anatomical landmarking, myocardial infarction, In-111 antimyosin Fab, 800ab(5)
compared to Tl-201 chloride, myocardial scintigraphy, infants, 1176
comparison of *in vitro* tumor cell labeling, 938ab(5)
exercise/rest SPECT in 4-hour protocol, regional quantitation, coronary heart disease, 791ab(5)
imaging in follow-up, differentiated thyroid carcinoma, 904ab(5)
In-111 antimyosin antibodies and, post-infarction myocardial viability, 800ab(5)
In-111 antimyosin Fab and, myocardial infarction, reperfusion, 757ab(5)
labeling procedure and stability, 865ab(5)
mechanisms of RP30 redistribution, post-ischemic myocardium, 757ab(5)
myocardial perfusion imaging, 790ab(5)
myocardial salvage, acute myocardial infarction, 801ab(5)
myocardial uptake, coronary occlusion, reperfusion, 756ab(5)
optimization of SPECT acquisition, processing parameters, 757ab(5)
quantitative planar imaging, compared to Tl-201, 1456
radial shortening and myocardial thickening, compared to echocardiography, 821ab(5)
serial myocardial SPECT studies, reperfusion, acute myocardial infarction, 800ab(5)
simultaneous angiography, myocardial perfusion imaging, 38
SPECT
acquisition parameters, 795ab(5)
180° and 360° data collection, myocardium, 295
pre- and post-thrombolysis, myocardial infarction, 820ab(5)
stress myocardial perfusion, left ventricular wall motion, angina, 864ab(5)
Tl-201 and
bronchial carcinoma, 845ab(5)
cultured cardiac cells, 860ab(5)
differences, coronary artery disease, 865ab(5)
right ventricular uptake, 820ab(5)
treadmill stress test and intravenous dipyridamole, myocardial perfusion imaging, coronary artery disease, 759ab(5)
variability of response to reperfusion, thrombolysis, SPECT, 820ab(5)
ventricular function and perfusion, gated tomographic imaging, ventriculography, 801ab(5)
Technetium-99m monoclonal antibody
carcinoma of lung, 1ab(11)
imaging of small cell lung carcinoma, 818ab(5)
NR-Lu-10, small cell lung cancer, 1749ab(10)
platelet activation after balloon arterial injury, experimental atherosclerotic model, 787ab(5)
radioimmunoscintigraphy, colorectal cancer, 748ab(5)
stage IV neuroblastoma, 904ab(5)
successful imaging, malignant melanoma, 25
Technetium-99m monoclonal anti-CEA antibody, immunoscintigraphy, liver metastases, colorectal carcinoma, 748ab(5)
Technetium-99m monoclonal anti-NCA-antibodies, localization, subacute and chronic inflammatory lesions, 805ab(5)
Technetium-99m MSG, Tc-99m MAG_3 and, renal imaging, dogs, 937ab(5)
Technetium-99m N_3S antibody, Tc-99m and Re-186/-188 immunoconjugates, kit preparation, catabolite excretory route control, 933ab(5)
Technetium-99m NCA-antibodies, bone marrow scintigraphy, breast carcinoma, malignant lymphomas, 819ab(5)
Technetium-99m PAO, new cerebral perfusion agent, 742ab(5)
Technetium-99m pertechnetate
absorption during nuclear cystography, bladder augmentation, 2ab(2)
degradation in syringes, aluminum-hubbed needles, 1758ab(10)
evaluation of testicular reperfusion, acute testicular torsion, 962ab(5)
platelet labeling, Sn(II)MPO, 922ab(5)
Technetium-99m phosphonate, bone scanning, In-111 leukocytes, infected hip prosthesis, 562(le)
Technetium-99m pyrophosphate
In-111 antimyosin and, detection of different stages, myocardial infarction, 862ab(5)
scintigraphy, malignant hyperthermia, 718(le)
Technetium-99m red blood cells
cardiac blood-pool scintigraphy, Tc-99m DTPA-HSA, 1713
early blood pool phases, diagnosis, hepatic hemangioma, 815ab(5)
interference in chronic renal failure patients, plasma-derived phenomenon, 869ab(5)
labeling kit, first human studies, 811ab(5)
left ventricular diastolic filling, left ventricular systolic dysfunction, 868ab(5)
scanning in soft tissue hemangiomas, vascular malformation, 799ab(5)
subtraction, In-111 WBC enhancement, hemodialysis fistulas, 10ab(4)
Technetium-99m rhenium colloid, simplified lymphoscintigraphic technique, breast cancer, 904ab(5)
Technetium-99m RP-30, detection of area at risk, coronary angioplasty, 791ab(5)
Technetium-99m RP-30A, myocardial perfusion

and ventricular function, coronary arteriography, exercise Tl-201 SPECT, 820ab(5)
Technetium-99m sestamibi
myocardial extraction, flow effects, thallium-201, 756ab(5)
myocardial perfusion imaging, 790ab(5)
treadmill stress test and intravenous dipyridamole, myocardial perfusion imaging, coronary artery disease, 759ab(5)
Technetium-99m SnF_2 colloid, leukocyte labeling kit, preparation, evaluation, 1257
Technetium-99m SQ30217
compared to Tl-201, myocardial perfusion imaging, 312
diagnostic utility, rapid imaging protocol, 730ab(5)
myocardial retention and clearance, canine heart, 860ab(5)
Technetium-99m sulcralfate, chemical aspects of labeling, 523
Technetium-99m sulfonamides, new bifunctional synthon, Tc-99m carbonic anhydrase, 940ab(5)
Technetium-99m sulfur colloid
bone marrow imaging, GM-CSF, 738ab(5)
detection of duodenal ulcer, 700
diagnostic role of nuclear medicine, acquired immunodeficiency syndrome, 1935
diffuse lung uptake, malaria, 117
effect of meal energy content, gastric emptying, 1106
influence on stress, gastric emptying, 794ab(5)
liver perfusion system, R-E cell function, 4ab(2)
radioparticle liver uptake, superior vena cava obstruction, 113
short-term ethanol consumption, R-E cell function, liver, 1ab(2), 815ab(5)
SPECT *vs.* planar liver scintigraphy, 57
surgical management, truncal melanoma, 844ab(5)
Technetium-99m teboroxime
multicenter clinical trial, perfusion agent, 1745ab(10)
regional myocardial perfusion imaging, dynamic SPECT, 1744ab(10), 1ab(11)
Technetium-99m Technegas, lung ventilation scintigraphy, 744ab(5)
Technetium-99m white blood cells, detection of infected orthopedic implants, 754ab(5)
Tellerium-118, antimony-118 generator development, PET application, 849ab(5)
Testicles
evaluation of reperfusion, Tc-99m pertechnetate, acute testicular torsion, 962ab(5)
nuclear imaging, 968ab(5)
return of testicular perfusion, ligation of testicular vessels, Xe-133, 967ab(5)
Tetalman Memorial Award, Mark A. Mintun, 1141
Thallium-201
automatic superposition of cardiac SPECT iamges, 871ab(5)
autoradiographic estimation, tumor and normal organ flow, 913ab(5)
blood levels, reversible myocardial defects, 1172
compared to Tc-99m MIBI, quantitative planar imaging, 1456
computer subtracted cardiac images, 4ab(2)
diagnosis of coronary stenosis, application, machine intelligence, 816ab(5)
dipyridamole imaging
comparative efficacy, adenosine infusion, 730ab(5)
lazy man's stress test, 281
transient mitral regurgitation, myocardial ischemia, 1271
dipyridamole-redistribution ECT, children, Kawasaki disease, 760ab(5)
distribution, stress/delayed renal scintigraphy, 824ab(5)
-dypyridamole SPECT, left bundle branch block, 2ab(11)
exercise SPECT, myocardial perfusion, Tc-99m RP-30A, 820ab(5)
false-positive localization, brown tumor of bone, 1264
flow effects, myocardial extraction, Tc-99m sestamibi, 756ab(5)
follow-up SPECT stress-redistribution studies, reproducibility, quantitative indices, 729ab(5)
I-123 fatty acid comparison, exercise-induced myocardial ischemia, 729ab(5)
I-131 scintigraphy comparison, follow-up, thyroid carcinoma, 914ab(5)
improved Tc-99m isonitrile uptake, myocardial salvage, thrombolysis, 800ab(5)
inherent limitations in LV wall thickness, SPECT, myocardial perfusion scans, 796ab(5)
kinetics in human myocardium, 863ab(5)
left ventricular dilation, importance, three-vessel disease, 749ab(5)
low sensitivity of parathyroid scintigraphy, adenomata, new subtraction method, 885ab(5)
myocardial imaging with SPECT, prone position, 750ab(5)
myocardial perfusion and regional wall motion, coronary anatomy, anterior infarction, 739ab(5)
myocardial SPECT, prone *vs.* supine position, 548, 1738(le)
myocardial tomography
polar probability map, 871ab(5)
solution, inferior wall attenuation, 398
myocardial uptake and clearance, effects of heart rate, 1972
parathyroid uptake, enhancement, thyroxine pretreatment, 886ab(5)
perfusion and radionuclide angiography, during exercise, coronary artery disease, 818ab(5)
planar perfusion defects, extent and severity, 863ab(5)
positive stress test, significance, silent ischemia, 863ab(5)
postexercise lung uptake, SPECT, 288
pulmonary uptake during exercise, 788ab(5)
radioiodinated fatty acid and, dual tracer autoradiography, cardiomyopathy, 80
redistribution, FDG imaging, metabolic activity, 863ab(5)
redistribution after thallium reinjection, relationship, coronary anatomy and regional wall motion, 740ab(5)
renal imaging, cardiac evaluation, 2ab(4)
resting/redistribution, coronary stenosis, unstable angina patients, 740ab(5)
rest-redistribution scintigraphy, myocardial viability, early post-thrombosis, 729ab(5)
rubidium-82 and, myocardial perfusion imaging, coronary artery disease, 759ab(5)
scintigraphy, primary breast carcinoma, axillary metastasis, 844ab(5)
scintigraphy after maximal coronary vasodilation, adenosine, 760ab(5)
scintigraphy in lymphoma, relationship, Ga-67, 915ab(5)
SPECT
abnormal stress test, normal coronary arteries, 750ab(5)
adenosine infusion, ischemic heart disease, 1745ab(10)
180° and 360° reconstructions, heart, 756ab(5)
attenuation correction, differential attenuation of thallium photons, 1746ab(10)
brain tumors, 913ab(5)
brain tumor usefulness, F-18 FDG PET, 895ab(5)
compared to exercise RNV, jeopardized myocardium detection, 861ab(5)
coronary artery disease, left bundle branch block, 419(le)
delayed images, viable or scarred myocardium, 864ab(5)
differentiation, malignant pulmonary lesions, 844ab(5)
evaluation, suspected lung cancer, 997
exercise, myocardial perfusion abnormality, 749ab(5)
false positive in men, exercise, 749ab(5)
future cardiac events, angina pectoris, 861ab(5)
high-risk patient identification, coronary artery disease, 862ab(5)
I-123 fatty acids, coronary artery disease, 739ab(5)
left ventricular wall motion, Tc-99m MIBI, 864ab(5)
low risk patients, coronary artery disease, 863ab(5)
new reconstruction algorithm, radial long-axis tomography, 881ab(5)
optimal specificity, imaging artifact recognition, 441
percent hypoperfused myocardium, algorithm, 750ab(5)
quantification, leg muscle perfusion, 458
Rb-82 PET, coronary artery disease detection, 829ab(5)
Rb-82 PET disparities, myocardial perfusion imaging, 861ab(5)
reconstruction, flood field correction, 3ab(2)
reversibility, quantitative analysis, 739ab(5)
silent myocardial ischemia, after myocardial infarction, 864ab(5)
simultaneous transmission/emission, moving line source, 964ab(5)
slant-hole, 1ab(2)
Tc-99m HEXAMIBI, coronary artery disease, 4ab(2)
spectral attentuation ciphers, attenuation correction, 1744ab(10)
stress-redistribution SPECT
false-positive reversible defects, "upward creep" of heart, 1718
quantitative, myocardial infarction, 780ab(5)
stress studies, frequency, late reversibility, 740ab(5)
Tc-99m HEXAMIBI
comparison, myocardial perfusion imaging, 301
hypoxia and ouabain effects, myocardial uptake kinetics, 1500
Tc-99m MIBI
differences, coronary artery disease, 865ab(5)
right ventricular uptake, 820ab(5)
uptake, bronchial carcinoma, 845ab(5)
uptake, cultured cardiac cells, 860ab(5)
Tc-99m SQ30217 comparison, myocardial perfusion imaging, 312
Tc-99m subtraction technique, scintigraphic detection, parathyroid abnormalities, 3ab(2)
-technetium parathyroid subtraction, global *vs.* regional image normalization, 769ab(5)
three-dimensional SPECT images, accuracy, cor-

onary disease detection, 834ab(5)
tomographic reconstruction, automatic program, long axis of left ventricular myocardium, 806ab(5)
uptake, rejecting and nonrejecting cardiac implants, 1464
Thallium-201 chloride, compared to Tc-99m MIBI, myocardial scintigraphy, infants, 1176
Thallium-201 colloid, diagnostic role of nuclear medicine, acquired immunodeficiency syndrome, 1935
Therapeutic nuclear medicine
development of treatment planning program, radioimmunotherapy, 884ab(5)
EGS4 Monte Carlo determination, beta dose kernel in water, 883ab(5)
estimation of bone marrow doses, delivery, radioimmunotherapy, 778ab(5)
Ho-165 activation, biodegradeable microspheres, 836ab(5)
human antimurine antibody responses, intraperitoneal radioimmunotherapy infusions, murine mAb, 827ab(5)
human pharmacokinetics of Sm-153 EDTMP, metastatic cancer, 1814
I-131 anti-idiotype monoclonal antibody, B cell lymphoma, 826ab(5)
I-131 lym-1, chronic lymphocytic leukemia, 827ab(5)
I-131 MIBG treatment
metastatic carcinoid tumor, 836ab(5)
resistant neuroblastoma, 903ab(5)
immunosuppression with local lymphoid irradiation, palladium-190, 890ab(5)
improved clinical response with strontium-89, increasing dose, metastatic prostate and breast cancer in bone, 843ab(5)
intraarterial yttrium-90 glass microspheres, therapy, hepatic metastasis, 836ab(5)
intraperitoneal yttrium-90 immunotherapy, ovarian cancer, 828ab(5)
labeling of human IgG, Rh-105 complexes, diethylenetriamine derivatives, 832ab(5)
palliation of painful skeletal metastases
186-Re(Sn)-HEDP, mechanism of action, 732ab(5)
186-Re(Sn)-HEDP, prostate cancer, 837ab(5)
radioimmunotherapy of colorectal carcinoma xenografts, Y-90 CO17-1A, mouse IgG, 935ab(5)
selected radionuclides, "S" factors, self-dose to large tumors, 883ab(5)
solitary autonomous thyroid nodules, iodine-131, long-term follow-up, 736ab(5)
Tc-99m and I-131 monoclonal antibody, stage IV neuroblastoma, 904ab(5)
Thiocarbohydrazine, antibodies labeled with Tc-99m, 793ab(5)
Three Mile Island, no health consequences seen, N427
Thrombocytopenia, use of In-111 oxine platelet scintigraphy, children, 1819
Thrombocytopenic purpura, autoimmune, platelet destruction, In-111 autologous platelet clearance, 629
Thrombolysis
coronary, metabolic and functional abnormalities, 837ab(5)
dipyridamole Tl-201 SPECT, compared to exercise RNV, jeopardized myocardium detection, 862ab(5)
economic analysis of clinical PET, Rb-82, heart, 707
imaging before and after, myocardial infarction, Tc-99m MIBI SPECT, 820ab(5)
improved Tc-99m isonitrile uptake, myocardial salvage, compared to Tl-201, 809ab(5)
Tc-99m monoclonal antibody, platelet reaction, 1743ab(10)
variability of response to reperfusion, acute myocardial infarction, MIBI-SPECT, 820ab(5)
Thrombosis
acute venous, model of, Tc-99m antifibrin uptake, 787ab(5)
deep vein
radionuclide blood pool venography, 1744ab(10)
rapid clot uptake, plasminogen activator, 787ab(5)
stroke, radioparticle venography, 917ab(5)
discrepant sulfur colloid, radioparticle liver uptake, superior vena cava obstruction, 113
dural sinus, correlative pediatric imaging, 15
efficient platelet labeling method, 737ab(5)
imaging
fibrin-specific monoclonal antibodies, 747ab(5)
radiolabeled anti-fibrin T2G1S monoclonal antibody, 963ab(5)
imaging with improved formulation, I-123 fragment E1, 817ab(5)
inhibition, platelets, calcium ion sequestrants, 859ab(5)
pitfalls in detection, transplanted grafts, Ga-67 DAS-DFO-fibrinogen, 914ab(5)
Thyroid
anti-thyroid medications, thyroid scan, Grave's disease, 1748ab(10)
cancer
effectiveness, radionuclide treatment, 737ab(5)
hepatic uptake of I-131, total body scans, 4ab(2)
risk from Chernobyl in Sweden, 721(le)
TSH suppressive treatment, triiodothyroacetic acid and levothyroxin, 886ab(5)
carcinoma: *see* Carcinoma, thyroid
colchicine-induced radioiodide retention, iodine-deficient male rats, 737ab(5)
differentiated cancer, effectiveness, radionuclide treatment, 737ab(5)
failure of percholate to inhibit Tc-99m isonitrile binding, myocardial perfusion studies, 885ab(5)
hyperthyroidism
irradiation for Hodgkin's disease, low radioiodine uptake, 255
radioiodine treatment, extra-thyroidal absorbed doses, 833ab(5)
TSH-receptor antibody measurements, clinicial significance, 786ab(5)
relative parathyroid Tl-201 uptake, enhancement, thyroxine pretreatment, 886ab(5)
scan and/or fine needle aspiration, evaluation, solitary thyroid nodules, 9ab(4), 736ab(5)
simultaneous measurement of serum T3 and T4, new radioimmunoassay, 919ab(5)
solitary autonomous nodules, iodine-131, long-term follow-up, 736ab(5)
SPECT quantitation, therapeutic radioiodine concentration, 737ab(5)
uptake of I-123, techniques for measurement, 886ab(5)
Thyroxine, relative parathyroid Tl-201 uptake, experimental enhancement, 886ab(5)
Tin(II)-mercaptopyridine *N*-oxide, platelet labeling, Tc-99m pertechnetate, 922ab(5)
Transferrin, transfer of In-111 and Ga-67, ferritin, phosphate containing compounds, 70
Transplantation
cardiac
clinical utility, radionuclide ventriculography, 781ab(5)
coronary artery disease, 3ab(2)
diagnosis of acute heart transplant rejection, In-111 antimyosin Fab mAb imaging, 847ab(5)
grafts, thrombi detection pitfalls, Ga-67 DAS-DFO-fibrinogen, 914ab(5)
heart, noninvasive follow-up, In-111 antimyosin scintigraphy, 862ab(5)
human heart-lung, regional pulmonary perfusion, 1297
human organ, evaluation of viability, magnetic resonance spectroscopy, 813ab(5)
human pancreas, In-111 platelets, 1470
liver, semiquantitative hepatobiliary scintigraphy, 888ab(5)
liver and kidney, In-111 DTPA plasma clearance, glomerular filtration rate, 942ab(5)
renal
measurements, Tc-99m MAG_3 uptake, 3ab(4)
radionuclide monitoring, 3ab(4)
Tc-99m MAG_3, I-131 OIH and Tc-99m DTPA comparisons, 4ab(4)
Tridodecylmethylammonium chloride, impregnation of silica gel, Os-191/Ir-191m generator, 538
Triiodothyroacetic acid, levothyroxin and, TSH suppressive treatment, thyroid cancer, 886ab(5)
1,1,1-Tris(4-methoxysalicylaldiminomethyl)ethane, Tc-99m complexes with ester analogues, 937ab(5)
1,1,1-Tris(5-methylsalicylaldiminomethyl)ethane, Tc-99m, biliary elimination, rat and guinea pigs, 937ab(5)
Tritium, bladder permeability to water, 2ab(4)
Tuberculoma, I-124 2-iodoisonicotinic acid hydrazide radiotracer, 1756ab(10)
Tubulin, colchicine-induced radioiodide retention, iodine-deficient male rats, 737ab(5)
Tumor-associated antigens, malignant melanoma, autoradiography, 906ab(5)
Tumor necrosis factor, indium-111-labeled, localization, breast carcinoma xenografts, 819ab(5)
Tumors: *see also* specific type
assessment of early response to therapy, metabolic imaging, PET, 789ab(5)
brain
dexamethasone effect, extracellular space, 899ab(5)
protein synthesis, C-11 L-methionine, 910ab(5)
Tl-201 SPECT, 913ab(5)
brain and liver, F-18 FDG PET, Posicam 6.5 camera, 966ab(5)
C-11 L-methionine uptake, response to irradation, 2012
carcinoid, metastasis, I-131 MIBG treatment, 836ab(5)
comparison of Tc-99m MIBI, *in vitro* tumor cell labeling, 938ab(5)
detection, surgical imaging probe, 891ab(5)
early ascites tumor model, 5-[^{123}I]iodo-2′-deoxyuridine, 882ab(5)
effect of Sn-117mDTPA, 1754ab(10)
experimental models
high specific activity, Sm-153 EDTA, 202
visualization, new Tc-99m labeled compound, 906ab(5)
gastrointestinal cancer, radiolabeled antibody imaging, chelating agents, 909ab(5)
Ga-67 uptake, whole body irradiated mice,

913ab(5)
glioma, intravascular streaming, intracarotid infusion, 839ab(5)
Hodgkin's and non-Hodgkin's lymphoma, bone marrow imaging, blind biopsy, 843ab(5)
imaging with In-111 metalloporphyrin, 738ab(5)
improved radiolabeled monoclonal antibody uptake, lavage, intraperitoneal carcinomatosis, 60
improved uptake with In-111/Ga-67/Ga-68, labeled bivalent haptens, immunoscintigraphy, 762ab(5)
lead-203-labeled immunoconjugates, 935ab(5)
liver, metabolic PET images, 878ab(5)
localization, epitope specificity, anti-CEA monoclonal antibodies, 747ab(5)
lung, C-11 methionine, F-18 fluorodeoxyglucose, 788ab(5)
measurement of tissue perfusion, Cu-64 PTSM, 1756ab(10)
mediastinal parathyroid adenoma, radioiodinated toluidine blue, scintigraphy, 768ab(5)
L-[methyl-C-11] methionine uptake
quantitative evaluation, PET, 1809
radiation effects, 739ab(5)
model, localization, paramagnetically-labeled LDL, 902ab(5)
monoclonal antibody
immunoreactivity, Lindmo double reciprocal analysis, 903ab(5)
percolation, modeling analysis, 903ab(5)
musculoskeletal sarcomas, evaluation, use of Gd-DTPA, 901ab(5)
no-carrier-added L-[5-C-11]ornithine synthesis, 782(ab), 783ab(5)
noncalcified splenic hemangioma, detection, radiouclide bone scan, 1111
noncerebral, Tc-99m HM-PAO and F-18 fluorodeoxyglucose, radiotherapy, 912ab(5)
ovarian carcinoma
anti-CA 12.5 radioimmunodetection, 758ab(5)
monoclonal antibody SM3, radioimmunoscintigraphy, 758ab(5)
prospective immunoscintigraphic study, 758ab(5)
palliation of painful skeletal metastases, 186-Re(Sn)-HEDP, prostate cancer, 837ab(5)
primary breast carcinoma and axillary metastasis, Tl-201 scintigraphy, 844ab(5)
prostate cancer, PAP and PSA, disease markers, 786ab(5)
quantitative perfusion measurement, Rb-81 PET, 911ab(5)
radioimmunotargeting, streptavidin and biotin, 819ab(5)
renal and lung, transport mechanism, Tc-99m glucoheptonate, 912ab(5)
Re-186 NR-CO-02 anti-CEA F(ab')$_2$ fragment, radioimmunotherapy, 779ab(5)
-specific mouse/human chimeric antibody, Tc-99m labeling, human γ3 constant region, 934ab(5)
squamous cell carcinoma of lung, diagnosis, monoclonal antibody radioimmunoassay, 918ab(5)
subcellular kinetics, In-111 monoclonal antibody, 907ab(5)
targeting, biotin conjugation to antibody, 832ab(5)
xenografts, localization, monoclonal antibody cocktails, 747ab(5)
Tumor-seeking agents
antibodies labeled with Tc-99m, use of thiocarbohydrazine, 793ab(5)
anti-CEA antibody, colorectal carcinoma, 908ab(5)
anti-CEA imaging, I-123 Fab' and F(ab')2 fragments, 903ab(5)
astatine-211 labeled F(ab')$_2$ fragment, immunoreactivity, tumor uptake, 778ab(5)
biodistribution studies, novel non-steroidal estrogen, I-123 IBHPE, 883ab(5)
bismuth-212 labeled antibody, human cancer peritoneal xenografts, 778ab(5)
comparison of Tc-99m MIBI, *in vitro* tumor cell labeling, 938ab(5)
Cu-64 *p*-carboxyalkylphenyldithiosemicarbazones, antibody labeling, 848ab(5)
development of antibody cocktail, radioimmunodetection, adenocarcinoma, 935ab(5)
enhanced regional delivery of monoclonal antibodies, peritoneal cavity, transdiaphragmatic blockade, 815ab(5)
estimate of immunoreactive fraction, curve fitting method, 915ab(5)
full retention of immunoreactivity, antibody labeling, site-specific methods, 831ab(5)
I-131 anti-colon specific antigen-p, therapeutic efficacy, monoclonal antibody, 826ab(5)
I-131 HMFG1 monoclonal antibody dosimetry, whole body scanning, 884ab(5)
I-131 lym-1, chronic lymphocytic leukemia, 827ab(5)
IgM monoclonal antibodies, pharmacokinetics, 909ab(5)
imaging of small cell lung carcinoma, Tc-99m monoclonal antibody, 818ab(5)
In-111 anti-CEA ZCE 025 monoclonal antibody, primary lung cancer, 905ab(5)
In-111/Ga-67/Ga-68, improved tumor uptake, immunoscintigraphy, 762ab(5)
In-111 monoclonal antibody, detection, recurrent colorectal carcinoma, 748ab(5)
intraperitoneal yttrium-90 immunotherapy, ovarian cancer, 828ab(5)
lysosomal role in tumor accumulation, Ga-67, dual-tracer studies, 921ab(5)
maleimidoethyl succinimyl succinate, spacer, Ga-67 deferoxamine labeled antibody, 832ab(5)
N_2S chelating agents, Tc-99m and Re-186/-188 immunoconjugates, kit preparation, 933ab(5)
octreotide, I-123 labeling, metabolism, 768ab(5)
patterns of HAMA development, In-111 ZCE 025 monoclonal antibody, colorectal carcinoma, 906ab(5)
preparation and characterization, Re-186 NR-CO-02 F(ab')$_2$, 793ab(5)
prospective immunoscintigraphic study, ovarian carcinoma, 758ab(5)
radioiodinated, yttrium-labeled anti-CEA mAb, radioimmunotherapy, 848ab(5)
radioiodinated phospholipid ethers, tumor imaging agents, 849ab(5)
TAG-72 and In-111 monoclonal antibody, tumor expression, relationship, 908ab(5)
Tc-99m DTPA, re-evaluation, neurofibromatosis, 915ab(5)
yttrium-90 EDTMP, 843ab(5)
Tungsten-188, zirconium-tunsten gel generators, 849ab(5)
***m*-Tyrosine analogs,** radiofluorinated, potential L-dopa PET tracers, 930ab(5)

U

U-50488 analogs, fluorinated, characterization, PET studies, 931ab(5)
Ulcer, duodenal, radionuclide detection, 700
Ulcerative colitis, colonic coverage, mesalamine enema, 764ab(5)
Ultrasound
correlative pediatric imaging, 15
scintigraphy and, giant hemangiomas, liver, 181
serial furosemide renography, asymptomatic hydronephrosis, 4ab(4)
Uranium, suspension of shipments by DOE, jeopardized Mo-99/Tc-99m supply, N1139
Ureter, vesico-ureteral reflux, radionuclide voiding cystography, expert system, 5ab(2)
Urinary tract
correlative pediatric imaging, 15
DMSA studies, infants under one year old, 5ab(4)
significance of activity, In-111 leukocyte scans, 889ab(5)
Uropathy
obstructive
position-dependent discrepancies, Whitaker test and diuresis renogram, 2ab(4)
surgery evaluation, parenchymal transit time index, 942ab(5)

V

Valine, rate of incorporation into proteins, autoradiography, brain tumor model, 913ab(5)
Valvuloplasty, percutaneous aortic balloon, radionuclide ventriculography, 867ab(5)
Vanadium-48 vanadyl-chlorin, new tumor imaging agent, 930ab(5)
Venography
best radionuclide, 564(le)
radionuclide blood pool, deep vein thrombosis, 1744ab(10)
radionuclide evaluation of indwelling catheters, chemotherapy, 845ab(5)
radioparticle, occult deep vein thrombosis, stroke, 917ab(5)
renal, scrotal scintigraphy comparison, variocele, 943ab(5)
Ventilation studies
krypton-81m reservoir administration systems, evaluation methods, 650
lung scintigraphy, Tc-99m Technegas, 744ab(5)
pre-operative, relative value, perfusion scans, 733ab(5)
pulmonary clearance of Tc-99m HM-PAO aerosols, new application, 743ab(5)
regional, PEEP effect, preterm lamb, 1342
ventilation/perfusion mismatch
clinical significance, 734ab(5)
non-thromboembolic lung disease, 734ab(5)
positive pressure ventilatory support, 1268
Ventricular function
assisted circulation and artifical hearts, 780ab(5)
biventricular forward and regurgitant flows, radioangiography, 560(le)
cardiovascular nuclear medicine, the next step, 1123
evaluation, coronary artery disease, 1149
evaluation of parameters, gated blood pool scans, sampling, 872ab(5)
first-pass Ir-191m radionuclide angiocardiography, 450
left
anaerobic threshold, peak exercise, 1744ab(10)
carbon-based generator system, Ir-191m clinical usefulness, 1025
coronary artery disease diagnosis, radionuclide angiography, 1966
impaired diastolic function, hypertension, 780ab(5)
patient-borne CsI-photodiode detector, ST seg-

ment, 868ab(5)
regional filling, myocardium, 165
salmonella-infected thrombus, Ga-67 citrate scintigraphy, 1277(le)
volume calculations, scintigraphy, 869ab(5)
left ventricular pressure-volume analysis, radionuclide angiography, 420(le)
model to evaluate ventricular insufficiency, first-pass radioventriculogram component analysis, 417(le)
myocardial perfusion and Tc-99m RP-30A, coronary arteriography, exercise Tl-201 SPECT, 820ab(5)
right
radionuclide evaluation, acute pulmonary emboli, 853ab(5)
uptake, Tc-99m MIBI and Tl-201, 820ab(5)
Ventriculography
cardiac RWMA, synthetic classification images, 816ab(5)
equilibrium gated radionuclide, post extra systolic potentiation, 870ab(5)
exercise radionuclide, cardiac events predictor, coronary insufficiency, 1745ab(10)
left, regional wall motion, gated myocardial PET, 1775
left ventricular diastolic filling patterns, hypertrophic cardiomyopathy, 868ab(5)
left ventricular wall motion, stress myocardial perfusion, Tc-99m MIBI, 864ab(5)
Ventriculography, radionuclide
central aorta pressure change, myocardial performance, 1657
clinical utility, cardiac transplantation, 781ab(5)
epirubicin application schemes, breast cancer, 867ab(5)
nature of background, 872ab(5)
percutaneous aortic balloon valvuloplasty, 867ab(5)
realistic dynamic cardiac phantom, 542
ventricular function and perfusion, gated tomographic imaging, Tc-99m MIBI, 801ab(5)
Vertebral column, identification of inflammatory diseases, new scintigraphic technique, 856ab(5)
VEST: *see* Ambulatory cardiac moitoring device
Videofluoroscopy, pulmonary aspiration, evaluation, 967ab(5)
Volume rendering, gated cardiac blood-pool studies, three-dimensional display, 2036
Volunteers, irradiation, nuclear medicine, 260, T22(le)

W

Walker 256 carcinoma, radioiodinated phospholipid ethers, tumor imaging agents, 849ab(5)
Waste, regulations as "backdoor threat", N1431
Water, tritiated, bladder permeability, 2ab(4)
White blood cells, scan and magnetic resonance imaging, infection, lower extremity, 856ab(5)

X

Xenografts
breast carcinoma, localization, In-111 tumor necrosis factor, 819ab(5)
colon carcinoma, comparative biodistribution, Y- and In-labeled monoclonal antibody B72.3, 672
colorectal carcinoma, radioimmunotherapy, Y-90 CO17-1A, 935ab(5)
human cancer peritoneal, bismuth-212 labeled antibody, 778ab(5)
human leukemia, immunoscintigraphy, radiolabel and antigen modulation, 889ab(5)
human tumor
F-18 FDG uptake, cancer imaging, 912ab(5)
heterogeneity, monoclonal antibody uptake, 777ab(5)
influence of antibody protein dose, antibody distribution, autoradiography, 759ab(5)
mammary carcinoma, curative radioimmunotherapy, I-131 monoclonal antibodies, 531
murine-human, variations in absorbed dose, radiolabeled monoclonal antibodies, 777ab(5)
renal cell carcinoma, external beam irradiation, radioimmunotherapy, 826ab(5)
tumor, localizaiton, monoclonal antibody cocktails, 747ab(5)
Xenon-133
abnormal regional response to verbal stimulation, developmental dysphasia, SPECT, 812ab(5)
back-flow testing of CPR airway valves, 1755ab(10)
central area of cerebral infarcts, spontaneous evolution, 781ab(5)
dynamic SPECT, obstructive pulmonary disease, 916ab(5)
hepatic retention ratio, 1708
PET, regional cerebral blood flow, 157
return of testicular perfusion, ligation of testicular vessels, 967ab(5)
reversed V/Q mismatch, clinical significance, 734ab(5)
SPECT
cerebral perfusion reserve, minor ischemic stroke, 897ab(5)
critical cerebral blood flow thresholds, 337
Tc-99m HMPAO uptake and, cerebral blood flow, 1752ab(10)
SPECT and Tc-99m HMPAO, presurgical evaulation, temporal lobe epilepsy, 896ab(5)
ventilation study, gastrointestinal visualization, tracheoesophageal fistula, 258
washout, penile blood flow, 1032
X-rays
bone mineral density analyzer, reproducibility, 1750ab(10)
vs. radioimmunoscintigraphy, size-related diagnostic sensitivity, 749ab(5)

Y

Young Investigator Award, cardiovascular nuclear medicine, N14
Yttrium-88 monoclonal antibody, compared to In-III monoclonal antibody, biodistribution, colon carcinoma xenografts, 672
Yttrium-90
intraarterial glass microspheres, therapy, hepatic metastasis, 836ab(5)
intraperitoneal immunotherapy, ovarian cancer, 828ab(5)
radioimmunotherapy of colorectal carcinoma xenografts, mouse IgG coinjection, 935ab(5)
radiolabeling of monoclonal antibodies, comparison, five bifunctional chelate techniques, 763ab(5)
Yttrium-90 anti-idiotype monoclonal antibody, therapy of non-Hodgkin's lymphoma, 778ab(5)
Yttrium-90 beta dose point kernels, potential use in radioimmunotherapy, 1036
Yttrium-90 EDTMP, bone-seeking radiotherapeutic agent, 843ab(5)
Yttrium-90 monoclonal antibody
effect of carrier IGG on biodistribution, 4ab(11)
macrocyclic bifunctional chelating agent, 763ab(5)

Z

Zinc-62, Cu-62 generator, PET radiopharmaceuticals, 1838
Zirconium-89, use as PET antibody label, 935ab(5)